
<html lang="en"     class="pb-page"  data-request-id="76f3328a-3965-4467-b00c-8ce03bc67fb1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.1c00217;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Jennifer Alisa  Amrhein" /></meta><meta name="dc.Creator" content="Stefan  Knapp" /></meta><meta name="dc.Creator" content="Thomas  Hanke" /></meta><meta name="dc.Description" content="Macrocycles are typically cyclic variants of inhibitors derived from uncyclized canonical molecules or from natural products. For medicinal chemistry, drug-like macrocycles have received increasing..." /></meta><meta name="Description" content="Macrocycles are typically cyclic variants of inhibitors derived from uncyclized canonical molecules or from natural products. For medicinal chemistry, drug-like macrocycles have received increasing..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 2, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00217" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00217" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00217" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00217" /></link>
        
    
    

<title>Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00217" /></meta><meta property="og:title" content="Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0020.jpeg" /></meta><meta property="og:description" content="Macrocycles are typically cyclic variants of inhibitors derived from uncyclized canonical molecules or from natural products. For medicinal chemistry, drug-like macrocycles have received increasing interest over the past few years, since it has been demonstrated that macrocyclization can favorably alter the biological and physiochemical properties as well as selectivity in comparison to the acyclic analogue. Recent drug approvals such as Lorlatinib, glecaprevir, or voxilaprevir underline the clinical relevance of drug-like macrocycles. However, the synthesis of drug-like macrocycles can be challenging, since the ring-closing reaction is generally challenging with yields depending on the size and geometry of the bridging linker. Nevertheless, macrocycles are one opportunity to expand the synthetic toolbox for medicinal chemistry to provide bioactive molecules. Therefore, we reviewed the past literature of drug-like macrocycles highlighting reactions that have been successfully used for the macrocyclization. We classified the cyclization reactions by their type, ring-size, yield, and macrocyclization efficiency index." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00217"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00217">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00217&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00217&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00217&amp;href=/doi/10.1021/acs.jmedchem.1c00217" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 7991-8009</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00100" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00300" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jennifer Alisa Amrhein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer Alisa Amrhein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany</div><div class="loa-info-affiliations-info">Structure Genomics Consortium Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+Alisa++Amrhein">Jennifer Alisa Amrhein</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan Knapp</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Knapp</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany</div><div class="loa-info-affiliations-info">Structure Genomics Consortium Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#84efeae5f4f4c4f4ece5f6e9e7ece1e9aaf1eaeda9e2f6e5eaefe2f1f6f0aae0e1"><span class="__cf_email__" data-cfemail="87ece9e6f7f7c7f7efe6f5eae4efe2eaa9f2e9eeaae1f5e6e9ece1f2f5f3a9e3e2">[email protected]</span></a>. Phone: (+49)69 798-29871.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Knapp">Stefan Knapp</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5995-6494" title="Orcid link">https://orcid.org/0000-0001-5995-6494</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Thomas Hanke</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Hanke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany</div><div class="loa-info-affiliations-info">Structure Genomics Consortium Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7a121b14111f3a0a121b081719121f17540f1413571c081b14111c0f080e541e1f"><span class="__cf_email__" data-cfemail="0e666f60656b4e7e666f7c636d666b63207b606723687c6f6065687b7c7a206a6b">[email protected]</span></a>. Phone: (+49)69 798-29313.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Hanke">Thomas Hanke</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7202-9468" title="Orcid link">https://orcid.org/0000-0001-7202-9468</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00217&amp;href=/doi/10.1021%2Facs.jmedchem.1c00217" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 7991–8009</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 2, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 February 2021</li><li><span class="item_label"><b>Published</b> online</span>2 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00217" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00217</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7991%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJennifer%2BAlisa%2BAmrhein%252C%2BStefan%2BKnapp%252C%2BThomas%2BHanke%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.1c00217%26title%3DSynthetic%2BOpportunities%2Band%2BChallenges%2Bfor%2BMacrocyclic%2BKinase%2BInhibitors%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8009%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00217"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2192</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00217" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Alisa Amrhein&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Knapp&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Hanke&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7991-8009&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00217&quot;},&quot;abstract&quot;:&quot;Macrocycles are typically cyclic variants of inhibitors derived from uncyclized canonical molecules or from natural products. For medicinal chemistry, drug-like macrocycles have received increasing interest over the past few years, since it has been demonstrated that macrocyclization can favorably alter the biological and physiochemical properties as well as selectivity in comparison to the acyclic analogue. Recent drug approvals such as Lorlatinib, glecaprevir, or voxilaprevir underline the clinical relevance of drug-like macrocycles. However, the synthesis of drug-like macrocycles can be challenging, since the ring-closing reaction is generally challenging with yields depending on the size and geometry of the bridging linker. Nevertheless, macrocycles are one opportunity to expand the synthetic toolbox for medicinal chemistry to provide bioactive molecules. Therefore, we reviewed the past literature of drug-like macrocycles highlighting reactions that have been successfully used for the macrocyclization. We&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00217&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00217" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00217&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00217" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00217&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00217" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00217&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00217&amp;href=/doi/10.1021/acs.jmedchem.1c00217" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00217" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00217" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00217%26sid%3Dliteratum%253Aachs%26pmid%3D34076436%26genre%3Darticle%26aulast%3DAmrhein%26date%3D2021%26atitle%3DSynthetic%2BOpportunities%2Band%2BChallenges%2Bfor%2BMacrocyclic%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D7991%26epage%3D8009%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291240" title="Cyclization">Cyclization</a>,</li><li><a href="/action/doSearch?ConceptID=291434" title="Macrocyclization">Macrocyclization</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291163" title="Macrocycles">Macrocycles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Macrocycles are typically cyclic variants of inhibitors derived from uncyclized canonical molecules or from natural products. For medicinal chemistry, drug-like macrocycles have received increasing interest over the past few years, since it has been demonstrated that macrocyclization can favorably alter the biological and physiochemical properties as well as selectivity in comparison to the acyclic analogue. Recent drug approvals such as Lorlatinib, glecaprevir, or voxilaprevir underline the clinical relevance of drug-like macrocycles. However, the synthesis of drug-like macrocycles can be challenging, since the ring-closing reaction is generally challenging with yields depending on the size and geometry of the bridging linker. Nevertheless, macrocycles are one opportunity to expand the synthetic toolbox for medicinal chemistry to provide bioactive molecules. Therefore, we reviewed the past literature of drug-like macrocycles highlighting reactions that have been successfully used for the macrocyclization. We classified the cyclization reactions by their type, ring-size, yield, and macrocyclization efficiency index.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In recent years, macrocycles have received increasing attention in drug discovery. The reason for this growing interest is based on several approvals of drug candidates as well as data suggesting that macrocyclization can change the biological and physiochemical properties in comparison to the acyclic counterparts.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> In general, one central focus of medicinal chemistry is to improve the potency of a lead toward its target of interest while also optimizing the selectivity of the compound to closely related off-targets. It has been demonstrated that both challenges can be addressed by macrocylization, which makes this strategy attractive for the drug discovery process. In addition, macrocycles offer an opportunity for chemical novelty over the existing scaffolds. For example, over 90% of the FDA-approved kinase inhibitors are conventional type I/II inhibitors, which means they all share often highly similar hinge-binding moieties. After more than three decades of kinase drug discovery, the chemical space for ATP-mimetic moieties is well explored, and establishing new hinge-binding moieties can be a significant challenge. Thus, macrocyclization has the potential to contribute to a new chemical space for the design of novel type I/II kinase inhibitors.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The utility of macrocycles as bioactive compounds or even as drugs was first limited to natural products, such as rapamycin (<b>1</b>) and its closely related rapalog derivatives, which are currently used as immunosuppressants or in the case of temsirolimus (<b>2</b>) as an oncology drug. Besides these examples, macrolide antibiotics were discovered almost 70 years ago with the first representative, erythromycin, still in use for the treatment of a variety of different bacterial infections. However, these first naturally derived macrocycles discourage the medicinal chemistry community from including macrocycles in a drug discovery process, since they are usually very big molecules and often violate the Lipinski rule of five.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, many macrocycles based on natural products include stereocenters, which makes the total synthesis a formidable challenge and slows down SAR exploitation.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Simpler macrocycles are synthetically more accessible and favorable; the pharmacological properties of many of these recently developed macrocycles has spawned research interest. Conformational restriction, a consequence of macrocyclization, is a common strategy in drug design to improve the potency of a lead compound by minimizing the entropic cost.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In addition, minimizing the conformational freedom and trapping small molecules in bioactive conformations would be expected to lead to a gain of selectivity and potency. In large protein families that harbor closely related active sites, selectivity is a major issue.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> One of these protein families is protein kinases, a major drug target family which contains more than 500 closely related proteins sharing a highly similar cofactor ATP binding site and overall catalytic domain architecture. Thus, the orthosteric binding pocket of protein kinases is highly conserved over this protein family and the development of macrocyclic kinase inhibitors is one approach that has been successfully utilized to overcome selectivity issues.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Many synthetic strategies for the development of macrocyclic kinase inhibitors have been elaborated, and some of these macrocycles have been approved as drugs or entered clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The first approved macrocyclic kinase inhibitors were the mTOR inhibitors <b>1</b>, <b>2</b>, and <b>3</b>, which were approved between 1999 and 2009. Temsirolimus (<b>2</b>) and Everolimus (<b>3</b>) are structurally related derivatives of Sirolimus (<b>1</b>), also called rapamycin. Sirolimus (<b>1</b>) has been approved to prevent transplant rejection after kidney transplantation,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> while <b>2</b> and <b>3</b> have been approved for the treatment of renal cell cancer.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Pacritinib (<b>5</b>), Zotiraciclib (<b>7</b>), and SB1578 (<b>10</b>) are 2-aminopyrimidine-based macrocycles which target JAK2/FLT3, CDK2/JAK2, and FLT3 and JAK2. All of them can be synthesized via ring-closing metathesis.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Pacritinib (<b>5</b>) is a JAK2/FLT3 inhibitor for treatment of myelofibrosis and lymphoma which is currently evaluated in phase 3 clinical trials.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> Zotiraciclib (<b>7</b>) entered phase 1/2 clinical trials in 2010 as a potential new agent for treatment of leukemia and multiple myeloma,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> whereas SB1578 (<b>10</b>) entered phase 1 clinical trials in 2010 for the treatment of autoimmune diseases and inflammatory disorders such as psoriasis and rheumatoid arthritis.<a onclick="showRef(event, 'ref14 ref20'); return false;" href="javascript:void(0);" class="ref ref14 ref20">(14,20)</a> E6201 (<b>6</b>) is a resorcyclic lactone, which was synthesized via a Mukaiyama reaction.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This MEK1 inhibitor entered clinical trials in 2007 to study its efficacy treating plaque psoriasis, and in 2017, a phase 1 study was initiated evaluating E6201 (<b>6</b>) in malignant melanoma.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Selitrectinib (<b>8</b>) and Recrotrectinib (<b>9</b>) are pyrazolopyrimidine based macrocycles, which have been synthesized via amide coupling.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Both inhibitors are potent TRKA/B/C inhibitors, whereas Recrotrectinib (<b>9</b>) additionally targets ROS1/ALK. Both compounds belong to the second-generation of TRK inhibitors and are macrocyclic analogues of the recently approved acyclic analogue Larotrectinib, a first-generation TRK inhibitor. However, resistance to this first generation of TRK inhibitors led to the development of both of these macrocyclic compounds which were designed to overcome this on-target resistance.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Selitrectinib (<b>8</b>) and Recrotrectinib (<b>9</b>) entered Phase1/2 clinical trials in 2017 for treatment of advanced solid tumors. JNJ26483327 (<b>11</b>) is based on a quinazoline scaffold, and it was synthesized via a Mitsunobu-reaction.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> It was entered into a phase 1 clinical trial in 2008 as a multitargeted tyrosine kinase inhibitor which was developed for the treatment of advanced and/or refractory solid malignancies.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Lorlatinib (<b>4</b>) was approved in 2018 as a highly potent and selective ROS1/ALK inhibitor, for the treatment of NSCLC.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Overview of Macrocyclic Kinase Inhibitors in Clinical Trials</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0019.gif" alt="" id="gr19" /></img><div></div></div><div class="NLM_p">The approval of the highly potent macrocyclic ALK/ROS kinase inhibitor Lorlatinib (<b>4</b>) is an excellent example of the implementation of macrocyclization in drug discovery.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a></div><div class="NLM_p">Lorlatinib (<b>4</b>) has outstanding central nervous system (CNS) penetration, and it is highly selective for its designated targeted ROS and ALK compared to its noncyclized template <i>R</i>-Crizotinib (<b>12</b>), which has broad activity on receptor tyrosine kinases as well as weaker potency on the main targets ALK and ROS (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. A. <i>R</i>-Crizotinib (<b>12</b>) and the ALK/ROS1 selective inhibitor Lorlatinib (<b>4</b>) and the cellular IC<sub>50</sub> values on ALK and ALK-L1196 M gatekeeper mutation and the MDR efflux ratio.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> B. Selectivity panel of <i>R-</i>Crizotinib (<b>12</b>) against 456 recombinant human protein kinases with a screening concentration of 1000 nM and Lorlatinib (<b>4</b>) against a panel of 206 kinases at a screening concentration of 1000 nM. The primary targets ALK and ROS1 are highlighted in blue. Values were adopted from refs <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and <a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>. C. IC<sub>50</sub> values of Lorlatinib (<b>4</b>) against it closest off-targets.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> D. Binding mode of acyclic compound <i>R</i>-Crizotinib (<b>12</b>) on human Anaplastic Lymphoma Kinase (ALK; PDB-ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>). E. Binding mode of macrocyclic compound Lorlatinib (<b>4</b>) on human Anaplastic Lymphoma Kinase (ALK; PDB-ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI">4CLI</a>). F. Alignment of acyclic compound <i>R</i>-Crizotinib (<b>12</b>) (orange) and macrocyclic compound Lorlatinib (<b>4</b>) (green) on human Anaplastic Lymphoma Kinase (PDB-ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>) in surface representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lorlatinib (<b>4</b>) was developed based on the bioactive conformation of <i>R</i>-Crizotinib (<b>12</b>) to gain a potent and more selective ALK/ROS inhibitor with improved CNS availability (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Lorlatinib (<b>4</b>) is effective against all known resistant mutants of the first and second generation of ALK inhibitors. Furthermore, it has considerably improved blood-brain barrier and cell penetration due to low efflux in cell lines overexpressing the efflux transporters P-glycoprotein and breast cancer resistant protein. Thus, in addition to the selectivity and potency gained, this macrocyclic third-generation ALK inhibitor has also markedly improved pharmacological properties.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overview over the optimization steps from the first to the third generation ALK/ROS inhibitors.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The optimization of <i>R</i>-Crizotinib (<b>12</b>) was carried out stepwise via a second-generation ALK inhibitor, a molecular design that was focused on avoiding the resistance of clinical mutations after <i>R</i>-Crizotinib (<b>12</b>) treatment as well as the high P-glycoprotein 1 efflux with a >2.5 MDR BA/AB ratio of its parent compound.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>13</b> is about 6-fold more potent on ALK wild-type, but it is also about 5-fold more potent on the ALK-L1196 M gatekeeper mutation compared to <i>R</i>-Crizotinib. Compound <b>13</b> showed a desirable low MDR efflux ratio, but it still lacked potency and suitable <i>in vivo</i> clearance.<a onclick="showRef(event, 'ref33 ref37'); return false;" href="javascript:void(0);" class="ref ref33 ref37">(33,37)</a> For further optimization, a macrocyclic inhibitor design was performed. Though a first variation of the ring size of 12–14 membered rings, the cellular potencies of these compounds reached 1- to 2-digit nanomolar EC<sub>50</sub> values for ALK as well as the L1196 M mutation. A picomolar binding affinity and a LipE value of 4.4 were achieved for the macrocycle <b>14</b>. The lipophilicity was reduced by exchanging an ether with a lactam linker in compound <b>4</b>. This resulted in a higher LipE value in comparison to the acyclic counterparts <b>12</b> and <b>13</b>, but also compared to the macrocycle <b>14</b>. By these modifications, it was possible to improve the potency of <i>R</i>-Crizotinib (<b>12</b>) by 62-fold for wild-type ALK kinase and 40–825-fold for clinical ALK mutants while also improving the selectivity.<a onclick="showRef(event, 'ref33 ref38'); return false;" href="javascript:void(0);" class="ref ref33 ref38">(33,38)</a> Lorlatinib (<b>4</b>) has a half-time of 19.0–28.8 h, and an <i>in vivo</i> metabolite assay showed the main metabolism through CYP3A4 and UGT1A4.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a></div><div class="NLM_p">Another excellent example of the improvement activity on resistant mutants and of pharmacokinetic properties through macrocyclization is BI-4020 (<b>19</b>). This inhibitor has been explored for the inhibition of the tertiary EGFR mutation that is present in 12–47% of non-small cell lung cancer (NSCLC) tumors.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The single mutations del19 and L858R can be treated with the first-, second-, and third-generation EGFR inhibitors such as Erlotinib, Gefitinib, Afatinib, or Osimertinib.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42−45)</a> However, a second mutation, the gatekeeper mutation T790M, occurs in 50–70% of patients who have already been treated successfully.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> This mutation can only be treated by covalent third-generation EGFR inhibitors, as it weakens the inhibition activity of the first- and second-generation inhibitors.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> However, even after successful treatment of cancers bearing the gatekeeper mutation, 20–40% of patients suffer a relapse due to the C797S mutation preventing covalent binding of Osimertinib.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Thus, the aim in developing BI-4020 (<b>19</b>) was to have access to a new generation of EGFR inhibitors, which are active against gatekeeper and C797S mutations while sparing wild-type EGFR and that maintain high selectivity across the human kinome. Engelhardt et al. identified the aminobenzimidazole <b>15</b> as a starting point for further optimizations (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This inhibitor exhibited an IC<sub>50</sub> value of 2100 nM and 250 nM for EGFR<sup>L858R T790 M C797S</sup> and EGFR<sup>del19 T790 M C797S</sup> while having no activity on EGFR<sup>wt</sup>. Through interesting QM-torsion angle scan optimizations and by additional interaction with the protein, <b>16</b> was discovered. This inhibitor has good potency for EGFR<sup>L858R T790 M C797S</sup> while sparing EGFR<sup>wt</sup>. However, the improved activity on EGFR mutants resulted also in poorer kinase selectivity. By removing the hydrogen-bond acceptor in the phosphate binding region, the kinase selectivity of compound <b>17</b> was improved while maintaining activity for EGFR mutants. Critically, reduction of ligand entropy through the macrocyclization led to a significant increase in potency. For this optimization step, macrocycles with varying linker length were synthesized. The first attempts showed a 5 times better cellular potency compared to the linear precursor <b>17</b>, in which potency was affected by conformational restrictions, which was addressed by introducing an <i>N</i>-methylpyrazole, and better selectivity against EGFR<sup>wt</sup> was achieved through installing an additional methyl group targeting a subpocket and introducing a stereo center in the linker to address the sugar binding pocket of EGFR. Compound <b>18</b> revealed an IC<sub>50</sub> EGFR<sup>del19 T790 M C797S</sup> of 1 nM, and the ratio of IC<sub>50</sub> EGFR<sup>wt</sup>/IC<sub>50</sub> EGFR<sup>del19 T790 M C797S</sup> > 1000. Further optimizations to improve the solubility and reduce the plasma protein binding were carried out by introducing a solubilizing group at position 6 at the phenyl core. BI-4020 (<b>19</b>) showed the most optimal combination of properties, including solubility, permeability, and fraction unbound in plasma. In addition, the cellular activity was improved most likely by the improved cell penetration of this macrocyclic compound to a subnanomolar EC<sub>50</sub> of 0.2 nM for EGFR<sup>del19 T790 M C797S</sup>. The antiproliferative effects against EGFR<sup>del19 T790 M C797S</sup>-dependent BaF3 cells was increased by a factor of 4000 in comparison to Osimertinib. In addition, for the EGFR<sup>del19</sup> BaF3 cells BI-4020 (<b>19</b>) exhibited the same activity as Osimertinib and on the NSCLS cell line PC-9<sup>del19 T790 M C797S</sup> where it showed a potency of 1.3 nM.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of PK/PD optimization steps from aminobenzimidazole <b>15</b> to macrocyclic aminobenzimidazole BI-4020 (<b>19</b>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The examples of Lorlatinib (<b>4</b>) and BI-4020 (<b>19</b>) convincingly demonstrated that locking the bioactive conformation of linear precursor molecules markedly improved target potency, kinome wide selectivity, as well as physiochemical and <i>in vivo</i> properties such as brain penetration. Nevertheless, the synthetic intractability for the ring-closing reaction is still a major concern for the medicinal chemist limiting the number of published studies using a macrocyclization strategy. Therefore, in this review we focus on synthetic strategies of small molecule macrocyclic kinase inhibitors and summarize data that have been published over the past 15 years. In general, ring systems of both synthetic macrocycles and analogues of natural products have been considered for this review containing 12 or more atoms, as this is a common definition for macrocycles.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In order to obtain a comprehensive overview of macrocyclic kinase inhibitors, we extracted all macrocyclic kinase inhibitors from structures deposited in the PDB. Additionally, we searched Pubmed and Scifinder in order to gather a comprehensive data set on synthetic efforts in this area.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">1.  Macrocyclization Reactions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of macrocycles contains two major difficulties. First, the ring-closing reaction involves typically two functional groups, which should preferentially interact in an intramolecular reaction and not in an intermolecular reaction, which would lead to dimerization, oligomerization, or polymerization. Therefore, the cyclization step requires typically highly diluted concentrations, which is an inefficient strategy and is impractical to study these molecules in a common SAR study. To identify at which concentration the cyclization reaction, dimerization or polymerization, prevails, Collins et al. established the macrocyclization efficiency index, Emac, which is defined in <a class="ref internalNav" href="#eq1" aria-label="formula 1">formula 1</a>.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> This value describes the feasibility of using a certain reaction in the drug discovery process and indicates the probability of being able to carry out the macrocyclization reaction on a sufficiently large scale. Collins et al. identified 896 reactions and determined the Emac values of this set. The determined values were between 2 and 9 with a mean of 5.8. Values between 8 and 9 are in an optimal range and do not require further optimization, while an Emac value of 6 represented an acceptable value, which, however, still may be optimized further for future reactions. Values between 2 and 5 were perceived as poor and needed to be improved.<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_m001.gif" alt="" id="_i5" /></img><span class="labelSpan">(1)</span></span>where <i>Y</i> = yield in % and <i>C</i> = concentration in mM.</div><div class="NLM_p">Second, the ring-closing reaction itself can be challenging, since several studies indicated that a conformational preorganization is important for the macrocyclization reaction to occur.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a></div><div class="NLM_p">Here, we searched the medicinal chemistry literature and sorted the reported synthetic routes by different reaction types used for the cyclization step. All in all, we identified 503 macrocyclization reactions, which have been published over the past 15 years. However, out of the 503 macrocyclization reactions just 302 have been considered here, since for the remaining 201 reactions no yields have been reported, or the yield has been reported only over several steps. Nevertheless, for the approximately 300 reactions analyzed, we observed that the most common reactions used to date are the ring-closing metathesis<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and a nucleophilic substitution.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> However, some rather unusual reaction types, which are rarely performed in a classical medicinal chemistry SAR study, have been used such as a Shiina esterification or Prins reactions (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58">(56−58)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overview of the different synthetic reaction types that have been used for macrocyclization. Approximately 300 different macrocyclization reactions have been reviewed, which have been performed in the past 15 years for the synthesis of macrocyclic kinase inhibitors with known yields. The upper panel displays the percentage of the macrocyclization reactions used, whereas in the lower panel, the “macrolactonization and macrolactamization”, the “palladium-catalyzed reactions”, the “C–O and C–N bond formations”, and “C–C bond formations” have been subdivided into the individual macrocyclization reaction types.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A set of 20 different macrocyclization reactions were examined to determine the dependence of the ring size and the reaction type on the yields. The following section is organized according to the different reaction types that have been identified.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">1.1.  Ring-Closing Metathesis</h3><div class="NLM_p">The ring-closing metathesis (RCM) is the most commonly used reaction type for the macrocyclization. 52% of the total summarized reactions were metathesis reactions. This is an efficient and potent possibility for the formation of a C–C bond, which goes back to the work of Grubbs et al.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> An example of an RCM reaction is the synthesis of the macrocyclic JAK2/FLT3 inhibitor Pacritinib (<b>5</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). For this reaction, a Grubbs catalyst of the second generation was used with a moderate yield of 56%.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The advantages of this ring-closing method are a high tolerance toward many functional groups and the availability of many different catalysts, which can be adapted to the corresponding reaction requirements.<a onclick="showRef(event, 'ref51 ref60'); return false;" href="javascript:void(0);" class="ref ref51 ref60">(51,60)</a> The disadvantage of this reaction type is the lack of control of the stereochemistry of the olefin product that leads to <i>E-</i>/<i>Z-</i>isomers. Therefore, the double bond was in most cases directly reduced to the saturated linker, to avoid tedious purification of the isomers. In addition, this double bond also provides an opportunity for the introduction of more diverse functionalities, such as epoxidation with further modifications.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The importance of this reaction type is also highlighted by 3 compounds which entered clinical trials and have been produced by this metathesis reaction.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Example of Macrocyclization through a Ring-Closing Metathesis<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The best yields were obtained with a ring size of 15 and 17, whereas the synthesis of 13-membered macrocycles has been associated with lower yields, which could indicate conformational constraints (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). For all analyzed reactions, the Emac values were determined as a function of the ring size. All of the Emac values were in a range between 5 and 6.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mean values of yields and Emac values depending on the ring size for the ring-closing metathesis reactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">1.2.  Nucleophilic Substitution</h3><div class="NLM_p">An example of a nucleophilic aromatic substitution with a good yield (87%) was reported for the macrocyclic PIM1/PIM2 inhibitor <b>22</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Nucleophilic substitution represents 13% of the total reactions, the second most common macrocyclization type. This well-known reaction type often requires the introduction of protecting groups, since depending on the type of nucleophile, not every functional group is equally tolerated. Nevertheless, the ring closure strategy offers a versatile reaction type with multiple available conditions, is easy to implement, and is also compatible for large ring systems with over 20 atoms.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The most common type of this reaction for macrocyclization is the nucleophilic aromatic substitution. A nitrogen or an oxygen has been typically used as a nucleophile, while a halide or a mesityl group was used as a favorable leaving group.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Example for a Macrocyclization Using an Intermolecular Nucleophilic Substitution<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The nucleophilic reaction has been used for many large ring systems (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The yields vary greatly depending on the ring size. While 15-, 16-, 46-, and 49-membered rings delivered less than 40% yield, other ring-closing reactions achieved moderate to good mean yields up to 82%. The Emac values for all of the analyzed reactions were between 5 and 8, thus moderate to good.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mean values of yields and Emac values as a function of the ring size for the nucleophilic substitution ring closure reactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">1.3.  Amide Coupling</h3><div class="NLM_p">The third most common reaction is the amide coupling. An example for this reaction type is the synthesis of a macrocyclic ASK1 (MAP3K5) inhibitor <b>24</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> An amide bond can be formed by activating the carboxylic acid, followed by the condensation with an amine. The different strategies for this reaction are, for example, the activation through uronium-derived reagents or the usage of carbodiimides in combination with additives.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Himmelbauer et al. used propanephosphonic acid anhydride (T<sub>3</sub>P) as a coupling reagent. However, other standard amide coupling reagents have also been described for the macrocyclization step, including HATU,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> TBTU,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> PyBOP,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> EDCl, and HOBt.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> This step is usually preceded by deprotection so that the functional groups can only react with each other in the desired step. The FDA-approved kinase inhibitor Lorlatinib (<b>4</b>) can also be obtained through an amide coupling which highlights this type of reaction. After the optimization, Lorlatinib (<b>4</b>) could be obtained with a yield of 56% for the first scale-up synthesis.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Example for a Macrocyclization Using Amide Coupling<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The yields for the closure of 12- to 16-membered rings were generally rather low (<40%), while the larger macrocycles with an 18- and 19-membered ring system had reported yields of around 60%. The low yields might indicate a general problem with macrocyclization under classical amide coupling conditions. Usually, this reaction follows a two-step procedure starting with the activation of the carboxylic acid by treating the carboxylic acid with common coupling reagents. After activating the carboxylic acid to the active ester, the amine is added to start the amide formation. This two-step procedure is typically conducted to avoid side reaction which occurs from the reaction of the amine with the coupling reagents. However, if both functionalities, the carboxylic acid and the amine, are in the same molecule, a preactivation of the carboxylic acid to the active ester is not possible and might be an explanation for the detected low yields. Nevertheless, the Emac values for all of them are reasonable and more or less in the same area. An explanation for that could be that the dilution concentration of the smaller rings was lower, and this leads to a low yield for the smaller cycles; however, the Emac values are in the same range as the bigger ring systems (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mean values of yields and Emac values depending on the ring size for the amide coupling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">1.4.  Macrolactonization and Macrolactamization</h3><div class="NLM_p">In this section, we describe macrolactonization and macrolactamization reactions, which differ from the classical amide coupling reagents. The macrolactonization is a very old and well-studied reaction, since it is one of the most commonly used reaction types for the total synthesis of many natural products.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Therefore, there are various synthetic options for the macrolactonization and also the macrolactamization reaction (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). One of them is the Yamaguchi esterification, where the carboxylic acid is activated by 2,4,6-trichlorobenzoyl chloride (Yamaguchi reagent) to form a mixed anhydride. Afterward, the ester bond can be formed by a reaction with an alcohol in the presence of DMAP.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Kraft et al. used this strategy for the synthesis of <b>26</b>, where the product was isolated with 90% yield.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Another option is the activation through 2-chloro-1-methylpyridinium iodide (Mukaiyama reagent). Mukaiyama et al. invented this reagent in order to establish a method for the preparation of an ester bond by the using an equimolar amount of a carboxylic acid, an alcohol, and the Mukaiyama reagent.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> However, this reagent has general utility as an efficient condensation agent, which can be used for a variety of many different dehydrative coupling reactions.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> With this reaction agent, <b>28</b>, an example of a macrolactam was achieved in modest yields.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> A third option is the usage of an aromatic anhydride such as 2-methyl-6-nitrobenzoic anhydride (MNBA). It is used as a dehydration condensation agent for the Shiina esterfication under basic conditions.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Another option for the formation of an ester bond with mixed anhydrides is in the presence of a Lewis acid catalyst. This strategy was investigated by Shiina et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a><b>30</b> resulted in 53% yields under basic conditions.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Ley et al. used the Steglich esterification for the macrocyclization step of <b>31</b> to obtain <b>32</b> with 71% yield.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> It also offers the possibility of coupling a wide variety of carboxylic acids and alcohols under mild basic conditions.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Examples of Macrolactonization and Macrolactamization Reactions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example for a macrocyclization using a A, Yamaguchi esterfication;<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> B, Mukaiyama reaction;<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> C, Shiina esterfication;<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> D, Steglich esterfication.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></p></p></figure><div class="NLM_p">The Yamaguchi esterfication was used for smaller and larger ring systems, but we observed a lack of published reactions for creating 15- to 19-membered cycles. The yields were generally between 50% and 80%, and the Emac values were in an acceptable area between 4 and 6, indicating that these procedures should still be improved. Due to the low number of documented reactions, the chart for the Mukaiyama reaction, Shiina and Steglich esterification showed only one ring size per reaction type (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). For all of them, the yields and Emac values were quite reasonable. Even though macrolactonization is a well-studied reaction for the synthesis of macrocycles, the usage of this reaction for the synthesis of macrocyclic kinase inhibitors had less impact, probably because ester linkages are considered prone to hydrolysis in the cellular environment and are therefore usually not drug-like moieties.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Summary of esterification ring-closing reactions. Mean values of yields and Emac values depending on the ring size for the Yamaguchi esterfication. The values for the Mukaiyama reaction, Shiina esterfication, and Steglich esterification are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">Figure S1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">1.5.  Palladium-Catalyzed Reaction</h3><div class="NLM_p">Palladium-catalyzed cross-coupling reactions are versatile reactions, which have been met with great interest especially due to their utility in drug discovery, since they enable the broad formation of different C–C bonds (aryl–aryl, aryl–alkyl, aryl–alkenyl, aryl–alkyne), but they can also be used for the formation of various C–O or C–N bonds.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> Therefore, it is not a surprise that attempts have been made to utilize palladium-catalyzed cross-coupling reactions also for the macrocyclization reaction. One of the most commonly used palladium-catalyzed C–C bond formation reactions is the Suzuki cross-coupling. It is typically a reaction between a boronic acid and an aryl halide in the presence of a palladium (0) complex and a base.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Johnson et al. used this reaction type for the formation of <b>34</b>, a macrocyclic ALK inhibitor; however, this reaction resulted only in poor yields. For this reaction, the boronic acid was generated <i>in situ</i> proceeding directly with the cross-coupling step. Further studies of these coupling reactions suggested that the yields could be potentially improved by carrying out the borylation and the cross-coupling separately.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Another way to form a C–C bond is the frequently used Heck reaction. This coupling reaction is a palladium-catalyzed cross-coupling between an unsaturated halide and an alkene in the presence of a base,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> which has been used for the synthesis of Lorlatinib-derivatives such as <b>36</b>, a macrocyclic ALK/ROS1 inhibitor, however in low yields.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Therefore, in an exploratory process development an alternatively synthetic route of Lorlatinib (<b>4</b>) has been published that includes an amidation reaction as ring-closing reaction.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Another possibility for the palladium-catalyzed formation of a C–N bond represents the Buchwald–Hartwig amination. This is a cross-coupling reaction between an amine and an aryl halide, and it offers an alternative to a reductive amination or a nitration followed by a reduction step with mild reaction conditions and with a higher tolerance to the presence of functional groups.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Wang et al. used this kind of reaction for the synthesis of <b>38</b> by using tris(dibenzylideneacetone)dipalladium(0) as a catalyst and Xantphos as an ligand (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). The desired product was isolated with a yield of 28%.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Examples of Palladium-Catalyzed Cross-Coupling Reactions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example for a macrocyclization through A, Suzuki reaction;<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> B, Heck reaction;<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> C, Buchwald-Hartwig amination.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></p></p></figure><div class="NLM_p last">As already mentioned above, the mean yields for the Suzuki coupling were quite low. The reason for this unsatisfying yield was probably due to a strategy in which the boronic acid was generated <i>in situ</i> and a potential improvement could be separating the introduction of the boronic acid and the cross-coupling step. The Emac values were in a moderate range. The values for the Heck reaction and the Buchwald–Hartwig amination were low to moderate. All these reactions were only used for the synthesis of small macrocycles with a ring size between 12 and 14 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">Figure S2</a>).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">1.6.  C–O and C–N Bond Formation</h3><div class="NLM_p">Besides the palladium-catalyzed cross-coupling reactions and the classical S<sub>N</sub>-reaction for the formation of C-heteroatom bonds (C–O/C–N), many more reactions are known, which can also be utilized for the macrocyclization reaction. The Mitsunobu reaction is an opportunity to form C–O bonds and could be used for a macrolactonization, as well as for the formation of macrocyclic ethers. The reaction typically requires an acidic functional group such as carboxylic acids, or phenols and an alcohol group where the hydroxy group is replaced. For the reaction, the alcohol group will be activated typically through the usage of triphenylphosphine and diisopropyl azodicarboxylate (DIAD) or diethyl azodicarboxylate (DEAD).<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83−85)</a><b>40</b> is an example for an macrocyclic EGFR inhibitor, which was isolated with 65% yield using DIAD for the generation of the ether bond.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Another example for a C–O bond formation is a Prins-driven reaction (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>B). The Prins reaction requires typically the attendance of an aldehyde and an alkene or alkyne, which reacts in an electrophilic addition and the subsequent reaction with different nucleophiles.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In <b>41</b>, all three different functionalities are present, which leads to the formation of <b>42</b>, which was achieved through this Prins-driven reaction.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> This reaction type is quiet unusual for a cyclization and introduces a 6-membered hydropyranyl ring systems, which might serve as a driving force for the formation of the 20-membered macrocycle in excellent yields. <b>45</b> represents a macrocyclic AXL kinase inhibitor. The macrocyclization step was performed via an C–N bond formation by using double Click chemistry.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> These reactions introduce a 1,2,3-triazole moiety through a modified Huisgen 1,3-dipolar cycloaddition. For that, an azide and an alkyne reacted in the presence of a copper(I) catalyst.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Another option for the formation of the C–N bond of <b>47</b> is the aryl amidation.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In addition, this reaction represents a copper(I) mediated reaction, which allows transformation of an aryl bromide or a aryl iodide into an amide. It has a high tolerance to functional groups and takes place in the presence of a base and a ligand like <i>N,N′</i>-dimethylethylenediamine (DMEDA).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><figure id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Examples of C–O and C–N Bond Formation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example of a macrocyclization through A, Mitsunobu reaction;<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> B, Prins-driven reaction;<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> C, Click reaction;<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> D, Aryl amidation.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></p></p></figure><div class="NLM_p">The mean yield for the Mitsunobu coupling of a 13-membered macrocycle is quite low at 17%, while the yields for formation of larger ring systems containing 14 and 15 atoms were around 65%. The effectiveness of the Click reactions was surprisingly low (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The yields for the formation of 15- and 18-membered ring systems were lower than 25%. The Prins-driven reaction and the aryl amidation were only used for larger ring formation reactions and exhibited a good yield around 80%. In addition, the Emac values for these reactions were above 6.</div><figure id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Summary of C–O and C–N bond formation. Mean values of yields and Emac values depending on the ring size for the A, Mitsunobu reaction; B, Click reaction. The values for the Prins-driven reaction and aryl amidation are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">Figure S3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">1.7.  C–C Bond Formation</h3><div class="NLM_p">Besides the aforementioned olefin methathesis, a few more options for the C–C bond ring-closing reaction have been described (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>; <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Schaubach et al. described an alkyne metathesis for the synthesis of <b>49</b>, which was carried out with 78% yield by the usage of a molybdenum catalyst <b>50</b>.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The authors of this study have shown that this reaction was equally applicable for the synthesis of the sesquiterpene lactone manshurolide, which has been described as a MAPK inhibitor.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> Another reaction we found was the copper(I)-calatyzed [2 + 2 + 2] cycloaddition. This reaction enables the selective creation of a C–C bond that introduces a new ring system into the molecule. Alkynes as well as nitriles or other unsaturated substances are possible educts for this reaction.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Zhang et al. used this strategy to synthesize <b>53</b>, however, with a poor yield of 9%.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The nickel-mediated alkyne–aldehyde reductive coupling resulted in <b>55</b> with 57% yield. This reaction is an <i>exo</i>-seletive coupling with a regioselectivity ≥95%.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Interestingly, this method is tolerant to a large number of functional groups and enables the introduction of a stereogenic center.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a><b>57</b> was produced by a Wittig reaction, introducing a double bond. For that, the triphenyl phosphonium ylide was first introduced, which then reacted intramolecularly with the aldehyde to <b>57</b> with a yield of 68%.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Jiang et al. used the McMurry reaction to produce <b>59</b>. For that, two aldehyde groups were coupled to a double bond, using titanium(IV) chloride and a reducing agent such as zinc or LiAlH<sub>4</sub>.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> The Nozaki–Hiyama–Kishi reaction was used for the synthesis of <b>61</b>.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> It is a reaction between an aldehyde and an allyl or vinyl halide with nickel and chromium as a catalyst. The reaction exhibits high selectively for aldehydes even in the presence of ketones. In addition, it is tolerant to many other functional groups.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> For <b>61</b>, a yield of 35% was achieved.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><figure id="sch7" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Examples of C–C Bond Formation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example of macrocyclization through A, alkyne metathesis;<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> B, [2 + 2 + 2] cycloaddition;<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> C, alkyne–aldehyde reductive coupling;<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> D, Wittig reaction;<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> E, McMurry reaction;<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> F, Nozaki–Hiyama–Kishi reaction.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></p></p></figure><figure id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Summary of C–C bond formations. Mean values of yields and Emac values depending on the ring size for the A, alkyne metathesis; B, [2 + 2 + 2] cycloaddition; C, alkyne–aldehyde reductive coupling. The values for the Wittig reaction, McMurry reaction, and Nozaki–Hiyama–Kishi reaction are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">Figure S4</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The alkyne metathesis seems to be a versatile tool for the macrocyclization. The yields for the smaller as well as the larger ring systems were between 70% and 80%. The [2 + 2 + 2] cycloaddition seemed not that efficient with yields under 15% and less favorable Emac values below 4. The alkyne–aldehyde reductive coupling was only used for smaller rings, but it showed moderate to good yields around 40%. Due to the low number of published ring closure reactions, the Wittig, McMurry, and Nozaki–Hiyama–Kishi reactions covered only one ring size per reaction type with moderate Emac values around 6.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">2.  Future Perspectives and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over the past decades, macrocycles have received increasing interest in the field of medicinal chemistry, due to their remarkable pharmacological properties. Their suitability as drugs is demonstrated by the rising numbers of FDA-approved macrocycles and inhibitors currently tested clinically. In the field of synthetic macrocyclic kinase inhibitors, just Lorlatinib (<b>4</b>) has entered the market, but many more are currently being evaluated in clinical trials such as Pacritinib (<b>5</b>) or its closely related derivatives SB1578 (<b>10</b>),<a onclick="showRef(event, 'ref14 ref20 ref104'); return false;" href="javascript:void(0);" class="ref ref14 ref20 ref104">(14,20,104)</a> Zotiraciclib (TG02; SB1317; <b>7</b>),<a onclick="showRef(event, 'ref18 ref105 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref18 ref105 ref106 ref107">(18,105−107)</a> the quinazoline based derivative JNJ26483327 (<b>11</b>),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> or the pyrazolopyrimidine-based TRK inhibitors Selitrectinib (LOXO-195) (<b>8</b>) and Repotrectinib (TPX-0005) (<b>9</b>). The macrocyclization reactions that have been used for these compounds are the ring-closing metathesis, Mitsunobu reactions, and amide coupling reactions. The success of these inhibitors indicates that their macrocyclization reactions are suitable also under scale-up conditions. Nevertheless, the synthesis of drug-like macrocycles is still challenging, and macrocyclization is often difficult to integrate into a classical SAR approach of a medicinal chemist. However, the synthetic toolbox for medicinal chemistry is currently poorly explored by focusing on a few reactions, which are frequently used.<a onclick="showRef(event, 'ref78 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref78 ref108 ref109">(78,108,109)</a> The synthesis of drug-like macrocyclic molecules represents an opportunity for new avenues expanding the synthetic toolbox as well as the chemical space for bioactive molecules. Therefore, we summarized in this review published experience on macrocyclization reactions that have been performed over the past 15 years to provide a representative sample of drug-like macrocyclization reactions. All in all, over 20 different reaction types were identified for the ring-closing reaction (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Brown and Boström et al. made a comprehensive analysis of the synthetic methodologies in medicinal chemistry over three decades.<a onclick="showRef(event, 'ref78 ref109'); return false;" href="javascript:void(0);" class="ref ref78 ref109">(78,109)</a> By a direct comparison between their comprehensive analyses of these reactions, which are frequently used in classical medicinal chemistry SAR approaches and for the macrocyclization reactions, it is obvious that a number of reactions appear in both studies as most frequently used reactions such as amide formation, aromatic nucleophilic substitution reaction (S<sub>N</sub>Ar), or Suzuki reaction. However, for the macrocyclizations reactions the most prominent reaction used by medicinal chemists was the ring-closing metathesis that strongly differs from the work of Brown and Boström.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> In addition, other reactions such as Mitsunobu reaction, click-reaction, or alykne metathesis may have the potential to be a versatile reaction for the synthesis of drug-like macrocycles. One aspect to bring potential candidates into clinical trials is the synthetic accessibility of these compounds often requiring high dilution in order to favor intermolecular reactions. Therefore, Collins et al. introduced the Emac value that offers a convenient comparative index for the assessment of macrocyclization efficiency.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In our analysis, we calculated the Emac values for all the previously described reactions. In our comprehensive analysis, we identified a mean value of 5.7 which is in good agreement with the reported mean of 5.8 from Collins et al.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The reaction types with the highest Emac values are the aryl amidation and the Prins driven reaction with values of 6.8 and 6.7, respectively. The lowest Emac values were observed using [2 + 2 + 2] cycloaddition and the Click reaction with values of 3.8 and 4.7, respectively. In general, the Emac value correlated with the obtained yields. However, the RCM with a ring size of 13 had a low yield (34%), but the Emac was with a value of 5.9 slightly above the mean, suggesting additional synthetic challenges. The same tendency was seen for the Click reaction. For reactions resulting in a ring size of 18, yields of 23% were achieved with an Emac value of 5.7. For these cases, it should be tested whether the yield can be improved by changing other reaction parameters, such as temperature or reaction time.</div><figure id="fig11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Comparison of the different macrocyclization methods and their dependence on the ring size.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Albeit there are many different reaction types, the implementation of macrocycles into the iterative process for a classical SAR approach is still challenging. Usually, the macrocyclization step is the last step in the synthesis, which slows down the synthesis of a broad set of closely related analogues. One option to overcome this obstacle would be to introduce a mild ring-closing reaction during earlier steps to create an opportunity for functionalization and diversification of a macrocyclic scaffold. Cernak et al. have recently summarized the possibilities for so-called late-stage functionalization (LSF), which describes especially the process of C–H activation to introduce new functional groups to highly complex molecules that allows further derivatization.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> However, ring expansion, ring contraction, or rearrangement reactions illustrate the diverse opportunities for late-stage functionalization.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p">The length of the linker has an enormous effect on determining the lowest-energy conformation of the macrocycle and the ability of the macrocyclic compound to adopt a bioactive conformation. Therefore, the implementation of different linkers should be included early in SAR approaches of macrocycles. Cruz-Lopez et al. have developed an interesting method for the ring-closing reaction by a double CuAAC reaction, which attached a linker on the one side of the core scaffold and closes the macrocycle by just one step. By using various double-azide analogues, this reaction type offers an option for the fast introduction of different linkers to form macrocycles with distinct ring sizes.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Future methodologies, which could be implemented more often for the improvement of cyclization reactions are, e.g., the continuous flow chemistry or the multicomponent reaction. The flow chemistry is a technique to reduce the high-dilution concentration and thus reduce the waste and prevent the unwanted oligomers and byproducts. Several examples have proven applicability for the synthesis of macrocycles through continuous flow chemistry.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> In addition, due to the possibility to run the macrocyclization reaction even under highly concentrated conditions, it allows the continuous flow chemistry in general as a more feasible scale-up of macrocyclic compounds. The multicomponent reaction represents a possibility to reduce the complexity of the synthesis of macrocycles. It is a method yielding a product from the simultaneous reaction of three or more compounds. An example and the most common MCR macrocyclization is the Ugi four component reaction (U-4CR), which involves a ketone or aldehyde, an isocyanide, an amine, and a carboxylic acid to form a bis-amide.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The MCR can be used for the formation of linear precursors, which are then closed in a cyclization reaction. However, it also can include the cyclization step, and this strategy has the potential to be a powerful tool for future synthesis of macrocyclic compounds and the generation of chemical libraries.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><div class="NLM_p last">Many of the challenges synthesizing macrocyclic kinase inhibitors have been addressed in the recent literature, and we believe therefore that the reports on macrocyclic inhibitors will increase in the near future. Lorlatinib (<b>4</b>) is the most prominent example that has proven that macrocyclization may have superior properties to its acyclic counterpart, which is in that case crizotinib. By macrocyclization of <i>R</i>-Crizotinib (<b>12</b>) to Lorlatinib (<b>4</b>), the <i>in vitro</i> and cellular potency was increased on its main targets. In addition, the selectivity profile of Lorlatinib (<b>4</b>) was superior to <i>R</i>-Crizotinib (<b>12</b>), and the CNS availability was also improved, which finally led to the approval of Lorlatinib (<b>4</b>) by the FDA as the first macrocyclic kinase inhibitor. Therefore, their often-favorable selectivity profiles, combined with the potential to increase the potency and have an influence on the PK properties compared to conventional inhibitors, makes macrocyclization strategies particular interesting for the development of kinase inhibitors.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00217" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08726" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08726" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00217?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00217</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figures: Summaries of esterification ring-closing reactions, palladium-catalyzed cross-coupling reactions, C–O, C–N, and C–C bond formation. All references used for the statistical analysis. (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf">jm1c00217_si_001.pdf (355.83 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00217" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Knapp</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Chemistry, Johann Wolfgang
Goethe-University, Max-von-Laue-Str.
9, D-60438 Frankfurt
am Main, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Structure
Genomics Consortium Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5995-6494" title="Orcid link">https://orcid.org/0000-0001-5995-6494</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f74717e6f6f5f6f777e6d727c777a72316a717632796d7e7174796a6d6b317b7a"><span class="__cf_email__" data-cfemail="a1cacfc0d1d1e1d1c9c0d3ccc2c9c4cc8fd4cfc88cc7d3c0cfcac7d4d3d58fc5c4">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Hanke</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Chemistry, Johann Wolfgang
Goethe-University, Max-von-Laue-Str.
9, D-60438 Frankfurt
am Main, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Structure
Genomics Consortium Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7202-9468" title="Orcid link">https://orcid.org/0000-0001-7202-9468</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#68000906030d281800091a050b000d05461d0601450e1a0906030e1d1a1c460c0d"><span class="__cf_email__" data-cfemail="650d040b0e0025150d041708060d00084b100b0c480317040b0e031017114b0100">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Alisa Amrhein</span> - <span class="hlFld-Affiliation affiliation">Institute
for Pharmaceutical Chemistry, Johann Wolfgang
Goethe-University, Max-von-Laue-Str.
9, D-60438 Frankfurt
am Main, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Structure
Genomics Consortium Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Jennifer Alisa Amrhein</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=BIO-d7e1683-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jennifer Alisa Amrhein</b> studied chemistry at the Goethe University in Frankfurt. Currently, she is doing her PhD at the Institute of Pharmaceutical Chemistry at the Goethe University under the supervision of Prof. Dr. S. Knapp. Her main focus is on the development and synthesis of macrocyclic kinase inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Stefan Knapp</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=BIO-d7e1689-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Stefan Knapp</b> studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He has a PhD in protein crystallography (Karolinska Institute). In 1999, he joined Pharmacia (Italy) and left the company in 2004 to set up a research group at the Structural Genomics Consortium (Oxford University). He was Professor of Structural Biology at Oxford University (UK) and from 2012 to 2015 the director for Chemical Biology at the Target Discovery Institute. He joined Frankfurt University in 2015 as a Professor of Pharmaceutical Chemistry. He is also the CSO of the SGC (Structure Genomics Consortium) node at the Goethe-University Frankfurt. His research interest is focused on the design of selective kinase inhibitors and inhibitors of protein interactions domains.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Thomas Hanke</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=BIO-d7e1694-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Thomas Hanke</b> studied Pharmacy at the Goethe University in Frankfurt. He did his PhD in the group of Prof. Dr. Schubert-Zsilavecz at Frankfurt University which included a sabbatical in the group of Prof. Dr. Werz at the University of Tübingen to study the anti-inflammatory responses of small molecules in vitro and in cellular systems. In 2014, he completed his PhD in pharmaceutical chemistry, investigating the synthesis and pharmacological characterization of dual 5-LO and mPGES-1 inhibitors. In 2015, he joined the group of Prof. Dr. Knapp where he is working as a senior scientist on the development of selective chemical probes targeting kinases, with the main focus on macrocyclic inhibitors.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The SGC is a registered charity (no: 1097737) that receives funds from AbbVie, Bayer AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Merck & Co (aka MSD outside Canada and US), Pfizer, São Paulo Research Foundation-FAPESP, Takeda and Wellcome [106169/ZZ14/Z].</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">ASK1</td><td class="NLM_def"><p class="first last">apoptosis signal-regulating kinase 1</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AXL</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase receptor UFO</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">DEAD</td><td class="NLM_def"><p class="first last">diethyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMEDA</td><td class="NLM_def"><p class="first last">1,2-dimethylethylenediamine</p></td></tr><tr><td class="NLM_term">EDCl</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fetal liver fms-related tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">50% inhibitory concentration</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">janus kinase 2</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">logD</td><td class="NLM_def"><p class="first last">octanol/buffer (pH 7.4) distribution coefficient</p></td></tr><tr><td class="NLM_term">LSF</td><td class="NLM_def"><p class="first last">late-stage functionalization</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MCR</td><td class="NLM_def"><p class="first last">multicomponent reaction</p></td></tr><tr><td class="NLM_term">MNBA</td><td class="NLM_def"><p class="first last">2-methyl-6-nitrobenzoic anhydride</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung carcinoma</p></td></tr><tr><td class="NLM_term">pALK</td><td class="NLM_def"><p class="first last">phospho-ALK</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein data bank</p></td></tr><tr><td class="NLM_term">PIM1</td><td class="NLM_def"><p class="first last">proto-oncogene serine/threonine-protein kinase Pim-1</p></td></tr><tr><td class="NLM_term">PIM2</td><td class="NLM_def"><p class="first last">serine/threonine-protein kinase Pim-2</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PyBOP</td><td class="NLM_def"><p class="first last">benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">QM</td><td class="NLM_def"><p class="first last">quantum mechanics</p></td></tr><tr><td class="NLM_term">RCM</td><td class="NLM_def"><p class="first last">ring-closing metathesis</p></td></tr><tr><td class="NLM_term">ROS1</td><td class="NLM_def"><p class="first last">c-ros oncogene 1</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">wt</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 115 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Macrocycles in New Drug Discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.4155%2Ffmc.12.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22857532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1409-1438&issue=11&author=J.+Mallinsonauthor=I.+Collins&title=Macrocycles+in+New+Drug+Discovery&doi=10.4155%2Ffmc.12.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles in new drug discovery</span></div><div class="casAuthors">Mallinson, Jamie; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1409-1438</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of drug-like macrocycles is emerging as an exciting area of medicinal chem., with several recent examples highlighting the favorable changes in biol. and physicochem. properties that macrocyclization can afford.  Natural product macrocycles and their synthetic derivs. have long been clin. useful and attention is now being focused on the wider use of macrocyclic scaffolds in medicinal chem. in the search for new drugs for increasingly challenging targets.  With the increasing awareness of concepts of drug-likeness and the dangers of mol. obesity', functionalized macrocyclic scaffolds could provide a way to generate ligand-efficient mols. with enhanced properties.  In this review we will sep. discuss the effects of macrocyclization upon potency, selectivity and physicochem. properties, concg. on recent case histories in oncol. drug discovery.  Addnl., we will highlight selected advances in the synthesis of macrocycles and provide an outlook on the future use of macrocyclic scaffolds in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSrzcbKW7Tc7Vg90H21EOLACvtfcHk0ljQBEvkvHHHkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO&md5=63ad275af92ac89ae6b36c5071b578f8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.93%26sid%3Dliteratum%253Aachs%26aulast%3DMallinson%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMacrocycles%2520in%2520New%2520Drug%2520Discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26issue%3D11%26spage%3D1409%26epage%3D1438%26doi%3D10.4155%2Ffmc.12.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driggers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span> <span> </span><span class="NLM_article-title">The Exploration of Macrocycles for Drug Discovery — an Underexploited Structural Class</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/nrd2590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnrd2590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=18591981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+Exploration+of+Macrocycles+for+Drug+Discovery+%E2%80%94+an+Underexploited+Structural+Class&doi=10.1038%2Fnrd2590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The exploration of macrocycles for drug discovery - an underexploited structural class</span></div><div class="casAuthors">Driggers, Edward M.; Hale, Stephen P.; Lee, Jinbo; Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">608-624</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products comprised of a macrocycle ring structure have proven their therapeutic applications as antibiotics, immunosuppressants as well as anticancer agents.  Despite this, macrocyclic compds. remain under-explored.  Terrett and colleagues review the properties and features of current macrocycle drugs, emphasizing the vast potential of synthetic macrocycles in drug discovery.  Macrocyclic natural products have evolved to fulfil numerous biochem. functions, and their profound pharmacol. properties have led to their development as drugs.  A macrocycle provides diverse functionality and stereochem. complexity in a conformationally pre-organized ring structure.  This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations.  Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery.  This is in part due to concerns about synthetic intractability and non-drug-like properties.  This Review describes the growing body of data in favor of macrocyclic therapeutics, and demonstrates that this class of compds. can be both fully drug-like in its properties and readily prepd. owing to recent advances in synthetic medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDtW8LpE4ru7Vg90H21EOLACvtfcHk0ljQBEvkvHHHkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D&md5=16e091818053e5b163b81078a8d03094</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2590%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520Exploration%2520of%2520Macrocycles%2520for%2520Drug%2520Discovery%2520%25E2%2580%2594%2520an%2520Underexploited%2520Structural%2520Class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624%26doi%3D10.1038%2Fnrd2590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelraheem, E. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurpiewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowska-Tłuscik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span> <span> </span><span class="NLM_article-title">Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8789</span>– <span class="NLM_lpage">8795</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.6b01430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b01430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOrt77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=8789-8795&issue=19&author=E.+M.+M.+Abdelraheemauthor=K.+Kurpiewskaauthor=J.+Kalinowska-T%C5%82uscikauthor=A.+Domling&title=Artificial+Macrocycles+by+Ugi+Reaction+and+Passerini+Ring+Closure&doi=10.1021%2Facs.joc.6b01430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Artificial macrocycles by Ugi reaction and Passerini ring closure</span></div><div class="casAuthors">Abdelraheem, Eman M. M.; Kurpiewska, Katarzyna; Kalinowska-Tluscik, Justyna; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8789-8795</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Artificial macrocycles can be convergently synthesized by a sequence of an Ugi multicomponent reaction (MCR) followed by an intramol. Passerini MCR used to close the macrocycle.  Significantly, in this work, the first intramol. macrocyclization through a Passerini reaction is described.  We describe 21 macrocycles of a size of 15-20.  The resulting macrocyclic depsipeptides are model compds. for natural products and could find applications in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoitRBwMEc1XLVg90H21EOLACvtfcHk0ljj0jmK-XZ9hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOrt77O&md5=cc97ee0a82cdeac2becf3166b3d5dcd2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b01430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b01430%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelraheem%26aufirst%3DE.%2BM.%2BM.%26aulast%3DKurpiewska%26aufirst%3DK.%26aulast%3DKalinowska-T%25C5%2582uscik%26aufirst%3DJ.%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DArtificial%2520Macrocycles%2520by%2520Ugi%2520Reaction%2520and%2520Passerini%2520Ring%2520Closure%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2016%26volume%3D81%26issue%3D19%26spage%3D8789%26epage%3D8795%26doi%3D10.1021%2Facs.joc.6b01430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0ljj0jmK-XZ9hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logusch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambiar, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au-Yeung, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Total Synthesis of Erythromcin. 1. Synthesis of an Erythronolide A Secoacid Derivative via Asymmetric Induction</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3210</span>– <span class="NLM_lpage">3213</span>, <span class="refDoi"> DOI: 10.1021/ja00401a049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00401a049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFyqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1981&pages=3210-3213&issue=11&author=R.+B.+Woodwardauthor=E.+Loguschauthor=K.+P.+Nambiarauthor=K.+Sakanauthor=D.+E.+Wardauthor=B.+W.+Au-Yeungauthor=P.+Balaramauthor=L.+J.+Browneauthor=P.+J.+Cardauthor=C.+H.+Chen&title=Asymmetric+Total+Synthesis+of+Erythromcin.+1.+Synthesis+of+an+Erythronolide+A+Secoacid+Derivative+via+Asymmetric+Induction&doi=10.1021%2Fja00401a049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric total synthesis of erythromycin. 1. Synthesis of an erythronolide A seco acid derivative via asymmetric induction</span></div><div class="casAuthors">Woodward, R. B.; Logusch, E.; Nambiar, K. P.; Sakan, K.; Ward, D. E.; Au-Yeung, B.-W.; Balaram, P.; Browne, L. J.; Card, P. J.; Chen, C. H.; Chenevert, R. B.; Fliri, A.; Frobel, K.; Gais, H.-J.; Garratt, D. G.; Hayakawa, K.; Heggie, W.; Hesson, D. P.; Hoppe, D.; Hoppe, I.; Hyatt, J. A.; Ikeda, D.; Jacobi, P. A.; Kim, K. S.; Kobuke, Y.; Kojima, K.; Krowicki, K.; Lee, V. J.; Leutert, T.; Malchenko, S.; Martens, J.; Matthews, R. S.; Ong, B. S.; Press, J. B.; RajanBabu, T. V.; Rousseau, G.; Sauter, H. M.; Suzuki, M.; Tatsuta, K.; Tolbert, L. M.; Truesdale, E. A.; Uchida, I.; Ueda, Y.; Uyehara, T.; Vaselia, A. T.; Vladuchick, W. C.; Wade, P. A.; Williams, R. M.; Wong, H. N.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3210-3213</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereocontrolled asym. synthesis of the erythronolide A seco acid deriv. I synthon of erythromycin via asym. induction and stereoselective aldolization of keto aldehyde, is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRfLRDEq6-w7Vg90H21EOLACvtfcHk0lglwyHkiG82OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFyqs7k%253D&md5=5533fe975c4ba248b8c516b2c4f9e74d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fja00401a049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00401a049%26sid%3Dliteratum%253Aachs%26aulast%3DWoodward%26aufirst%3DR.%2BB.%26aulast%3DLogusch%26aufirst%3DE.%26aulast%3DNambiar%26aufirst%3DK.%2BP.%26aulast%3DSakan%26aufirst%3DK.%26aulast%3DWard%26aufirst%3DD.%2BE.%26aulast%3DAu-Yeung%26aufirst%3DB.%2BW.%26aulast%3DBalaram%26aufirst%3DP.%26aulast%3DBrowne%26aufirst%3DL.%2BJ.%26aulast%3DCard%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DAsymmetric%2520Total%2520Synthesis%2520of%2520Erythromcin.%25201.%2520Synthesis%2520of%2520an%2520Erythronolide%2520A%2520Secoacid%2520Derivative%2520via%2520Asymmetric%2520Induction%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1981%26volume%3D103%26issue%3D11%26spage%3D3210%26epage%3D3213%26doi%3D10.1021%2Fja00401a049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Conformational Restriction: An Effective Tactic in ‘Follow-on’-Based Drug Discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&issue=8&author=Z.+Fangauthor=Y.+Songauthor=P.+Zhanauthor=Q.+Zhangauthor=X.+Liu&title=Conformational+Restriction%3A+An+Effective+Tactic+in+%E2%80%98Follow-on%E2%80%99-Based+Drug+Discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0lglwyHkiG82OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DConformational%2520Restriction%253A%2520An%2520Effective%2520Tactic%2520in%2520%25E2%2580%2598Follow-on%25E2%2580%2599-Based%2520Drug%2520Discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26issue%3D8%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">The Ins and Outs of Selective Kinase Inhibitor Development</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnchembio.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26485069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=818-821&author=S.+M%C3%BCllerauthor=A.+Chaikuadauthor=N.+S.+Grayauthor=S.+Knapp&title=The+Ins+and+Outs+of+Selective+Kinase+Inhibitor+Development&doi=10.1038%2Fnchembio.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of selective kinase inhibitor development</span></div><div class="casAuthors">Muller, Susanne; Chaikuad, Apirat; Gray, Nathanael S.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-821</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases have emerged as one of the most successful families of drug targets.  To date, most selective kinase inhibitors have been discovered serendipitously either through broad selectivity screening or through the discovery of unique binding modes.  Here the authors discuss design strategies that could lead to a broader coverage of the kinome with selective inhibitors and to a more rational approach for developing them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQzaMrxSYx_rVg90H21EOLACvtfcHk0lglwyHkiG82OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF&md5=f5adf0bbaa388c87b26bae23cfad0bae</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1938%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DThe%2520Ins%2520and%2520Outs%2520of%2520Selective%2520Kinase%2520Inhibitor%2520Development%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D818%26epage%3D821%26doi%3D10.1038%2Fnchembio.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Duffhues, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benderitter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Wijhe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia de Vinuesa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caradec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goumans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eekhoff, E. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Piga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachiller-Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoflack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells</span>. <i>JBMR Plus</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">11</span>), <span class="NLM_elocation-id">e10230</span> <span class="refDoi"> DOI: 10.1002/jbm4.10230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fjbm4.10230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=31768489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&issue=11&author=G.+S%C3%A1nchez-Duffhuesauthor=E.+Williamsauthor=P.+Benderitterauthor=V.+Orlovaauthor=M.+van+Wijheauthor=A.+Garcia+de+Vinuesaauthor=G.+Kerrauthor=J.+Caradecauthor=K.+Lodderauthor=H.+C.+de+Boerauthor=M.+J.+Goumansauthor=E.+M.+W.+Eekhoffauthor=A.+Morales-Pigaauthor=J.+Bachiller-Corralauthor=P.+Koolwijkauthor=A.+N.+Bullockauthor=J.+Hoflackauthor=P.+Ten+Dijke&title=Development+of+Macrocycle+Kinase+Inhibitors+for+ALK2+Using+Fibrodysplasia+Ossificans+Progressiva-Derived+Endothelial+Cells&doi=10.1002%2Fjbm4.10230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells</span></div><div class="casAuthors">Sanchez-Duffhues, Gonzalo; Williams, Eleanor; Benderitter, Pascal; Orlova, Valeria; van Wijhe, Michiel; Garcia de Vinuesa, Amaya; Kerr, Georgina; Caradec, Josselin; Lodder, Kirsten; de Boer, Hetty C.; Goumans, Marie-Jose; Eekhoff, Elisabeth M. W.; Morales-Piga, Antonio; Bachiller-Corral, Javier; Koolwijk, Pieter; Bullock, Alex N.; Hoflack, Jan; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">JBMR Plus</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e10230</span>CODEN:
                <span class="NLM_cas:coden">JPBLA6</span>;
        ISSN:<span class="NLM_cas:issn">2473-4039</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital form of heterotopic ossification (HO), caused by heterozygous mutations in the activin A type I receptor (ACVR1), that encodes the bone morphogenetic protein (BMP) type I receptor ALK2.  These mutations enable ALK2 to induce downstream signaling in response to activins, thereby turning them into bone-inducing agents.  To date, there is no cure for FOP.  The further development of FOP patient-derived models may contribute to the discovery of novel biomarkers and therapeutic approaches.  Nevertheless, this has traditionally been a challenge, as biopsy sampling often triggers HO.  We have characterized peripheral blood-derived endothelial colony-forming cells (ECFCs) from three independent FOP donors as a new model for FOP.  FOP ECFCs are prone to undergo endothelial-to-mesenchymal transition and exhibit increased ALK2 downstream signaling and subsequent osteogenic differentiation upon stimulation with activin A. Moreover, we have identified a new class of small mol. macrocycles with potential activity against ALK2 kinase.  Finally, using FOP ECFCs, we have selected OD36 and OD52 as potent inhibitors with excellent kinase selectivity profiles that potently antagonize mutant ALK2 signaling and osteogenic differentiation.  We expect that these results will contribute to the development of novel ALK2 clin. candidates for the treatment of FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdMImAbYILErVg90H21EOLACvtfcHk0lglwyHkiG82OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE&md5=19b74fb9ff4bc6c0cbc7a5071b876f87</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fjbm4.10230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbm4.10230%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Duffhues%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBenderitter%26aufirst%3DP.%26aulast%3DOrlova%26aufirst%3DV.%26aulast%3Dvan%2BWijhe%26aufirst%3DM.%26aulast%3DGarcia%2Bde%2BVinuesa%26aufirst%3DA.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DCaradec%26aufirst%3DJ.%26aulast%3DLodder%26aufirst%3DK.%26aulast%3Dde%2BBoer%26aufirst%3DH.%2BC.%26aulast%3DGoumans%26aufirst%3DM.%2BJ.%26aulast%3DEekhoff%26aufirst%3DE.%2BM.%2BW.%26aulast%3DMorales-Piga%26aufirst%3DA.%26aulast%3DBachiller-Corral%26aufirst%3DJ.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DHoflack%26aufirst%3DJ.%26aulast%3DTen%2BDijke%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520Macrocycle%2520Kinase%2520Inhibitors%2520for%2520ALK2%2520Using%2520Fibrodysplasia%2520Ossificans%2520Progressiva-Derived%2520Endothelial%2520Cells%26jtitle%3DJBMR%2520Plus%26date%3D2019%26volume%3D3%26issue%3D11%26doi%3D10.1002%2Fjbm4.10230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span>; <span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Macrocyclic Kinase Inhibitors</span>. In  <i>Kinase Drug Discovery: Modern Approaches</i>; <span class="NLM_publisher-name">The Royal Society of Chemistry</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">127</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=97-127&author=A.+Poulsen&author=B.+Dymock&title=Kinase+Drug+Discovery%3A+Modern+Approaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26atitle%3DSmall%2520Molecule%2520Macrocyclic%2520Kinase%2520Inhibitors%26btitle%3DKinase%2520Drug%2520Discovery%253A%2520Modern%2520Approaches%26pub%3DThe%2520Royal%2520Society%2520of%2520Chemistry%26date%3D2019%26spage%3D97%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, R. G. S.</span></span> <span> </span><span class="NLM_article-title">A Worldwide, Phase III, Randomized, Controlled, Safety and Efficacy Study of a Sirolimus/Cyclosporine Regimen for Prevention of Acute Rejection in Recipients of Primary Mismatched Renal Allografts</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1097/00007890-200101270-00019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1097%2F00007890-200101270-00019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=11213073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtF2msrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2001&pages=271-280&issue=2&author=A.+S.+MacDonaldauthor=R.+G.+S.+Group&title=A+Worldwide%2C+Phase+III%2C+Randomized%2C+Controlled%2C+Safety+and+Efficacy+Study+of+a+Sirolimus%2FCyclosporine+Regimen+for+Prevention+of+Acute+Rejection+in+Recipients+of+Primary+Mismatched+Renal+Allografts&doi=10.1097%2F00007890-200101270-00019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts</span></div><div class="casAuthors">MacDonald, Allan S.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Despite the various immunosuppressive regimens presently in use, acute rejection in the early postoperative period continues to occur in 20 to 40% of renal transplant patients.  In a double-blind, multicentered study, we investigated the ability of two different doses of sirolimus (rapamycin, RAPAMUNE), a new class of immunosuppressant that blocks cell cycle progression, to prevent acute rejection in recipients of primary mismatched renal allografts when added to a regimen of cyclosporine (cyclosporin A, CsA) and corticosteroids.  Between Oct. 1996 and Sept. 1997, 576 recipients of primary mismatched cadaveric or living donor renal allografts were randomly assigned in a 2:2:1 ratio (before the transplant operation) to receive an initial loading dose of either 6 or 15 mg of orally administered sirolimus, followed by a daily dose of either 2 or 5 mg/day, or to receive a matched placebo.  All groups received cyclosporine (microemulsion formula, CsA) and corticosteroids.  The primary endpoint was a composite of first occurrence of biopsy-confirmed acute rejection, graft loss, or death during the first 6 mo after transplantation.  Safety data were monitored by an independent drug safety monitoring board.  Based on an intention-to-treat anal. of 576 patients, there were no significant differences in patient demog. or baseline characteristics among treatment groups.  The overall rate of the primary composite endpoint for the 6-mo period after transplantation was 30.0% (68/227) in the 2 mg/day sirolimus group and 25.6% (56/219) in the 5 mg/day sirolimus group, significantly lower than the 47.7% (62/130) in the placebo group (P=0.002, P<0.001, resp.).  During this period, the incidence of biopsy-confirmed acute rejection was 24.7% (56/227) in the 2 mg/day sirolimus group and 19.2% (42/219) in the 5 mg/day sirolimus group, compared with 41.5% (54/130) in the placebo group (P=0.003, P<0.001, resp.), representing a significant redn. in acute rejection of 40.5 and 53.7%, resp.  The need for antibody therapy to treat the first episode of biopsy-confirmed acute rejection was significantly reduced in the 5 mg/day sirolimus group (3.2%) compared to the placebo group (8.5%; P=0.044).  The results 1 yr after transplantation were similar for the efficacy parameters studied.  Adverse events and infections occurred in all groups.  The addn. of either 2 mg/day sirolimus or 5 mg/day sirolimus to CsA/corticosteroid therapy significantly reduces the incidence of acute rejection episodes in primary mismatched renal allograft recipients, without an increase in immunosuppressant-related side effects, including infections and malignancy, at 6 mo and at 1 yr after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe9OgHBtog_LVg90H21EOLACvtfcHk0lj7h8VoHAKhhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtF2msrw%253D&md5=cce72319995391bbcc8eaa9f55cb2bf6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1097%2F00007890-200101270-00019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007890-200101270-00019%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DA.%2BS.%26aulast%3DGroup%26aufirst%3DR.%2BG.%2BS.%26atitle%3DA%2520Worldwide%252C%2520Phase%2520III%252C%2520Randomized%252C%2520Controlled%252C%2520Safety%2520and%2520Efficacy%2520Study%2520of%2520a%2520Sirolimus%252FCyclosporine%2520Regimen%2520for%2520Prevention%2520of%2520Acute%2520Rejection%2520in%2520Recipients%2520of%2520Primary%2520Mismatched%2520Renal%2520Allografts%26jtitle%3DTransplantation%26date%3D2001%26volume%3D71%26issue%3D2%26spage%3D271%26epage%3D280%26doi%3D10.1097%2F00007890-200101270-00019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malizzia, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, A.</span></span> <span> </span><span class="NLM_article-title">Temsirolimus, an MTOR Inhibitor for Treatment of Patients with Advanced Renal Cell Carcinoma</span>. <i>Clin. J. Oncol. Nurs.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1188/08.CJON.639-646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1188%2F08.CJON.639-646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=18676330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpsFSjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=639-646&issue=4&author=L.+J.+Malizziaauthor=A.+Hsu&title=Temsirolimus%2C+an+MTOR+Inhibitor+for+Treatment+of+Patients+with+Advanced+Renal+Cell+Carcinoma&doi=10.1188%2F08.CJON.639-646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma</span></div><div class="casAuthors">Malizzia Lois J; Hsu Arlene</div><div class="citationInfo"><span class="NLM_cas:title">Clinical journal of oncology nursing</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">639-46</span>
        ISSN:<span class="NLM_cas:issn">1092-1095</span>.
    </div><div class="casAbstract">Temsirolimus is a targeted therapy that inhibits mammalian target of rapamycin (mTOR), a central regulator of tumor cell responses to growth stimuli.  Temsirolimus has a broad anticancer activity profile that impacts tumor cell growth, proliferation, and survival through its specific inhibition of mTOR.  In a randomized phase III trial that enrolled previously untreated patients with advanced renal cell carcinoma (RCC) and poor prognostic features, temsirolimus significantly prolonged overall survival compared with interferon-alpha, a standard therapy (p = 0.008).  Because of the results, temsirolimus was approved by the U.  S.  Food and Drug Administration for treatment and is considered a first-line treatment for patients with advanced RCC with poor prognostic features.  Temsirolimus is administered at a flat weekly IV dose of 25 mg given over 30-60 minutes.  Gastrointestinal disorders (stomatitis, anorexia, nausea, diarrhea, and vomiting), rash, fatigue, edema, infections, and dyspnea, as well as hematologic and metabolic laboratory abnormalities occur in patients receiving temsirolimus.  Metabolic side effects include hyperglycemia, hypercholesterolemia, hypertriglyceridemia, and hypophosphatemia.  Most adverse reactions associated with temsirolimus can be managed medically or addressed by supportive measures.  Nurses can improve patient outcomes through early recognition of side effects and prompt interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhGd6q3qw8O8ERNNga7KD-fW6udTcc2ebNuEC917i8Mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpsFSjuw%253D%253D&md5=9557444f6d23c2572ac8e1957e6b1f08</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1188%2F08.CJON.639-646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1188%252F08.CJON.639-646%26sid%3Dliteratum%253Aachs%26aulast%3DMalizzia%26aufirst%3DL.%2BJ.%26aulast%3DHsu%26aufirst%3DA.%26atitle%3DTemsirolimus%252C%2520an%2520MTOR%2520Inhibitor%2520for%2520Treatment%2520of%2520Patients%2520with%2520Advanced%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520J.%2520Oncol.%2520Nurs.%26date%3D2008%26volume%3D12%26issue%3D4%26spage%3D639%26epage%3D646%26doi%3D10.1188%2F08.CJON.639-646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünwald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollaender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravaud, A.</span></span> <span> </span><span class="NLM_article-title">Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4265</span>, <span class="refDoi"> DOI: 10.1002/cncr.25219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcncr.25219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20549832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2rtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4256-4265&issue=18&author=R.+J.+Motzerauthor=B.+Escudierauthor=S.+Oudardauthor=T.+E.+Hutsonauthor=C.+Portaauthor=S.+Bracardaauthor=V.+Gr%C3%BCnwaldauthor=J.+A.+Thompsonauthor=R.+A.+Figlinauthor=N.+Hollaenderauthor=A.+Kayauthor=A.+Ravaud&title=Phase+3+Trial+of+Everolimus+for+Metastatic+Renal+Cell+Carcinoma%3A+Final+Results+and+Analysis+of+Prognostic+Factors&doi=10.1002%2Fcncr.25219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 trial of everolimus for metastatic renal cell carcinoma</span></div><div class="casAuthors">Motzer, Robert J.; Escudier, Bernard; Oudard, Stephane; Hutson, Thomas E.; Porta, Camillo; Bracarda, Sergio; Grunwald, Viktor; Thompson, John A.; Figlin, Robert A.; Hollaender, Norbert; Kay, Andrea; Ravaud, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4256-4265</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: A phase 3 trial demonstrated superiority at interim anal. for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor-tyrosine kinase inhibitors.  Final results and anal. of prognostic factors are reported.  METHODS: Patients with mRCC (N = 416) were randomized (2:1) to everolimus 10 mg/d (n = 277) or placebo (n = 139) plus best supportive care.  Progression-free survival (PFS) and safety were assessed to the end of double-blind treatment.  Mature overall survival (OS) data were analyzed, and prognostic factors for survival were investigated by multivariate analyses.  A rank-preserving structural failure time model estd. the effect on OS, correcting for crossover from placebo to everolimus.  RESULTS: The median PFS was 4.9 mo (everolimus) vs. 1.9 mo (placebo) (hazard ratio [HR], 0.33; P < .001) by independent central review and 5.5 mo (everolimus) vs. 1.9 mo (placebo) (HR, 0.32; P < .001) by investigators.  Serious adverse events with everolimus, independent of causality, in ≥5% of patients included infections (all types, 10%), dyspnea (7%), and fatigue (5%).  The median OS was 14.8 mo (everolimus) vs. 14.4 mo (placebo) (HR, 0.87; P = .162), with 80% of patients in the placebo arm crossed over to everolimus.  By the rank-preserving structural failure time model, the survival cor. for crossover was 1.9-fold longer (95% confidence interval, 0.5-8.5) with everolimus compared with placebo only.  Independent prognostic factors for shorter OS in the study included low performance status, high cor. calcium, low Hb, and prior sunitinib (P < .01).  CONCLUSIONS: These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIQ2QwMk40ZLVg90H21EOLACvtfcHk0lj7h8VoHAKhhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2rtrrF&md5=97fc47e5d8c4f3f7e112394e8f98e680</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fcncr.25219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.25219%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBracarda%26aufirst%3DS.%26aulast%3DGr%25C3%25BCnwald%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DHollaender%26aufirst%3DN.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DRavaud%26aufirst%3DA.%26atitle%3DPhase%25203%2520Trial%2520of%2520Everolimus%2520for%2520Metastatic%2520Renal%2520Cell%2520Carcinoma%253A%2520Final%2520Results%2520and%2520Analysis%2520of%2520Prognostic%2520Factors%26jtitle%3DCancer%26date%3D2010%26volume%3D116%26issue%3D18%26spage%3D4256%26epage%3D4265%26doi%3D10.1002%2Fcncr.25219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C. H.</span></span> <span> </span><span class="NLM_article-title">Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.2533/chimia.2015.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.2533%2Fchimia.2015.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26507218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1antL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2015&pages=142-145&issue=3&author=A.+D.+Williamauthor=A.+C.+H.+Lee&title=Acid+Mediated+Ring+Closing+Metathesis%3A+A+Powerful+Synthetic+Tool+Enabling+the+Synthesis+of+Clinical+Stage+Kinase+Inhibitors&doi=10.2533%2Fchimia.2015.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acid mediated ring closing metathesis: a powerful synthetic tool enabling the synthesis of clinical stage kinase inhibitors</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">142-145</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>;
        ISSN:<span class="NLM_cas:issn">0009-4293</span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">The powerful olefin metathesis reaction was employed for the construction of late-phase clin. agents SB1317 and SB1518.  In both cases RCM seems to proceed only in the presence of an acid and to predominantly furnish trans isomers.  In case of SB1518 it proceeded in the presence of acid HCl, while for SB1317, it mainly proceeds in the presence of TFA (trifluroacetic acid).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG25wFaoHw7Vg90H21EOLACvtfcHk0lg19LG2iJKKLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1antL4%253D&md5=c2eb64eaebb19fa6fa610f4e4be2218b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2015.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2015.142%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%2BH.%26atitle%3DAcid%2520Mediated%2520Ring%2520Closing%2520Metathesis%253A%2520A%2520Powerful%2520Synthetic%2520Tool%2520Enabling%2520the%2520Synthesis%2520of%2520Clinical%2520Stage%2520Kinase%2520Inhibitors%26jtitle%3DChimia%26date%3D2015%26volume%3D69%26issue%3D3%26spage%3D142%26epage%3D145%26doi%3D10.2533%2Fchimia.2015.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-Yl)Ethoxy)-7,12,25-Trioxa-19,21,24-Triaza-Tetracyclo[18.3.1.1(2,5).1(14,18)]Hexacosa-1(24),2,4,9,14(26),15,17,20,22-Nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-like Tyrosine Kinase-3 (JAK</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2623</span>– <span class="NLM_lpage">2640</span>, <span class="refDoi"> DOI: 10.1021/jm201454n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201454n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFShsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2623-2640&issue=6&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=A.+Poulsenauthor=K.+C.+Gohauthor=B.+Madanauthor=S.+Hartauthor=E.+Tanauthor=H.+Wangauthor=H.+Nagarajauthor=D.+Chenauthor=C.+P.+Leeauthor=E.+T.+Sunauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+Macrocycle+%289E%29-15-%282-%28Pyrrolidin-1-Yl%29Ethoxy%29-7%2C12%2C25-Trioxa-19%2C21%2C24-Triaza-Tetracyclo%5B18.3.1.1%282%2C5%29.1%2814%2C18%29%5DHexacosa-1%2824%29%2C2%2C4%2C9%2C14%2826%29%2C15%2C17%2C20%2C22-Nonaene+%28SB1578%29%2C+a+Potent+Inhibitor+of+Janus+Kinase+2%2FFms-like+Tyrosine+Kinase-3+%28JAK&doi=10.1021%2Fjm201454n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Poulsen, Anders; Goh, Kee Chuan; Madan, Babita; Hart, Stefan; Tan, Evelyn; Wang, Haishan; Nagaraj, Harish; Chen, Dizhong; Lee, Chai Ping; Sun, Eric T.; Jayaraman, Ramesh; Pasha, Mohammad Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2623-2640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we describe the synthesis and SAR of a series of small mol. macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase.  Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly sol. 14l (I) was selected as the optimal compd.  Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported 14l as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA.  Compd. 14l (SB1578) was progressed into development and is currently undergoing phase 1 clin. trials in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Ig0dX6810bVg90H21EOLACvtfcHk0lg19LG2iJKKLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFShsLY%253D&md5=efe684c2f2ff0b506d02c2ef911bfb2f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201454n%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520Macrocycle%2520%25289E%2529-15-%25282-%2528Pyrrolidin-1-Yl%2529Ethoxy%2529-7%252C12%252C25-Trioxa-19%252C21%252C24-Triaza-Tetracyclo%255B18.3.1.1%25282%252C5%2529.1%252814%252C18%2529%255DHexacosa-1%252824%2529%252C2%252C4%252C9%252C14%252826%2529%252C15%252C17%252C20%252C22-Nonaene%2520%2528SB1578%2529%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Janus%2520Kinase%25202%252FFms-like%2520Tyrosine%2520Kinase-3%2520%2528JAK%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D6%26spage%3D2623%26epage%3D2640%26doi%3D10.1021%2Fjm201454n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-Yl-Ethoxy)-14,19-Dioxa-5,7, 26-Triaza-Tetracyclo[19.3.1.1(2,6).1(8,12)]Heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-Decaene (SB1518), a Potent Janus Kinase 2/Fms-like Tyrosine Kinase-3 (JAK2/FLT3) Inhibito</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4658</span>, <span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&issue=13&author=A.+D.+Williamauthor=A.+C.+H.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+Macrocycle+11-%282-Pyrrolidin-1-Yl-Ethoxy%29-14%2C19-Dioxa-5%2C7%2C+26-Triaza-Tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5DHeptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-Decaene+%28SB1518%29%2C+a+Potent+Janus+Kinase+2%2FFms-like+Tyrosine+Kinase-3+%28JAK2%2FFLT3%29+Inhibito&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lgvrEYDVIuFWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%2BH.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520Macrocycle%252011-%25282-Pyrrolidin-1-Yl-Ethoxy%2529-14%252C19-Dioxa-5%252C7%252C%252026-Triaza-Tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255DHeptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-Decaene%2520%2528SB1518%2529%252C%2520a%2520Potent%2520Janus%2520Kinase%25202%252FFms-like%2520Tyrosine%2520Kinase-3%2520%2528JAK2%252FFLT3%2529%2520Inhibito%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D13%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. W.</span></span> <span> </span><span class="NLM_article-title">SB1518, a Novel Macrocyclic Pyrimidine-Based JAK2 Inhibitor for the Treatment of Myeloid and Lymphoid Malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fleu.2011.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21691275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&issue=11&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+Novel+Macrocyclic+Pyrimidine-Based+JAK2+Inhibitor+for+the+Treatment+of+Myeloid+and+Lymphoid+Malignancies&doi=10.1038%2Fleu.2011.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span></div><div class="casAuthors">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A. D.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ong, K. H.; Ethirajulu, K.; Dymock, B. W.; Wood, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 n for JAK2WT and JAK2V617F, resp.) within the JAK family (IC50=1280, 520 and 50 n for JAK1, JK3 and TYK2, resp.) and fms-like tyrosine kinase-3 (FLT3; IC50=22 n).  SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs.  As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.  SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2V617F-driven disease model.  SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a s.c. model generated with SET-2 cells derived from a JAK2V617F patient with megakaryoblastic leukemia.  Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease.  In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models.  These favorable properties are now being confirmed in clin. studies in patients with myelofibrosis and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOG8Fk52CR87Vg90H21EOLACvtfcHk0lgvrEYDVIuFWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL&md5=ae5a5ae0efaaa8f51909e8c82c84610d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.148%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520Novel%2520Macrocyclic%2520Pyrimidine-Based%2520JAK2%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Myeloid%2520and%2520Lymphoid%2520Malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26issue%3D11%26spage%3D1751%26epage%3D1759%26doi%3D10.1038%2Fleu.2011.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egyed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvorov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakucs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Boekhorst, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nangalia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span> <span> </span><span class="NLM_article-title">Pacritinib versus Best Available Therapy for the Treatment of Myelofibrosis Irrespective of Baseline Cytopenias (PERSIST-1): An International, Randomised, Phase 3 Trial</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e225</span> <span class="refDoi"> DOI: 10.1016/S2352-3026(17)30027-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS2352-3026%2817%2930027-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=28336242" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&author=R.+A.+Mesaauthor=A.+M.+Vannucchiauthor=A.+Meadauthor=M.+Egyedauthor=A.+Szokeauthor=A.+Suvorovauthor=J.+Jakucsauthor=A.+Perkinsauthor=R.+Prasadauthor=J.+Mayerauthor=J.+Demeterauthor=P.+Ganlyauthor=J.+W.+Singerauthor=H.+Zhouauthor=J.+P.+Deanauthor=P.+A.+Te+Boekhorstauthor=J.+Nangaliaauthor=J.-J.+Kiladjianauthor=C.+N.+Harrison&title=Pacritinib+versus+Best+Available+Therapy+for+the+Treatment+of+Myelofibrosis+Irrespective+of+Baseline+Cytopenias+%28PERSIST-1%29%3A+An+International%2C+Randomised%2C+Phase+3+Trial&doi=10.1016%2FS2352-3026%2817%2930027-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2817%2930027-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252817%252930027-3%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DEgyed%26aufirst%3DM.%26aulast%3DSzoke%26aufirst%3DA.%26aulast%3DSuvorov%26aufirst%3DA.%26aulast%3DJakucs%26aufirst%3DJ.%26aulast%3DPerkins%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DR.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DDemeter%26aufirst%3DJ.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DJ.%2BW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DJ.%2BP.%26aulast%3DTe%2BBoekhorst%26aufirst%3DP.%2BA.%26aulast%3DNangalia%26aufirst%3DJ.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26atitle%3DPacritinib%2520versus%2520Best%2520Available%2520Therapy%2520for%2520the%2520Treatment%2520of%2520Myelofibrosis%2520Irrespective%2520of%2520Baseline%2520Cytopenias%2520%2528PERSIST-1%2529%253A%2520An%2520International%252C%2520Randomised%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Haematol.%26date%3D2017%26volume%3D4%26doi%3D10.1016%2FS2352-3026%2817%2930027-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-Oxa-5,7,14,26-Tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]Heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-Decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus K</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1021/jm201112g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=169-196&issue=1&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=K.+C.+Gohauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.-L.+Teoauthor=H.+Nagarajauthor=C.+P.+Leeauthor=H.+Wangauthor=M.+Williamsauthor=E.+T.+Sunauthor=C.+Huauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+Kinase+Spectrum+Selective+Macrocycle+%2816E%29-14-Methyl-20-Oxa-5%2C7%2C14%2C26-Tetraazatetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5DHeptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2827%29%2C9%2C11%2C16%2C21%2C23-Decaene+%28SB1317%2FTG02%29%2C+a+Potent+Inhibitor+of+Cyclin+Dependent+Kinases+%28CDKs%29%2C+Janus+K&doi=10.1021%2Fjm201112g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Goh, Kee Chuan; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Lee, Chai Ping; Wang, Haishan; Williams, Meredith; Sun, Eric T.; Hu, Changyong; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we describe the design, synthesis, and SAR of a series of unique small mol. macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3.  The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, soly., CYP450 inhibition, and microsomal stability.  This screening cascade revealed 26h (I) as a preferred compd. with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, resp.  Pharmacokinetic (PK) studies of 26h in preclin. species showed good oral exposures.  Oral efficacy was obsd. in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the obsd. PK/PD correlation.  26H (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clin. trials in advanced leukemias and multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMvOv-_pFzbVg90H21EOLACvtfcHk0liZAPj1p1zXVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P&md5=50affe14bd28594735131d6b5841502a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201112g%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.-L.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520Kinase%2520Spectrum%2520Selective%2520Macrocycle%2520%252816E%2529-14-Methyl-20-Oxa-5%252C7%252C14%252C26-Tetraazatetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255DHeptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-Decaene%2520%2528SB1317%252FTG02%2529%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin%2520Dependent%2520Kinases%2520%2528CDKs%2529%252C%2520Janus%2520K%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D1%26spage%3D169%26epage%3D196%26doi%3D10.1021%2Fjm201112g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Aziz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedhouse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span> <span> </span><span class="NLM_article-title">The Multi-Kinase Inhibitor TG02 Overcomes Signalling Activation by Survival Factors to Deplete MCL1 and XIAP and Induce Cell Death in Primary Acute Myeloid Leukaemia Cells</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>159</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1111/bjh.12018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1111%2Fbjh.12018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22934750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2012&pages=191-203&issue=2&author=M.+Pallisauthor=A.+Abdul-Azizauthor=F.+Burrowsauthor=C.+Seedhouseauthor=M.+Grundyauthor=N.+Russell&title=The+Multi-Kinase+Inhibitor+TG02+Overcomes+Signalling+Activation+by+Survival+Factors+to+Deplete+MCL1+and+XIAP+and+Induce+Cell+Death+in+Primary+Acute+Myeloid+Leukaemia+Cells&doi=10.1111%2Fbjh.12018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells</span></div><div class="casAuthors">Pallis, Monica; Abdul-Aziz, Amina; Burrows, Francis; Seedhouse, Claire; Grundy, Martin; Russell, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-203</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summmary : The novel multi-kinase inhibitor TG02 has selectivity against cell cycle and transcriptional cyclin dependent kinases (CDKs) as well as fms-like tyrosine kinase receptor-3 (FLT3).  Inhibition of transcriptional CDKs preferentially depletes short-lived proteins such as MCL1.  We evaluated the in vitro toxicity of TG02 to primary acute myeloid leukemia (AML) cells in the presence of survival signalling pathway activation by cytokines and fibronectin.  One hundred nanomolar TG02 induced a median decrease of 40% in bulk cell survival and 43% in the CD34+CD38-CD123+subset.  A 90% inhibitory concn. of 500 nmol/l indicated that TG02 toxicity is not halted by protective cell cycle arrest.  Samples with FLT3 internal tandem duplication were not preferentially targeted.  By flow cytometry, TG02 treatment caused loss of RNA Polymerase II serine 2 phosphorylation in patient samples, which correlated strongly with BAX activation (R2=0·89), suggesting these as potential biomarkers for clin. studies.  MCL1 and XIAP expression also decreased.  Repeated brief exposure to TG02 in MOLM-13 cells did not result in compensatory up-regulation of survival protein expression.  In conclusion, TG02 is potently cytotoxic towards CD34+CD38-CD123+ and bulk AML cells, despite protective signalling pathway activation.  This antitumor activity is most likely mediated by dephosphorylation of RNA Polymerase II leading to depletion of survival mols. such as MCL1 and XIAP, with subsequent BAX activation and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3mvr_3yc0bVg90H21EOLACvtfcHk0liZAPj1p1zXVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J&md5=e8da0f2e7a1a5fcf03f90e68311ab294</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12018%26sid%3Dliteratum%253Aachs%26aulast%3DPallis%26aufirst%3DM.%26aulast%3DAbdul-Aziz%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DSeedhouse%26aufirst%3DC.%26aulast%3DGrundy%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DN.%26atitle%3DThe%2520Multi-Kinase%2520Inhibitor%2520TG02%2520Overcomes%2520Signalling%2520Activation%2520by%2520Survival%2520Factors%2520to%2520Deplete%2520MCL1%2520and%2520XIAP%2520and%2520Induce%2520Cell%2520Death%2520in%2520Primary%2520Acute%2520Myeloid%2520Leukaemia%2520Cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2012%26volume%3D159%26issue%3D2%26spage%3D191%26epage%3D203%26doi%3D10.1111%2Fbjh.12018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>189</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4123</span>– <span class="NLM_lpage">4134</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1200675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.4049%2Fjimmunol.1200675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22962687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4123-4134&issue=8&author=B.+Madanauthor=K.+C.+Gohauthor=S.+Hartauthor=A.+D.+Williamauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+M.+Wood&title=SB1578%2C+a+Novel+Inhibitor+of+JAK2%2C+FLT3%2C+and+c-Fms+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.4049%2Fjimmunol.1200675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Madan, Babita; Goh, Kee Chuan; Hart, Stefan; William, Anthony D.; Jayaraman, Ramesh; Ethirajulu, Kantharaj; Dymock, Brian W.; Wood, Jeanette M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4123-4134</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">SB1578 is a novel, orally bioavailable JAK2 inhibitor with specificity for JAK2 within the JAK family and also potent activity against FLT3 and c-Fms.  These three tyrosine kinases play a pivotal role in activation of pathways that underlie the pathogenesis of rheumatoid arthritis.  SB1578 blocks the activation of these kinases and their downstream signaling in pertinent cells, leading to inhibition of pathol. cellular responses.  The biochem. and cellular activities of SB1578 translate into its high efficacy in two rodent models of arthritis.  SB1578 not only prevents the onset of arthritis but is also potent in treating established disease in collagen-induced arthritis mice with beneficial effects on histopathol. parameters of bone resorption and cartilage damage.  SB1578 abrogates the inflammatory response and prevents the infiltration of macrophages and neutrophils into affected joints.  It also leads to inhibition of Ag-presenting dendritic cells and inhibits the autoimmune component of the disease.  In summary, SB1578 has a unique kinase spectrum, and its pharmacol. profile provides a strong rationale for the ongoing clin. development in autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_db10A8l4KrVg90H21EOLACvtfcHk0liZAPj1p1zXVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrtL%252FK&md5=ccdccb1155e1186b96ffc3d91f179a20</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1200675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1200675%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DSB1578%252C%2520a%2520Novel%2520Inhibitor%2520of%2520JAK2%252C%2520FLT3%252C%2520and%2520c-Fms%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26issue%3D8%26spage%3D4123%26epage%3D4134%26doi%3D10.4049%2Fjimmunol.1200675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusovsky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemelin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikemori-Kawada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaderbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Anti-Inflammatory Clinical Candidate E6201, Inspired from Resorcylic Lactone LL-Z1640–2, III</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3155</span>– <span class="NLM_lpage">3157</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmcl.2010.03.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20399648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3155-3157&issue=10&author=Y.+Shenauthor=R.+Boivinauthor=N.+Yonedaauthor=H.+Duauthor=S.+Schillerauthor=T.+Matsushimaauthor=M.+Gotoauthor=H.+Shirotaauthor=F.+Gusovskyauthor=C.+Lemelinauthor=Y.+Jiangauthor=Z.+Zhangauthor=R.+Pelletierauthor=M.+Ikemori-Kawadaauthor=Y.+Kawakamiauthor=A.+Inoueauthor=M.+Schnaderbeckauthor=Y.+Wang&title=Discovery+of+Anti-Inflammatory+Clinical+Candidate+E6201%2C+Inspired+from+Resorcylic+Lactone+LL-Z1640%E2%80%932%2C+III&doi=10.1016%2Fj.bmcl.2010.03.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III</span></div><div class="casAuthors">Shen, Yongchun; Boivin, Roch; Yoneda, Naoki; Du, Hong; Schiller, Shawn; Matsushima, Tomohiro; Goto, Masaki; Shirota, Hiroshi; Gusovsky, Fabian; Lemelin, Charles; Jiang, Yimin; Zhang, Zhiyi; Pelletier, Robert; Ikemori-Kawada, Megumi; Kawakami, Yoshiyuki; Inoue, Atsushi; Schnaderbeck, Matthew; Wang, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3155-3157</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inspired by natural product, LL-Z1640-2, clin. candidate, E6201 (22) was discovered in a medicinal chem. effort through total synthesis.  The modification on C14-position to N-alkyl substitution showed to be potent in vitro and orally active in vivo in anti-inflammatory assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBJwF8hgoEbVg90H21EOLACvtfcHk0lgYalCUKqY5ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLY%253D&md5=c4748deae07e6ec54747db568955c962</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.087%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DBoivin%26aufirst%3DR.%26aulast%3DYoneda%26aufirst%3DN.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DSchiller%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DShirota%26aufirst%3DH.%26aulast%3DGusovsky%26aufirst%3DF.%26aulast%3DLemelin%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DPelletier%26aufirst%3DR.%26aulast%3DIkemori-Kawada%26aufirst%3DM.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DSchnaderbeck%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Anti-Inflammatory%2520Clinical%2520Candidate%2520E6201%252C%2520Inspired%2520from%2520Resorcylic%2520Lactone%2520LL-Z1640%25E2%2580%25932%252C%2520III%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D10%26spage%3D3155%26epage%3D3157%26doi%3D10.1016%2Fj.bmcl.2010.03.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span> <span> </span><span class="NLM_article-title">The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3Mutations</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1528</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1158%2F0008-5472.CAN-15-1580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26822154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlWqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1528-1537&issue=6&author=W.+Zhangauthor=G.+Borthakurauthor=C.+Gaoauthor=Y.+Chenauthor=H.+Muauthor=V.+R.+Ruvoloauthor=K.+Nomotoauthor=N.+Zhaoauthor=M.+Konoplevaauthor=M.+Andreeff&title=The+Dual+MEK%2FFLT3+Inhibitor+E6201+Exerts+Cytotoxic+Activity+against+Acute+Myeloid+Leukemia+Cells+Harboring+Resistance-Conferring+FLT3Mutations&doi=10.1158%2F0008-5472.CAN-15-1580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations</span></div><div class="casAuthors">Zhang, Weiguo; Borthakur, Gautam; Gao, Chen; Chen, Ye; Mu, Hong; Ruvolo, Vivian R.; Nomoto, Kenichi; Zhao, Nanding; Konopleva, Marina; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1528-1537</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) inhibition has elicited encouraging responses in acute myeloid leukemia (AML) therapy.  Unfortunately, unless combined with a bone marrow transplant, disease relapse is frequent.  In addn. to the acquired point mutations in the FLT3 kinase domain that contribute to FLT3 inhibitor resistance, MEK/ERK signaling is persistently activated in AML cells even when FLT3 phosphorylation is continually suppressed.  Thus, concomitant targeting of FLT3 and MAPK may potentially exert synergistic activity to counteract the resistance of AML cells to FLT3-targeted therapy.  In this study, we investigated the antileukemia activity of a MEK1 and FLT3 dual inhibitor, E6201, in AML cells resistant to FLT3 inhibition.  We found that E6201 exerted profound apoptogenic effects on AML cells harboring resistance-conferring FLT3 mutations.  This activity appeared to be p53 dependent, and E6201-induced cytotoxicity was retained under hypoxic culture conditions and during coculture with mesenchymal stem cells that mimic the AML microenvironment.  Furthermore, E6201 markedly reduced leukemia burden and improved the survival of mice in a human FLT3-mutated AML model.  Collectively, our data provide a preclin. basis for the clin. evaluation of E6201 in AML patients harboring FLT3 mutations, including those who relapse following FLT3-targeted monotherapy.  Cancer Res; 76(6); 1528-37. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXaiNWtNG2yLVg90H21EOLACvtfcHk0lgYalCUKqY5ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlWqurg%253D&md5=49f08d90208542c13413f1e772b2a5af</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1580%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMu%26aufirst%3DH.%26aulast%3DRuvolo%26aufirst%3DV.%2BR.%26aulast%3DNomoto%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DN.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DThe%2520Dual%2520MEK%252FFLT3%2520Inhibitor%2520E6201%2520Exerts%2520Cytotoxic%2520Activity%2520against%2520Acute%2520Myeloid%2520Leukemia%2520Cells%2520Harboring%2520Resistance-Conferring%2520FLT3Mutations%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D6%26spage%3D1528%26epage%3D1537%26doi%3D10.1158%2F0008-5472.CAN-15-1580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babiker, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byron, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, W. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vondrak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyugan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cridebring, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span> <span> </span><span class="NLM_article-title">E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1007/s10637-018-0668-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs10637-018-0668-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30264293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSqsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=636-645&issue=4&author=H.+M.+Babikerauthor=S.+A.+Byronauthor=W.+P.+D.+Hendricksauthor=W.+F.+Elmquistauthor=G.+Gampaauthor=J.+Vondrakauthor=J.+Aldrichauthor=L.+Cuyuganauthor=J.+Adkinsauthor=V.+De+Lucaauthor=R.+Tibesauthor=M.+J.+Boradauthor=K.+Marceauauthor=T.+J.+Myersauthor=L.+J.+Paradisoauthor=W.+S.+Liangauthor=R.+L.+Kornauthor=D.+Cridebringauthor=D.+D.+Von+Hoffauthor=J.+D.+Carptenauthor=D.+W.+Craigauthor=J.+M.+Trentauthor=M.+S.+Gordon&title=E6201%2C+an+Intravenous+MEK1+Inhibitor%2C+Achieves+an+Exceptional+Response+in+BRAF+V600E-Mutated+Metastatic+Malignant+Melanoma+with+Brain+Metastases&doi=10.1007%2Fs10637-018-0668-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases</span></div><div class="casAuthors">Babiker, Hani M.; Byron, Sara A.; Hendricks, William P. D.; Elmquist, William F.; Gampa, Gautham; Vondrak, Jessica; Aldrich, Jessica; Cuyugan, Lori; Adkins, Jonathan; De Luca, Valerie; Tibes, Raoul; Borad, Mitesh J.; Marceau, Katie; Myers, Thomas J.; Paradiso, Linda J.; Liang, Winnie S.; Korn, Ronald L.; Cridebring, Derek; Von Hoff, Daniel D.; Carpten, John D.; Craig, David W.; Trent, Jeffrey M.; Gordon, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">636-645</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Malignant melanoma (MM) exhibits a high propensity for central nervous system dissemination with ∼50% of metastatic MM patients developing brain metastases (BM).  Targeted therapies and immune checkpoint inhibitors have improved overall survival for MM patients with BM.  However, responses are usually of short duration and new agents that effectively penetrate the blood brain barrier (BBB) are needed.  Here, we report a MM patient with BM who experienced an exceptional response to E6201, an ATP-competitive MEK1 inhibitor, on a Phase 1 study, with ongoing near-complete response and overall survival extending beyond 8 years.  Whole exome and transcriptome sequencing revealed a high mutational burden tumor (22 mutations/Megabase) with homozygous BRAF V600E mutation.  Correlative preclin. studies demonstrated broad activity for E6201 across BRAF V600E mutant melanoma cell lines and effective BBB penetration in vivo.  Together, these results suggest that E6201 may represent a potential new treatment option for BRAF-mutant MM patients with BM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDJhKT3i3KfbVg90H21EOLACvtfcHk0lj8tEMSHcp3YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSqsL7O&md5=7fe6fca66cd369e222a7238443fbc8cf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0668-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0668-8%26sid%3Dliteratum%253Aachs%26aulast%3DBabiker%26aufirst%3DH.%2BM.%26aulast%3DByron%26aufirst%3DS.%2BA.%26aulast%3DHendricks%26aufirst%3DW.%2BP.%2BD.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26aulast%3DGampa%26aufirst%3DG.%26aulast%3DVondrak%26aufirst%3DJ.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DCuyugan%26aufirst%3DL.%26aulast%3DAdkins%26aufirst%3DJ.%26aulast%3DDe%2BLuca%26aufirst%3DV.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DMarceau%26aufirst%3DK.%26aulast%3DMyers%26aufirst%3DT.%2BJ.%26aulast%3DParadiso%26aufirst%3DL.%2BJ.%26aulast%3DLiang%26aufirst%3DW.%2BS.%26aulast%3DKorn%26aufirst%3DR.%2BL.%26aulast%3DCridebring%26aufirst%3DD.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26atitle%3DE6201%252C%2520an%2520Intravenous%2520MEK1%2520Inhibitor%252C%2520Achieves%2520an%2520Exceptional%2520Response%2520in%2520BRAF%2520V600E-Mutated%2520Metastatic%2520Malignant%2520Melanoma%2520with%2520Brain%2520Metastases%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26issue%3D4%26spage%3D636%26epage%3D645%26doi%3D10.1007%2Fs10637-018-0668-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecules with Anti-Inflammatory Properties in Clinical Development</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.pharmthera.2015.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26627986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=163-187&author=T.+Hankeauthor=D.+Merkauthor=D.+Steinhilberauthor=G.+Geisslingerauthor=M.+Schubert-Zsilavecz&title=Small+Molecules+with+Anti-Inflammatory+Properties+in+Clinical+Development&doi=10.1016%2Fj.pharmthera.2015.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules with anti-inflammatory properties in clinical development</span></div><div class="casAuthors">Hanke, Thomas; Merk, Daniel; Steinhilber, Dieter; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-187</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inflammation is a crucial physiol. response of our body to any kind of noxa be it an infection or tissue injury.  However, this physiol. process can be detrimental if dysregulated, and when the acute inflammatory response fails to resolve the cause of inflammation, there can be a switch to chronification.  According to ICD 10 (WHO) over 3.000 diseases exist with the suffix "-itis" which terms an inflammatory disease.  For the treatment of inflammation, non-steroidal anti-inflammatory drugs (NSAIDs) are the most widespread drugs while glucocorticoids are among our strongest weapons against inflammation, making them emergency treatments for acute episodes of chronic inflammation.  For the treatment of many inflammatory disorders, both are not satisfying.  Consequently, industrial and academic research on anti-inflammatory drugs is very intensive.  In this review, we evaluate current treatments and unmet needs of chronic inflammatory diseases with high prevalence (rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, and psoriasis), and systematically review small mols. with anti-inflammatory properties presently in clin. trials for the aforementioned diseases.  As the pathophysiol. knowledge of diseases increased over the last decades, a more specific intervention of inflammatory pathways becomes possible.  After one hundred years of NSAIDs and over fifty years of glucocorticoids, more specific drugs for anti-inflammatory therapy such as roflumilast or fingolimod are rising.  The aim of this article is to critically review the literature on small anti-inflammatory mols. in clin. trials to generate an idea of what we can expect in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOd16UM0wRSbVg90H21EOLACvtfcHk0lj8tEMSHcp3YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM&md5=a9f5e04d82aad54d600e21307ca4bfb2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DSmall%2520Molecules%2520with%2520Anti-Inflammatory%2520Properties%2520in%2520Clinical%2520Development%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D157%26spage%3D163%26epage%3D187%26doi%3D10.1016%2Fj.pharmthera.2015.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Spencer, S.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Haas, J.</span>; <span class="NLM_string-name">Eary, C. T.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Pyrazolo[1,5-A]Pyrimidines and Salts Thereof</span>. International Patent WO <span class="NLM_patent">2019005796</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Q.+Zhao&author=S.+Spencer&author=Y.+Jiang&author=J.+Haas&author=C.+T.+Eary&title=Process+for+the+Preparation+of+Pyrazolo%5B1%2C5-A%5DPyrimidines+and+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Pyrazolo%255B1%252C5-A%255DPyrimidines%2520and%2520Salts%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">TRK Inhibitors in TRK Fusion-Positive Cancers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">VIII23</span>– <span class="NLM_lpage">VIII30</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdz282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1093%2Fannonc%2Fmdz282" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=VIII23-VIII30&author=A.+Drilon&title=TRK+Inhibitors+in+TRK+Fusion-Positive+Cancers&doi=10.1093%2Fannonc%2Fmdz282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz282%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DTRK%2520Inhibitors%2520in%2520TRK%2520Fusion-Positive%2520Cancers%26jtitle%3DAnn.%2520Oncol.%26date%3D2019%26volume%3D30%26spage%3DVIII23%26epage%3DVIII30%26doi%3D10.1093%2Fannonc%2Fmdz282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Janssen Pharmaceutica N. V.</span> <span> </span><span class="NLM_article-title">MTKI Quinazoline
Derivatives</span>. International Patent WO <span class="NLM_patent">2006061417</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Janssen+Pharmaceutica+N.+V.&title=MTKI+Quinazoline%0ADerivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DMTKI%2520Quinazoline%250ADerivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konings, I. R. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De
Jonge, M. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Gaast, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beijsterveldt, L. E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F. A. L. M.</span></span> <span> </span><span class="NLM_article-title">Phase 1 and Pharmacological Study of the Broad-Spectrum Tyrosine Kinase Inhibitor JNJ-26483327 in Patients with Advanced Solid Tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fsj.bjc.6605867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20823884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=987-992&issue=7&author=I.+R.+H.+M.+Koningsauthor=M.+J.+A.+De%0AJongeauthor=H.+Burgerauthor=A.+Van+Der%0AGaastauthor=L.+E.+C.+Van+Beijsterveldtauthor=H.+Winklerauthor=J.+Verweijauthor=Z.+Yuanauthor=P.+Hellemansauthor=F.+A.+L.+M.+Eskens&title=Phase+1+and+Pharmacological+Study+of+the+Broad-Spectrum+Tyrosine+Kinase+Inhibitor+JNJ-26483327+in+Patients+with+Advanced+Solid+Tumours&doi=10.1038%2Fsj.bjc.6605867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours</span></div><div class="casAuthors">Konings, I. R. H. M.; de Jonge, M. J. A.; Burger, H.; van der Gaast, A.; van Beijsterveldt, L. E. C.; Winkler, H.; Verweij, J.; Yuan, Z.; Hellemans, P.; Eskens, F. A. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor receptor (VEGFR)-3 and Src family (Lyn, Fyn, Yes) at low nanomolar concns.  This phase I, accelerated titrn. study assessed max. tolerated dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327.  Methods: Nineteen patients with advanced cancers received JNJ-26483327 continuous twice daily (BID) in escalating dose cohorts ranging from 100 to 2100 mg.  Pharmacodynamic effects were assessed in paired skin biopsies and blood.  Results: JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue.  At 2100 mg, two episodes of dose-limiting toxicity were obsd., consisting of grade 3 anorexia and a combination of grade 3 anorexia and fatigue, resp.  Pharmacokinetics were dose proportional up to 1500 mg in which plasma levels were obtained showing anti-tumor activity in xenograft mouse models.  Pharmacodynamic anal. did not show a substantial effect on expression of Ki-67, p27kip1, phosphorylated mitogen-activated protein kinase, phosphorylated Akt and EGFR, and serum levels of sVEGFR-2, VEGF-C and VEGF-D remained unchanged.  Stable disease was noted in six patients (32%).  Conclusion: JNJ-26483327 is well tolerated and shows a predictable pharmacokinetic profile; the recommended dose for further studies is 1500 mg BID.  British Journal of Cancer (2010) 103, 987-992; doi:10.1038/sj.bjc.6605867 www.bjcancer.com Published online 7 Sept. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP2g2VkUKueLVg90H21EOLACvtfcHk0lg3CtwChx2OKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL&md5=5f8f04fc2656ce1ec6c55e5ee4c870c6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605867%26sid%3Dliteratum%253Aachs%26aulast%3DKonings%26aufirst%3DI.%2BR.%2BH.%2BM.%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DVan%2BDer%2BGaast%26aufirst%3DA.%26aulast%3DVan%2BBeijsterveldt%26aufirst%3DL.%2BE.%2BC.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26atitle%3DPhase%25201%2520and%2520Pharmacological%2520Study%2520of%2520the%2520Broad-Spectrum%2520Tyrosine%2520Kinase%2520Inhibitor%2520JNJ-26483327%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26issue%3D7%26spage%3D987%26epage%3D992%26doi%3D10.1038%2Fsj.bjc.6605867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span> <span> </span><span class="NLM_article-title">First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2029</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2027187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1056%2FNEJMoa2027187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=33207094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=2018-2029&issue=21&author=A.+T.+Shawauthor=T.+M.+Bauerauthor=F.+de+Marinisauthor=E.+Felipauthor=Y.+Gotoauthor=G.+Liuauthor=J.+Mazieresauthor=D.-W.+Kimauthor=T.+Mokauthor=A.+Polliauthor=H.+Thurmauthor=G.+Calellaauthor=G.+Peltzauthor=B.+J.+Solomon&title=First-Line+Lorlatinib+or+Crizotinib+in+Advanced+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa2027187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Liu, Geoffrey; Mazieres, Julien; Kim, Dong-Wan; Mok, Tony; Polli, Anna; Thurm, Holger; Calella, Anna M.; Peltz, Gerson; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2018-2029</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-pos. non-small-cell lung cancer (NSCLC).  The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-pos. NSCLC is unclear.  We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-pos. NSCLC who had received no previous systemic treatment for metastatic disease.  The primary end point was progression-free survival as assessed by blinded independent central review.  Secondary end points included independently assessed objective response and intracranial response.  An interim anal. of efficacy was planned after approx. 133 of 177 (75%) expected events of disease progression or death had occurred.  The percentage of patients who were alive without disease progression at 12 mo was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P<0.001).  An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lorlatinib group and 58% (95% CI, 49 to 66) of those in the crizotinib group; among those with measurable brain metastases, 82% (95% CI, 57 to 96) and 23% (95% CI, 5 to 54), resp., had an intracranial response, and 71% of the patients who received lorlatinib had an intracranial complete response.  The most common adverse events with lorlatinib were hyperlipidemia, edema, increased wt., peripheral neuropathy, and cognitive effects.  Lorlatinib was assocd. with more grade 3 or 4 adverse events (mainly altered lipid levels) than crizotinib (in 72% vs. 56%).  Discontinuation of treatment because of adverse events occurred in 7% and 9% of the patients, resp.  In an interim anal. of results among patients with previously untreated advanced ALK-pos. NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib.  The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPkJPLVUj8rVg90H21EOLACvtfcHk0lg3CtwChx2OKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN&md5=97baa919b685e4ece2c03e7788c76702</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2027187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2027187%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DCalella%26aufirst%3DG.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26atitle%3DFirst-Line%2520Lorlatinib%2520or%2520Crizotinib%2520in%2520Advanced%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26issue%3D21%26spage%3D2018%26epage%3D2029%26doi%3D10.1056%2FNEJMoa2027187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pithavala, Y. K.</span></span> <span> </span><span class="NLM_article-title">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1007/s12325-019-01198-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs12325-019-01198-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=31863284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=745-758&issue=2&author=J.+Chenauthor=H.+Xuauthor=S.+Pawlakauthor=L.+P.+Jamesauthor=G.+Peltzauthor=K.+Leeauthor=K.+Ginmanauthor=M.+Bergersonauthor=Y.+K.+Pithavala&title=The+Effect+of+Rifampin+on+the+Pharmacokinetics+and+Safety+of+Lorlatinib%3A+Results+of+a+Phase+One%2C+Open-Label%2C+Crossover+Study+in+Healthy+Participants&doi=10.1007%2Fs12325-019-01198-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span></div><div class="casAuthors">Chen, Joseph; Xu, Huiping; Pawlak, Sylvester; James, Leonard P.; Peltz, Gerson; Lee, Kimberly; Ginman, Katherine; Bergeron, Michelle; Pithavala, Yazdi K.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">745-758</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-pos. metastatic non-small cell lung cancer; cytochrome P 450 (CYP) 3A plays an important role in the metab. of lorlatinib.  Methods: This phase 1, open-label, two-period, crossover study estd. the effect of oral rifampin (a strong CYP3A inducer) on the pharmacokinetics and safety of oral lorlatinib (NCT02804399).  Healthy participants received single-dose lorlatinib 100 mg in period 1 followed by rifampin 600 mg/day (days 1-12) and single-dose lorlatinib 100 mg (day 8) in period 2.  Blood samples were collected for 120 h after each dose of lorlatinib.  Results: When a single dose of lorlatinib was administered during daily dosing with rifampin (period 2), the area under the plasma concn.-time profile extrapolated to infinity (AUCinf) and max. plasma concn. (Cmax) of lorlatinib were 14.74% [90% confidence interval (CI) 12.78%, 17.01%] and 23.88% (90% CI 21.58%, 26.43%), resp., of those in period 1 (lorlatinib alone).  A single dose of lorlatinib was well tolerated in period 1, but elevations in transaminase values were obsd. in all participants (grade 2-4 in 11 participants) within 1-3 days after a single dose of lorlatinib was administered with ongoing rifampin in period 2.  Rifampin dosing was therefore halted.  Transaminase levels subsequently returned to normal (median time to recovery: 15 days).  No elevations in bilirubin were obsd.  Conclusions: The addn. of a single dose of lorlatinib to daily dosing with rifampin significantly reduced lorlatinib plasma exposure relative to a single dose of lorlatinib administered alone and was assocd. with severe but self-limiting transaminase elevations in all healthy participants.  These observations support the contraindication in the product label against concomitant use of lorlatinib with all strong CYP3A inducers.  Trial registration: ClinicalTrials.gov identifier, NCT02804399.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7FDPfToKTLVg90H21EOLACvtfcHk0lg3CtwChx2OKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL&md5=8ce821a071e701d5cea6934b6cbf0bcb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs12325-019-01198-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-019-01198-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPawlak%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DGinman%26aufirst%3DK.%26aulast%3DBergerson%26aufirst%3DM.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26atitle%3DThe%2520Effect%2520of%2520Rifampin%2520on%2520the%2520Pharmacokinetics%2520and%2520Safety%2520of%2520Lorlatinib%253A%2520Results%2520of%2520a%2520Phase%2520One%252C%2520Open-Label%252C%2520Crossover%2520Study%2520in%2520Healthy%2520Participants%26jtitle%3DAdv.%2520Ther.%26date%3D2020%26volume%3D37%26issue%3D2%26spage%3D745%26epage%3D758%26doi%3D10.1007%2Fs12325-019-01198-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, Y. L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ock, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchekmedyian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syn, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span> <span> </span><span class="NLM_article-title">An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2020.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.jtho.2020.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=32360579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsFCiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1484-1496&issue=9&author=V.+W.+Zhuauthor=Y.+T.+Linauthor=D.+W.+Kimauthor=H.+H.+Loongauthor=M.+Nagasakaauthor=H.+Toauthor=Y.+L.+E.+Angauthor=C.+Y.+Ockauthor=N.+Tchekmedyianauthor=S.+H.+I.+Ouauthor=N.+L.+Synauthor=T.+Reungwetwattanaauthor=C.+C.+Linauthor=R.+A.+Soo&title=An+International+Real-World+Analysis+of+the+Efficacy+and+Safety+of+Lorlatinib+Through+Early+or+Expanded+Access+Programs+in+Patients+With+Tyrosine+Kinase+Inhibitor-Refractory+ALK-Positive+or+ROS1-Positive+NSCLC&doi=10.1016%2Fj.jtho.2020.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC</span></div><div class="casAuthors">Zhu, Viola W.; Lin, Yen-Ting; Kim, Dong-Wan; Loong, Herbert H.; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L.; Reungwetwattana, Thanyanan; Lin, Chia-Chi; Soo, Ross A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1484-1496</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Lorlatinib, next-generation central nervous system-penetrant ALK/ROS1 tyrosine kinase inhibitor approved to treat TKI-refractory ALK-pos. NSCLC based on results from phase 2 study.  A real-world anal. was performed on ALK+ or ROS1-pos. patients with NSCLC enrolled in lorlatinib early or expanded access programs in Hong Kong, Singapore, South Korea, Taiwan, Thailand, and the United States.  A total of 95 patients with NSCLC were analyzed.  ALK+ patients treated with less than two previous TKIs, two or more previous TKIs, and three or more previous TKIs, objective response rates and median progression-free survival were 42% and not reached, 35% (95% CI: 22-49; n = 55) and 11.2 mo (95% CI: 4.5-NR; n = 66), and 18% (95% CI: 4-43; n = 17) and 6.5 mo (95% CI: 3.5-11.6; n = 21), resp.  The ORRs and mPFSs were 13% (95% CI: 0-53; n = 8) and 9.2 mo (95% CI: 3.3-NR; n = 9) for patients treated with one second-generation ALK TKI as the only ALK TKI received.  For ROS1+ patients, ORRs and mPFSs were 41% (95% CI: 18-67; n = 17) and 11.9 mo (95% CI: 6.4-NR; n = 19).  The intracranial ORRs were 35% (95% CI: 22-49) and 55% (95% CI: 23-83) for 52 ALK+ and 11 ROS1+ patients. mPFS was 9.3 mo (95% CI: 1.0-NR; n = 13) for patients with leptomeningeal carcinomatosis.  No new safety signals were noted.Lorlatinib exhibited meaningful activity in TKI-refractory ALK+ or ROS1+ patients with NSCLC enrolled in early or expanded access programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh3Zns3D0a1bVg90H21EOLACvtfcHk0lgEnq_5m8zyDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsFCiu7o%253D&md5=3734803a1595600ce93e77f0dfd01e91</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2020.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2020.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DLin%26aufirst%3DY.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DLoong%26aufirst%3DH.%2BH.%26aulast%3DNagasaka%26aufirst%3DM.%26aulast%3DTo%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DY.%2BL.%2BE.%26aulast%3DOck%26aufirst%3DC.%2BY.%26aulast%3DTchekmedyian%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DSyn%26aufirst%3DN.%2BL.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DC.%2BC.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26atitle%3DAn%2520International%2520Real-World%2520Analysis%2520of%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Lorlatinib%2520Through%2520Early%2520or%2520Expanded%2520Access%2520Programs%2520in%2520Patients%2520With%2520Tyrosine%2520Kinase%2520Inhibitor-Refractory%2520ALK-Positive%2520or%2520ROS1-Positive%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3D1484%26epage%3D1496%26doi%3D10.1016%2Fj.jtho.2020.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pithavala, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1007/s11523-020-00702-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs11523-020-00702-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=32060867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BB387itl2jtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=55-65&issue=1&author=T.+M.+Bauerauthor=A.+T.+Shawauthor=M.+L.+Johnsonauthor=A.+Navarroauthor=J.+F.+Gainorauthor=H.+Thurmauthor=Y.+K.+Pithavalaauthor=A.+Abbattistaauthor=G.+Peltzauthor=E.+Felip&title=Brain+Penetration+of+Lorlatinib%3A+Cumulative+Incidences+of+CNS+and+Non-CNS+Progression+with+Lorlatinib+in+Patients+with+Previously+Treated+ALK-Positive+Non-Small-Cell+Lung+Cancer&doi=10.1007%2Fs11523-020-00702-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Bauer Todd M; Johnson Melissa L; Shaw Alice T; Gainor Justin F; Navarro Alejandro; Felip Enriqueta; Thurm Holger; Pithavala Yazdi K; Abbattista Antonello; Peltz Gerson</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood-brain barrier.  OBJECTIVE:  We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lorlatinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) previously treated with ALK TKIs.  PATIENTS AND METHODS:  In an ongoing phase II study (NCT01970865), 198 patients with ALK-positive NSCLC with ≥ 1 prior ALK TKI were enrolled into expansion cohorts (EXP) based on treatment history.  Patients received lorlatinib 100 mg once daily.  Patients were analyzed for progressive disease, categorized as CNS or non-CNS progression, by independent central review.  Cumulative incidence probabilities were calculated adopting a competing risks approach.  RESULTS:  Fifty-nine patients received crizotinib as their only prior ALK TKI (EXP2-3A); cumulative incidence rates (CIRs) of CNS and non-CNS progression were both 22% at 12 months in patients with baseline CNS metastases (n = 37), and CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients without baseline CNS metastases [43% vs. 9% (n = 22)].  In patients who received ≥ 1 prior second-generation ALK TKI [EXP3B-5 (n = 139)], CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients both with and without baseline CNS metastases (35% vs. 23% (n = 94) and 55% vs. 12% (n = 45), respectively).  CONCLUSIONS:  Lorlatinib showed substantial intracranial activity in patients with pretreated ALK-positive NSCLC, with or without baseline CNS metastases, whose disease progressed on crizotinib or second-generation ALK TKIs.  CLINICALTRIALS.  GOV IDENTIFIER:  NCT01970865.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA-ZQG6zODSBpyrDyM_m9cfW6udTcc2eb3sjkBBHrAwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387itl2jtg%253D%253D&md5=4cda9ece660ae5f1bb736770b4e35dbd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs11523-020-00702-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-020-00702-4%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DBrain%2520Penetration%2520of%2520Lorlatinib%253A%2520Cumulative%2520Incidences%2520of%2520CNS%2520and%2520Non-CNS%2520Progression%2520with%2520Lorlatinib%2520in%2520Patients%2520with%2520Previously%2520Treated%2520ALK-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DTarget%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D55%26epage%3D65%26doi%3D10.1007%2Fs11523-020-00702-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10 R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17- Tetrahydro- 2H −8,4-(Metheno)Pyrazolo[4,3- h ][2,5,11]- Benzoxadiazacyclotetradecine-3-Carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) And</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810+R%29-7-Amino-12-Fluoro-2%2C10%2C16-Trimethyl-15-Oxo-10%2C15%2C16%2C17-+Tetrahydro-+2H+%E2%88%928%2C4-%28Metheno%29Pyrazolo%5B4%2C3-+h+%5D%5B2%2C5%2C11%5D-+Benzoxadiazacyclotetradecine-3-Carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+And&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lgEnq_5m8zyDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810%2520R%2529-7-Amino-12-Fluoro-2%252C10%252C16-Trimethyl-15-Oxo-10%252C15%252C16%252C17-%2520Tetrahydro-%25202H%2520%25E2%2588%25928%252C4-%2528Metheno%2529Pyrazolo%255B4%252C3-%2520h%2520%255D%255B2%252C5%252C11%255D-%2520Benzoxadiazacyclotetradecine-3-Carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520And%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span> <span> </span><span class="NLM_article-title">PF-06463922 Is a Potent and Selective next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-Resistant ROS1Mutations</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3498</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420785112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1073%2Fpnas.1420785112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=25733882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3493-3498&issue=11&author=H.+Y.+Zouauthor=Q.+Liauthor=L.+D.+Engstromauthor=M.+Westauthor=V.+Applemanauthor=K.+A.+Wongauthor=M.+McTigueauthor=Y.+L.+Dengauthor=W.+Liuauthor=A.+Broounauthor=S.+Timofeevskiauthor=S.+R.+P.+McDonnellauthor=P.+Jiangauthor=M.+D.+Falkauthor=P.+B.+Lappinauthor=T.+Affolterauthor=T.+Nicholsauthor=W.+Huauthor=J.+Lamauthor=T.+W.+Johnsonauthor=T.+Smealauthor=A.+Charestauthor=V.+R.+Fantin&title=PF-06463922+Is+a+Potent+and+Selective+next-Generation+ROS1%2FALK+Inhibitor+Capable+of+Blocking+Crizotinib-Resistant+ROS1Mutations&doi=10.1073%2Fpnas.1420785112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Engstrom, Lars D.; West, Melissa; Appleman, Vicky; Wong, Katy A.; McTigue, Michele; Deng, Ya-Li; Liu, Wei; Brooun, Alexei; Timofeevski, Sergei; McDonnell, Scott R. P.; Jiang, Ping; Falk, Matthew D.; Lappin, Patrick B.; Affolter, Timothy; Nichols, Tim; Hu, Wenyue; Lam, Justine; Johnson, Ted W.; Smeal, Tod; Charest, Al; Fantin, Valeria R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3493-3498</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Oncogenic c-ros oncogene 1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy.  The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clin. activity in ROS1 fusion-pos. non-small cell lung cancer.  However, emerging clin. evidence has shown that patients can develop resistance by acquiring secondary point mutations in ROS1 kinase.  In this study the authors characterized the ROS1 activity of PF-06463922, a novel, orally available, CNS-penetrant, ATP-competitive small-mol. inhibitor of ALK/ROS1.  In vitro, PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1G2032R mutation and the ROS1G2026M gatekeeper mutation.  Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase.  A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable interactions contributing to the high-affinity binding.  In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1G2032R mutation.  Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.  Taken together, the authors' results indicate that PF-06463922 has potential for treating ROS1 fusion-pos. cancers, including those requiring agents with CNS-penetrating properties, as well as for overcoming crizotinib resistance driven by ROS1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5t2o5BKPhK7Vg90H21EOLACvtfcHk0lj8gp8Iu6Zb-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D&md5=8f549572dfac12c74b88705d57979c09</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420785112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420785112%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%2BP.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DCharest%26aufirst%3DA.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26atitle%3DPF-06463922%2520Is%2520a%2520Potent%2520and%2520Selective%2520next-Generation%2520ROS1%252FALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520Crizotinib-Resistant%2520ROS1Mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26issue%3D11%26spage%3D3493%26epage%3D3498%26doi%3D10.1073%2Fpnas.1420785112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stukalov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göktürk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strömberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colinge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Stereospecific Targeting of MTH1 by (S)-Crizotinib as an Anticancer Strategy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span> (<span class="NLM_issue">7495</span>),  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1038/nature13194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnature13194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=24695225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlWrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=222-227&issue=7495&author=K.+V.+M.+Huberauthor=E.+Salahauthor=B.+Radicauthor=M.+Gridlingauthor=J.+M.+Elkinsauthor=A.+Stukalovauthor=A.+S.+Jemthauthor=C.+G%C3%B6kt%C3%BCrkauthor=K.+Sanjivauthor=K.+Str%C3%B6mbergauthor=T.+Phamauthor=U.+W.+Berglundauthor=J.+Colingeauthor=K.+L.+Bennettauthor=J.+I.+Loizouauthor=T.+Helledayauthor=S.+Knappauthor=G.+Superti-Furga&title=Stereospecific+Targeting+of+MTH1+by+%28S%29-Crizotinib+as+an+Anticancer+Strategy&doi=10.1038%2Fnature13194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy</span></div><div class="casAuthors">Huber, Kilian V. M.; Salah, Eidarus; Radic, Branka; Gridling, Manuela; Elkins, Jonathan M.; Stukalov, Alexey; Jemth, Ann-Sofie; Gokturk, Camilla; Sanjiv, Kumar; Stroemberg, Kia; Pham, Therese; Berglund, Ulrika Warpman; Colinge, Jacques; Bennett, Keiryn L.; Loizou, Joanna I.; Helleday, Thomas; Knapp, Stefan; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7495</span>),
    <span class="NLM_cas:pages">222-227</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activated RAS GTPase signaling is a crit. driver of oncogenic transformation and malignant disease.  Cellular models of RAS-dependent cancers have been used to identify exptl. small mols., such as SCH51344, but their mol. mechanism of action remains generally unknown.  Here, using a chem. proteomic approach, the authors identify the target of SCH51344 as the human mutT homolog MTH1 (also known as NUDT1), a nucleotide pool sanitizing enzyme.  Loss-of-function of MTH1 impaired growth of KRAS tumor cells, whereas MTH1 overexpression mitigated sensitivity towards SCH51344.  Searching for more drug-like inhibitors, the authors identified the kinase inhibitor crizotinib as a nanomolar suppressor of MTH1 activity.  Surprisingly, the clin. used (R)-enantiomer of the drug was inactive, whereas the (S)-enantiomer selectively inhibited MTH1 catalytic activity.  Enzymic assays, chem. proteomic profiling, kinome-wide activity surveys and MTH1 co-crystal structures of both enantiomers provide a rationale for this remarkable stereospecificity.  Disruption of nucleotide pool homeostasis via MTH1 inhibition by (S)-crizotinib induced an increase in DNA single-strand breaks, activated DNA repair in human colon carcinoma cells, and effectively suppressed tumor growth in animal models.  The authors' results propose (S)-crizotinib as an attractive chem. entity for further pre-clin. evaluation, and small-mol. inhibitors of MTH1 in general as a promising novel class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrbUm7UP6kIrVg90H21EOLACvtfcHk0lj8gp8Iu6Zb-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlWrsb4%253D&md5=ca3df11a6782fd9140b6d8ba0c16e5ab</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature13194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13194%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DRadic%26aufirst%3DB.%26aulast%3DGridling%26aufirst%3DM.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DStukalov%26aufirst%3DA.%26aulast%3DJemth%26aufirst%3DA.%2BS.%26aulast%3DG%25C3%25B6kt%25C3%25BCrk%26aufirst%3DC.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DStr%25C3%25B6mberg%26aufirst%3DK.%26aulast%3DPham%26aufirst%3DT.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DStereospecific%2520Targeting%2520of%2520MTH1%2520by%2520%2528S%2529-Crizotinib%2520as%2520an%2520Anticancer%2520Strategy%26jtitle%3DNature%26date%3D2014%26volume%3D508%26issue%3D7495%26spage%3D222%26epage%3D227%26doi%3D10.1038%2Fnature13194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mireles, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Morais, S. M.</span></span> <span> </span><span class="NLM_article-title">In Vitro P-Glycoprotein Assays to Predict the in Vivo Interactions of P-Glycoprotein with Drugs in the Central Nervous System</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1124%2Fdmd.107.017434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=17962372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=268-275&issue=2&author=B.+Fengauthor=J.+B.+Millsauthor=R.+E.+Davidsonauthor=R.+J.+Mirelesauthor=J.+S.+Janiszewskiauthor=M.+D.+Troutmanauthor=S.+M.+de+Morais&title=In+Vitro+P-Glycoprotein+Assays+to+Predict+the+in+Vivo+Interactions+of+P-Glycoprotein+with+Drugs+in+the+Central+Nervous+System&doi=10.1124%2Fdmd.107.017434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system</span></div><div class="casAuthors">Feng, Bo; Mills, Jessica B.; Davidson, Ralph E.; Mireles, Rouchelle J.; Janiszewski, John S.; Troutman, Matthew D.; de Morais, Sonia M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-275</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compds. were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.  Addnl., the permeability for these compds. was measured in two in vitro models: parallel artificial membrane permeation assay and apical-to-basolateral apparent permeability in MDCK.  The exposure of the same set of compds. in brain and plasma was measured in P-gp knockout (KO) and wild-type (WT) mice after s.c. administration.  One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compds., and 6 of the 7 non-CNS drugs were detd. to have pos. efflux using ratio of ratios in MDR1-MDCK vs. MDCK transwell assays.  Data from transwell studies correlated well with the brain-to-plasma area under the curve ratios between P-gp KO and WT mice for the 32 CNS compds.  In addn., 3300 Pfizer compds. were tested in MDR1-MDCK and Mdr1a-MDCK transwell assays, with a good correlation (R2 = 0.92) between the efflux ratios in human MDR1-MDCK and mouse Mdr1a-MDCK cells.  Permeability data showed that the majority of the 32 CNS compds. have moderate to high passive permeability.  This work has demonstrated that in vitro transporter assays help in understanding the role of P-gp-mediated efflux activity in detg. the disposition of CNS drugs in vivo, and the transwell assay is a valuable in vitro assay to evaluate human P-gp interaction with compds. for assessing brain penetration of new chem. entities to treat CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQyRSOySyGLVg90H21EOLACvtfcHk0lhCdQv7K0ShpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D&md5=bbf8b6969bd6d6b3d741b6ef9e7853f3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017434%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DJ.%2BB.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DMireles%26aufirst%3DR.%2BJ.%26aulast%3DJaniszewski%26aufirst%3DJ.%2BS.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26atitle%3DIn%2520Vitro%2520P-Glycoprotein%2520Assays%2520to%2520Predict%2520the%2520in%2520Vivo%2520Interactions%2520of%2520P-Glycoprotein%2520with%2520Drugs%2520in%2520the%2520Central%2520Nervous%2520System%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D2%26spage%3D268%26epage%3D275%26doi%3D10.1124%2Fdmd.107.017434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&issue=4&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+Potent+and+Selective+Inhibitors+to+Overcome+Clinical+Anaplastic+Lymphoma+Kinase+Mutations+Resistant+to+Crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0lhCdQv7K0ShpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520to%2520Overcome%2520Clinical%2520Anaplastic%2520Lymphoma%2520Kinase%2520Mutations%2520Resistant%2520to%2520Crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D4%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latif, M.</span></span> <span> </span><span class="NLM_article-title">First Macrocyclic 3rd-Generation ALK Inhibitor for Treatment of ALK/ROS1 Cancer: Clinical and Designing Strategy Update of Lorlatinib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.ejmech.2017.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=28431340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2017&pages=348-356&author=S.+Basitauthor=Z.+Ashrafauthor=K.+Leeauthor=M.+Latif&title=First+Macrocyclic+3rd-Generation+ALK+Inhibitor+for+Treatment+of+ALK%2FROS1+Cancer%3A+Clinical+and+Designing+Strategy+Update+of+Lorlatinib&doi=10.1016%2Fj.ejmech.2017.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib</span></div><div class="casAuthors">Basit, Sulman; Ashraf, Zaman; Lee, Kwangho; Latif, Muhammad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">348-356</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to 2nd-generation ALK inhibitors.  Lorlatinib (PF-06463922) is a 3rd-generation macrocyclic ALK-TKI that demonstrates many advantages over 2nd-generation ALK inhibitors.  Lorlatinib has demonstrated decent kinase selectivity, promising pharmacokinetic profile, selective brain-penetration and strong antiproliferative activity in several ALK/ROS1-driven tumor models.  The current review describes the activity spectrum, key events from discovery to clin. applications and the evidences that lorlatinib acts as an ALK/ROS1 inhibitor in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqgvg4dapRHrVg90H21EOLACvtfcHk0ljxG2xdWSye2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D&md5=13f3886be0e0973a5627f33c6c50cf26</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DBasit%26aufirst%3DS.%26aulast%3DAshraf%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLatif%26aufirst%3DM.%26atitle%3DFirst%2520Macrocyclic%25203rd-Generation%2520ALK%2520Inhibitor%2520for%2520Treatment%2520of%2520ALK%252FROS1%2520Cancer%253A%2520Clinical%2520and%2520Designing%2520Strategy%2520Update%2520of%2520Lorlatinib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D134%26spage%3D348%26epage%3D356%26doi%3D10.1016%2Fj.ejmech.2017.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akamine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyokawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span> <span> </span><span class="NLM_article-title">Spotlight on Lorlatinib and Its Potential in the Treatment of NSCLC: The Evidence to Date</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5093</span>– <span class="NLM_lpage">5101</span>, <span class="refDoi"> DOI: 10.2147/OTT.S165511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.2147%2FOTT.S165511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30174447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOisrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=5093-5101&author=T.+Akamineauthor=G.+Toyokawaauthor=T.+Tagawaauthor=T.+Seto&title=Spotlight+on+Lorlatinib+and+Its+Potential+in+the+Treatment+of+NSCLC%3A+The+Evidence+to+Date&doi=10.2147%2FOTT.S165511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date</span></div><div class="casAuthors">Akamine, Takaki; Toyokawa, Gouji; Tagawa, Tetsuzo; Seto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5093-5101</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The identification of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of non-small cell lung cancer (NSCLC).  Targeting ALK using tyrosine kinase inhibitors (TKI) has dramatically improved the prognosis of patients with ALK-rearranged NSCLC.  However, most patients relapse on ALK-TKI therapy within a few years because of acquired resistance.  One mechanism of acquiring resistance is a second mutation on the ALK gene, and the representative mutation is L1996M in the gatekeeper residue.  In particular, the solvent-front ALK G1202R mutation is the common cause of resistance against first- and second-generation ALK-TKIs.  Another major concern regarding ALK-TKI is metastasis to the central nervous system, commonly obsd. in patients relapsing after ALK-TKI therapy.  The next-generation ALK inhibitor lorlatinib (PF-06463922) has therefore been developed to inhibit resistant ALK mutations, including ALK G1202R, and to penetrate the blood-brain barrier.  In a Phase I/II trial, the safety and efficacy of lorlatinib were demonstrated in patients with advanced ALK-pos. NSCLC, most of whom had central nervous system metastases and had previous ALK-TKI treatment.  In this review, we discuss the structure, pharmacodynamics, and pharmacokinetics of lorlatinib and compare its characteristics with those of other ALK inhibitors.  Furthermore, clin. trials for lorlatinib are summarized, and future perspectives in the management of patients with ALK-rearranged NSCLC are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXh2qxSCiqKrVg90H21EOLACvtfcHk0ljxG2xdWSye2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOisrfL&md5=ea74baa4efdbdbc7f06c95f1aa2b34db</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2147%2FOTT.S165511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S165511%26sid%3Dliteratum%253Aachs%26aulast%3DAkamine%26aufirst%3DT.%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DTagawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DT.%26atitle%3DSpotlight%2520on%2520Lorlatinib%2520and%2520Its%2520Potential%2520in%2520the%2520Treatment%2520of%2520NSCLC%253A%2520The%2520Evidence%2520to%2520Date%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D5093%26epage%3D5101%26doi%3D10.2147%2FOTT.S165511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pithavala, Y. K.</span></span> <span> </span><span class="NLM_article-title">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1007/s12325-019-01198-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs12325-019-01198-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=31863284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=745-758&issue=2&author=J.+Chenauthor=H.+Xuauthor=S.+Pawlakauthor=L.+P.+Jamesauthor=G.+Peltzauthor=K.+Leeauthor=K.+Ginmanauthor=M.+Bergeronauthor=Y.+K.+Pithavala&title=The+Effect+of+Rifampin+on+the+Pharmacokinetics+and+Safety+of+Lorlatinib%3A+Results+of+a+Phase+One%2C+Open-Label%2C+Crossover+Study+in+Healthy+Participants&doi=10.1007%2Fs12325-019-01198-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span></div><div class="casAuthors">Chen, Joseph; Xu, Huiping; Pawlak, Sylvester; James, Leonard P.; Peltz, Gerson; Lee, Kimberly; Ginman, Katherine; Bergeron, Michelle; Pithavala, Yazdi K.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">745-758</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-pos. metastatic non-small cell lung cancer; cytochrome P 450 (CYP) 3A plays an important role in the metab. of lorlatinib.  Methods: This phase 1, open-label, two-period, crossover study estd. the effect of oral rifampin (a strong CYP3A inducer) on the pharmacokinetics and safety of oral lorlatinib (NCT02804399).  Healthy participants received single-dose lorlatinib 100 mg in period 1 followed by rifampin 600 mg/day (days 1-12) and single-dose lorlatinib 100 mg (day 8) in period 2.  Blood samples were collected for 120 h after each dose of lorlatinib.  Results: When a single dose of lorlatinib was administered during daily dosing with rifampin (period 2), the area under the plasma concn.-time profile extrapolated to infinity (AUCinf) and max. plasma concn. (Cmax) of lorlatinib were 14.74% [90% confidence interval (CI) 12.78%, 17.01%] and 23.88% (90% CI 21.58%, 26.43%), resp., of those in period 1 (lorlatinib alone).  A single dose of lorlatinib was well tolerated in period 1, but elevations in transaminase values were obsd. in all participants (grade 2-4 in 11 participants) within 1-3 days after a single dose of lorlatinib was administered with ongoing rifampin in period 2.  Rifampin dosing was therefore halted.  Transaminase levels subsequently returned to normal (median time to recovery: 15 days).  No elevations in bilirubin were obsd.  Conclusions: The addn. of a single dose of lorlatinib to daily dosing with rifampin significantly reduced lorlatinib plasma exposure relative to a single dose of lorlatinib administered alone and was assocd. with severe but self-limiting transaminase elevations in all healthy participants.  These observations support the contraindication in the product label against concomitant use of lorlatinib with all strong CYP3A inducers.  Trial registration: ClinicalTrials.gov identifier, NCT02804399.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7FDPfToKTLVg90H21EOLACvtfcHk0ljxG2xdWSye2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL&md5=8ce821a071e701d5cea6934b6cbf0bcb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs12325-019-01198-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-019-01198-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPawlak%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DGinman%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DM.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26atitle%3DThe%2520Effect%2520of%2520Rifampin%2520on%2520the%2520Pharmacokinetics%2520and%2520Safety%2520of%2520Lorlatinib%253A%2520Results%2520of%2520a%2520Phase%2520One%252C%2520Open-Label%252C%2520Crossover%2520Study%2520in%2520Healthy%2520Participants%26jtitle%3DAdv.%2520Ther.%26date%3D2020%26volume%3D37%26issue%3D2%26spage%3D745%26epage%3D758%26doi%3D10.1007%2Fs12325-019-01198-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Midha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, R.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (MutMapII)</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26609494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=2892-2911&issue=9&author=A.+Midhaauthor=S.+Deardenauthor=R.+McCormack&title=EGFR+Mutation+Incidence+in+Non-Small-Cell+Lung+Cancer+of+Adenocarcinoma+Histology%3A+A+Systematic+Review+and+Global+Map+by+Ethnicity+%28MutMapII%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)</span></div><div class="casAuthors">Midha Anita; Dearden Simon; McCormack Rose</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2892-911</span>
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) histology (NSCLC/ADC).  Robust data exist regarding the prevalence of EGFR mutations in Western and Asian patients with NSCLC/ADC, yet there is a lack of data for patients of other ethnicities.  This review collated available data with the aim of creating a complete, global picture of EGFR mutation frequency in patients with NSCLC/ADC by ethnicity.  Worldwide literature reporting EGFR mutation frequency in patients with NSCLC/ADC was reviewed, to create a map of the world populated with EGFR mutation frequency by country (a 'global EGFR mutMap').  A total of 151 worldwide studies (n=33162 patients with NSCLC/ADC, of which 9749 patients had EGFR mutation-positive NSCLC/ADC) were included.  There was substantial variation in EGFR mutation frequency between studies, even when grouped by geographic region or individual country.  As expected, the Asia-Pacific NSCLC/ADC subgroup had the highest EGFR mutation frequency (47% [5958/12819; 87 studies; range 20%-76%]) and the lowest EGFR mutation frequency occurred in the Oceania NSCLC/ADC subgroup (12% [69/570; 4 studies; range 7%-36%]); however, comparisons between regions were limited due to the varying sizes of the patient populations studied.  In all regional (geographic) subgroups where data were available, EGFR mutation frequency in NSCLC/ADC was higher in women compared with men, and in never-compared with ever-smokers.  This review provides the foundation for a global map of EGFR mutation frequency in patients with NSCLC/ADC.  The substantial lack of data from several large geographic regions of the world, notably Africa, the Middle East, Central Asia, and Central and South America, highlights a potential lack of routine mutation testing and the need for further investigations in these regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1x7LyD77C4UH3Rlp_k91zfW6udTcc2ebVhNy9iimjzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D&md5=9ea4c9ffa42551cb066bb04142991fd4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMidha%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DR.%26atitle%3DEGFR%2520Mutation%2520Incidence%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520of%2520Adenocarcinoma%2520Histology%253A%2520A%2520Systematic%2520Review%2520and%2520Global%2520Map%2520by%2520Ethnicity%2520%2528MutMapII%2529%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26issue%3D9%26spage%3D2892%26epage%3D2911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-Small-Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70364-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS1470-2045%2809%2970364-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20022809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=121-128&issue=2&author=T.+Mitsudomiauthor=S.+Moritaauthor=Y.+Yatabeauthor=S.+Negoroauthor=I.+Okamotoauthor=J.+Tsurutaniauthor=T.+Setoauthor=M.+Satouchiauthor=H.+Tadaauthor=T.+Hirashimaauthor=K.+Asamiauthor=N.+Katakamiauthor=M.+Takadaauthor=H.+Yoshiokaauthor=K.+Shibataauthor=S.+Kudohauthor=E.+Shimizuauthor=H.+Saitoauthor=S.+Toyookaauthor=K.+Nakagawaauthor=M.+Fukuoka&title=Gefitinib+versus+Cisplatin+plus+Docetaxel+in+Patients+with+Non-Small-Cell+Lung+Cancer+Harbouring+Mutations+of+the+Epidermal+Growth+Factor+Receptor+%28WJTOG3405%29%3A+An+Open+Label%2C+Randomised+Phase+3+Trial&doi=10.1016%2FS1470-2045%2809%2970364-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span></div><div class="casAuthors">Mitsudomi, Tetsuya; Morita, Satoshi; Yatabe, Yasushi; Negoro, Shunichi; Okamoto, Isamu; Tsurutani, Junji; Seto, Takashi; Satouchi, Miyako; Tada, Hirohito; Hirashima, Tomonori; Asami, Kazuhiro; Katakami, Nobuyuki; Takada, Minoru; Yoshioka, Hiroshige; Shibata, Kazuhiko; Kudoh, Shinzoh; Shimizu, Eiji; Saito, Hiroshi; Toyooka, Shinichi; Nakagawa, Kazuhiko; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer harboring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib.  However, whether gefitinib is better than std. platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.  We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harboring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimization technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m2, i.v.) plus docetaxel (60 mg/m2, i.v.; n=89), administered every 21 days for three to six cycles.  The primary endpoint was progression-free survival.  Survival anal. was done with the modified intention-to-treat population.  This study is registered with UMIN (University Hospital Medical Information Network in Japan), no. 000000539.  Five patients were excluded (two patients were found to have thyroid and colon cancer after randomization, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel).  Thus, 172 patients (86 in each group) were included in the survival analyses.  The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel group, with a median progression-free survival time of 9.2 mo (95% CI 8.0-13.9) vs. 6.3 mo (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001).  Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhea were more frequent in the gefitinib group.  Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.  Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.  Funding: West Japan Oncol. Group (WJOG): a non-profit organization supported by unrestricted donations from several pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKXuDlK2x9o7Vg90H21EOLACvtfcHk0liy4jDdlpKKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D&md5=5856ce118d00919627e3f21525abe453</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970364-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970364-X%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNegoro%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DHirashima%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DK.%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520versus%2520Cisplatin%2520plus%2520Docetaxel%2520in%2520Patients%2520with%2520Non-Small-Cell%2520Lung%2520Cancer%2520Harbouring%2520Mutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528WJTOG3405%2529%253A%2520An%2520Open%2520Label%252C%2520Randomised%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26issue%3D2%26spage%3D121%26epage%3D128%26doi%3D10.1016%2FS1470-2045%2809%2970364-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kölbeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazulina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30033-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS1470-2045%2816%2930033-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=27083334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=577-589&issue=5&author=K.+Parkauthor=E.+H.+Tanauthor=K.+O%E2%80%99Byrneauthor=L.+Zhangauthor=M.+Boyerauthor=T.+Mokauthor=V.+Hirshauthor=J.+C.+H.+Yangauthor=K.+H.+Leeauthor=S.+Luauthor=Y.+Shiauthor=S.+W.+Kimauthor=J.+Laskinauthor=D.+W.+Kimauthor=C.+D.+Arvisauthor=K.+K%C3%B6lbeckauthor=S.+A.+Laurieauthor=C.+M.+Tsaiauthor=M.+Shahidiauthor=M.+Kimauthor=D.+Masseyauthor=V.+Zazulinaauthor=L.+Paz-Ares&title=Afatinib+versus+Gefitinib+as+First-Line+Treatment+of+Patients+with+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28LUX-Lung+7%29%3A+A+Phase+2B%2C+Open-Label%2C+Randomised+Controlled+Trial&doi=10.1016%2FS1470-2045%2816%2930033-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial</span></div><div class="casAuthors">Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-589</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-pos. non-small-cell lung cancer (NSCLC).  We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.  This multicentre, international, open-label, exploratory, randomised controlled phase 2B trial (LUX-Lung 7) was done at 64 centers in 13 countries.  Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator.  Randomisation, stratified by EGFR mutation type and status of brain metastases, was done centrally using a validated no. generating system implemented via an interactive voice or web-based response system with a block size of four.  Clinicians and patients were not masked to treatment allocation; independent review of tumor response was done in a blinded manner.  Coprimary endpoints were progression-free survival by independent central review, time-to-treatment failure, and overall survival.  Efficacy analyses were done in the intention-to-treat population and safety analyses were done in patients who received at least one dose of study drug.  This ongoing study is registered with ClinicalTrials.gov, no. NCT01466660.  Between Dec 13, 2011, and Aug 8, 2013, 319 patients were randomly assigned (160 to afatinib and 159 to gefitinib).  Median follow-up was 27·3 mo (IQR 15·3-33·9).  Progression-free survival (median 11·0 mo [95% CI 10·6-12·9] with afatinib vs 10·9 mo [9·1-11·5] with gefitinib; hazard ratio [HR] 0·73 [95% CI 0·57-0·95], p=0·017) and time-to-treatment failure (median 13·7 mo [95% CI 11·9-15·0] with afatinib vs 11·5 mo [10·1-13·1] with gefitinib; HR 0·73 [95% CI 0·58-0·92], p=0·0073) were significantly longer with afatinib than with gefitinib.  Overall survival data are not mature.  The most common treatment-related grade 3 or 4 adverse events were diarrhoea (20 [13%] of 160 patients given afatinib vs two [1%] of 159 given gefitinib) and rash or acne (15 [9%] patients given afatinib vs five [3%] of those given gefitinib) and liver enzyme elevations (no patients given afatinib vs 14 [9%] of those given gefitinib).  Serious treatment-related adverse events occurred in 17 (11%) patients in the afatinib group and seven (4%) in the gefitinib group.  Ten (6%) patients in each group discontinued treatment due to drug-related adverse events. 15 (9%) fatal adverse events occurred in the afatinib group and ten (6%) in the gefitinib group.  All but one of these deaths were considered unrelated to treatment; one patient in the gefitinib group died from drug-related hepatic and renal failure.  Afatinib significantly improved outcomes in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable tolerability profile.  These data are potentially important for clin. decision making in this patient population.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSTXQpDomR7Vg90H21EOLACvtfcHk0liy4jDdlpKKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D&md5=33d5697aa6a01e4f3fc89a34cb3b1e61</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930033-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930033-X%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DLaskin%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DK%25C3%25B6lbeck%26aufirst%3DK.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DTsai%26aufirst%3DC.%2BM.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DMassey%26aufirst%3DD.%26aulast%3DZazulina%26aufirst%3DV.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DAfatinib%2520versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520of%2520Patients%2520with%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528LUX-Lung%25207%2529%253A%2520A%2520Phase%25202B%252C%2520Open-Label%252C%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D5%26spage%3D577%26epage%3D589%26doi%3D10.1016%2FS1470-2045%2816%2930033-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in Untreated EGFR -Mutated Advanced Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.-C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.-C.+Suauthor=J.+E.+Grayauthor=S.-M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimertinib+in+Untreated+EGFR+-Mutated+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0lj5RJgYoqZA7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.-M.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimertinib%2520in%2520Untreated%2520EGFR%2520-Mutated%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, C.</span></span> <span> </span><span class="NLM_article-title">Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70184-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS1470-2045%2811%2970184-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21783417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=735-742&issue=8&author=C.+Zhouauthor=Y.+L.+Wuauthor=G.+Chenauthor=J.+Fengauthor=X.+Q.+Liuauthor=C.+Wangauthor=S.+Zhangauthor=J.+Wangauthor=S.+Zhouauthor=S.+Renauthor=S.+Luauthor=L.+Zhangauthor=C.+Huauthor=C.+Huauthor=Y.+Luoauthor=L.+Chenauthor=M.+Yeauthor=J.+Huangauthor=X.+Zhiauthor=Y.+Zhangauthor=Q.+Xiuauthor=J.+Maauthor=L.+Zhangauthor=C.+You&title=Erlotinib+versus+Chemotherapy+as+First-Line+Treatment+for+Patients+with+Advanced+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28OPTIMAL%2C+CTONG-0802%29%3A+A+Multicentre%2C+Open-Label%2C+Randomised%2C+Phase+3+Study&doi=10.1016%2FS1470-2045%2811%2970184-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study</span></div><div class="casAuthors">Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">735-742</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC).  The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib vs. std. chemotherapy in the first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  We undertook an open-label, randomised, phase 3 trial at 22 centers in China.  Patients older than 18 years with histol. confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received either oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects, or up to four cycles of gemcitabine plus carboplatin.  Patients were randomly assigned (1:1) with a minimization procedure and were stratified according to EGFR mutation type, histol. subtype (adenocarcinoma vs non-adenocarcinoma), and smoking status.  The primary outcome was progression-free survival, analyzed in patients with confirmed disease who received at least one dose of study treatment.  The trial is registered at ClinicalTrials.gov, no. NCT00874419, and has completed enrollment; patients are still in follow-up.  83 Patients were randomly assigned to receive erlotinib and 82 to receive gemcitabine plus carboplatin; 82 in the erlotinib group and 72 in the chemotherapy group were included in anal. of the primary endpoint.  Median progression-free survival was significantly longer in erlotinib-treated patients than in those on chemotherapy (13.1 [95% CI 10.58-16.53] vs 4.6 [4.21-5.42] months; hazard ratio 0.16, 95% CI 0.10-0.26; p<0.0001).  Chemotherapy was assocd. with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concns. (three [4%] of 83 patients) and skin rash (two [2%] patients).  Chemotherapy was also assocd. with increased treatment-related serious adverse events (ten [14%] of 72 patients [decreased platelet count, n = 8; decreased neutrophil count, n = 1; hepatic dysfunction, n = 1] vs two [2%] of 83 patients [both hepatic dysfunction]).  Compared with std. chemotherapy, erlotinib conferred a significant progression-free survival benefit in patients with advanced EGFR mutation-pos. NSCLC and was assocd. with more favorable tolerability.  These findings suggest that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  Funding: F Hoffmann-La Roche Ltd (China); Science and Technol. Commission of Shanghai Municipality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNzw1hk1km7Vg90H21EOLACvtfcHk0lj5RJgYoqZA7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D&md5=92097cc6e942e9137a40fd6cae675297</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970184-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970184-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%2BQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DC.%26atitle%3DErlotinib%2520versus%2520Chemotherapy%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520Advanced%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528OPTIMAL%252C%2520CTONG-0802%2529%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26issue%3D8%26spage%3D735%26epage%3D742%26doi%3D10.1016%2FS1470-2045%2811%2970184-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">872</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1158%2F2159-8290.CD-12-0387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=23071030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=872-875&issue=10&author=C.+M.+Blakelyauthor=T.+G.+Bivona&title=Resiliency+of+Lung+Cancers+to+EGFR+Inhibitor+Treatment+Unveiled+Offering+Opportunities+to+Divide+and+Conquer+EGFR+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-12-0387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span></div><div class="casAuthors">Blakely, Collin M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">872-875</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Summary: The clin. success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance.  Two reports in this issue of Cancer Discovery uncover addnl. mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment.  These findings pave the way for clin. testing of new rational therapeutic strategies to prevent or overcome resistance to EGFR kinase inhibitors in the clinic.  Cancer Discov; 2(10); 872-5. ©2012 AACR.  Commentary on Ercan et al., p. 934.  Commentary on Takezawa et al., p. 922.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiyRcMFbYgYrVg90H21EOLACvtfcHk0lj5RJgYoqZA7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM&md5=ec81e2c701acb7c836306926ca9b5074</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0387%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DResiliency%2520of%2520Lung%2520Cancers%2520to%2520EGFR%2520Inhibitor%2520Treatment%2520Unveiled%2520Offering%2520Opportunities%2520to%2520Divide%2520and%2520Conquer%2520EGFR%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D10%26spage%3D872%26epage%3D875%26doi%3D10.1158%2F2159-8290.CD-12-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Third-Generation Inhibitors Targeting EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26733151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSjt7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=1-7&issue=1&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-Generation+Inhibitors+Targeting+EGFR+T790M+Mutation+in+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2</span></div><div class="casAuthors">Ma, De-Ning; Chai, Zong-Tao; Zhu, Xiao-Dong; Zhang, Ning; Zhan, Di-Hua; Ye, Bo-Gen; Wang, Cheng-Hao; Qin, Cheng-Dong; Zhao, Yi-Ming; Zhu, Wei-Ping; Cao, Man-Qing; Gao, Dong-Mei; Sun, Hui-Chuan; Tang, Zhao-You</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1/1-1/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Our previous study reported that microRNA-26a (miR-26a) inhibited tumor progression by inhibiting tumor angiogenesis and intratumoral macrophage infiltration in hepatocellular carcinoma (HCC).  The direct roles of miR-26a on tumor cell invasion remain poorly understood.  In this study, we aim to explore the mechanism of miR- 26a in modulating epithelial-mesenchymal transition (EMT) in HCC.  Methods: In vitro cell morphol. and cell migration were compared between the hepatoma cell lines HCCLM3 and HepG2, which were established in the previous study.  Overexpression and down-regulation of miR-26a were induced in these cell lines, and Western blot and immunofluorescence assays were used to detect the expression of EMT markers.  Xenograft nude mouse models were used to observe tumor growth and pulmonary metastasis.  Immunohistochem. assays were conducted to study the relationships between miR-26a expression and enhancer of zeste homolog 2 (EZH2) and E-cadherin expression in human HCC samples.  Results: Down-regulation of miR-26a in HCCLM3 and HepG2 cells resulted in an EMT-like cell morphol. and high motility in vitro and increased in tumor growth and pulmonary metastasis in vivo.  Through down-regulation of EZH2 expression and up-regulation of E-cadherin expression, miR-26a inhibited the EMT process in vitro and in vivo.  Luciferase reporter assay showed that miR-26a directly interacted with EZH2 mRNA (mRNA).  Furthermore, the expression of miR-26a was pos. correlated with E-cadherin expression and inversely correlated with EZH2 expression in human HCC tissue.  Conclusions: miR-26a inhibited the EMT process in HCC by down-regulating EZH2 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDsPy-LLFpBbVg90H21EOLACvtfcHk0lg6usvoyuaO7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSjt7jP&md5=62d073e3eb93ec6ae477d46992a3acda</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-Generation%2520Inhibitors%2520Targeting%2520EGFR%2520T790M%2520Mutation%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26issue%3D1%26spage%3D1%26epage%3D7%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mediates Resistance to AZD9291 in Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=A.+P.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mediates+Resistance+to+AZD9291+in+Advanced+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lg6usvoyuaO7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DA.%2BP.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+Novel+Resistance+Mechanisms+to+Third-Generation+EGFR+Tyrosine+Kinase+Inhibitor+Osimertinib+in+Non-Small+Cell+Lung+Cancer+Patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lg6usvoyuaO7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520Novel%2520Resistance%2520Mechanisms%2520to%2520Third-Generation%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitor%2520Osimertinib%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+Selective+and+Rigidify%3A+The+Discovery+Path+toward+a+Next+Generation+of+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lgWw5i9WusW2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520Selective%2520and%2520Rigidify%253A%2520The%2520Discovery%2520Path%2520toward%2520a%2520Next%2520Generation%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. L.</span></span> <span> </span><span class="NLM_article-title">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1961</span>– <span class="NLM_lpage">2004</span>, <span class="refDoi"> DOI: 10.1021/jm1012374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+Are+Great+Cycles%3A+Applications%2C+Opportunities%2C+and+Challenges+of+Synthetic+Macrocycles+in+Drug+Discovery&doi=10.1021%2Fjm1012374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span></div><div class="casAuthors">Marsault, Eric; Peterson, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1961-2004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles occupy a unique segment of chem. space.  In the past decade, their chem. diversity expanded significantly, supported by advances in bioinformatics and synthetic methodol.  As a consequence, this structural type has now been successfully tested on most biol. target classes.  The goal of this article is to put into perspective the current applications, opportunities, and challenges assocd. with synthetic macrocycles in drug discovery.  Accordingly, the first part of this article is dedicated to the drug discovery aspects of macrocycles and highlights salient features of their medicinal chem.  This section is organized by target class, a choice aimed at providing the reader an appreciation of the structural diversity generated for each class.  To give the reader an appreciation of the tools available to construct macrocyclic scaffolds, the site and method of the pivotal macrocyclization step are indicated in the figures.  Readers are referred to the source articles for further details.  In the second part, the technologies and synthetic approaches that already have demonstrated utility or possess a high potential for macrocycle-based drug discovery are discussed.  Finally, a perspective on the future of synthetic macrocycles in medicinal chem. is offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrygQLE6JraHrVg90H21EOLACvtfcHk0lgWw5i9WusW2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D&md5=97c1120896e90a85790a9ac1274259f3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520Are%2520Great%2520Cycles%253A%2520Applications%252C%2520Opportunities%252C%2520and%2520Challenges%2520of%2520Synthetic%2520Macrocycles%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004%26doi%3D10.1021%2Fjm1012374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span> <span> </span><span class="NLM_article-title">Emac - A Comparative Index for the Assessment of Macrocyclization Efficiency</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1039/C2MD20176C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC2MD20176C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1489-1495&issue=12&author=J.+C.+Collinsauthor=K.+James&title=Emac+-+A+Comparative+Index+for+the+Assessment+of+Macrocyclization+Efficiency&doi=10.1039%2FC2MD20176C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Emac - a comparative index for the assessment of macrocyclization efficiency</span></div><div class="casAuthors">Collins, James C.; James, Keith</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1489-1495</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Macrocycle-based drug design represents an exciting new frontier in drug discovery, and consequently there is considerable interest in methodologies for the efficient construction of macrocyclic motifs.  However, typical high-diln. macrocyclization conditions are inefficient and impractical in a pharmaceutical setting from cost, capacity and green chem. perspectives.  This crit. review reports the results of a comprehensive literature survey of recent macrocyclization reactions and proposes a macrocyclization efficiency index, Emac, which takes into account both reaction yield and concn.  Anal. and discussion of the literature dataset using this novel metric are presented, along with selected examples of high and low efficiency macrocyclizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7MQcJUad-wrVg90H21EOLACvtfcHk0lgWw5i9WusW2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsrzK&md5=5d44068e847eb24e7fdb318404a7c590</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FC2MD20176C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20176C%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DJ.%2BC.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DEmac%2520-%2520A%2520Comparative%2520Index%2520for%2520the%2520Assessment%2520of%2520Macrocyclization%2520Efficiency%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D1489%26epage%3D1495%26doi%3D10.1039%2FC2MD20176C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martí-Centelles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burguete, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luis, S. V.</span></span> <span> </span><span class="NLM_article-title">Macrocyclization Reactions: The Importance of Conformational, Configurational, and Template-Induced Preorganization</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">8736</span>– <span class="NLM_lpage">8834</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12lu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=8736-8834&author=V.+Mart%C3%AD-Centellesauthor=M.+D.+Pandeyauthor=M.+I.+Burgueteauthor=S.+V.+Luis&title=Macrocyclization+Reactions%3A+The+Importance+of+Conformational%2C+Configurational%2C+and+Template-Induced+Preorganization&doi=10.1021%2Facs.chemrev.5b00056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclization Reactions: The Importance of Conformational, Configurational, and Template-Induced Preorganization</span></div><div class="casAuthors">Marti-Centelles, Vicente; Pandey, Mrituanjay D.; Burguete, M. Isabel; Luis, Santiago V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8736-8834</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Structural preorganization of precursors is of importance for macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnstxniwDETrVg90H21EOLACvtfcHk0lh2cRd6IjkS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12lu7nJ&md5=bf3407bbbde3460506b709d2f0167f42</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00056%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25AD-Centelles%26aufirst%3DV.%26aulast%3DPandey%26aufirst%3DM.%2BD.%26aulast%3DBurguete%26aufirst%3DM.%2BI.%26aulast%3DLuis%26aufirst%3DS.%2BV.%26atitle%3DMacrocyclization%2520Reactions%253A%2520The%2520Importance%2520of%2520Conformational%252C%2520Configurational%252C%2520and%2520Template-Induced%2520Preorganization%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D8736%26epage%3D8834%26doi%3D10.1021%2Facs.chemrev.5b00056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankenstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Conformation-Directed Macrocyclization Reactions</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1949</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200400751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fejoc.200400751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=1949&issue=10&author=J.+Blankensteinauthor=J.+Zhu&title=Conformation-Directed+Macrocyclization+Reactions&doi=10.1002%2Fejoc.200400751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200400751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200400751%26sid%3Dliteratum%253Aachs%26aulast%3DBlankenstein%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DConformation-Directed%2520Macrocyclization%2520Reactions%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2005%26volume%3D2005%26issue%3D10%26spage%3D1949%26doi%3D10.1002%2Fejoc.200400751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gradillas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castells, J.</span></span> <span> </span><span class="NLM_article-title">Macrocyclization by Ring-Closing Metathesis in the Total Synthesis of Natural Products: Reaction Conditions and Limitations</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">6086</span>– <span class="NLM_lpage">6101</span>, <span class="refDoi"> DOI: 10.1002/anie.200600641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fanie.200600641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVWnsr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6086-6101&issue=37&author=A.+Gradillasauthor=J.+P%C3%A9rez-Castells&title=Macrocyclization+by+Ring-Closing+Metathesis+in+the+Total+Synthesis+of+Natural+Products%3A+Reaction+Conditions+and+Limitations&doi=10.1002%2Fanie.200600641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclization by ring-closing metathesis in the total synthesis of natural products: reaction conditions and limitations</span></div><div class="casAuthors">Gradillas, Ana; Perez-Castells, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">6086-6101</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The construction of macrocycles by ring-closing metathesis (RCM) is often used as the key step in the synthesis of natural products contg. large rings.  This reaction is attractive because of its high functional group compatibility and the possibility for further transformations.  The finding of suitable reaction conditions is crit. for the success of the synthesis.  This review summarizes the efficient RCM reactions of the total synthesis of natural macrocyclic products and should reduce the time-consuming phase of the optimization of the reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YDIbEWf4ALVg90H21EOLACvtfcHk0lh2cRd6IjkS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVWnsr3P&md5=b1430b45488e86d48f29848cd4b2f725</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fanie.200600641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200600641%26sid%3Dliteratum%253Aachs%26aulast%3DGradillas%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez-Castells%26aufirst%3DJ.%26atitle%3DMacrocyclization%2520by%2520Ring-Closing%2520Metathesis%2520in%2520the%2520Total%2520Synthesis%2520of%2520Natural%2520Products%253A%2520Reaction%2520Conditions%2520and%2520Limitations%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26issue%3D37%26spage%3D6086%26epage%3D6101%26doi%3D10.1002%2Fanie.200600641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, I.</span></span> <span> </span><span class="NLM_article-title">An Effective Method for the Synthesis of Carboxylic Esters and Lactones Using Substituted Benzoic Anhydrides with Lewis Acid Catalysts</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1587</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2003.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.tet.2003.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1587-1599&issue=7&author=I.+Shiina&title=An+Effective+Method+for+the+Synthesis+of+Carboxylic+Esters+and+Lactones+Using+Substituted+Benzoic+Anhydrides+with+Lewis+Acid+Catalysts&doi=10.1016%2Fj.tet.2003.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">An effective method for the synthesis of carboxylic esters and lactones using substituted benzoic anhydrides with Lewis acid catalysts</span></div><div class="casAuthors">Shiina, Isamu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1587-1599</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">An efficient mixed-anhydride method for the synthesis of carboxylic esters and lactones using benzoic anhydride having electron withdrawing substituent(s) is developed by the promotion of Lewis acid catalysts.  In the presence of a catalytic amt. of TiCl2(ClO4)2, various carboxylic esters are prepd. in high yields through the formation of the corresponding mixed-anhydrides from 3,5-bis(trifluoromethyl)benzoic anhydride and carboxylic acids.  The combined catalyst consisting of TiCl2(ClO4)2 together with chlorotrimethylsilane functions as an effective catalyst for the synthesis of carboxylic esters from free carboxylic acids and alcs. with 4-(trifluoromethyl)benzoic anhydride.  Various macrolactones are prepd. from the free ω-hydroxycarboxylic acids by the combined use of 4-(trifluoromethyl)benzoic anhydride and titanium(IV) catalysts together with chlorotrimethylsilane under mild reaction conditions.  The lactonization of trimethylsilyl ω-(trimethylsiloxy)carboxylates using 4-(trifluoromethyl)benzoic anhydride is also promoted at room temp. in the presence of a catalytic amt. of TiCl2(ClO4)2.  An 8-membered ring lactone, a synthetic intermediate of cephalosporolide D, is successfully synthesized according to this mixed-anhydride method using 4-(trifluoromethyl)benzoic anhydride by the promotion of a catalytic amt. of Hf(OTf)4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDJAtkgZ5nkrVg90H21EOLACvtfcHk0lh2cRd6IjkS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFWktQ%253D%253D&md5=af46a2832f81bab0c3aed26731e83aaa</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2003.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2003.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DShiina%26aufirst%3DI.%26atitle%3DAn%2520Effective%2520Method%2520for%2520the%2520Synthesis%2520of%2520Carboxylic%2520Esters%2520and%2520Lactones%2520Using%2520Substituted%2520Benzoic%2520Anhydrides%2520with%2520Lewis%2520Acid%2520Catalysts%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26issue%3D7%26spage%3D1587%26epage%3D1599%26doi%3D10.1016%2Fj.tet.2003.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibuka, R.</span></span> <span> </span><span class="NLM_article-title">A Novel and Efficient Macrolactonization of ω-Hydroxycarboxylic Acids Using 2-Methyl-6-Nitrobenzoic Anhydride (MNBA)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">42</span>),  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7539</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(02)01819-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS0040-4039%2802%2901819-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVWlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=7535-7539&issue=42&author=I.+Shiinaauthor=M.+Kubotaauthor=R.+Ibuka&title=A+Novel+and+Efficient+Macrolactonization+of+%CF%89-Hydroxycarboxylic+Acids+Using+2-Methyl-6-Nitrobenzoic+Anhydride+%28MNBA%29&doi=10.1016%2FS0040-4039%2802%2901819-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A novel and efficient macrolactonization of ω-hydroxycarboxylic acids using 2-methyl-6-nitrobenzoic anhydride (MNBA)</span></div><div class="casAuthors">Shiina, Isamu; Kubota, Mari; Ibuka, Ryoutarou</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">7535-7539</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A variety of lactones were prepd. in high yields at room temp. from the corresponding ω-hydroxycarboxylic acids using 2-methyl-6-nitrobenzoic anhydride in the presence of 4-(dimethylamino)pyridine.  A similar reaction also occurs with triethylamine when using a catalytic amt. of 4-(dimethylamino)pyridine 1-oxide as an effective promoter for the intramol. condensation reaction.  These methods were successfully applied to the synthesis of erythro-aleuritic acid lactone and the efficiency of the cyclizations is compared to those of other reported mixed anhydride methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3QFqUhehBf7Vg90H21EOLACvtfcHk0lh2cRd6IjkS3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVWlu7k%253D&md5=827022b65e6972fc385da3978701fc55</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2802%2901819-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252802%252901819-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiina%26aufirst%3DI.%26aulast%3DKubota%26aufirst%3DM.%26aulast%3DIbuka%26aufirst%3DR.%26atitle%3DA%2520Novel%2520and%2520Efficient%2520Macrolactonization%2520of%2520%25CF%2589-Hydroxycarboxylic%2520Acids%2520Using%25202-Methyl-6-Nitrobenzoic%2520Anhydride%2520%2528MNBA%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2002%26volume%3D43%26issue%3D42%26spage%3D7535%26epage%3D7539%26doi%3D10.1016%2FS0040-4039%2802%2901819-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wender, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeChristopher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, A. J.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Driven Macrocyclization Strategy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6658</span>– <span class="NLM_lpage">6659</span>, <span class="refDoi"> DOI: 10.1021/ja8015632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja8015632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlamt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=6658-6659&issue=21&author=P.+A.+Wenderauthor=B.+A.+DeChristopherauthor=A.+J.+Schrier&title=Efficient+Synthetic+Access+to+a+New+Family+of+Highly+Potent+Bryostatin+Analogues+via+a+Prins-Driven+Macrocyclization+Strategy&doi=10.1021%2Fja8015632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Driven Macrocyclization Strategy</span></div><div class="casAuthors">Wender, Paul A.; DeChristopher, Brian A.; Schrier, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6658-6659</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The step-economical synthesis of a new class of bryostatin analogs, e.g. I, that contain the complete oxycarbocyclic core ring system of the bryostatin natural products is reported.  These agents are convergently assembled via a highly efficient, functional-group-tolerant, and stereoselective Prins-driven macrocyclization.  These tetrahydropyranyl B-ring analogs are among our most potent and efficacious analogs to date, exhibiting nanomolar and picomolar activities in protein kinase C affinity assays as well as in cellular antiproliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcrnxjdmrRLVg90H21EOLACvtfcHk0ljMwewMpFPzPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlamt74%253D&md5=96423f7f8731ac6230323622201cf547</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fja8015632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja8015632%26sid%3Dliteratum%253Aachs%26aulast%3DWender%26aufirst%3DP.%2BA.%26aulast%3DDeChristopher%26aufirst%3DB.%2BA.%26aulast%3DSchrier%26aufirst%3DA.%2BJ.%26atitle%3DEfficient%2520Synthetic%2520Access%2520to%2520a%2520New%2520Family%2520of%2520Highly%2520Potent%2520Bryostatin%2520Analogues%2520via%2520a%2520Prins-Driven%2520Macrocyclization%2520Strategy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26issue%3D21%26spage%3D6658%26epage%3D6659%26doi%3D10.1021%2Fja8015632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubbs, R. H.</span></span> <span> </span><span class="NLM_article-title">Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">40</span>),  <span class="NLM_fpage">9606</span>– <span class="NLM_lpage">9614</span>, <span class="refDoi"> DOI: 10.1021/ja961626l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja961626l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaK28Xls12ltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=9606-9614&issue=40&author=S.+J.+Millerauthor=H.+E.+Blackwellauthor=R.+H.+Grubbs&title=Application+of+Ring-Closing+Metathesis+to+the+Synthesis+of+Rigidified+Amino+Acids+and+Peptides&doi=10.1021%2Fja961626l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides</span></div><div class="casAuthors">Miller, Scott J.; Blackwell, Helen E.; Grubbs, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">9606-9614</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ruthenium complexes I (R = Ph, CH:CPh2) have been applied to the ring-closing metathesis (RCM) reactions of a no. of dienic substrates.  The substrate scope includes rings of 6 to 20 members.  In addressing macrocyclic peptides, a class of tetrapeptide disulfides inspired the synthesis of the carbon-carbon bond analogs.  Replacement of cysteine residues with allylglycines resulted in the acyclic precursors which were subjected to RCM to afford the corresponding macrocycles.  In addn., several macrocycles were prepd. which were not based upon disulfide-bridge-contg. species found in nature.  The method was found to function on dienic peptides which were either dissolved in org. solvents or bound to solid supports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom4hQK1LSVhbVg90H21EOLACvtfcHk0ljMwewMpFPzPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xls12ltLo%253D&md5=7085a5ca04b442050a953ec5146934c2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fja961626l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja961626l%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DS.%2BJ.%26aulast%3DBlackwell%26aufirst%3DH.%2BE.%26aulast%3DGrubbs%26aufirst%3DR.%2BH.%26atitle%3DApplication%2520of%2520Ring-Closing%2520Metathesis%2520to%2520the%2520Synthesis%2520of%2520Rigidified%2520Amino%2520Acids%2520and%2520Peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26issue%3D40%26spage%3D9606%26epage%3D9614%26doi%3D10.1021%2Fja961626l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fürstner, A.</span></span> <span> </span><span class="NLM_article-title">Olefin Metathesis and Beyond</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3012</span>– <span class="NLM_lpage">3043</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20000901)39:17<3012::AID-ANIE3012>3.0.CO;2-G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFWgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=3012-3043&issue=17&author=A.+F%C3%BCrstner&title=Olefin+Metathesis+and+Beyond&doi=10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Olefin metathesis and beyond</span></div><div class="casAuthors">Fuerstner, Alois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3012-3043</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  The advent of well-defined catalysts for olefin metathesis which combine high activity, durability, and excellent tolerance towards polar functional groups has revolutionized the field.  The past decade has seen the rapid embrace of these reagents as tools for advanced org. and polymer chem. and the success of this development is witnessed by a plethora of elegant applications to the synthesis of natural and nonnatural products.  This review article, with >200 refs., provides an overview of these developments and familiarizes the reader with some very recent advances which hold the promise to expand the scope of the reaction even further.  Moreover, the pos. impact of metathesis on the fundamental logic of retrosynthetic planning is shown by means of typical examples.  Finally, metathesis is by no means restricted to alkene substrates, and some comments on metathesis reactions following unconventional mechanistic pathways are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEFuxPpFyvl7Vg90H21EOLACvtfcHk0ljMwewMpFPzPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFWgtLg%253D&md5=34a56b85c96f16750f2f75d8e55fea92</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820000901%252939%253A17%253C3012%253A%253AAID-ANIE3012%253E3.0.CO%253B2-G%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26atitle%3DOlefin%2520Metathesis%2520and%2520Beyond%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2000%26volume%3D39%26issue%3D17%26spage%3D3012%26epage%3D3043%26doi%3D10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF-R Inhibitors with Potent Antiproliferative Activities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcmdc.200600199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=17131463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=63-77&issue=1&author=U.+L%C3%BCckingauthor=G.+Siemeisterauthor=M.+Sch%C3%A4ferauthor=H.+Briemauthor=M.+Kr%C3%BCgerauthor=P.+Lienauauthor=R.+Jautelat&title=Macrocyclic+Aminopyrimidines+as+Multitarget+CDK+and+VEGF-R+Inhibitors+with+Potent+Antiproliferative+Activities&doi=10.1002%2Fcmdc.200600199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities</span></div><div class="casAuthors">Luecking, Ulrich; Siemeister, Gerhard; Schaefer, Martina; Briem, Hans; Krueger, Martin; Lienau, Philip; Jautelat, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-77</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">X-ray structures from CDK2-aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework.  A modular synthesis approach that relies on a new late-stage macrocyclization protocol that enables fast and efficient synthesis of macrocyclic aminopyrimidines was developed.  A set of structurally diverse derivs. was prepd.  Macrocyclic aminopyrimidines were shown to be multitarget inhibitors of CDK1/2 and VEGF-RTKs.  In addn., potent antiproliferative activities toward various human tumor cells and a human tumor xenograft model were demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJSYJjccvBpLVg90H21EOLACvtfcHk0lhH9iUFRaWSrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbY%253D&md5=80a2329d666086a24e0e98070305841c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600199%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DKr%25C3%25BCger%26aufirst%3DM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DJautelat%26aufirst%3DR.%26atitle%3DMacrocyclic%2520Aminopyrimidines%2520as%2520Multitarget%2520CDK%2520and%2520VEGF-R%2520Inhibitors%2520with%2520Potent%2520Antiproliferative%2520Activities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D1%26spage%3D63%26epage%3D77%26doi%3D10.1002%2Fcmdc.200600199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Himmelbauer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyedy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilfillan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Turiso, F. G. L.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10740</span>– <span class="NLM_lpage">10756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01206</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01206" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10740-10756&issue=23&author=M.+K.+Himmelbauerauthor=Z.+Xinauthor=J.+H.+Jonesauthor=I.+Enyedyauthor=K.+Kingauthor=D.+J.+Marcotteauthor=P.+Muruganauthor=J.+C.+Santoroauthor=T.+Hessonauthor=K.+Spilkerauthor=J.+L.+Johnsonauthor=M.+J.+Luzzioauthor=R.+Gilfillanauthor=F.+G.+L.+De+Turiso&title=Rational+Design+and+Optimization+of+a+Novel+Class+of+Macrocyclic+Apoptosis+Signal-Regulating+Kinase+1+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors</span></div><div class="casAuthors">Himmelbauer, Martin K.; Xin, Zhili; Jones, J. Howard; Enyedy, Istvan; King, Kristopher; Marcotte, Douglas J.; Murugan, Paramasivam; Santoro, Joseph C.; Hesson, Thomas; Spilker, Kerri; Johnson, Joshua L.; Luzzio, Michael J.; Gilfillan, Rab; de Turiso, Felix Gonzalez-Lopez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10740-10756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural anal. of a known ASK1 inhibitor bound to its kinase domain led to the design and synthesis of the novel macrocyclic inhibitor I (cell IC50 = 1.2μM).  The profile of this compd. was optimized for CNS penetration following two independent strategies: a rational design approach leading to II and a parallel synthesis approach leading to III.  Both analogs are potent ASK1 inhibitors in biochem. and cellular assays (II, cell IC50 = 95 nM; III, cell IC50 = 123 nM) and have moderate to low efflux ratio (ER) in an MDR1-MDCK assay (II, ER = 5.2; III, ER = 1.5).  In vivo PK studies revealed that inhibitor II had moderate CNS penetration (Kp,uu = 0.17) and analog III had high CNS penetration (Kp,uu = 1.0).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriuHDeLuhp8bVg90H21EOLACvtfcHk0lhH9iUFRaWSrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqsrnL&md5=bceb203a92c314a775b1d8d116cafcad</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01206%26sid%3Dliteratum%253Aachs%26aulast%3DHimmelbauer%26aufirst%3DM.%2BK.%26aulast%3DXin%26aufirst%3DZ.%26aulast%3DJones%26aufirst%3DJ.%2BH.%26aulast%3DEnyedy%26aufirst%3DI.%26aulast%3DKing%26aufirst%3DK.%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DMurugan%26aufirst%3DP.%26aulast%3DSantoro%26aufirst%3DJ.%2BC.%26aulast%3DHesson%26aufirst%3DT.%26aulast%3DSpilker%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DJ.%2BL.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DGilfillan%26aufirst%3DR.%26aulast%3DDe%2BTuriso%26aufirst%3DF.%2BG.%2BL.%26atitle%3DRational%2520Design%2520and%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520Macrocyclic%2520Apoptosis%2520Signal-Regulating%2520Kinase%25201%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D23%26spage%3D10740%26epage%3D10756%26doi%3D10.1021%2Facs.jmedchem.9b01206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Recent Development of Peptide Coupling Reagents in Organic Synthesis</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2447</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.01.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.tet.2004.01.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFeqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2447-2467&issue=11&author=S.-Y.+Hanauthor=Y.-A.+Kim&title=Recent+Development+of+Peptide+Coupling+Reagents+in+Organic+Synthesis&doi=10.1016%2Fj.tet.2004.01.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Recent development of peptide coupling reagents in organic synthesis</span></div><div class="casAuthors">Han, So-Yeop; Kim, Young-Ah</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2447-2467</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Various types of peptide coupling reagents (i.e., phosphonium, uronium, immonium, carbodiimide, imidazolium, organophosphorus, acid halogenating compds., chloroformate, pyridinium, etc.) are discussed for the synthesis of bioactive mols. contg. peptide linkages.  Methods used to suppress racemization during the peptide coupling step are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MxkBBhDXubVg90H21EOLACvtfcHk0lhH9iUFRaWSrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFeqsro%253D&md5=8c9ca02776710dd0e204262a85da630b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.01.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.01.020%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.-Y.%26aulast%3DKim%26aufirst%3DY.-A.%26atitle%3DRecent%2520Development%2520of%2520Peptide%2520Coupling%2520Reagents%2520in%2520Organic%2520Synthesis%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26issue%3D11%26spage%3D2447%26epage%3D2467%26doi%3D10.1016%2Fj.tet.2004.01.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIver, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcmdc.201600589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=28032464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=207-213&issue=3&author=A.+L.+McIverauthor=W.+Zhangauthor=Q.+Liuauthor=X.+Jiangauthor=M.+A.+Stashkoauthor=J.+Nicholsauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=M.+Machiusauthor=D.+DeRyckereauthor=E.+Woodauthor=D.+K.+Grahamauthor=H.+S.+Earpauthor=D.+Kireevauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+Macrocyclic+Pyrimidines+as+MerTK-Specific+Inhibitors&doi=10.1002%2Fcmdc.201600589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors</span></div><div class="casAuthors">McIver, Andrew L.; Zhang, Weihe; Liu, Qingyang; Jiang, Xinpeng; Stashko, Michael A.; Nichols, James; Miley, Michael J.; Norris-Drouin, Jacqueline; Machius, Mischa; DeRyckere, Deborah; Wood, Edgar; Graham, Douglas K.; Earp, H. Shelton; Kireev, Dmitri; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocycles have attracted significant attention in drug discovery recently.  In fact, a few de novo designed macrocyclic kinase inhibitors are currently in clin. trials with good potency and selectivity for their intended target.  In this study, we successfully engaged a structure-based drug design approach to discover macrocyclic pyrimidines as potent Mer tyrosine kinase (MerTK)-specific inhibitors.  An ELISA (ELISA) in 384-well format was employed to evaluate the inhibitory activity of macrocycles in a cell-based assay assessing tyrosine phosphorylation of MerTK.  Through structure-activity relationship (SAR) studies, analog 11 [UNC2541; (S)-7-amino-N-(4-fluorobenzyl)-8-oxo-2,9,16-triaza-1(2,4)-pyrimidinacyclohexadecaphane-1-carboxamide] was identified as a potent and MerTK-specific inhibitor that exhibits sub-micromolar inhibitory activity in the cell-based ELISA.  In addn., an X-ray structure of MerTK protein in complex with 11 was resolved to show that these macrocycles bind in the MerTK ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOfJewlO7H8bVg90H21EOLACvtfcHk0lgXdXa5u0u4lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D&md5=09a963efb36d595e3f4a301676b685f1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600589%26sid%3Dliteratum%253Aachs%26aulast%3DMcIver%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520Macrocyclic%2520Pyrimidines%2520as%2520MerTK-Specific%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D207%26epage%3D213%26doi%3D10.1002%2Fcmdc.201600589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiratori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Macrocyclic 2-Amino-6-Arylpyrimidine Hsp90 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.11.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmcl.2011.11.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22192591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFalsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1136-1141&issue=2&author=A.+Sudaauthor=H.+Koyanoauthor=T.+Hayaseauthor=K.+Hadaauthor=K.+I.+Kawasakiauthor=S.+Komiyamaauthor=K.+Hasegawaauthor=T.+A.+Fukamiauthor=S.+Satoauthor=T.+Miuraauthor=N.+Onoauthor=T.+Yamazakiauthor=R.+Saitohauthor=N.+Shimmaauthor=Y.+Shiratoriauthor=T.+Tsukuda&title=Design+and+Synthesis+of+Novel+Macrocyclic+2-Amino-6-Arylpyrimidine+Hsp90+Inhibitors&doi=10.1016%2Fj.bmcl.2011.11.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors</span></div><div class="casAuthors">Suda, Atsushi; Koyano, Hiroshi; Hayase, Tadakatsu; Hada, Kihito; Kawasaki, Ken-ichi; Komiyama, Susumu; Hasegawa, Kiyoshi; Fukami, Takaaki A.; Sato, Shigeo; Miura, Takaaki; Ono, Naomi; Yamazaki, Toshikazu; Saitoh, Ryoichi; Shimma, Nobuo; Shiratori, Yasuhiko; Tsukuda, Takuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1136-1141</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Macrocyclic compds. bearing a 2-amino-6-arylpyrimidine moiety were identified as potent heat shock protein 90 (Hsp90) inhibitors by modification of 2-amino-6-aryltriazine deriv. (CH5015765).  We employed a macrocyclic structure as a skeleton of new inhibitors to mimic the geldanamycin-Hsp90 interactions.  Among the identified inhibitors, CH5164840 showed high binding affinity for N-terminal Hsp90α (K d = 0.52 nM) and strong anti-proliferative activity against human cancer cell lines (HCT116 IC50 = 0.15 μM, NCI-N87 IC50 = 0.066 μM).  CH5164840 displayed high oral bioavailability in mice (F = 70.8%) and potent antitumor efficacy in a HCT116 human colorectal cancer xenograft model (tumor growth inhibition = 83%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPCQV64QCJ6LVg90H21EOLACvtfcHk0lgXdXa5u0u4lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFalsw%253D%253D&md5=3bfb99b56abd1ee3cceb584edf12d2db</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.100%26sid%3Dliteratum%253Aachs%26aulast%3DSuda%26aufirst%3DA.%26aulast%3DKoyano%26aufirst%3DH.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DHada%26aufirst%3DK.%26aulast%3DKawasaki%26aufirst%3DK.%2BI.%26aulast%3DKomiyama%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DSaitoh%26aufirst%3DR.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DShiratori%26aufirst%3DY.%26aulast%3DTsukuda%26aufirst%3DT.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Macrocyclic%25202-Amino-6-Arylpyrimidine%2520Hsp90%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D1136%26epage%3D1141%26doi%3D10.1016%2Fj.bmcl.2011.11.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raggon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J.</span></span> <span> </span><span class="NLM_article-title">Exploratory Process Development of Lorlatinib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1289-1293&issue=9&author=B.+Liauthor=R.+W.+Barnhartauthor=J.+E.+Hoffmanauthor=A.+Nematallaauthor=J.+Raggonauthor=P.+Richardsonauthor=N.+Sachauthor=J.+Weaver&title=Exploratory+Process+Development+of+Lorlatinib&doi=10.1021%2Facs.oprd.8b00210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Exploratory Process Development of Lorlatinib</span></div><div class="casAuthors">Li, Bryan; Barnhart, Richard W.; Hoffman, Jacqui E.; Nematalla, Asaad; Raggon, Jeffrey; Richardson, Paul; Sach, Neal; Weaver, John</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1289-1293</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The original synthesis of lorlatinib (I) was applied and improved in the first GMP campaign.  In this approach, a slow addn. of the boronate ester was crit. in suppressing the formation of a homocoupled impurity in the Suzuki-Miyaura coupling, and the chemoselective hydrolysis of Me ester was accomplished by potassium trimethylsilanoate.  The synthesis was completed with macrocyclic amidation followed by deprotection of the Boc groups.  A thorough process safety evaluation of HATU enabled its use as the coupling reagent for the macrocyclic amidation, which improved the yield and eliminated the only chromatog. operation in the synthetic sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRVJZSwiHBgrVg90H21EOLACvtfcHk0lgXdXa5u0u4lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI&md5=4bb70a5071d2a8cb45661a3d223fb96f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00210%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DBarnhart%26aufirst%3DR.%2BW.%26aulast%3DHoffman%26aufirst%3DJ.%2BE.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DRaggon%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DWeaver%26aufirst%3DJ.%26atitle%3DExploratory%2520Process%2520Development%2520of%2520Lorlatinib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26issue%3D9%26spage%3D1289%26epage%3D1293%26doi%3D10.1021%2Facs.oprd.8b00210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parenty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagne, J.-M.</span></span> <span> </span><span class="NLM_article-title">Macrolactonizations in the Total Synthesis of Natural Products</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1021/cr0301402</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0301402" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD28XoslWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=911-939&issue=3&author=A.+Parentyauthor=X.+Moreauauthor=J.-M.+Campagne&title=Macrolactonizations+in+the+Total+Synthesis+of+Natural+Products&doi=10.1021%2Fcr0301402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Macrolactonizations in the total synthesis of natural products</span></div><div class="casAuthors">Parenty, A.; Moreau, X.; Campagne, J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">911-939</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review was presented of the macrolactonization of seco acids in the total synthesis of natural products.  The need for macrolactonizations has inspired many clever solns. either by activation of the alc. or activation of the acid moiety.  Among future challenges will be further developments of enantio-, atrop- and diastereoselective macrolactonizations and the development of a truly atom-economic macrolactonization method under moderate diln. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBvzQqeR5E1rVg90H21EOLACvtfcHk0lgXdXa5u0u4lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XoslWqtw%253D%253D&md5=b79baebd6aec74f1f19163ae025237b8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fcr0301402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0301402%26sid%3Dliteratum%253Aachs%26aulast%3DParenty%26aufirst%3DA.%26aulast%3DMoreau%26aufirst%3DX.%26aulast%3DCampagne%26aufirst%3DJ.-M.%26atitle%3DMacrolactonizations%2520in%2520the%2520Total%2520Synthesis%2520of%2520Natural%2520Products%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26issue%3D3%26spage%3D911%26epage%3D939%26doi%3D10.1021%2Fcr0301402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inanaga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span> <span> </span><span class="NLM_article-title">A Rapid Esterification by Means of Mixed Anhydride and Its Application to Large-Ring Lactonization</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1993</span>, <span class="refDoi"> DOI: 10.1246/bcsj.52.1989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1246%2Fbcsj.52.1989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaE1MXltl2rt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1979&pages=1989-1993&issue=7&author=J.+Inanagaauthor=K.+Hirataauthor=H.+Saekiauthor=T.+Katsukiauthor=M.+Yamaguchi&title=A+Rapid+Esterification+by+Means+of+Mixed+Anhydride+and+Its+Application+to+Large-Ring+Lactonization&doi=10.1246%2Fbcsj.52.1989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid esterification by mixed anhydride and its application to large-ring lactonization</span></div><div class="casAuthors">Inanaga, Junji; Hirata, Kuniko; Saeki, Hiroko; Katsuki, Tsutomu; Yamaguchi, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1989-93</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">A rapid and mild esterification method using carboxylic 2,4,6-trichlorobenzoic anhydrides in the presence of 4-(dimethylamino)pyridine was developed.  The method was also successfully applied to the synthesis of large-ring lactones, including DL-2,4,6-tridemethyl-3-deoxymethynolide (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwvGlZSKrReLVg90H21EOLACvtfcHk0ljGYy3nfjIHKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltl2rt78%253D&md5=73880dc7e3aebc06844628a0e9ff6a68</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.52.1989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.52.1989%26sid%3Dliteratum%253Aachs%26aulast%3DInanaga%26aufirst%3DJ.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DKatsuki%26aufirst%3DT.%26aulast%3DYamaguchi%26aufirst%3DM.%26atitle%3DA%2520Rapid%2520Esterification%2520by%2520Means%2520of%2520Mixed%2520Anhydride%2520and%2520Its%2520Application%2520to%2520Large-Ring%2520Lactonization%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1979%26volume%3D52%26issue%3D7%26spage%3D1989%26epage%3D1993%26doi%3D10.1246%2Fbcsj.52.1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poudel, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peach, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, G. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Des-B-Ring Bryostatin Analogue Leads to an Unexpected Ring Expansion of the Bryolactone Core</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">38</span>),  <span class="NLM_fpage">13202</span>– <span class="NLM_lpage">13208</span>, <span class="refDoi"> DOI: 10.1021/ja5078188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5078188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFamsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=13202-13208&issue=38&author=M.+B.+Kraftauthor=Y.+B.+Poudelauthor=N.+Kedeiauthor=N.+E.+Lewinauthor=M.+L.+Peachauthor=P.+M.+Blumbergauthor=G.+E.+Keck&title=Synthesis+of+a+Des-B-Ring+Bryostatin+Analogue+Leads+to+an+Unexpected+Ring+Expansion+of+the+Bryolactone+Core&doi=10.1021%2Fja5078188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a des-B-Ring Bryostatin Analogue Leads to an Unexpected Ring Expansion of the Bryolactone Core</span></div><div class="casAuthors">Kraft, Matthew B.; Poudel, Yam B.; Kedei, Noemi; Lewin, Nancy E.; Peach, Megan L.; Blumberg, Peter M.; Keck, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13202-13208</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convergent synthesis of a des-B-ring bryostatin analog (I) is described.  This analog was found to undergo an unexpected ring expansion of the bryolactone core to generate the corresponding 21-membered macrocycle.  The parent analog and the ring-expanded product both displayed nanomolar binding affinity for PKC.  Despite contg. A-ring substitution identical to that of bryostatin 1 and displaying bryostatin-like biol. function, the des-B-ring analogs displayed a phorbol-like biol. function in cells.  These studies shed new light on the role of the bryostatin B-ring in conferring bryo-like biol. function to bryostatin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIYnyXd1FAILVg90H21EOLACvtfcHk0ljGYy3nfjIHKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFamsLvK&md5=a61875f7e73cc25267c03622605d735c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fja5078188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5078188%26sid%3Dliteratum%253Aachs%26aulast%3DKraft%26aufirst%3DM.%2BB.%26aulast%3DPoudel%26aufirst%3DY.%2BB.%26aulast%3DKedei%26aufirst%3DN.%26aulast%3DLewin%26aufirst%3DN.%2BE.%26aulast%3DPeach%26aufirst%3DM.%2BL.%26aulast%3DBlumberg%26aufirst%3DP.%2BM.%26aulast%3DKeck%26aufirst%3DG.%2BE.%26atitle%3DSynthesis%2520of%2520a%2520Des-B-Ring%2520Bryostatin%2520Analogue%2520Leads%2520to%2520an%2520Unexpected%2520Ring%2520Expansion%2520of%2520the%2520Bryolactone%2520Core%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26issue%3D38%26spage%3D13202%26epage%3D13208%26doi%3D10.1021%2Fja5078188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saigo, K.</span></span> <span> </span><span class="NLM_article-title">A Convenient Method for the Synthesis of Carboxylic Esters</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1246/cl.1975.1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1246%2Fcl.1975.1045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1975&pages=1045-1048&author=T.+Mukaiyamaauthor=M.+Usuiauthor=E.+Shimadaauthor=K.+Saigo&title=A+Convenient+Method+for+the+Synthesis+of+Carboxylic+Esters&doi=10.1246%2Fcl.1975.1045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1246%2Fcl.1975.1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1975.1045%26sid%3Dliteratum%253Aachs%26aulast%3DMukaiyama%26aufirst%3DT.%26aulast%3DUsui%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DE.%26aulast%3DSaigo%26aufirst%3DK.%26atitle%3DA%2520Convenient%2520Method%2520for%2520the%2520Synthesis%2520of%2520Carboxylic%2520Esters%26jtitle%3DChem.%2520Lett.%26date%3D1975%26volume%3D4%26spage%3D1045%26epage%3D1048%26doi%3D10.1246%2Fcl.1975.1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novosjolova, I.</span></span> <span> </span><span class="NLM_article-title">The Mukaiyama Reagent: An Efficient Condensation Agent</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1055/s-0032-1317530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1055%2Fs-0032-1317530" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=135-136&issue=1&author=I.+Novosjolova&title=The+Mukaiyama+Reagent%3A+An+Efficient+Condensation+Agent&doi=10.1055%2Fs-0032-1317530"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1055%2Fs-0032-1317530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0032-1317530%26sid%3Dliteratum%253Aachs%26aulast%3DNovosjolova%26aufirst%3DI.%26atitle%3DThe%2520Mukaiyama%2520Reagent%253A%2520An%2520Efficient%2520Condensation%2520Agent%26jtitle%3DSynlett%26date%3D2012%26volume%3D24%26issue%3D1%26spage%3D135%26epage%3D136%26doi%3D10.1055%2Fs-0032-1317530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lograsso, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micalizio, G. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Benzoquinone Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4800</span>– <span class="NLM_lpage">4804</span>, <span class="refDoi"> DOI: 10.1002/anie.201301323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fanie.201301323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1altLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=4800-4804&issue=18&author=V.+Jesoauthor=S.+Iqbalauthor=P.+Hernandezauthor=M.+D.+Cameronauthor=H.+Parkauthor=P.+V.+Lograssoauthor=G.+C.+Micalizio&title=Synthesis+of+Benzoquinone+Ansamycin-Inspired+Macrocyclic+Lactams+from+Shikimic+Acid&doi=10.1002%2Fanie.201301323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Benzoquinone Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid</span></div><div class="casAuthors">Jeso, Valer; Iqbal, Sarah; Hernandez, Pamela; Cameron, Michael D.; Park, Ha Jeung; LoGrasso, Philip V.; Micalizio, Glenn C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4800-4804</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The authors describe a stereoselective route to natural product-inspired agents from shikimic acid.  The route is selective, flexible, and convergent, delivering complex macrocyclic lactams in just 7 steps form simple coupling partners I, (E)-HC≡C(CH2)2CH:CHCO2Et, and II (X = CH, N, Y = Br; X = CH, Y = NHMe).  The authors also discovered a natural product-inspired skeleton, which is uniquely isoform selective (compared to natural products and known analogs), thus favoring inhibition of cytosolic and nuclear Hsp90 over the ER-assocd. Grp94.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-Gwt2H6cH7Vg90H21EOLACvtfcHk0liX0HMO2Ry-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1altLY%253D&md5=fdc9df6f2b04f2640c24ec588e0cf5f8</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fanie.201301323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201301323%26sid%3Dliteratum%253Aachs%26aulast%3DJeso%26aufirst%3DV.%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLograsso%26aufirst%3DP.%2BV.%26aulast%3DMicalizio%26aufirst%3DG.%2BC.%26atitle%3DSynthesis%2520of%2520Benzoquinone%2520Ansamycin-Inspired%2520Macrocyclic%2520Lactams%2520from%2520Shikimic%2520Acid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26issue%3D18%26spage%3D4800%26epage%3D4804%26doi%3D10.1002%2Fanie.201301323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, M.</span></span> <span> </span><span class="NLM_article-title">An Effective Use of Benzoic Anhydride and Its Derivatives for the Synthesis of Carboxylic Esters and Lactones: A Powerful and Convenient Mixed Anhydride Method Promoted by Basic Catalysts</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/jo030367x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo030367x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=1822-1830&issue=6&author=I.+Shiinaauthor=M.+Kubotaauthor=H.+Oshiumiauthor=M.+Hashizume&title=An+Effective+Use+of+Benzoic+Anhydride+and+Its+Derivatives+for+the+Synthesis+of+Carboxylic+Esters+and+Lactones%3A+A+Powerful+and+Convenient+Mixed+Anhydride+Method+Promoted+by+Basic+Catalysts&doi=10.1021%2Fjo030367x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">An Effective Use of Benzoic Anhydride and Its Derivatives for the Synthesis of Carboxylic Esters and Lactones: A Powerful and Convenient Mixed Anhydride Method Promoted by Basic Catalysts</span></div><div class="casAuthors">Shiina, Isamu; Kubota, Mari; Oshiumi, Hiromi; Hashizume, Minako</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1822-1830</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Various carboxylic esters are obtained at room temp. in excellent yields with high chemoselectivities from nearly equimolar amts. of carboxylic acids and alcs. using 2-methyl-6-nitrobenzoic anhydride with triethylamine by the promotion of a basic catalyst such as 4-(dimethylamino)pyridine.  A variety of lactones are also prepd. in high yields at room temp. from the corresponding ω-hydroxycarboxylic acids with use of 2-methyl-6-nitrobenzoic anhydride in the presence of 4-(dimethylamino)pyridine.  A similar reaction occurs with triethylamine when using a catalytic amt. of 4-(dimethylamino)pyridine 1-oxide as an effective promoter for the intramol. condensation reaction.  These methods are successfully applied to the synthesis of erythro-aleuritic acid lactone and an eight-membered-ring lactone moiety of octalactin A and oxalactin B.  The efficiency of the cyclizations is compared to those of other reported lactonizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWPmid5ViEPLVg90H21EOLACvtfcHk0liX0HMO2Ry-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGhsLk%253D&md5=69490a7a809afcf8b71b04e42d1abf94</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjo030367x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030367x%26sid%3Dliteratum%253Aachs%26aulast%3DShiina%26aufirst%3DI.%26aulast%3DKubota%26aufirst%3DM.%26aulast%3DOshiumi%26aufirst%3DH.%26aulast%3DHashizume%26aufirst%3DM.%26atitle%3DAn%2520Effective%2520Use%2520of%2520Benzoic%2520Anhydride%2520and%2520Its%2520Derivatives%2520for%2520the%2520Synthesis%2520of%2520Carboxylic%2520Esters%2520and%2520Lactones%253A%2520A%2520Powerful%2520and%2520Convenient%2520Mixed%2520Anhydride%2520Method%2520Promoted%2520by%2520Basic%2520Catalysts%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26issue%3D6%26spage%3D1822%26epage%3D1830%26doi%3D10.1021%2Fjo030367x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ketcham, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volchkov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krische, M. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">40</span>),  <span class="NLM_fpage">13415</span>– <span class="NLM_lpage">13423</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b08695</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b08695" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKis77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=13415-13423&issue=40&author=J.+M.+Ketchamauthor=I.+Volchkovauthor=T.+Y.+Chenauthor=P.+M.+Blumbergauthor=N.+Kedeiauthor=N.+E.+Lewinauthor=M.+J.+Krische&title=Evaluation+of+Chromane-Based+Bryostatin+Analogues+Prepared+via+Hydrogen-Mediated+C-C+Bond+Formation%3A+Potency+Does+Not+Confer+Bryostatin-like+Biology&doi=10.1021%2Fjacs.6b08695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology</span></div><div class="casAuthors">Ketcham, John M.; Volchkov, Ivan; Chen, Te-Yu; Blumberg, Peter M.; Kedei, Noemi; Lewin, Nancy E.; Krische, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">13415-13423</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of chromane-contg. bryostatin analogs WN-2-WN-7 and the previously reported salicylate-based analog WN-8 are described.  Analogs WN-2-WN-7 are prepd. through convergent assembly of the chromane-contg. fragment B-I (I) with the "binding domain" fragment A-I (II) or its C26-des-Me congener, fragment A-II (III).  The synthesis of fragment B-I features enantioselective double C-H allylation of 1,3-propanediol to form the C2-sym. diol 3 (IV) and Heck cyclization of bromo-diene 5 (V) to form the chromane core.  The synthesis of salicylate WN-8 is accomplished through the union of fragments A-III (VI) and B-II (VII).  The highest binding affinities for PKCα are obsd. for the C26-des-Me analogs WN-3 (Ki = 63.9 nM) and WN-7 (Ki = 63.1 nM).  All analogs, WN-2-WN-8, inhibited growth of Toledo cells, with the most potent analog being WN-7.  This response, however, does not distinguish between phorbol ester-like and bryostatin-like behavior.  In contrast, while many of the analogs contain a conserved C-ring in the binding domain and other features common to analogs with bryostatin-like properties, all analogs evaluated in the U937 proliferation and cell attachment assays displayed phorbol ester-like and/or toxic behavior, including WN-8, for which "bryostatin-like PKC modulatory activities" previously was suggested solely on the basis of PKC binding.  These results underscore the importance of considering downstream biol. effects, as tumor suppression cannot be inferred from potent PKC binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCS-pZRlnpQbVg90H21EOLACvtfcHk0liX0HMO2Ry-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKis77O&md5=f0d36e2a731f6355841be2968f1ca4bc</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b08695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b08695%26sid%3Dliteratum%253Aachs%26aulast%3DKetcham%26aufirst%3DJ.%2BM.%26aulast%3DVolchkov%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DT.%2BY.%26aulast%3DBlumberg%26aufirst%3DP.%2BM.%26aulast%3DKedei%26aufirst%3DN.%26aulast%3DLewin%26aufirst%3DN.%2BE.%26aulast%3DKrische%26aufirst%3DM.%2BJ.%26atitle%3DEvaluation%2520of%2520Chromane-Based%2520Bryostatin%2520Analogues%2520Prepared%2520via%2520Hydrogen-Mediated%2520C-C%2520Bond%2520Formation%253A%2520Potency%2520Does%2520Not%2520Confer%2520Bryostatin-like%2520Biology%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26issue%3D40%26spage%3D13415%26epage%3D13423%26doi%3D10.1021%2Fjacs.6b08695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tackett, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddess, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouklovsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomero, M. Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavey, J. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaubelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilling, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, M. C.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of Rapamycin</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2874</span>– <span class="NLM_lpage">2914</span>, <span class="refDoi"> DOI: 10.1002/chem.200801656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fchem.200801656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=19204960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Ggsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=2874-2914&issue=12&author=S.+V.+Leyauthor=M.+N.+Tackettauthor=M.+L.+Maddessauthor=J.+C.+Andersonauthor=P.+E.+Brennanauthor=M.+W.+Cappiauthor=J.+P.+Heerauthor=C.+Helgenauthor=M.+Koriauthor=C.+Kouklovskyauthor=S.+P.+Marsdenauthor=J.+Normanauthor=D.+P.+Osbornauthor=M.+%C3%81.+Palomeroauthor=J.+B.+J.+Paveyauthor=C.+Pinelauthor=L.+A.+Robinsonauthor=J.+Schnaubeltauthor=J.+S.+Scottauthor=C.+D.+Spillingauthor=H.+Watanabeauthor=K.+E.+Wessonauthor=M.+C.+Willis&title=Total+Synthesis+of+Rapamycin&doi=10.1002%2Fchem.200801656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of rapamycin</span></div><div class="casAuthors">Ley, Steven V.; Tackett, Miles N.; Maddess, Matthew L.; Anderson, James C.; Brennan, Paul E.; Cappi, Michael W.; Heer, Jag P.; Helgen, Celine; Kori, Masakuni; Kouklovsky, Cyrille; Marsden, Stephen P.; Norman, Joanne; Osborn, David P.; Palomero, Maria A.; Pavey, John B. J.; Pinel, Catherine; Robinson, Lesley A.; Schnaubelt, Jurgen; Scott, James S.; Spilling, Christopher D.; Watanabe, Hidenori; Wesson, Kieron E.; Willis, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2874-2914</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Rapamycin I is prepd. stereoselectively and enantioselectively using the Dieckmann condensation of a catechol-contg. macrolactone as the key steps.  Degrdn. studies of I as well as unsuccessful attempts at its synthesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DlWNgMxlXbVg90H21EOLACvtfcHk0ljClCibaEtTgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Ggsr8%253D&md5=fd1c331d95e457f002e474419b38df13</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fchem.200801656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200801656%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DTackett%26aufirst%3DM.%2BN.%26aulast%3DMaddess%26aufirst%3DM.%2BL.%26aulast%3DAnderson%26aufirst%3DJ.%2BC.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DCappi%26aufirst%3DM.%2BW.%26aulast%3DHeer%26aufirst%3DJ.%2BP.%26aulast%3DHelgen%26aufirst%3DC.%26aulast%3DKori%26aufirst%3DM.%26aulast%3DKouklovsky%26aufirst%3DC.%26aulast%3DMarsden%26aufirst%3DS.%2BP.%26aulast%3DNorman%26aufirst%3DJ.%26aulast%3DOsborn%26aufirst%3DD.%2BP.%26aulast%3DPalomero%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DPavey%26aufirst%3DJ.%2BB.%2BJ.%26aulast%3DPinel%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DL.%2BA.%26aulast%3DSchnaubelt%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DSpilling%26aufirst%3DC.%2BD.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DWesson%26aufirst%3DK.%2BE.%26aulast%3DWillis%26aufirst%3DM.%2BC.%26atitle%3DTotal%2520Synthesis%2520of%2520Rapamycin%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2009%26volume%3D15%26issue%3D12%26spage%3D2874%26epage%3D2914%26doi%3D10.1002%2Fchem.200801656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neises, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steglich, W.</span></span> <span> </span><span class="NLM_article-title">Esterification of Carboxylic Acids with Dicyclohexylcarbodiimide/4-Dimethylaminopyridine: Tert-Butyl Ethyl Fumarate</span>. <i>Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">183</span>, <span class="refDoi"> DOI: 10.15227/orgsyn.063.0183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.15227%2Forgsyn.063.0183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaL28Xht12ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1985&pages=183&author=B.+Neisesauthor=W.+Steglich&title=Esterification+of+Carboxylic+Acids+with+Dicyclohexylcarbodiimide%2F4-Dimethylaminopyridine%3A+Tert-Butyl+Ethyl+Fumarate&doi=10.15227%2Forgsyn.063.0183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Esterification of carboxylic acids with dicyclohexylcarbodiimide/4-dimethylaminopyridine: tert-butyl ethyl fumarate ((E)-2-butenedioic acid, ethyl 1,1-dimethylethyl ester)</span></div><div class="casAuthors">Neises, B.; Steglich, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Organic Syntheses</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-7</span>CODEN:
                <span class="NLM_cas:coden">ORSYAT</span>;
        ISSN:<span class="NLM_cas:issn">0078-6209</span>.
    </div><div class="casAbstract">(E)-EtO2CCH:CHCO2H is esterified with Me3COH in CH2Cl2 contg. DCC and 4-dimethylaminopyridine as catalyst.  The yields are 76-81%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobzFGRV_FW_rVg90H21EOLACvtfcHk0ljClCibaEtTgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xht12ntbo%253D&md5=112932d6384d4106d6f2755b248a9fa7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.15227%2Forgsyn.063.0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15227%252Forgsyn.063.0183%26sid%3Dliteratum%253Aachs%26aulast%3DNeises%26aufirst%3DB.%26aulast%3DSteglich%26aufirst%3DW.%26atitle%3DEsterification%2520of%2520Carboxylic%2520Acids%2520with%2520Dicyclohexylcarbodiimide%252F4-Dimethylaminopyridine%253A%2520Tert-Butyl%2520Ethyl%2520Fumarate%26jtitle%3DOrg.%2520Synth.%26date%3D1985%26volume%3D63%26spage%3D183%26doi%3D10.15227%2Forgsyn.063.0183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biffis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centomo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Zotto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecca, M.</span></span> <span> </span><span class="NLM_article-title">Pd Metal Catalysts for Cross-Couplings and Related Reactions in the 21st Century: A Critical Review</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2249</span>– <span class="NLM_lpage">2295</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=2249-2295&issue=4&author=A.+Biffisauthor=P.+Centomoauthor=A.+Del+Zottoauthor=M.+Zecca&title=Pd+Metal+Catalysts+for+Cross-Couplings+and+Related+Reactions+in+the+21st+Century%3A+A+Critical+Review&doi=10.1021%2Facs.chemrev.7b00443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Pd Metal Catalysts for Cross-Couplings and Related Reactions in the 21st Century: A Critical Review</span></div><div class="casAuthors">Biffis, Andrea; Centomo, Paolo; Del Zotto, Alessandro; Zecca, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2249-2295</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review provides a crit. overview on the recent applications of Pd metal catalysts.  Particular attention is devoted to the discussion of the mechanistic pathways that was proposed to explain the catalytic role of Pd metal.  Furthermore, the most outstanding Pd metal based catalytic systems that had emerged are illustrated, together with the development of novel approaches to boost the reactivity of Pd metal.  A section summarizing the current industrial applications of Pd metal catalyzed reactions of this kind concludes the review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzHQ_wn0ZpA7Vg90H21EOLACvtfcHk0ljClCibaEtTgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgur8%253D&md5=b940a8d24f44a28175a49f103d89ee5c</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00443%26sid%3Dliteratum%253Aachs%26aulast%3DBiffis%26aufirst%3DA.%26aulast%3DCentomo%26aufirst%3DP.%26aulast%3DDel%2BZotto%26aufirst%3DA.%26aulast%3DZecca%26aufirst%3DM.%26atitle%3DPd%2520Metal%2520Catalysts%2520for%2520Cross-Couplings%2520and%2520Related%2520Reactions%2520in%2520the%252021st%2520Century%253A%2520A%2520Critical%2520Review%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26issue%3D4%26spage%3D2249%26epage%3D2295%26doi%3D10.1021%2Facs.chemrev.7b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4443</span>– <span class="NLM_lpage">4458</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4443-4458&issue=10&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Analysis+of+Past+and+Present+Synthetic+Methodologies+on+Medicinal+Chemistry%3A+Where+Have+All+the+New+Reactions+Gone%3F&doi=10.1021%2Facs.jmedchem.5b01409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4443-4458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  An anal. of chem. reactions used in current medicinal chem. (2014), three decades ago (1984), and in natural product total synthesis has been conducted.  The anal. revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and 1990s (Suzuki-Miyaura and Buchwald-Hartwig).  This suggests an inherent high bar of impact for new synthetic reactions in drug discovery.  The most frequently used reactions were amide bond formation, Suzuki-Miyaura coupling, and SNAr reactions, most likely due to com. availability of reagents, high chemoselectivity, and a pressure on delivery.  The authors show that these practices result in overpopulation of certain types of mol. shapes to the exclusion of others using simple PMI plots.  The authors hope that these results will help catalyze improvements in integration of new synthetic methodologies as well as new library design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLWvt5DxktAbVg90H21EOLACvtfcHk0liWdvSo7UUBSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM&md5=fd56ba8418f6d4e8c271f4e977ee2a93</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01409%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DAnalysis%2520of%2520Past%2520and%2520Present%2520Synthetic%2520Methodologies%2520on%2520Medicinal%2520Chemistry%253A%2520Where%2520Have%2520All%2520the%2520New%2520Reactions%2520Gone%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4443%26epage%3D4458%26doi%3D10.1021%2Facs.jmedchem.5b01409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">A New Stereospecific Cross-Coupling by the Palladium-Catalyzed Reaction of 1-Alkenylboranes with 1-Alkenyl or 1-Alkynyl Halides</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">3437</span>– <span class="NLM_lpage">3440</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)95429-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS0040-4039%2801%2995429-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1979&pages=3437-3440&issue=36&author=N.+Miyauraauthor=K.+Yamadaauthor=A.+Suzuki&title=A+New+Stereospecific+Cross-Coupling+by+the+Palladium-Catalyzed+Reaction+of+1-Alkenylboranes+with+1-Alkenyl+or+1-Alkynyl+Halides&doi=10.1016%2FS0040-4039%2801%2995429-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2995429-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252995429-2%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DA%2520New%2520Stereospecific%2520Cross-Coupling%2520by%2520the%2520Palladium-Catalyzed%2520Reaction%2520of%25201-Alkenylboranes%2520with%25201-Alkenyl%2520or%25201-Alkynyl%2520Halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D20%26issue%3D36%26spage%3D3437%26epage%3D3440%26doi%3D10.1016%2FS0040-4039%2801%2995429-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheprakov, A. V.</span></span> <span> </span><span class="NLM_article-title">The Heck Reaction as a Sharpening Stone of Palladium Catalysis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3009</span>– <span class="NLM_lpage">3066</span>, <span class="refDoi"> DOI: 10.1021/cr9903048</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9903048" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVSitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=3009-3066&issue=8&author=I.+P.+Beletskayaauthor=A.+V.+Cheprakov&title=The+Heck+Reaction+as+a+Sharpening+Stone+of+Palladium+Catalysis&doi=10.1021%2Fcr9903048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Heck Reaction as a Sharpening Stone of Palladium Catalysis</span></div><div class="casAuthors">Beletskaya, Irina P.; Cheprakov, Andrei V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3009-3066</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 419 refs. concerning the title topics including the Heck catalytic engine, studies to det. highest activity, and extensions of common Heck chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZu0ODgrh7gLVg90H21EOLACvtfcHk0liWdvSo7UUBSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVSitb8%253D&md5=2acb213d2ab82a99253b339cdf57ccdc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fcr9903048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9903048%26sid%3Dliteratum%253Aachs%26aulast%3DBeletskaya%26aufirst%3DI.%2BP.%26aulast%3DCheprakov%26aufirst%3DA.%2BV.%26atitle%3DThe%2520Heck%2520Reaction%2520as%2520a%2520Sharpening%2520Stone%2520of%2520Palladium%2520Catalysis%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26issue%3D8%26spage%3D3009%26epage%3D3066%26doi%3D10.1021%2Fcr9903048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forero-Cortés, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydl, A. M.</span></span> <span> </span><span class="NLM_article-title">The 25th Anniversary of the Buchwald-Hartwig Amination: Development, Applications, and Outlook</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yhs77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1478-1483&issue=8&author=P.+A.+Forero-Cort%C3%A9sauthor=A.+M.+Haydl&title=The+25th+Anniversary+of+the+Buchwald-Hartwig+Amination%3A+Development%2C+Applications%2C+and+Outlook&doi=10.1021%2Facs.oprd.9b00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The 25th Anniversary of the Buchwald-Hartwig Amination: Development, Applications, and Outlook</span></div><div class="casAuthors">Forero-Cortes, Paola A.; Haydl, Alexander M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1478-1483</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The palladium-catalyzed cross-coupling of amines and aryl (pseudo)halides, now commonly referred to as the Buchwald-Hartwig amination was first reported 25 years ago.  Since the simultaneous breakthrough reports of Buchwald and Hartwig dating 1995, this reaction has transformed the way synthetic chemists think about synthesizing arom. amines.  In this highlight article, a short showcasing discussion about the genesis of this reaction is provided, as well as selected examples showing the impact of this transformation in synthetic chem., both in academic and industrial settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDqjUPVJ2XvrVg90H21EOLACvtfcHk0liWdvSo7UUBSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yhs77J&md5=11ee132c194b07792110102e2ed63bf7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00161%26sid%3Dliteratum%253Aachs%26aulast%3DForero-Cort%25C3%25A9s%26aufirst%3DP.%2BA.%26aulast%3DHaydl%26aufirst%3DA.%2BM.%26atitle%3DThe%252025th%2520Anniversary%2520of%2520the%2520Buchwald-Hartwig%2520Amination%253A%2520Development%252C%2520Applications%252C%2520and%2520Outlook%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26issue%3D8%26spage%3D1478%26epage%3D1483%26doi%3D10.1021%2Facs.oprd.9b00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Series of Novel Macrocycle Janus Kinase 2 Inhibitors</span>. <i>Chin. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1002/cjoc.201900316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcjoc.201900316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1259-1263&issue=12&author=Y.+Wangauthor=H.+Geauthor=D.+Wangauthor=H.+Heauthor=L.+Liauthor=Y.+Diaoauthor=Z.+Shenauthor=L.+Zhuauthor=S.+Liauthor=Z.+Zhaoauthor=H.+Li&title=Design+and+Synthesis+of+a+Series+of+Novel+Macrocycle+Janus+Kinase+2+Inhibitors&doi=10.1002%2Fcjoc.201900316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Series of Novel Macrocycle Janus Kinase 2 Inhibitors</span></div><div class="casAuthors">Wang, Yanling; Ge, Huan; Wang, Disha; He, Huan; Li, Lu; Diao, Yanyan; Shen, Zihao; Zhu, Lili; Li, Shiliang; Zhao, Zhenjiang; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1259-1263</span>CODEN:
                <span class="NLM_cas:coden">CJOCEV</span>;
        ISSN:<span class="NLM_cas:issn">1001-604X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of macrocyclic derivs. I [R = H, CN] and II [X = NH, O; X1 = X2, X3 = CH, N] designed from anaplastic lymphoma kinase (ALK) inhibitor lorlatinib were synthesized as Janus kinase 2 (JAK2) selective inhibitors.  Among them, III had the best inhibitory activity (IC50 = 0.177 μmol·L-1) and selectivity for JAK2 over JAK1 and JAK3, which indicated that design of the macrocyclic derivs. might be a feasible strategy for the discovery of novel selective JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM_ELqqWSDU7Vg90H21EOLACvtfcHk0lhV1Ay0bc-qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjsbzP&md5=fb3dc497dabb9d95b36b6bb299a37d94</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fcjoc.201900316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcjoc.201900316%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDiao%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Series%2520of%2520Novel%2520Macrocycle%2520Janus%2520Kinase%25202%2520Inhibitors%26jtitle%3DChin.%2520J.%2520Chem.%26date%3D2019%26volume%3D37%26issue%3D12%26spage%3D1259%26epage%3D1263%26doi%3D10.1002%2Fcjoc.201900316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsunobu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Esters of Carboxylic and Phosphoric Acid via Quaternary Phosphonium Salts</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2382</span>, <span class="refDoi"> DOI: 10.1246/bcsj.40.2380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1246%2Fbcsj.40.2380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaF1cXht1Citw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1967&pages=2380-2382&author=O.+Mitsunobuauthor=M.+Yamada&title=Preparation+of+Esters+of+Carboxylic+and+Phosphoric+Acid+via+Quaternary+Phosphonium+Salts&doi=10.1246%2Fbcsj.40.2380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of esters of carboxylic and phosphoric acid via quaternary phosphonium salts</span></div><div class="casAuthors">Mitsunobu, Oyo; Yamada, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2380-2</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">When n-valeric acid was treated with (EtO)2POCH2CH:CH2 and EtO2CN:NCO2Et (I), allyl valerate and EtO2CN[P(O)(OEt)2]NHCO2Et were obtained in good yields.  Similarly PhCO2Et was obtained in nearly quant. yield by the reaction of PhCO2H with P(OEt)3 and I.  The reaction of carboxylic acids with Ph3P and I in the presence of an alc. resulted in the formation of the corresponding esters of the carboxylic acid, Ph3PO, and EtO2CNHNHCO2Et.  The mechanisms of these reactions were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPl9JLDIoZHrVg90H21EOLACvtfcHk0lhV1Ay0bc-qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXht1Citw%253D%253D&md5=bfaa7d793e6e2a0f5cc7cd97436f039f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.40.2380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.40.2380%26sid%3Dliteratum%253Aachs%26aulast%3DMitsunobu%26aufirst%3DO.%26aulast%3DYamada%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Esters%2520of%2520Carboxylic%2520and%2520Phosphoric%2520Acid%2520via%2520Quaternary%2520Phosphonium%2520Salts%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1967%26volume%3D40%26spage%3D2380%26epage%3D2382%26doi%3D10.1246%2Fbcsj.40.2380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsakos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffert, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villadsen, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. B.</span></span> <span> </span><span class="NLM_article-title">Ester Coupling Reactions-an Enduring Challenge in the Chemical Synthesis of Bioactive Natural Products</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1039/C4NP00106K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC4NP00106K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=25572105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=605-632&issue=4&author=M.+Tsakosauthor=E.+S.+Schaffertauthor=L.+L.+Clementauthor=N.+L.+Villadsenauthor=T.+B.+Poulsen&title=Ester+Coupling+Reactions-an+Enduring+Challenge+in+the+Chemical+Synthesis+of+Bioactive+Natural+Products&doi=10.1039%2FC4NP00106K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ester coupling reactions - an enduring challenge in the chemical synthesis of bioactive natural products</span></div><div class="casAuthors">Tsakos, Michail; Schaffert, Eva S.; Clement, Lise L.; Villadsen, Nikolaj L.; Poulsen, Thomas B.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-632</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  In this review we investigate the use of complex ester fragment couplings within natural product total synthesis campaigns.  We first outline the different biosynthetic and chem. strategies for performing complex ester couplings and on this mechanistic background we then present and discuss a collection of successful examples from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCI9sqkIswyrVg90H21EOLACvtfcHk0lhV1Ay0bc-qag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvF2nug%253D%253D&md5=b1f30f5e0d109c06a28307e80d201f65</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1039%2FC4NP00106K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4NP00106K%26sid%3Dliteratum%253Aachs%26aulast%3DTsakos%26aufirst%3DM.%26aulast%3DSchaffert%26aufirst%3DE.%2BS.%26aulast%3DClement%26aufirst%3DL.%2BL.%26aulast%3DVilladsen%26aufirst%3DN.%2BL.%26aulast%3DPoulsen%26aufirst%3DT.%2BB.%26atitle%3DEster%2520Coupling%2520Reactions-an%2520Enduring%2520Challenge%2520in%2520the%2520Chemical%2520Synthesis%2520of%2520Bioactive%2520Natural%2520Products%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2015%26volume%3D32%26issue%3D4%26spage%3D605%26epage%3D632%26doi%3D10.1039%2FC4NP00106K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celik, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjaden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span> <span> </span><span class="NLM_article-title">Optimization of Pyrazolo[1,5-a]Pyrimidines Lead to the Identification of a Highly Selective Casein Kinase 2 Inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>,  <span class="NLM_fpage">112770</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.ejmech.2020.112770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=32883634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BB38bkt1Crsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&pages=112770&author=A.+Kr%C3%A4merauthor=C.+G.+Kurzauthor=B.+T.+Bergerauthor=I.+E.+Celikauthor=A.+Tjadenauthor=F.+A.+Grecoauthor=S.+Knappauthor=T.+Hanke&title=Optimization+of+Pyrazolo%5B1%2C5-a%5DPyrimidines+Lead+to+the+Identification+of+a+Highly+Selective+Casein+Kinase+2+Inhibitor&doi=10.1016%2Fj.ejmech.2020.112770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor</span></div><div class="casAuthors">Kramer Andreas; Kurz Christian Georg; Berger Benedict-Tilman; Tjaden Amelie; Greco Francesco Aleksy; Celik Ibrahim Ethem; Knapp Stefan; Hanke Thomas</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112770</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Casein kinase 2 (CK2) is a constitutively expressed serine/threonine kinase that has a large diversity of cellular substrates.  Thus, CK2 has been associated with a plethora of regulatory functions and dysregulation of CK2 has been linked to disease development in particular to cancer.  The broad implications in disease pathology makes CK2 an attractive target.  To date, the most advanced CK2 inhibitor is silmitasertib, which has been investigated in clinical trials for treatment of various cancers, albeit several off-targets for silmitasertib have been described.  To ascertain the role of CK2 inhibition in cancer, other disease and normal physiology the development of a selective CK2 inhibitor would be highly desirable.  In this study we explored the pyrazolo [1,5-a]pyrimidine hinge-binding moiety for the development of selective CK2 inhibitors.  Optimization of this scaffold, which included macrocyclization, led to IC20 (31) a compound that displayed high in vitro potency for CK2 (KD = 12 nM) and exclusive selectivity for CK2.  X-ray analysis revealed a canonical type-I binding mode for IC20 (31).  However, the polar carboxylic acid moiety that is shared by many CK2 inhibitors including silmitasertib was required for potency but limits the cellular activity of IC20 (31) and the cellular IC50 dropped to the low micromolar range.  In summary, IC20 (31) represents a highly selective and potent inhibitor of CK2, which can be used as a tool compound to study CK2 biology and potential new applications for the treatment of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQ1mfNnMQs-wHqQV89nF-2fW6udTcc2eaFHu1nVzyTr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bkt1Crsg%253D%253D&md5=43588eec2c74d87f8904febeb28e8cfc</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112770%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DC.%2BG.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DCelik%26aufirst%3DI.%2BE.%26aulast%3DTjaden%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DHanke%26aufirst%3DT.%26atitle%3DOptimization%2520of%2520Pyrazolo%255B1%252C5-a%255DPyrimidines%2520Lead%2520to%2520the%2520Identification%2520of%2520a%2520Highly%2520Selective%2520Casein%2520Kinase%25202%2520Inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26spage%3D112770%26doi%3D10.1016%2Fj.ejmech.2020.112770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arundale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikeska, L. A.</span></span> <span> </span><span class="NLM_article-title">The Olefin-Aldehyde Condensation. The Prins Reaction</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1952</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1021/cr60160a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr60160a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaG3sXjtFOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1952&pages=505-555&issue=3&author=E.+Arundaleauthor=L.+A.+Mikeska&title=The+Olefin-Aldehyde+Condensation.+The+Prins+Reaction&doi=10.1021%2Fcr60160a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The olefin-aldehyde condensation. The Prins reaction</span></div><div class="casAuthors">Arundale, E.; Mikeska, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">505-55</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 156 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUXzX7veRoJrVg90H21EOLACvtfcHk0liM5zFVfauPaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3sXjtFOlsg%253D%253D&md5=f2f45ad6e4954f97a8183e1d9d19abdc</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fcr60160a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr60160a004%26sid%3Dliteratum%253Aachs%26aulast%3DArundale%26aufirst%3DE.%26aulast%3DMikeska%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Olefin-Aldehyde%2520Condensation.%2520The%2520Prins%2520Reaction%26jtitle%3DChem.%2520Rev.%26date%3D1952%26volume%3D51%26issue%3D3%26spage%3D505%26epage%3D555%26doi%3D10.1021%2Fcr60160a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-López, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco-Montalban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">21620</span>– <span class="NLM_lpage">21626</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b03525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b03525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Ojs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=21620-21626&issue=25&author=O.+Cruz-L%C3%B3pezauthor=C.+Tempsauthor=B.+Longoauthor=S.+H.+Myersauthor=F.+Franco-Montalbanauthor=A.+Unciti-Broceta&title=Synthesis+and+Characterization+of+a+Click-Assembled+18-Atom+Macrocycle+That+Displays+Selective+AXL+Kinase+Inhibitory+Activity&doi=10.1021%2Facsomega.9b03525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity</span></div><div class="casAuthors">Cruz-Lopez, Olga; Temps, Carolin; Longo, Beatrice; Myers, Samuel H.; Franco-Montalban, Francisco; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">21620-21626</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel macrocyclic construct consisting of a pyrazolopyrimidine scaffold concatenated to a benzene ring through two triazoles has been developed to investigate uncharted chem. space with bioactive potential.  The 18-atom macrocycle was assembled via a double copper-catalyzed alkyne-azide cycloaddn. (CuAAC) reaction between 1,3-bis(azidomethyl)benzene and a bis-propargylated pyrazolo[3,4-d]pyrimidine core.  The resulting macrocycle was functionalized further into a multicyclic analog that displays selective inhibitory activity against the receptor tyrosine kinase AXL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdmd6LYVlXM7Vg90H21EOLACvtfcHk0liM5zFVfauPaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Ojs7bL&md5=c09116dea662095311dba7cdcb308015</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b03525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b03525%26sid%3Dliteratum%253Aachs%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DO.%26aulast%3DTemps%26aufirst%3DC.%26aulast%3DLongo%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DFranco-Montalban%26aufirst%3DF.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520Characterization%2520of%2520a%2520Click-Assembled%252018-Atom%2520Macrocycle%2520That%2520Displays%2520Selective%2520AXL%2520Kinase%2520Inhibitory%2520Activity%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26issue%3D25%26spage%3D21620%26epage%3D21626%26doi%3D10.1021%2Facsomega.9b03525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rostovtsev, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2596</span>– <span class="NLM_lpage">2599</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=2596-2599&issue=14&author=V.+V.+Rostovtsevauthor=L.+G.+Greenauthor=V.+V.+Fokinauthor=K.+B.+Sharpless&title=A+Stepwise+Huisgen+Cycloaddition+Process%3A+Copper%28I%29-Catalyzed+Regioselective+%E2%80%9CLigation%E2%80%9D+of+Azides+and+Terminal+Alkynes&doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes</span></div><div class="casAuthors">Rostovtsev, Vsevolod V.; Green, Luke G.; Fokin, Valery V.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2596-2599</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">1,4-Disubstituted 1,2,3-triazoles I (R1 = PhCH2, PhCH2OCH2, 1-adamantyl, etc.; R2 = HO2C, Ph, PhOCH2, Et2NCH2, etc.) were readily and cleanly prepd. via highly efficient and regioselective copper(I)-catalyzed cycloaddn. of azides R1N3 with terminal alkynes R2C≡CH in 82-93% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptcW2JUNM1r7Vg90H21EOLACvtfcHk0liM5zFVfauPaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D&md5=4603664be6639353b5e70f19b9f8d59f</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820020715%252941%253A14%253C2596%253A%253AAID-ANIE2596%253E3.0.CO%253B2-4%26sid%3Dliteratum%253Aachs%26aulast%3DRostovtsev%26aufirst%3DV.%2BV.%26aulast%3DGreen%26aufirst%3DL.%2BG.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DA%2520Stepwise%2520Huisgen%2520Cycloaddition%2520Process%253A%2520Copper%2528I%2529-Catalyzed%2520Regioselective%2520%25E2%2580%259CLigation%25E2%2580%259D%2520of%2520Azides%2520and%2520Terminal%2520Alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2002%26volume%3D41%26issue%3D14%26spage%3D2596%26epage%3D2599%26doi%3D10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, J. S.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of the Hsp90 Inhibitor Geldanamycin</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2477</span>– <span class="NLM_lpage">2479</span>, <span class="refDoi"> DOI: 10.1021/ol800749w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol800749w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=2477-2479&issue=12&author=H.-L.+Qinauthor=J.+S.+Panek&title=Total+Synthesis+of+the+Hsp90+Inhibitor+Geldanamycin&doi=10.1021%2Fol800749w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of the Hsp90 Inhibitor Geldanamycin</span></div><div class="casAuthors">Qin, Hua-Li; Panek, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2477-2479</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An enantioselective synthesis of the Hsp90 inhibitor geldanamycin (I) was achieved in 20 linear steps and 2.0% overall yield from 2-methoxyhydroquinone.  The synthesis is highlighted by a regio- and stereoselective hydroboration reaction; a Sc(OTf)3/Et3SiH-mediated pyran ring-opening reaction; an enantioselective crotylation to simultaneously install the C8-C9 (E)-trisubstituted olefin, the C10 and C11 stereocenters; a chelation-controlled asym. metalated acetylide addn.; and an intramol. copper(I)-mediated aryl amidation reaction to close the 19-membered macrolactam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSqIH-BMiIm7Vg90H21EOLACvtfcHk0lggrMeEISDb7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsbs%253D&md5=5551b7fe64071cd24303cdf6e95e6ca6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fol800749w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol800749w%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.-L.%26aulast%3DPanek%26aufirst%3DJ.%2BS.%26atitle%3DTotal%2520Synthesis%2520of%2520the%2520Hsp90%2520Inhibitor%2520Geldanamycin%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26issue%3D12%26spage%3D2477%26epage%3D2479%26doi%3D10.1021%2Fol800749w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A General and Efficient Copper Catalyst for the Amidation of Aryl Halides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">7421</span>– <span class="NLM_lpage">7428</span>, <span class="refDoi"> DOI: 10.1021/ja0260465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0260465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFagt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=7421-7428&issue=25&author=A.+Klaparsauthor=X.+Huangauthor=S.+L.+Buchwald&title=A+General+and+Efficient+Copper+Catalyst+for+the+Amidation+of+Aryl+Halides&doi=10.1021%2Fja0260465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A General and Efficient Copper Catalyst for the Amidation of Aryl Halides</span></div><div class="casAuthors">Klapars, Artis; Huang, Xiaohua; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7421-7428</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An exptl. simple and inexpensive catalyst system was developed for the amidation of aryl halides by using 0.2-10 mol % of CuI, 5-20 mol % of a 1,2-diamine ligand, and K3PO4, K2CO3, or Cs2CO3 as base.  Catalyst systems based on N,N'-dimethylethylenediamine or trans-N,N'-dimethyl-1,2-cyclohexanediamine were found to be the most active even though several other 1,2-diamine ligands could be used in the easiest cases.  Aryl iodides, bromides, and in some cases even aryl chlorides can be efficiently amidated.  A variety of functional groups are tolerated in the reaction, including many that are not compatible with Pd-catalyzed amidation or amination methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFC_EwXo2vprVg90H21EOLACvtfcHk0lggrMeEISDb7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFagt70%253D&md5=648d4f16f8ea9223e4548dc898654784</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fja0260465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0260465%26sid%3Dliteratum%253Aachs%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520General%2520and%2520Efficient%2520Copper%2520Catalyst%2520for%2520the%2520Amidation%2520of%2520Aryl%2520Halides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26issue%3D25%26spage%3D7421%26epage%3D7428%26doi%3D10.1021%2Fja0260465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaubach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungeheuer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmeister, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirtz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürstner, A.</span></span> <span> </span><span class="NLM_article-title">A Two-Component Alkyne Metathesis Catalyst System with an Improved Substrate Scope and Functional Group Tolerance: Development and Applications to Natural Product Synthesis</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">8494</span>– <span class="NLM_lpage">8507</span>, <span class="refDoi"> DOI: 10.1002/chem.201601163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fchem.201601163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=27203803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Kgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=8494-8507&issue=25&author=S.+Schaubachauthor=K.+Gebauerauthor=F.+Ungeheuerauthor=L.+Hoffmeisterauthor=M.+K.+Ilgauthor=C.+Wirtzauthor=A.+F%C3%BCrstner&title=A+Two-Component+Alkyne+Metathesis+Catalyst+System+with+an+Improved+Substrate+Scope+and+Functional+Group+Tolerance%3A+Development+and+Applications+to+Natural+Product+Synthesis&doi=10.1002%2Fchem.201601163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A Two-Component Alkyne Metathesis Catalyst System with an Improved Substrate Scope and Functional Group Tolerance: Development and Applications to Natural Product Synthesis</span></div><div class="casAuthors">Schaubach, Sebastian; Gebauer, Konrad; Ungeheuer, Felix; Hoffmeister, Laura; Ilg, Marina K.; Wirtz, Conny; Fuerstner, Alois</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8494-8507</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although molybdenum alkylidyne complexes such as 1 (I; R = OSiPh3) endowed with triarylsilanolate ligands are excellent catalysts for alkyne metathesis, they can encounter limitations when (multiple) protic sites are present in a given substrate and/or when forcing conditions are necessary.  In such cases, a catalyst formed in situ upon mixing of the trisamidomolybenum alkylidyne complex 3 [III; R' = tert-butyl(3,5-dimethylphenyl)amino] and the readily available trisilanol derivs. 8 = R''Si[CH2CH2(SiPh2OH)]3 (VIII; R'' = Me, Ph) or 11 (XI; X = [CH2CH2CH2(SiPh2OH)]3; R''' = H, Et) shows significantly better performance.  This two-component system worked well for a series of model compds. comprising primary, secondary or phenolic -OH groups, as well as for a set of challenging (bis)propargylic substrates.  Its remarkable efficiency is also evident from applications to the total syntheses of manshurolide, a highly strained sesquiterpene lactone with kinase inhibitory activity, and the structurally demanding immunosuppressive cyclodiyne ivorenolide A; in either case, the std. catalyst 1 largely failed to effect the crit. macrocyclization, whereas the two-component system was fully operative.  A study directed toward the quinolizidine alkaloid lythrancepine I features yet another instructive example, in that a triyne substrate was metathesized with the help of 3/11 such that two of the triple bonds participated in ring closure, while the third one passed uncompromised.  As a spin-off of this project, a much improved ruthenium catalyst for the redox isomerization of propargyl alcs. to the corresponding enones was developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcab5j8I9PGLVg90H21EOLACvtfcHk0lggrMeEISDb7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Kgsrc%253D&md5=c1b5a9e5489627fb345618e96611f953</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1002%2Fchem.201601163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201601163%26sid%3Dliteratum%253Aachs%26aulast%3DSchaubach%26aufirst%3DS.%26aulast%3DGebauer%26aufirst%3DK.%26aulast%3DUngeheuer%26aufirst%3DF.%26aulast%3DHoffmeister%26aufirst%3DL.%26aulast%3DIlg%26aufirst%3DM.%2BK.%26aulast%3DWirtz%26aufirst%3DC.%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26atitle%3DA%2520Two-Component%2520Alkyne%2520Metathesis%2520Catalyst%2520System%2520with%2520an%2520Improved%2520Substrate%2520Scope%2520and%2520Functional%2520Group%2520Tolerance%253A%2520Development%2520and%2520Applications%2520to%2520Natural%2520Product%2520Synthesis%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26issue%3D25%26spage%3D8494%26epage%3D8507%26doi%3D10.1002%2Fchem.201601163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span> <span> </span><span class="NLM_article-title">Extracellular Signal-Regulated Kinases (ERK) Inhibitors from Aristolochia Yunnanensis</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1021/np300887d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np300887d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2ntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=664-671&issue=4&author=Z.+B.+Chengauthor=W.-W.+Shaoauthor=Y.-N.+Liuauthor=Q.+Liaoauthor=T.-T.+Linauthor=X.-Y.+Shenauthor=S.+Yin&title=Extracellular+Signal-Regulated+Kinases+%28ERK%29+Inhibitors+from+Aristolochia+Yunnanensis&doi=10.1021%2Fnp300887d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Signal-Regulated Kinases (ERK) Inhibitors from Aristolochia yunnanensis</span></div><div class="casAuthors">Cheng, Zhong-Bin; Shao, Wei-Wei; Liu, Ye-Na; Liao, Qiong; Lin, Ting-Ting; Shen, Xiao-Yan; Yin, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">664-671</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Six new sesquiterpenoids, aristoyunnolins A-F (1-6), an artifact of isolation [7-O-Et madolin W (7)], and 12 known analogs were isolated from stems of Aristolochia yunnanensis.  The structures were detd. by combined chem. and spectral methods, and the abs. configurations of compds. 2, 3, 5-7, 9, 14, and 17 were detd. by the modified Mosher's method and CD anal.  Compds. 1-19 were screened using a bioassay system designed to evaluate the effect on mitogen-activated protein kinases (MAPKs) signaling pathways.  Among three MAPKs (ERK1/2, JNK, and p38), compds. 1, 4, 10-13, 16, 18, and 19 exhibited selective inhibition of the phosphorylation of ERK1/2.  Compds. 16 and 19 were more active than the pos. control PD98059, a known inhibitor of the ERK1/2 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoomMv6jzPozrVg90H21EOLACvtfcHk0lggrMeEISDb7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2ntrg%253D&md5=662de2f3c6bd40093d137360864967b7</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fnp300887d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp300887d%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.%2BB.%26aulast%3DShao%26aufirst%3DW.-W.%26aulast%3DLiu%26aufirst%3DY.-N.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DT.-T.%26aulast%3DShen%26aufirst%3DX.-Y.%26aulast%3DYin%26aufirst%3DS.%26atitle%3DExtracellular%2520Signal-Regulated%2520Kinases%2520%2528ERK%2529%2520Inhibitors%2520from%2520Aristolochia%2520Yunnanensis%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2013%26volume%3D76%26issue%3D4%26spage%3D664%26epage%3D671%26doi%3D10.1021%2Fnp300887d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rücker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Güllmann, A.</span></span> <span> </span><span class="NLM_article-title">Manshurolide, a Sesquiterpene Lactone from Aristolochia Manshuriensis</span>. <i>Phytochemistry</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1016/0031-9422(90)80062-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2F0031-9422%2890%2980062-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaK3cXksFGrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=983-985&issue=3&author=G.+R%C3%BCckerauthor=C.+W.+Mingauthor=R.+Mayerauthor=G.+Willauthor=A.+G%C3%BCllmann&title=Manshurolide%2C+a+Sesquiterpene+Lactone+from+Aristolochia+Manshuriensis&doi=10.1016%2F0031-9422%2890%2980062-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Manshurolide, a sesquiterpene lactone from Aristolochia manshuriensis</span></div><div class="casAuthors">Ruecker, Gerhard; Ming, Chen Wei; Mayer, Ralf; Will, Georg; Guellmann, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">983-5</span>CODEN:
                <span class="NLM_cas:coden">PYTCAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-9422</span>.
    </div><div class="casAbstract">A sesquiterpene lactone, manshurolide (I), with a previously unknown carbon skeleton was isolated from the stems of A. manshuriensis.  Its structure was elucidated by spectroscopic means and x-ray anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKQ-6AQoXFkLVg90H21EOLACvtfcHk0liZ3qVleVrWgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXksFGrt7g%253D&md5=1d7a7e63f0b2119d8ca98181f02e0781</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2F0031-9422%2890%2980062-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0031-9422%252890%252980062-L%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCcker%26aufirst%3DG.%26aulast%3DMing%26aufirst%3DC.%2BW.%26aulast%3DMayer%26aufirst%3DR.%26aulast%3DWill%26aufirst%3DG.%26aulast%3DG%25C3%25BCllmann%26aufirst%3DA.%26atitle%3DManshurolide%252C%2520a%2520Sesquiterpene%2520Lactone%2520from%2520Aristolochia%2520Manshuriensis%26jtitle%3DPhytochemistry%26date%3D1990%26volume%3D29%26issue%3D3%26spage%3D983%26epage%3D985%26doi%3D10.1016%2F0031-9422%2890%2980062-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castells, J.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in [2 + 2+2] Cycloaddition Reactions</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3444</span>, <span class="refDoi"> DOI: 10.1039/c1cs15029d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2Fc1cs15029d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21431173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns12msrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=3430-3444&author=G.+Dom%C3%ADnguezauthor=J.+P%C3%A9rez-Castells&title=Recent+Advances+in+%5B2+%2B+2%2B2%5D+Cycloaddition+Reactions&doi=10.1039%2Fc1cs15029d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in [2+2+2] cycloaddition reactions</span></div><div class="casAuthors">Dominguez, Gema; Perez-Castells, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3430-3444</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The [2+2+2] cycloaddn. is an elegant, atom-efficient and group tolerant process for the synthesis of carbo- and heterocycles, mostly arom., involving the formation of several C-C bonds in a single step.  Cyclotrimerization is catalyzed by a variety of organometallic complexes, including more than 15 different metals.  The aim of this tutorial review is to point out the most recent advances in this field and to encourage the use of this reaction enroute to complex mols.  After summarizing the most common catalysts and reaction conditions generally used, the mechanistic features currently accepted for this reaction were surveyed.  Section 4 covered the scope of the different [2+2+2] cycloaddn. versions starting with the cyclotrimerization of three triple bonds, including nitriles, with especial emphasis on asym. reactions that create central, axial or planar chirality.  Then, reactions that use double bonds are addressed.  Finally, the most outstanding examples of natural products synthesis using [2+2+2] cycloaddn. as a key step reported recently were shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE2nLfnG73B7Vg90H21EOLACvtfcHk0liZ3qVleVrWgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns12msrs%253D&md5=ba2e8a6b5234865072b485c3612f0318</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15029d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15029d%26sid%3Dliteratum%253Aachs%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DG.%26aulast%3DP%25C3%25A9rez-Castells%26aufirst%3DJ.%26atitle%3DRecent%2520Advances%2520in%2520%255B2%2520%252B%25202%252B2%255D%2520Cycloaddition%2520Reactions%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D3430%26epage%3D3444%26doi%3D10.1039%2Fc1cs15029d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boñaga, L. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derian, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Novel Bis(Indolyl)Maleimide Pyridinophanes That Are Potent, Selective Inhibitors of Glycogen Synthase Kinase-3</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2863</span>– <span class="NLM_lpage">2868</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.02.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmcl.2007.02.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=17350261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslyjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2863-2868&issue=10&author=H.+C.+Zhangauthor=L.+V.+R.+Bo%C3%B1agaauthor=H.+Yeauthor=C.+K.+Derianauthor=B.+P.+Damianoauthor=B.+E.+Maryanoff&title=Novel+Bis%28Indolyl%29Maleimide+Pyridinophanes+That+Are+Potent%2C+Selective+Inhibitors+of+Glycogen+Synthase+Kinase-3&doi=10.1016%2Fj.bmcl.2007.02.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3</span></div><div class="casAuthors">Zhang, Han-Cheng; Bonaga, Llorente V. R.; Ye, Hong; Derian, Claudia K.; Damiano, Bruce P.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2863-2868</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Novel bis(indolyl)maleimide pyridinophanes, e.g., I, were prepd. by cobalt-mediated [2+2+2] cycloaddn. of an appropriate α,ω-diynes with an N,N-dialkylcyanamides.  These macrocyclic heterophanes were found to be potent and selective inhibitors of glycogen synthase kinase-3β.  An X-ray structure of a co-crystal of GSK-3β and I (IC50 = 3 nM) depicts the hydrogen bonding and hydrophobic interactions in the ATP-binding pocket of this serine/threonine protein kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv2DI3JjEomrVg90H21EOLACvtfcHk0ljaq1Pf9f-Dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslyjsrk%253D&md5=91c6530b0cb6ef7e291ce7d98d5668d3</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.02.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.02.059%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BC.%26aulast%3DBo%25C3%25B1aga%26aufirst%3DL.%2BV.%2BR.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DDerian%26aufirst%3DC.%2BK.%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DNovel%2520Bis%2528Indolyl%2529Maleimide%2520Pyridinophanes%2520That%2520Are%2520Potent%252C%2520Selective%2520Inhibitors%2520of%2520Glycogen%2520Synthase%2520Kinase-3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D10%26spage%3D2863%26epage%3D2868%26doi%3D10.1016%2Fj.bmcl.2007.02.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, C. L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span> <span> </span><span class="NLM_article-title">An Efficient Synthesis of an Exo-Enone Analogue of LL-Z1640–2 and Evaluation of Its Protein Kinase Inhibitory Activities</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1039/C5OB01948F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC5OB01948F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26541872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCms7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=639-645&issue=2&author=S.+Q.+Wangauthor=S.+S.+Gohauthor=C.+L.+L.+Chaiauthor=A.+Chen&title=An+Efficient+Synthesis+of+an+Exo-Enone+Analogue+of+LL-Z1640%E2%80%932+and+Evaluation+of+Its+Protein+Kinase+Inhibitory+Activities&doi=10.1039%2FC5OB01948F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of an exo-enone analogue of LL-Z1640-2 and evaluation of its protein kinase inhibitory activities</span></div><div class="casAuthors">Wang, Stephanie Q.; Goh, Shermin S.; Chai, Christina L. L.; Chen, Anqi</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">639-645</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient synthesis of an exo-enone analog of resorcylic acid lactone (RAL), natural product LL-Z1640-2 (1), has been achieved using a Ni-catalyzed regioselective reductive coupling macrocyclization of an alkyne-aldehyde as a key step.  The synthetic route is significantly shorter than those for the natural product and avoids the isomerization problem of the cis-double bond in the mol.  The preliminary biol. evaluation showed that the exo-enone analog is a potent inhibitor of several important kinases relevant to cancer drug development.  The synthesis of the target compd. was achieved using 5-[(1E)-3-[(4S,5R)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-propen-1-yl]-7-methoxy-2,2-dimethyl-4H-1,3-Benzodioxin-4-one [i.e., a deriv. of 2-deoxy-3,4-O-(1-methylethylidene)-D-erythro-pentose] as a starting material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMRPSd-zdwdrVg90H21EOLACvtfcHk0ljaq1Pf9f-Dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCms7rM&md5=6f6f624e54fabb249706677ea5da56a2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1039%2FC5OB01948F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB01948F%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DGoh%26aufirst%3DS.%2BS.%26aulast%3DChai%26aufirst%3DC.%2BL.%2BL.%26aulast%3DChen%26aufirst%3DA.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%2520an%2520Exo-Enone%2520Analogue%2520of%2520LL-Z1640%25E2%2580%25932%2520and%2520Evaluation%2520of%2520Its%2520Protein%2520Kinase%2520Inhibitory%2520Activities%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26issue%3D2%26spage%3D639%26epage%3D645%26doi%3D10.1039%2FC5OB01948F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauff, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span> <span> </span><span class="NLM_article-title">Exo-Selective Reductive Macrocyclization of Ynals</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1493</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.5b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.5b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1493-1496&issue=6&author=H.+Wangauthor=S.+Negrettiauthor=A.+R.+Knauffauthor=J.+Montgomery&title=Exo-Selective+Reductive+Macrocyclization+of+Ynals&doi=10.1021%2Facs.orglett.5b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Exo-Selective Reductive Macrocyclization of Ynals</span></div><div class="casAuthors">Wang, Hengbin; Negretti, Solymar; Knauff, Allison R.; Montgomery, John</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1496</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general protocol for the highly exo-selective macrocyclization of ynals using a nickel/N-heterocyclic carbene catalyst system has been developed [e.g., I → II (69%, regioselective ratio >95:5)].  A series of 10- to 21-membered macrocycles bearing an exomethylene substituent was synthesized in good yields with excellent regioselectivity (exo/endo >95:5).  Very high levels of long-range diastereocontrol can also be achieved for some classes of macrocycles.  Complementary to previously reported endo-selective macrocyclizations, this method provides accesses to exoalkylidene macrocycles from simple ynals in high selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnrsETnKnxzbVg90H21EOLACvtfcHk0ljaq1Pf9f-Dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsrw%253D&md5=668004eeb4654c4205450ae3c9727e12</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.5b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.5b00381%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNegretti%26aufirst%3DS.%26aulast%3DKnauff%26aufirst%3DA.%2BR.%26aulast%3DMontgomery%26aufirst%3DJ.%26atitle%3DExo-Selective%2520Reductive%2520Macrocyclization%2520of%2520Ynals%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26issue%3D6%26spage%3D1493%26epage%3D1496%26doi%3D10.1021%2Facs.orglett.5b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaumlöffel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, G.</span></span> <span> </span><span class="NLM_article-title">A Synthesis-Driven Structure Revision of “Plagiochin E”, a Highly Bioactive Bisbibenzyl</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2009</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1852</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1217510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1055%2Fs-0029-1217510" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=1852-1858&issue=11&author=A.+Speicherauthor=M.+Grohauthor=J.+Zappauthor=A.+Schauml%C3%B6ffelauthor=M.+Knauerauthor=G.+Bringmann&title=A+Synthesis-Driven+Structure+Revision+of+%E2%80%9CPlagiochin+E%E2%80%9D%2C+a+Highly+Bioactive+Bisbibenzyl&doi=10.1055%2Fs-0029-1217510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1217510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1217510%26sid%3Dliteratum%253Aachs%26aulast%3DSpeicher%26aufirst%3DA.%26aulast%3DGroh%26aufirst%3DM.%26aulast%3DZapp%26aufirst%3DJ.%26aulast%3DSchauml%25C3%25B6ffel%26aufirst%3DA.%26aulast%3DKnauer%26aufirst%3DM.%26aulast%3DBringmann%26aufirst%3DG.%26atitle%3DA%2520Synthesis-Driven%2520Structure%2520Revision%2520of%2520%25E2%2580%259CPlagiochin%2520E%25E2%2580%259D%252C%2520a%2520Highly%2520Bioactive%2520Bisbibenzyl%26jtitle%3DSynlett%26date%3D2009%26volume%3D2009%26issue%3D11%26spage%3D1852%26epage%3D1858%26doi%3D10.1055%2Fs-0029-1217510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Macrocyclic Bisbibenzyl Derivatives and Their Anticancer Effects as Anti-Tubulin Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2382</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmc.2012.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22365913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVOrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2382-2391&issue=7&author=J.+Jiangauthor=B.+Sunauthor=Y.+Y.+Wangauthor=M.+Cuiauthor=L.+Zhangauthor=C.+Z.+Cuiauthor=Y.+F.+Wangauthor=X.+G.+Liuauthor=H.+X.+Lou&title=Synthesis+of+Macrocyclic+Bisbibenzyl+Derivatives+and+Their+Anticancer+Effects+as+Anti-Tubulin+Agents&doi=10.1016%2Fj.bmc.2012.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents</span></div><div class="casAuthors">Jiang, Juan; Sun, Bin; Wang, Yan-yan; Cui, Min; Zhang, Li; Cui, Chang-zhi; Wang, Yan-feng; Liu, Xi-gong; Lou, Hong-xiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2382-2391</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on the core skeleton of the total synthesized bisbibenzyl marchantin C, riccardin D and plagiochin E, a series of brominated and aminomethylated derivs. of above three bisbibenzyls have been synthesized and their cytotoxic activity against KB, MCF-7 and PC3 cell lines has been preliminary evaluated.  The bio-test results revealed that the brominated derivs. exhibited excellent antiproliferative activity, with IC50 value lower than their parent compds.  As a most potent microtubule depolymn. agent, compd. I was found to arrest cells at the G2/M phase of the cell cycle as detd. by the flow cytometry assay in PC3 cell line.  The remarkable biol. profile and novel structure of these bisbibenzyl derivs. make them possible as promising candidates for clin. development as chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrJouJ_QomvbVg90H21EOLACvtfcHk0ljjM3e3KLR6gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVOrt78%253D&md5=54e75255e4c183b84158abcc67c5394b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BY.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DC.%2BZ.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BG.%26aulast%3DLou%26aufirst%3DH.%2BX.%26atitle%3DSynthesis%2520of%2520Macrocyclic%2520Bisbibenzyl%2520Derivatives%2520and%2520Their%2520Anticancer%2520Effects%2520as%2520Anti-Tubulin%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D7%26spage%3D2382%26epage%3D2391%26doi%3D10.1016%2Fj.bmc.2012.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ephritikhine, M.</span></span> <span> </span><span class="NLM_article-title">A New Look at the McMurry Reaction</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_fpage">2549</span>– <span class="NLM_lpage">2554</span>, <span class="refDoi"> DOI: 10.1039/a804394i</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2Fa804394i" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=2549-2554&author=M.+Ephritikhine&title=A+New+Look+at+the+McMurry+Reaction&doi=10.1039%2Fa804394i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A new look at the McMurry reaction</span></div><div class="casAuthors">Ephritikhine, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2549-2554</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The article emphasizes the contradictory features of the McMurry reaction.  The historical view shows how chemists were firmly convinced of the occurrence of pinacolate intermediates and rejected, in spite of some evidence, the alternative pathway via carbenoid species.  The McMurry reaction continues to find new important applications but suffers from problems of reproducibility.  New practical reagents and simplified methods have been developed but rather complicated systems have been designed for obtaining higher selectivities.  Recent investigations confirmed that pinacolates would be the precursors to alkenes but also revealed the possible involvement of carbenoid species, putting forward the dual nature of the mechanism of the McMurry reaction.  Review with 50 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj6X1RHknSH7Vg90H21EOLACvtfcHk0ljjM3e3KLR6gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVCms7s%253D&md5=daa4c62b4a97e1f93839cac5397e4596</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1039%2Fa804394i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa804394i%26sid%3Dliteratum%253Aachs%26aulast%3DEphritikhine%26aufirst%3DM.%26atitle%3DA%2520New%2520Look%2520at%2520the%2520McMurry%2520Reaction%26jtitle%3DChem.%2520Commun.%26date%3D1998%26spage%3D2549%26epage%3D2554%26doi%3D10.1039%2Fa804394i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okude, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozaki, H.</span></span> <span> </span><span class="NLM_article-title">Grignard-Type Carbonyl Addition of Allyl Halides by Means of Chromous Salt. A Chemospecific Synthesis of Homoallyl Alcohols</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3179</span>– <span class="NLM_lpage">3181</span>, <span class="refDoi"> DOI: 10.1021/ja00451a061</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00451a061" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaE2sXktVGgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1977&pages=3179-3181&issue=9&author=Y.+Okudeauthor=S.+Hiranoauthor=T.+Hiyamaauthor=H.+Nozaki&title=Grignard-Type+Carbonyl+Addition+of+Allyl+Halides+by+Means+of+Chromous+Salt.+A+Chemospecific+Synthesis+of+Homoallyl+Alcohols&doi=10.1021%2Fja00451a061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Grignard-type carbonyl addition of allyl halides by means of chromous salt.  A chemospecific synthesis of homoallyl alcohols</span></div><div class="casAuthors">Okude, Yoshitaka; Hirano, Shigeo; Hiyama, Tamejiro; Nozaki, Hitosi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3179-81</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Addn. reaction of R2C:CHCH2X (R = H, Me; X = Br, iodo, Cl) with CrCl2 and R1CHO [R1 = 1-hexyl, alkenyl, Ph, oxoalkyl, (CH2)4CO2Me, ω-cyanoalkenyl] yielded the resp. R1CH(OH)CR2C:CH2.  Cyclohexanone, CrCl2, and prenyl bromide gave 1-(1,1-dimethylallyl)cyclohexanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotzMfBlwrNkLVg90H21EOLACvtfcHk0ljjM3e3KLR6gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXktVGgsLc%253D&md5=816d991c69609e85aa20431aaffeee3f</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fja00451a061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00451a061%26sid%3Dliteratum%253Aachs%26aulast%3DOkude%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DS.%26aulast%3DHiyama%26aufirst%3DT.%26aulast%3DNozaki%26aufirst%3DH.%26atitle%3DGrignard-Type%2520Carbonyl%2520Addition%2520of%2520Allyl%2520Halides%2520by%2520Means%2520of%2520Chromous%2520Salt.%2520A%2520Chemospecific%2520Synthesis%2520of%2520Homoallyl%2520Alcohols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1977%26volume%3D99%26issue%3D9%26spage%3D3179%26epage%3D3181%26doi%3D10.1021%2Fja00451a061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargaden, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiry, P. J.</span></span> <span> </span><span class="NLM_article-title">The Development of the Asymmetric Nozaki-Hiyama-KishiReaction</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">2407</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.1002/adsc.200700324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fadsc.200700324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVahtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2007&pages=2407-2424&author=G.+C.+Hargadenauthor=P.+J.+Guiry&title=The+Development+of+the+Asymmetric+Nozaki-Hiyama-KishiReaction&doi=10.1002%2Fadsc.200700324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The development of the asymmetric Nozaki-Hiyama-Kishi reaction</span></div><div class="casAuthors">Hargaden, Grainne C.; Guiry, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2407-2424</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review collates the literature to date on the development of the Nozaki-Hiyama-Kishi (NHK) reaction into an important chromium-mediated, carbon-carbon bond forming process.  The initial research employed stoichiometric quantities of chromium and this was exploited in the key steps of a range of total syntheses.  Thereafter, the NHK reaction was further developed with the discovery of the catalytic variant.  The focus of recent investigations is on the application of this reaction in asym. synthesis.  The asym. NHK typically employed a range of salen- and oxazoline-derived chiral ligands and tethered bis(8-quinolinato)-chromium complexes.  To date, good to high enantioselectivities were obtained in a variety of NHK-type processes, including allylation, crotylation, methallylation, allenylation, propargylation, and vinylation of a range of aldehydes, with limited examples employing ketones as substrates.  Selected examples of the asym. NHK in total synthesis will also be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbV_I8rG5D37Vg90H21EOLACvtfcHk0ljjM3e3KLR6gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVahtb%252FN&md5=7e9cf193e4761a9e585d436d98ce2a83</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200700324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200700324%26sid%3Dliteratum%253Aachs%26aulast%3DHargaden%26aufirst%3DG.%2BC.%26aulast%3DGuiry%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520Development%2520of%2520the%2520Asymmetric%2520Nozaki-Hiyama-KishiReaction%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2007%26volume%3D349%26spage%3D2407%26epage%3D2424%26doi%3D10.1002%2Fadsc.200700324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeClair, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of LL-Z1640–2 Utilizing a Late-Stage Intramolecular Nozaki-Hiyama-Kishi Reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">6852</span>– <span class="NLM_lpage">6855</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.10.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.tetlet.2010.10.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21516235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2ksbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=6852-6855&issue=52&author=C.+A.+LeClairauthor=M.+B.+Boxerauthor=C.+J.+Thomasauthor=D.+J.+Maloney&title=Total+Synthesis+of+LL-Z1640%E2%80%932+Utilizing+a+Late-Stage+Intramolecular+Nozaki-Hiyama-Kishi+Reaction&doi=10.1016%2Fj.tetlet.2010.10.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of LL-Z1640-2 utilizing a late-stage intramolecular Nozaki-Hiyama-Kishi reaction</span></div><div class="casAuthors">LeClair, Christopher A.; Boxer, Matthew B.; Thomas, Craig J.; Maloney, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">6852-6855</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A total synthesis of LL-Z1640-2 (I), a potent and selective kinase inhibitor, has been completed.  The key step of the convergent synthesis utilized a late-stage intramol. Nozaki-Hiyama-Kishi (NHK) reaction to close the macrocycle at the C6'-C7' bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpggHqdk4VerbVg90H21EOLACvtfcHk0ljTgvjLkQLuaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2ksbzF&md5=0b5964303dab3d692ed30205473609dc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.10.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.10.092%26sid%3Dliteratum%253Aachs%26aulast%3DLeClair%26aufirst%3DC.%2BA.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26atitle%3DTotal%2520Synthesis%2520of%2520LL-Z1640%25E2%2580%25932%2520Utilizing%2520a%2520Late-Stage%2520Intramolecular%2520Nozaki-Hiyama-Kishi%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26issue%3D52%26spage%3D6852%26epage%3D6855%26doi%3D10.1016%2Fj.tetlet.2010.10.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Oxygen-Linked Macrocyclic Kinase Inhibitors: Discovery of SB1518 and SB1578, Potent Inhibitors of Janus Kinase 2 (JAK2) and Fms-like Tyrosine Kinase-3 (FLT3)</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9572-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs10822-012-9572-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22527961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVKjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&issue=4&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-Based+Design+of+Oxygen-Linked+Macrocyclic+Kinase+Inhibitors%3A+Discovery+of+SB1518+and+SB1578%2C+Potent+Inhibitors+of+Janus+Kinase+2+%28JAK2%29+and+Fms-like+Tyrosine+Kinase-3+%28FLT3%29&doi=10.1007%2Fs10822-012-9572-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Lee, Angeline; Nagaraj, Harish; Wang, Haishan; Teo, Eeling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-450</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Macrocycles from our Aurora project were screened in a kinase panel and were found to be active on other kinase targets, mainly JAKs, FLT3 and CDKs.  Subsequently these compds. became leads in our JAK2 project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  This residue is conserved in most CDKs resulting in potent pan CDK inhibition.  One of the main project objectives was to achieve JAK2 potency with 100-fold selectivity against CDKs.  Macrocycles with an ether linker have potent JAK2 activity with the ether oxygen forming a hydrogen bond to Ser936.  A hydrogen bond to the equiv. residues of JAK3 and most CDKs cannot be formed resulting in good selectivity for JAK2 over JAK3 and CDKs.  Further optimization of the macrocyclic linker and side chain increased JAK2 and FLT3 activity as well as improving DMPK properties.  The selective JAK2/FLT3 inhibitor 11 (Pacritinib, SB1518) has successfully finished phase 2 clin. trials for myelofibrosis and lymphoma.  Another selective JAK2/FLT3 inhibitor, 33 (SB1578), has entered phase 1 clin. development for the non-oncol. indication rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkXiVkwLI_T7Vg90H21EOLACvtfcHk0ljTgvjLkQLuaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVKjsrc%253D&md5=41bffa51612967861695c5ea27cb38f5</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9572-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9572-z%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-Based%2520Design%2520of%2520Oxygen-Linked%2520Macrocyclic%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520Potent%2520Inhibitors%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26issue%3D4%26spage%3D437%26epage%3D450%26doi%3D10.1007%2Fs10822-012-9572-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Nitrogen-Linked Macrocyclic Kinase Inhibitors Leading to the Clinical Candidate SB1317/TG02, a Potent Inhibitor of Cyclin Dependant Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3)</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1007/s00894-012-1528-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs00894-012-1528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22820730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=119-130&issue=1&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=H.+Nagarajauthor=M.+Williamsauthor=H.+Wangauthor=A.+Leeauthor=E.+Sunauthor=E.-L.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-Based+Design+of+Nitrogen-Linked+Macrocyclic+Kinase+Inhibitors+Leading+to+the+Clinical+Candidate+SB1317%2FTG02%2C+a+Potent+Inhibitor+of+Cyclin+Dependant+Kinases+%28CDKs%29%2C+Janus+Kinase+2+%28JAK2%29%2C+and+Fms-like+Tyrosine+Kinase-3+%28FLT3%29&doi=10.1007%2Fs00894-012-1528-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Nagaraj, Harish; Williams, Meredith; Wang, Haishan; Lee, Angeline; Sun, Eric; Teo, Ee-Ling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A high-throughput screen against Aurora A kinase revealed several promising submicromolar pyrimidine-aniline leads.  The bioactive conformation found by docking these leads into the Aurora A ATP-binding site had a semicircular shape.  Macrocycle formation was proposed to achieve novelty and selectivity via ring-closing metathesis of a diene precursor.  The nature of the optimal linker and its size was directed by docking.  In a kinase panel screen, selected macrocycles were active on other kinase targets, mainly FLT3, JAK2, and CDKs.  These compds. then became leads in a CDK/FLT3/JAK2 inhibitor project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  Interaction with this residue explains the obsd. selectivity.  The Asp86 residue is conserved in most CDKs, resulting in potent pan-CDK inhibition by these compds.  Optimized macrocycles generally have good DMPK properties, and are efficacious in mouse models of cancer.  Compd. 5 (SB1317/TG02), a pan-CDK/FLT3/JAK2 inhibitor, was selected for preclin. development, and is now in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnGiv82CuwbVg90H21EOLACvtfcHk0ljTgvjLkQLuaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D&md5=3f65c0a7f61329cabb9e85656a2c3dcf</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DTeo%26aufirst%3DE.-L.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-Based%2520Design%2520of%2520Nitrogen-Linked%2520Macrocyclic%2520Kinase%2520Inhibitors%2520Leading%2520to%2520the%2520Clinical%2520Candidate%2520SB1317%252FTG02%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin%2520Dependant%2520Kinases%2520%2528CDKs%2529%252C%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%252C%2520and%2520Fms-like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26issue%3D1%26spage%3D119%26epage%3D130%26doi%3D10.1007%2Fs00894-012-1528-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantharaj, E.</span></span> <span> </span><span class="NLM_article-title">Preclinical Metabolism and Pharmacokinetics of SB1317 (TG02), a Potent CDK/JAK2/FLT3 Inhibitor</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.2174/187231212800229336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.2174%2F187231212800229336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22372550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=33-42&issue=1&author=M.+K.+Pashaauthor=R.+Jayaramanauthor=V.+P.+Reddyauthor=P.+Yeoauthor=E.+Gohauthor=A.+Williamsauthor=K.+C.+Gohauthor=E.+Kantharaj&title=Preclinical+Metabolism+and+Pharmacokinetics+of+SB1317+%28TG02%29%2C+a+Potent+CDK%2FJAK2%2FFLT3+Inhibitor&doi=10.2174%2F187231212800229336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor</span></div><div class="casAuthors">Pasha, Mohammed Khalid; Jayaraman, Ramesh; Reddy, Venkatesh Pilla; Yeo, Pauline; Goh, Evelyn; Williams, Anthony; Goh, Kee Chuan; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">SB1317 (TG02) is a novel small mol. potent CDK/JAK2/FLT3 inhibitor.  To evaluate full potential of this development candidate, we conducted drug metab. and pharmacokinetic studies of this novel anti-cancer agent.  SB1317 was sol., highly permeable in Caco-2 cells, and showed >99% binding to plasma from mice, dog and humans.  It was metabolically stable in human and dog liver microsomes relative to mouse and rat.  SB1317 was mainly metabolized by CYP3A4 and CY1A2 in vitro.  SB1317 did not inhibit any of the major human CYPs in vitro except CYP2D6 (IC50 = 1 μM).  SB1317 did not significantly induce CYP1A and CYP3A4 in human hepatocytes in vitro.  The metabolic profiles in liver microsomes from preclin. species were qual. similar to humans.  In pharmacokinetic studies SB1317 showed moderate to high systemic clearance (relative to liver blood flow), high vol. of distribution (>0.6 L/kg), oral bioavailability of 24%, ∼4 and 37% in mice, rats and dogs, resp.; and extensive tissue distribution in mice.  The favorable ADME of SB1317 supported its preclin. development as an oral drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIusZ0BdJyPbVg90H21EOLACvtfcHk0li-_b914_Pc1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D&md5=fbc9c2d6453202c5130db50ed1df75c3</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.2174%2F187231212800229336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231212800229336%26sid%3Dliteratum%253Aachs%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DPreclinical%2520Metabolism%2520and%2520Pharmacokinetics%2520of%2520SB1317%2520%2528TG02%2529%252C%2520a%2520Potent%2520CDK%252FJAK2%252FFLT3%2520Inhibitor%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2012%26volume%3D6%26issue%3D1%26spage%3D33%26epage%3D42%26doi%3D10.2174%2F187231212800229336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a Novel Oral Multi-Kinase Inhibitor of CDKs, JAK2 and FLT3 with Potent Anti-Leukemic Properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&issue=2&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+Novel+Oral+Multi-Kinase+Inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+Potent+Anti-Leukemic+Properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0li-_b914_Pc1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520Novel%2520Oral%2520Multi-Kinase%2520Inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520Potent%2520Anti-Leukemic%2520Properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D2%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span> <span> </span><span class="NLM_article-title">The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3451</span>– <span class="NLM_lpage">3479</span>, <span class="refDoi"> DOI: 10.1021/jm200187y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200187y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3451-3479&issue=10&author=S.+Roughleyauthor=A.+M.+Jordan&title=The+Medicinal+Chemist%E2%80%99s+Toolbox%3A+An+Analysis+of+Reactions+Used+in+the+Pursuit+of+Drug+Candidates&doi=10.1021%2Fjm200187y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The Medicinal Chemist's Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates</span></div><div class="casAuthors">Roughley, Stephen D.; Jordan, Allan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3451-3479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A survey of selected medicinal chem. literature from 2008 was undertaken in order to det. the most common chem. reactions used in the prepn. of drug candidates.  In addn. to an examn. of the reactions, the frequency of occurrence of various functional groups in the drug targets was analyzed.  The Lipinski parameters and chirality of the surveyed compds. were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTUrcluTkPBLVg90H21EOLACvtfcHk0li-_b914_Pc1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsrg%253D&md5=a94df26d82bbd58b269ed20aa3253f56</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm200187y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200187y%26sid%3Dliteratum%253Aachs%26aulast%3DRoughley%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Toolbox%253A%2520An%2520Analysis%2520of%2520Reactions%2520Used%2520in%2520the%2520Pursuit%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D10%26spage%3D3451%26epage%3D3479%26doi%3D10.1021%2Fjm200187y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span> <span> </span><span class="NLM_article-title">Expanding the Medicinal Chemistry Synthetic Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnrd.2018.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30140018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=709-727&issue=10&author=J.+Bostr%C3%B6mauthor=D.+G.+Brownauthor=R.+J.+Youngauthor=G.+M.+Keser%C3%BC&title=Expanding+the+Medicinal+Chemistry+Synthetic+Toolbox&doi=10.1038%2Fnrd.2018.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the medicinal chemistry synthetic toolbox</span></div><div class="casAuthors">Bostrom Jonas; Brown Dean G; Young Robert J; Keseru Gyorgy M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The key objectives of medicinal chemistry are to efficiently design and synthesize bioactive compounds that have the potential to become safe and efficacious drugs.  Most medicinal chemistry programmes rely on screening compound collections populated by a range of molecules derived from a set of known and robust chemistry reactions.  Analysis of the role of synthetic organic chemistry in subsequent hit and lead optimization efforts suggests that only a few reactions dominate.  Thus, the uptake of new synthetic methodologies in drug discovery is limited.  Starting from the known limitations of reaction parameters, synthesis design tools, synthetic strategies and innovative chemistries, here we highlight opportunities for the expansion of the medicinal chemists' synthetic toolbox.  More intense crosstalk between synthetic and medicinal chemists in industry and academia should enable enhanced impact of new methodologies in future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy8c_ueHSwcYMcDoIzZtNkfW6udTcc2eYyBnRD0RwjRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D&md5=d87e988602808139597576ced56faa88</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.116%26sid%3Dliteratum%253Aachs%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DExpanding%2520the%2520Medicinal%2520Chemistry%2520Synthetic%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26issue%3D10%26spage%3D709%26epage%3D727%26doi%3D10.1038%2Fnrd.2018.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykstra, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krska, S. W.</span></span> <span> </span><span class="NLM_article-title">The Medicinal Chemist’s Toolbox for Late Stage Functionalization of Drug-like Molecules</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1039/C5CS00628G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC5CS00628G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26507237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslams7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=546-576&issue=3&author=T.+Cernakauthor=K.+D.+Dykstraauthor=S.+Tyagarajanauthor=P.+Vachalauthor=S.+W.+Krska&title=The+Medicinal+Chemist%E2%80%99s+Toolbox+for+Late+Stage+Functionalization+of+Drug-like+Molecules&doi=10.1039%2FC5CS00628G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The medicinal chemist's toolbox for late stage functionalization of drug-like molecules</span></div><div class="casAuthors">Cernak, Tim; Dykstra, Kevin D.; Tyagarajan, Sriram; Vachal, Petr; Krska, Shane W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">546-576</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The advent of modern C-H functionalization chemistries has enabled medicinal chemists to consider a synthetic strategy, late stage functionalization (LSF), which utilizes the C-H bonds of drug leads as points of diversification for generating new analogs.  LSF approaches offer the promise of rapid exploration of structure activity relationships (SAR), the generation of oxidized metabolites, the blocking of metabolic hot spots and the prepn. of biol. probes.  This review details a toolbox of intermol. C-H functionalization chemistries with proven applicability to drug-like mols., classified by regioselectivity patterns, and gives guidance on how to systematically develop LSF strategies using these patterns and other considerations.  In addn., a no. of examples illustrate how LSF approaches have been used to impact actual drug discovery and chem. biol. efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7N9sPaaVAQbVg90H21EOLACvtfcHk0li6kmXt0yp6Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslams7nN&md5=a52fc5692f5515e5cadab0f2746fd6f7</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1039%2FC5CS00628G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00628G%26sid%3Dliteratum%253Aachs%26aulast%3DCernak%26aufirst%3DT.%26aulast%3DDykstra%26aufirst%3DK.%2BD.%26aulast%3DTyagarajan%26aufirst%3DS.%26aulast%3DVachal%26aufirst%3DP.%26aulast%3DKrska%26aufirst%3DS.%2BW.%26atitle%3DThe%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Toolbox%2520for%2520Late%2520Stage%2520Functionalization%2520of%2520Drug-like%2520Molecules%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2016%26volume%3D45%26issue%3D3%26spage%3D546%26epage%3D576%26doi%3D10.1039%2FC5CS00628G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campos, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbaccio, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truppo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmee, E. R.</span></span> <span> </span><span class="NLM_article-title">The Importance of Synthetic Chemistry in the Pharmaceutical Industry</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">6424</span>), <span class="NLM_elocation-id">eaat0805</span> <span class="refDoi"> DOI: 10.1126/science.aat0805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1126%2Fscience.aat0805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30655413" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2019&issue=6424&author=K.+R.+Camposauthor=P.+J.+Colemanauthor=J.+C.+Alvarezauthor=S.+D.+Dreherauthor=R.+M.+Garbaccioauthor=N.+K.+Terrettauthor=R.+D.+Tillyerauthor=M.+D.+Truppoauthor=E.+R.+Parmee&title=The+Importance+of+Synthetic+Chemistry+in+the+Pharmaceutical+Industry&doi=10.1126%2Fscience.aat0805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat0805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat0805%26sid%3Dliteratum%253Aachs%26aulast%3DCampos%26aufirst%3DK.%2BR.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DAlvarez%26aufirst%3DJ.%2BC.%26aulast%3DDreher%26aufirst%3DS.%2BD.%26aulast%3DGarbaccio%26aufirst%3DR.%2BM.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DTillyer%26aufirst%3DR.%2BD.%26aulast%3DTruppo%26aufirst%3DM.%2BD.%26aulast%3DParmee%26aufirst%3DE.%2BR.%26atitle%3DThe%2520Importance%2520of%2520Synthetic%2520Chemistry%2520in%2520the%2520Pharmaceutical%2520Industry%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2019%26volume%3D363%26issue%3D6424%26doi%3D10.1126%2Fscience.aat0805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogdan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span> <span> </span><span class="NLM_article-title">Efficient Access to New Chemical Space through Flow-Construction of Druglike Macrocycles through Copper-Surface-Catalyzed Azide-Alkyne Cycloaddition Reactions</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">14506</span>– <span class="NLM_lpage">14512</span>, <span class="refDoi"> DOI: 10.1002/chem.201002215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fchem.201002215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21038332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit1Ghsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=14506-14512&issue=48&author=A.+R.+Bogdanauthor=K.+James&title=Efficient+Access+to+New+Chemical+Space+through+Flow-Construction+of+Druglike+Macrocycles+through+Copper-Surface-Catalyzed+Azide-Alkyne+Cycloaddition+Reactions&doi=10.1002%2Fchem.201002215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Access to New Chemical Space Through Flow-Construction of Drug-like Macrocycles Through Copper-Surface-Catalyzed Azide-Alkyne Cycloaddition Reactions</span></div><div class="casAuthors">Bogdan, Andrew R.; James, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14506-14512, S14506/1-S14506/99</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of 12- to 22-membered macrocycles, with drug-like functionality and properties, have been generated by using a simple and efficient copper-catalyzed azide-acetylene cycloaddn. reaction, conducted in flow in high-temp. copper tubing, under environmentally friendly conditions.  The triazole-contg. macrocycles, e.g. I, have been generated in up to 90 % yield in a 5 min reaction, without resorting to the high-diln. conditions typical of macrocyclization reactions.  This approach represents a very efficient method for constructing this important class of mols., in terms of yield, concn., and environmental considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLlKc9m7WrrVg90H21EOLACvtfcHk0li6kmXt0yp6Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Ghsg%253D%253D&md5=6eb1233b27fc48ae1417672c9cc21f5b</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1002%2Fchem.201002215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201002215%26sid%3Dliteratum%253Aachs%26aulast%3DBogdan%26aufirst%3DA.%2BR.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DEfficient%2520Access%2520to%2520New%2520Chemical%2520Space%2520through%2520Flow-Construction%2520of%2520Druglike%2520Macrocycles%2520through%2520Copper-Surface-Catalyzed%2520Azide-Alkyne%2520Cycloaddition%2520Reactions%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2010%26volume%3D16%26issue%3D48%26spage%3D14506%26epage%3D14512%26doi%3D10.1002%2Fchem.201002215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bédard, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Régnier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. K.</span></span> <span> </span><span class="NLM_article-title">Continuous Flow Macrocyclization at High Concentrations: Synthesis of Macrocyclic Lipids</span>. <i>Green Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1962</span>– <span class="NLM_lpage">1966</span>, <span class="refDoi"> DOI: 10.1039/c3gc40872h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2Fc3gc40872h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVejt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1962-1966&issue=7&author=A.+C.+B%C3%A9dardauthor=S.+R%C3%A9gnierauthor=S.+K.+Collins&title=Continuous+Flow+Macrocyclization+at+High+Concentrations%3A+Synthesis+of+Macrocyclic+Lipids&doi=10.1039%2Fc3gc40872h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous flow macrocyclization at high concentrations: synthesis of macrocyclic lipids</span></div><div class="casAuthors">Bedard, Anne-Catherine; Regnier, Sophie; Collins, Shawn K.</div><div class="citationInfo"><span class="NLM_cas:title">Green Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1962-1966</span>CODEN:
                <span class="NLM_cas:coden">GRCHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9262</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A phase sepn./continuous flow macrocyclization protocol eliminates the need for high-diln. conditions and can be used to prep. gram quantities of biol. relevant macrocyclic lipid structures.  The method presents several green advantages towards macrocycle synthesis: (1) the prevention of unwanted oligomers and waste, (2) a redn. in the large quantities of toxic, volatile org. solvents and (3) the use of PEG as an environmentally benign reaction media.  Macrocycles could be synthesized in high yields (up to 99%) in short reaction times (1.5 h) and on gram scales without the need to alter the reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWLZ8f3RBNNrVg90H21EOLACvtfcHk0ljq_4ovQcyQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVejt7o%253D&md5=8194830bfb2277936bc1e9d1c9730918</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1039%2Fc3gc40872h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3gc40872h%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9dard%26aufirst%3DA.%2BC.%26aulast%3DR%25C3%25A9gnier%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DS.%2BK.%26atitle%3DContinuous%2520Flow%2520Macrocyclization%2520at%2520High%2520Concentrations%253A%2520Synthesis%2520of%2520Macrocyclic%2520Lipids%26jtitle%3DGreen%2520Chem.%26date%3D2013%26volume%3D15%26issue%3D7%26spage%3D1962%26epage%3D1966%26doi%3D10.1039%2Fc3gc40872h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ugi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrückner, C.</span></span> <span> </span><span class="NLM_article-title">Isonitrile, IX. A-Addition von Immonium-Ionen Und Carbonsäure-Anionen an Isonitrile</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">734</span>, <span class="refDoi"> DOI: 10.1002/cber.19610940323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcber.19610940323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaF3MXotFKqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1961&pages=734&issue=10&author=I.+Ugiauthor=C.+Steinbr%C3%BCckner&title=Isonitrile%2C+IX.+A-Addition+von+Immonium-Ionen+Und+Carbons%C3%A4ure-Anionen+an+Isonitrile&doi=10.1002%2Fcber.19610940323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Isonitriles. II. Reaction of isonitriles with carbonyl compounds, amines, and hydrazoic acid</span></div><div class="casAuthors">Ugi, Ivar; Steinbrucker, Cornelius</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">734-42</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">cf. CA 54, 9802f.  Isonitriles with aldehydes or ketones, an amine, and NH3 yielded 1,5-disubstituted tetrazoles; instead of carbonyl compds. and amines, their condensation products, such as Schiff bases and enamines could be used.  The mechanism and the scope of the reaction was discussed.  Piperidine (2.55 g.), 3.00 cc. 10N HCl, 3.00 cc. 10M CH2O, and 5.00 cc. MeOH treated with cooling during 5 min. with 2.73 g. cyclohexyl isocyanide (I), the mixt. acidified with 20 cc. 2N HCl, washed with C6H6, treated with 10 cc. 40% aq. NaOH, and extd. with CH2Cl2 gave 5.33 g. N-cyclohexylpiperidinoacetamide, m. 73-4° (1:5 C6H6-petr. ether).  Et2NH (2.19 g.), 3.00 cc. 10M CH2O, 3.28 g. 2,6-Me2C6H3NC in 3.00 cc. 10N HCl, 5 cc. H2O, and 10 cc. Me2CO kept 100 hrs. at 20-5° yielded 4.69 g. N,N-diethylglycine 2,6-dimethylanilide, m. 66-8°.  PhNHMe, CH2O, and I during 5 hrs. at 20° yielded 41% N-methyl-N-phenylglycine cyclohexylamide, m. 200-202°.  Piperidine, iso-PrCHO, and I during 2 days at 20° gave 60% α-piperidinoisovaleric acid cyclohexylamide, m. 170-2°.  BuNH2, CH2O, and I during 24 hrs. at 20° yielded 50% butyliminodiacetic acid bis(cyclohexylamide), m. 120-1°.  Piperidine (2.55 g.) in 30 cc. Me2CO treated with cooling and stirring with 3.0 cc. 10M CH2O, 6.0 cc. 5N HCl, 1.95 g. NaN3 in 15 cc. H2O, and 2.73 g. I, the mixt. warmed during 3 min. to 20°, satd. after 0.5 hr. with K2CO3, the aq. layer extd. with Me2CO, and the org. phase worked up gave 5.83 g. 1-cyclohexyl-5-(piperidinomethyl)tetrazole (II), needles, m. 115-16° (1:1 C6H6-cyclohexane).  Dipiperidinomethane (4.26 g.) and 2.18 g. I in 5.0 cc. MeOH treated with cooling with 27.9 cc. 7.7% NH3-C6H6 and the mixt. worked up after 10 min. gave 4.85 g. II.  PrCHO (4.32 g.), 7.65 g. m-ClC6H4NH2, 10 cc. MeOH, 35.2 cc. 7.3%, HN3-C6H6, and 5.99 g. I kept 1 hr. at 20° gave 16.52 g. 1-cyclohexyl-5-[1-(m-chloroanilino)butyl]tetrazole, m. 107-9° (1:1 C6H6-petr. ether).  Iso-PrCH:NPr (3.40 g.), 2.73 g. I, 1.95 g. NaN3 in 15 cc. H2O, 40 cc. Me2CO, and 3.0 cc. 10N HCl kept 18 hrs. at 20° yielded 3.51 g. 1-cyclohexyl-5-(1-propylamino-2-methylpropyl)tetrazole (III), m. 55-7° (petr. ether).  Iso-PrCH:NPr (3.40 g.), 2.73 g. I, 20 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 0.5 hr. at 20° yielded 6.49 g. III.  Iso-PrCHO (2.16 g.), 2.55 g. piperidine, 1.95 g. NaN3 in 15 cc. H2O, 3.0 cc. 10N HCl, and 2.73 g. I in 30 cc. Me2CO kept 0.5 hr. at 20° gave 5.79 g. (crude) 1-cyclohexyl-5-(1-piperidino-2-methylpropyl)tetrazole (IV), m. 147-8° (1:1 C6H6-cyclohexane).  1-Piperidino-2-methyl-1-propene (3.48 g.), 2.73 g. I, 5 cc. MeOH, and 19.5 cc. 5.5% HN3-C6H6 kept 15 min. at 0° yielded 6.91 g. IV.  Piperazine and 2 mole equivs. each iso-PrCHO, HN3, and I in CHCl3-MeOH kept 10 min. at 0° yielded 97% (crude) 1,4-bis[1-(1-cyclohexyl-5-tetrazolyl)isobutyl] piperazine, m. 281-5° (decompn.) (CHCl3-cyclohexane).  BzH (3.18 g.), 2.55 g. piperidine, 40 cc. Me2CO, 1.95 g. NaN3, 20 cc. H2O, 3.0 cc. 10N HCl, and 2.73 g. I kept 20 hrs. at 20° yielded 3.67 g. 1-cyclohexyl-5-(α-piperidinobenzyl)tetrazole-HCl (V.HCl), m. 225-7° (decompn.) (MeOH); V m. 127-8° (ligroine, b. 80-110°).  BzH (3.18 g.), 2.55 g. piperidine, 10 cc. MeOH, 2.73 g. I, and 23.4 cc. 5.5% HN3-C6H6 kept 3 hrs. at 20° gave 7.41 g. V, m. 127-8°.  Iso-PrN:CMe2 (2.97 g.), 1.95 g. NaN3, 20 cc. H2O, 2.73 g. I, 30 cc. Me2CO, and 3.0 cc. 10N HCl kept 70 hrs. at 20° gave 2.76 g. 1-cyclohexyl-5-(α-isopropylaminoisopropyl)tetrazole (VI), m. 62-2.5° (petr. ether); VI.HCl m. 171-2° (decompn.).  Iso-PrN:CMe2 (2.97 g.), 2.73 g. I, 10 cc. MeOH, and 17.6 cc. 7.3% HN3-C6H6 kept 15 hrs. at 20° yielded 5.81 g. VI.  Piperidine (2.55 g.), 2.73 g. I, 30 cc. Me2CO, 10 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 120 hrs. at 20° yielded 6.46 g. 1-cyclohexyl-5-(α-piperidinoisopropyl)tetrazole, m. 127-8° (1:3 C6H6-petr. ether). p-MeOC6H4NH2 (2.77 g.), 20 cc. Me2CO, 17.6 cc. 7.3% HN3-C6H6, 2.45 g. I, and 5 cc. MeOH kept 12 days at 20° gave 6.39 g. 1-cyclohexyl-5-[α-(p-methoxyanilino)isopropyl]tetrazole, m. 130-2° (2:1 C6H6-petr. ether).  Cyclohexanonebutylimide (VII) (4.60 g.), 2.73 g. I, 1.95 g. NaN3 in 15 cc. H2O, 30 cc. Me2CO, and 3.0 cc. 10N HCl kept 12 hrs. at 20° gave 5.21 g. 1-cyclohexyl-5-(1-butylaminocyclohexyl)tetrazole (VIII), m. 107-9° (petr. ether).  VII (4.60 g.), 2.73 g. I, 20 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 10 min. at 20° yielded 7.56 g. VIII.  1-Piperidinocyclohexene (4.96 g.), 2.73 g. I, 10 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 10 min. at 0° gave 7.70 g. 5-(1-piperidinocyclohexyl) analog of VIII, m. 149-50° (petr. ether).  AcPh (7.20 g.), 5.22 g. morpholine, 5.99 g. I, 45 cc. MeOH, and 35.2 cc. 7.3% HN3-C6H6 kept 3 weeks at 20-5° gave 12.98 g. (crude) 5-(1-morpholino-1-phenylethyl) analog (IX) of VIII, m. 213-15° (C6H6).  1-Morpholino-1-phenylethylene (3.31 g.), b1 110-12°, 1.63 g. I, 5 cc. MeOH, and 10.3 cc. 7.3% HN3-C6H6 kept 15 min. at 0-10° gave 4.82 g. IX.  PhCH2Ac (4.02 g.), 2.61 g. morpholine, 20 cc. MeOH, 2.73 g. I, and 17.6 cc. 7.3% HN3-C6H6 kept 72 hrs. at 20-5° gave 8.57 g. (crude) 1-cyclohexyl-5-(α-morpholino-β-phenylisopropyl)tetrazole (X), m. 189-91° (3:1 C6H6-petr. ether).  2-Morpholino-1-phenylpropene (6.09 g.), 2.73 g. I, 5 cc. MeOH, and 17.6 cc. 7.3% HN3-C6H6 kept 5 hrs. at 10-20° yielded 8.39 g.X.  Me3CN:CH2 (5.10 g.), 7.21 g. 2,6-Me2C6H3NC, 30 cc. MeOH, and 35.2 cc. 7.3% HN3-C6H6 kept 15 hrs. at 20° yielded 12.69 g. (crude) 1-(2-6-dimethylphenyl)-5-(tert-butylaminomethyl)tetrazole (XI), m. 79-81° (C6H6).  Iso-PrCHO (4.32 g.), 5.10 g. piperidine, 40 cc. MeOH, 6.56 g. 2,6-Me2C6H3NC, and 35.2 cc. 7.3% HN3-C6H6 kept 5 hrs. at 20° yielded 15.41 g. (crude) 5-(1-piperidino-2-methylpropyl) analog of XI, m. 126-7° (1:2 C6H6-Et2O).  The infrared absorption spectrum of IX was recorded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprIzv-ZuZHBLVg90H21EOLACvtfcHk0ljq_4ovQcyQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXotFKqsQ%253D%253D&md5=dfabc705854ead4af1874007a7b64a31</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fcber.19610940323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19610940323%26sid%3Dliteratum%253Aachs%26aulast%3DUgi%26aufirst%3DI.%26aulast%3DSteinbr%25C3%25BCckner%26aufirst%3DC.%26atitle%3DIsonitrile%252C%2520IX.%2520A-Addition%2520von%2520Immonium-Ionen%2520Und%2520Carbons%25C3%25A4ure-Anionen%2520an%2520Isonitrile%26jtitle%3DChem.%2520Ber.%26date%3D1961%26volume%3D94%26issue%3D10%26spage%3D734%26doi%3D10.1002%2Fcber.19610940323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wessjohann, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vercillo, O. E.</span></span> <span> </span><span class="NLM_article-title">Multiple Multicomponent Macrocyclizations (MiBs): A Strategie Development toward Macrocycle Diversity</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">796</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1021/cr8003407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr8003407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=796-814&issue=2&author=L.+A.+Wessjohannauthor=D.+G.+Riveraauthor=O.+E.+Vercillo&title=Multiple+Multicomponent+Macrocyclizations+%28MiBs%29%3A+A+Strategie+Development+toward+Macrocycle+Diversity&doi=10.1021%2Fcr8003407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Multicomponent Macrocyclizations (MiBs): A Strategic Development Toward Macrocycle Diversity</span></div><div class="casAuthors">Wessjohann, Ludger A.; Rivera, Daniel G.; Vercillo, Otilie E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">796-814</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review presents basic principles of multiple multi-component macrocyclization methods.  The approach is expected to develop to a valuable strategy for the synthesis of peptide-like or artificial macrocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcgRP4IhK-vbVg90H21EOLACvtfcHk0ljq_4ovQcyQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVChtb0%253D&md5=d32b92ff49300a68adc2fa152e4cd8d0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fcr8003407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr8003407%26sid%3Dliteratum%253Aachs%26aulast%3DWessjohann%26aufirst%3DL.%2BA.%26aulast%3DRivera%26aufirst%3DD.%2BG.%26aulast%3DVercillo%26aufirst%3DO.%2BE.%26atitle%3DMultiple%2520Multicomponent%2520Macrocyclizations%2520%2528MiBs%2529%253A%2520A%2520Strategie%2520Development%2520toward%2520Macrocycle%2520Diversity%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26issue%3D2%26spage%3D796%26epage%3D814%26doi%3D10.1021%2Fcr8003407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. A. <i>R</i>-Crizotinib (<b>12</b>) and the ALK/ROS1 selective inhibitor Lorlatinib (<b>4</b>) and the cellular IC<sub>50</sub> values on ALK and ALK-L1196 M gatekeeper mutation and the MDR efflux ratio.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> B. Selectivity panel of <i>R-</i>Crizotinib (<b>12</b>) against 456 recombinant human protein kinases with a screening concentration of 1000 nM and Lorlatinib (<b>4</b>) against a panel of 206 kinases at a screening concentration of 1000 nM. The primary targets ALK and ROS1 are highlighted in blue. Values were adopted from refs <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and <a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>. C. IC<sub>50</sub> values of Lorlatinib (<b>4</b>) against it closest off-targets.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> D. Binding mode of acyclic compound <i>R</i>-Crizotinib (<b>12</b>) on human Anaplastic Lymphoma Kinase (ALK; PDB-ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>). E. Binding mode of macrocyclic compound Lorlatinib (<b>4</b>) on human Anaplastic Lymphoma Kinase (ALK; PDB-ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI">4CLI</a>). F. Alignment of acyclic compound <i>R</i>-Crizotinib (<b>12</b>) (orange) and macrocyclic compound Lorlatinib (<b>4</b>) (green) on human Anaplastic Lymphoma Kinase (PDB-ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2">2XP2</a>) in surface representation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overview over the optimization steps from the first to the third generation ALK/ROS inhibitors.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of PK/PD optimization steps from aminobenzimidazole <b>15</b> to macrocyclic aminobenzimidazole BI-4020 (<b>19</b>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overview of the different synthetic reaction types that have been used for macrocyclization. Approximately 300 different macrocyclization reactions have been reviewed, which have been performed in the past 15 years for the synthesis of macrocyclic kinase inhibitors with known yields. The upper panel displays the percentage of the macrocyclization reactions used, whereas in the lower panel, the “macrolactonization and macrolactamization”, the “palladium-catalyzed reactions”, the “C–O and C–N bond formations”, and “C–C bond formations” have been subdivided into the individual macrocyclization reaction types.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Example of Macrocyclization through a Ring-Closing Metathesis<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mean values of yields and Emac values depending on the ring size for the ring-closing metathesis reactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Example for a Macrocyclization Using an Intermolecular Nucleophilic Substitution<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mean values of yields and Emac values as a function of the ring size for the nucleophilic substitution ring closure reactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Example for a Macrocyclization Using Amide Coupling<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Mean values of yields and Emac values depending on the ring size for the amide coupling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Examples of Macrolactonization and Macrolactamization Reactions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example for a macrocyclization using a A, Yamaguchi esterfication;<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> B, Mukaiyama reaction;<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> C, Shiina esterfication;<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> D, Steglich esterfication.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></p></p></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Summary of esterification ring-closing reactions. Mean values of yields and Emac values depending on the ring size for the Yamaguchi esterfication. The values for the Mukaiyama reaction, Shiina esterfication, and Steglich esterification are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">Figure S1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Examples of Palladium-Catalyzed Cross-Coupling Reactions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example for a macrocyclization through A, Suzuki reaction;<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> B, Heck reaction;<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> C, Buchwald-Hartwig amination.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></p></p></figure><figure data-id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Examples of C–O and C–N Bond Formation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example of a macrocyclization through A, Mitsunobu reaction;<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> B, Prins-driven reaction;<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> C, Click reaction;<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> D, Aryl amidation.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></p></p></figure><figure data-id="fig9" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Summary of C–O and C–N bond formation. Mean values of yields and Emac values depending on the ring size for the A, Mitsunobu reaction; B, Click reaction. The values for the Prins-driven reaction and aryl amidation are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">Figure S3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Examples of C–C Bond Formation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Example of macrocyclization through A, alkyne metathesis;<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> B, [2 + 2 + 2] cycloaddition;<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> C, alkyne–aldehyde reductive coupling;<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> D, Wittig reaction;<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> E, McMurry reaction;<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> F, Nozaki–Hiyama–Kishi reaction.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></p></p></figure><figure data-id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Summary of C–C bond formations. Mean values of yields and Emac values depending on the ring size for the A, alkyne metathesis; B, [2 + 2 + 2] cycloaddition; C, alkyne–aldehyde reductive coupling. The values for the Wittig reaction, McMurry reaction, and Nozaki–Hiyama–Kishi reaction are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf" class="ext-link">Figure S4</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/medium/jm1c00217_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Comparison of the different macrocyclization methods and their dependence on the ring size.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00217/20210616/images/large/jm1c00217_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00217&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02211" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02211" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 115 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Macrocycles in New Drug Discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.93</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.4155%2Ffmc.12.93" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22857532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1409-1438&issue=11&author=J.+Mallinsonauthor=I.+Collins&title=Macrocycles+in+New+Drug+Discovery&doi=10.4155%2Ffmc.12.93"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles in new drug discovery</span></div><div class="casAuthors">Mallinson, Jamie; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1409-1438</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of drug-like macrocycles is emerging as an exciting area of medicinal chem., with several recent examples highlighting the favorable changes in biol. and physicochem. properties that macrocyclization can afford.  Natural product macrocycles and their synthetic derivs. have long been clin. useful and attention is now being focused on the wider use of macrocyclic scaffolds in medicinal chem. in the search for new drugs for increasingly challenging targets.  With the increasing awareness of concepts of drug-likeness and the dangers of mol. obesity', functionalized macrocyclic scaffolds could provide a way to generate ligand-efficient mols. with enhanced properties.  In this review we will sep. discuss the effects of macrocyclization upon potency, selectivity and physicochem. properties, concg. on recent case histories in oncol. drug discovery.  Addnl., we will highlight selected advances in the synthesis of macrocycles and provide an outlook on the future use of macrocyclic scaffolds in medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSrzcbKW7Tc7Vg90H21EOLACvtfcHk0lhb40HzNnicxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCht7rO&md5=63ad275af92ac89ae6b36c5071b578f8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.93%26sid%3Dliteratum%253Aachs%26aulast%3DMallinson%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMacrocycles%2520in%2520New%2520Drug%2520Discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26issue%3D11%26spage%3D1409%26epage%3D1438%26doi%3D10.4155%2Ffmc.12.93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driggers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span> <span> </span><span class="NLM_article-title">The Exploration of Macrocycles for Drug Discovery — an Underexploited Structural Class</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/nrd2590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnrd2590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=18591981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+Exploration+of+Macrocycles+for+Drug+Discovery+%E2%80%94+an+Underexploited+Structural+Class&doi=10.1038%2Fnrd2590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The exploration of macrocycles for drug discovery - an underexploited structural class</span></div><div class="casAuthors">Driggers, Edward M.; Hale, Stephen P.; Lee, Jinbo; Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">608-624</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products comprised of a macrocycle ring structure have proven their therapeutic applications as antibiotics, immunosuppressants as well as anticancer agents.  Despite this, macrocyclic compds. remain under-explored.  Terrett and colleagues review the properties and features of current macrocycle drugs, emphasizing the vast potential of synthetic macrocycles in drug discovery.  Macrocyclic natural products have evolved to fulfil numerous biochem. functions, and their profound pharmacol. properties have led to their development as drugs.  A macrocycle provides diverse functionality and stereochem. complexity in a conformationally pre-organized ring structure.  This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations.  Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery.  This is in part due to concerns about synthetic intractability and non-drug-like properties.  This Review describes the growing body of data in favor of macrocyclic therapeutics, and demonstrates that this class of compds. can be both fully drug-like in its properties and readily prepd. owing to recent advances in synthetic medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDtW8LpE4ru7Vg90H21EOLACvtfcHk0lgbYaRHv7o7yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D&md5=16e091818053e5b163b81078a8d03094</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2590%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520Exploration%2520of%2520Macrocycles%2520for%2520Drug%2520Discovery%2520%25E2%2580%2594%2520an%2520Underexploited%2520Structural%2520Class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624%26doi%3D10.1038%2Fnrd2590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelraheem, E. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurpiewska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowska-Tłuscik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span> <span> </span><span class="NLM_article-title">Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8789</span>– <span class="NLM_lpage">8795</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.6b01430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b01430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOrt77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=8789-8795&issue=19&author=E.+M.+M.+Abdelraheemauthor=K.+Kurpiewskaauthor=J.+Kalinowska-T%C5%82uscikauthor=A.+Domling&title=Artificial+Macrocycles+by+Ugi+Reaction+and+Passerini+Ring+Closure&doi=10.1021%2Facs.joc.6b01430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Artificial macrocycles by Ugi reaction and Passerini ring closure</span></div><div class="casAuthors">Abdelraheem, Eman M. M.; Kurpiewska, Katarzyna; Kalinowska-Tluscik, Justyna; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8789-8795</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Artificial macrocycles can be convergently synthesized by a sequence of an Ugi multicomponent reaction (MCR) followed by an intramol. Passerini MCR used to close the macrocycle.  Significantly, in this work, the first intramol. macrocyclization through a Passerini reaction is described.  We describe 21 macrocycles of a size of 15-20.  The resulting macrocyclic depsipeptides are model compds. for natural products and could find applications in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoitRBwMEc1XLVg90H21EOLACvtfcHk0lgbYaRHv7o7yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOrt77O&md5=cc97ee0a82cdeac2becf3166b3d5dcd2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b01430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b01430%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelraheem%26aufirst%3DE.%2BM.%2BM.%26aulast%3DKurpiewska%26aufirst%3DK.%26aulast%3DKalinowska-T%25C5%2582uscik%26aufirst%3DJ.%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DArtificial%2520Macrocycles%2520by%2520Ugi%2520Reaction%2520and%2520Passerini%2520Ring%2520Closure%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2016%26volume%3D81%26issue%3D19%26spage%3D8789%26epage%3D8795%26doi%3D10.1021%2Facs.joc.6b01430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lgbYaRHv7o7yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logusch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambiar, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au-Yeung, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Total Synthesis of Erythromcin. 1. Synthesis of an Erythronolide A Secoacid Derivative via Asymmetric Induction</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3210</span>– <span class="NLM_lpage">3213</span>, <span class="refDoi"> DOI: 10.1021/ja00401a049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00401a049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFyqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1981&pages=3210-3213&issue=11&author=R.+B.+Woodwardauthor=E.+Loguschauthor=K.+P.+Nambiarauthor=K.+Sakanauthor=D.+E.+Wardauthor=B.+W.+Au-Yeungauthor=P.+Balaramauthor=L.+J.+Browneauthor=P.+J.+Cardauthor=C.+H.+Chen&title=Asymmetric+Total+Synthesis+of+Erythromcin.+1.+Synthesis+of+an+Erythronolide+A+Secoacid+Derivative+via+Asymmetric+Induction&doi=10.1021%2Fja00401a049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric total synthesis of erythromycin. 1. Synthesis of an erythronolide A seco acid derivative via asymmetric induction</span></div><div class="casAuthors">Woodward, R. B.; Logusch, E.; Nambiar, K. P.; Sakan, K.; Ward, D. E.; Au-Yeung, B.-W.; Balaram, P.; Browne, L. J.; Card, P. J.; Chen, C. H.; Chenevert, R. B.; Fliri, A.; Frobel, K.; Gais, H.-J.; Garratt, D. G.; Hayakawa, K.; Heggie, W.; Hesson, D. P.; Hoppe, D.; Hoppe, I.; Hyatt, J. A.; Ikeda, D.; Jacobi, P. A.; Kim, K. S.; Kobuke, Y.; Kojima, K.; Krowicki, K.; Lee, V. J.; Leutert, T.; Malchenko, S.; Martens, J.; Matthews, R. S.; Ong, B. S.; Press, J. B.; RajanBabu, T. V.; Rousseau, G.; Sauter, H. M.; Suzuki, M.; Tatsuta, K.; Tolbert, L. M.; Truesdale, E. A.; Uchida, I.; Ueda, Y.; Uyehara, T.; Vaselia, A. T.; Vladuchick, W. C.; Wade, P. A.; Williams, R. M.; Wong, H. N.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3210-3213</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereocontrolled asym. synthesis of the erythronolide A seco acid deriv. I synthon of erythromycin via asym. induction and stereoselective aldolization of keto aldehyde, is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRfLRDEq6-w7Vg90H21EOLACvtfcHk0lgFMnQ6VEHMGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFyqs7k%253D&md5=5533fe975c4ba248b8c516b2c4f9e74d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fja00401a049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00401a049%26sid%3Dliteratum%253Aachs%26aulast%3DWoodward%26aufirst%3DR.%2BB.%26aulast%3DLogusch%26aufirst%3DE.%26aulast%3DNambiar%26aufirst%3DK.%2BP.%26aulast%3DSakan%26aufirst%3DK.%26aulast%3DWard%26aufirst%3DD.%2BE.%26aulast%3DAu-Yeung%26aufirst%3DB.%2BW.%26aulast%3DBalaram%26aufirst%3DP.%26aulast%3DBrowne%26aufirst%3DL.%2BJ.%26aulast%3DCard%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DC.%2BH.%26atitle%3DAsymmetric%2520Total%2520Synthesis%2520of%2520Erythromcin.%25201.%2520Synthesis%2520of%2520an%2520Erythronolide%2520A%2520Secoacid%2520Derivative%2520via%2520Asymmetric%2520Induction%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1981%26volume%3D103%26issue%3D11%26spage%3D3210%26epage%3D3213%26doi%3D10.1021%2Fja00401a049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Conformational Restriction: An Effective Tactic in ‘Follow-on’-Based Drug Discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&issue=8&author=Z.+Fangauthor=Y.+Songauthor=P.+Zhanauthor=Q.+Zhangauthor=X.+Liu&title=Conformational+Restriction%3A+An+Effective+Tactic+in+%E2%80%98Follow-on%E2%80%99-Based+Drug+Discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0lgFMnQ6VEHMGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DConformational%2520Restriction%253A%2520An%2520Effective%2520Tactic%2520in%2520%25E2%2580%2598Follow-on%25E2%2580%2599-Based%2520Drug%2520Discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26issue%3D8%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">The Ins and Outs of Selective Kinase Inhibitor Development</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">821</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnchembio.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26485069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=818-821&author=S.+M%C3%BCllerauthor=A.+Chaikuadauthor=N.+S.+Grayauthor=S.+Knapp&title=The+Ins+and+Outs+of+Selective+Kinase+Inhibitor+Development&doi=10.1038%2Fnchembio.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of selective kinase inhibitor development</span></div><div class="casAuthors">Muller, Susanne; Chaikuad, Apirat; Gray, Nathanael S.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-821</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases have emerged as one of the most successful families of drug targets.  To date, most selective kinase inhibitors have been discovered serendipitously either through broad selectivity screening or through the discovery of unique binding modes.  Here the authors discuss design strategies that could lead to a broader coverage of the kinome with selective inhibitors and to a more rational approach for developing them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQzaMrxSYx_rVg90H21EOLACvtfcHk0lgFMnQ6VEHMGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF&md5=f5adf0bbaa388c87b26bae23cfad0bae</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1938%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DThe%2520Ins%2520and%2520Outs%2520of%2520Selective%2520Kinase%2520Inhibitor%2520Development%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D818%26epage%3D821%26doi%3D10.1038%2Fnchembio.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Duffhues, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benderitter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Wijhe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia de Vinuesa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caradec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goumans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eekhoff, E. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Piga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachiller-Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolwijk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoflack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells</span>. <i>JBMR Plus</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">11</span>), <span class="NLM_elocation-id">e10230</span> <span class="refDoi"> DOI: 10.1002/jbm4.10230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fjbm4.10230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=31768489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&issue=11&author=G.+S%C3%A1nchez-Duffhuesauthor=E.+Williamsauthor=P.+Benderitterauthor=V.+Orlovaauthor=M.+van+Wijheauthor=A.+Garcia+de+Vinuesaauthor=G.+Kerrauthor=J.+Caradecauthor=K.+Lodderauthor=H.+C.+de+Boerauthor=M.+J.+Goumansauthor=E.+M.+W.+Eekhoffauthor=A.+Morales-Pigaauthor=J.+Bachiller-Corralauthor=P.+Koolwijkauthor=A.+N.+Bullockauthor=J.+Hoflackauthor=P.+Ten+Dijke&title=Development+of+Macrocycle+Kinase+Inhibitors+for+ALK2+Using+Fibrodysplasia+Ossificans+Progressiva-Derived+Endothelial+Cells&doi=10.1002%2Fjbm4.10230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells</span></div><div class="casAuthors">Sanchez-Duffhues, Gonzalo; Williams, Eleanor; Benderitter, Pascal; Orlova, Valeria; van Wijhe, Michiel; Garcia de Vinuesa, Amaya; Kerr, Georgina; Caradec, Josselin; Lodder, Kirsten; de Boer, Hetty C.; Goumans, Marie-Jose; Eekhoff, Elisabeth M. W.; Morales-Piga, Antonio; Bachiller-Corral, Javier; Koolwijk, Pieter; Bullock, Alex N.; Hoflack, Jan; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">JBMR Plus</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e10230</span>CODEN:
                <span class="NLM_cas:coden">JPBLA6</span>;
        ISSN:<span class="NLM_cas:issn">2473-4039</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital form of heterotopic ossification (HO), caused by heterozygous mutations in the activin A type I receptor (ACVR1), that encodes the bone morphogenetic protein (BMP) type I receptor ALK2.  These mutations enable ALK2 to induce downstream signaling in response to activins, thereby turning them into bone-inducing agents.  To date, there is no cure for FOP.  The further development of FOP patient-derived models may contribute to the discovery of novel biomarkers and therapeutic approaches.  Nevertheless, this has traditionally been a challenge, as biopsy sampling often triggers HO.  We have characterized peripheral blood-derived endothelial colony-forming cells (ECFCs) from three independent FOP donors as a new model for FOP.  FOP ECFCs are prone to undergo endothelial-to-mesenchymal transition and exhibit increased ALK2 downstream signaling and subsequent osteogenic differentiation upon stimulation with activin A. Moreover, we have identified a new class of small mol. macrocycles with potential activity against ALK2 kinase.  Finally, using FOP ECFCs, we have selected OD36 and OD52 as potent inhibitors with excellent kinase selectivity profiles that potently antagonize mutant ALK2 signaling and osteogenic differentiation.  We expect that these results will contribute to the development of novel ALK2 clin. candidates for the treatment of FOP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdMImAbYILErVg90H21EOLACvtfcHk0li20uIlujcSUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKitbjE&md5=19b74fb9ff4bc6c0cbc7a5071b876f87</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fjbm4.10230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbm4.10230%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Duffhues%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DE.%26aulast%3DBenderitter%26aufirst%3DP.%26aulast%3DOrlova%26aufirst%3DV.%26aulast%3Dvan%2BWijhe%26aufirst%3DM.%26aulast%3DGarcia%2Bde%2BVinuesa%26aufirst%3DA.%26aulast%3DKerr%26aufirst%3DG.%26aulast%3DCaradec%26aufirst%3DJ.%26aulast%3DLodder%26aufirst%3DK.%26aulast%3Dde%2BBoer%26aufirst%3DH.%2BC.%26aulast%3DGoumans%26aufirst%3DM.%2BJ.%26aulast%3DEekhoff%26aufirst%3DE.%2BM.%2BW.%26aulast%3DMorales-Piga%26aufirst%3DA.%26aulast%3DBachiller-Corral%26aufirst%3DJ.%26aulast%3DKoolwijk%26aufirst%3DP.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DHoflack%26aufirst%3DJ.%26aulast%3DTen%2BDijke%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520Macrocycle%2520Kinase%2520Inhibitors%2520for%2520ALK2%2520Using%2520Fibrodysplasia%2520Ossificans%2520Progressiva-Derived%2520Endothelial%2520Cells%26jtitle%3DJBMR%2520Plus%26date%3D2019%26volume%3D3%26issue%3D11%26doi%3D10.1002%2Fjbm4.10230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span>; <span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Macrocyclic Kinase Inhibitors</span>. In  <i>Kinase Drug Discovery: Modern Approaches</i>; <span class="NLM_publisher-name">The Royal Society of Chemistry</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">127</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=97-127&author=A.+Poulsen&author=B.+Dymock&title=Kinase+Drug+Discovery%3A+Modern+Approaches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26atitle%3DSmall%2520Molecule%2520Macrocyclic%2520Kinase%2520Inhibitors%26btitle%3DKinase%2520Drug%2520Discovery%253A%2520Modern%2520Approaches%26pub%3DThe%2520Royal%2520Society%2520of%2520Chemistry%26date%3D2019%26spage%3D97%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, R. G. S.</span></span> <span> </span><span class="NLM_article-title">A Worldwide, Phase III, Randomized, Controlled, Safety and Efficacy Study of a Sirolimus/Cyclosporine Regimen for Prevention of Acute Rejection in Recipients of Primary Mismatched Renal Allografts</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1097/00007890-200101270-00019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1097%2F00007890-200101270-00019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=11213073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtF2msrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2001&pages=271-280&issue=2&author=A.+S.+MacDonaldauthor=R.+G.+S.+Group&title=A+Worldwide%2C+Phase+III%2C+Randomized%2C+Controlled%2C+Safety+and+Efficacy+Study+of+a+Sirolimus%2FCyclosporine+Regimen+for+Prevention+of+Acute+Rejection+in+Recipients+of+Primary+Mismatched+Renal+Allografts&doi=10.1097%2F00007890-200101270-00019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts</span></div><div class="casAuthors">MacDonald, Allan S.</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Despite the various immunosuppressive regimens presently in use, acute rejection in the early postoperative period continues to occur in 20 to 40% of renal transplant patients.  In a double-blind, multicentered study, we investigated the ability of two different doses of sirolimus (rapamycin, RAPAMUNE), a new class of immunosuppressant that blocks cell cycle progression, to prevent acute rejection in recipients of primary mismatched renal allografts when added to a regimen of cyclosporine (cyclosporin A, CsA) and corticosteroids.  Between Oct. 1996 and Sept. 1997, 576 recipients of primary mismatched cadaveric or living donor renal allografts were randomly assigned in a 2:2:1 ratio (before the transplant operation) to receive an initial loading dose of either 6 or 15 mg of orally administered sirolimus, followed by a daily dose of either 2 or 5 mg/day, or to receive a matched placebo.  All groups received cyclosporine (microemulsion formula, CsA) and corticosteroids.  The primary endpoint was a composite of first occurrence of biopsy-confirmed acute rejection, graft loss, or death during the first 6 mo after transplantation.  Safety data were monitored by an independent drug safety monitoring board.  Based on an intention-to-treat anal. of 576 patients, there were no significant differences in patient demog. or baseline characteristics among treatment groups.  The overall rate of the primary composite endpoint for the 6-mo period after transplantation was 30.0% (68/227) in the 2 mg/day sirolimus group and 25.6% (56/219) in the 5 mg/day sirolimus group, significantly lower than the 47.7% (62/130) in the placebo group (P=0.002, P<0.001, resp.).  During this period, the incidence of biopsy-confirmed acute rejection was 24.7% (56/227) in the 2 mg/day sirolimus group and 19.2% (42/219) in the 5 mg/day sirolimus group, compared with 41.5% (54/130) in the placebo group (P=0.003, P<0.001, resp.), representing a significant redn. in acute rejection of 40.5 and 53.7%, resp.  The need for antibody therapy to treat the first episode of biopsy-confirmed acute rejection was significantly reduced in the 5 mg/day sirolimus group (3.2%) compared to the placebo group (8.5%; P=0.044).  The results 1 yr after transplantation were similar for the efficacy parameters studied.  Adverse events and infections occurred in all groups.  The addn. of either 2 mg/day sirolimus or 5 mg/day sirolimus to CsA/corticosteroid therapy significantly reduces the incidence of acute rejection episodes in primary mismatched renal allograft recipients, without an increase in immunosuppressant-related side effects, including infections and malignancy, at 6 mo and at 1 yr after transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe9OgHBtog_LVg90H21EOLACvtfcHk0li20uIlujcSUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtF2msrw%253D&md5=cce72319995391bbcc8eaa9f55cb2bf6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1097%2F00007890-200101270-00019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00007890-200101270-00019%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DA.%2BS.%26aulast%3DGroup%26aufirst%3DR.%2BG.%2BS.%26atitle%3DA%2520Worldwide%252C%2520Phase%2520III%252C%2520Randomized%252C%2520Controlled%252C%2520Safety%2520and%2520Efficacy%2520Study%2520of%2520a%2520Sirolimus%252FCyclosporine%2520Regimen%2520for%2520Prevention%2520of%2520Acute%2520Rejection%2520in%2520Recipients%2520of%2520Primary%2520Mismatched%2520Renal%2520Allografts%26jtitle%3DTransplantation%26date%3D2001%26volume%3D71%26issue%3D2%26spage%3D271%26epage%3D280%26doi%3D10.1097%2F00007890-200101270-00019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malizzia, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, A.</span></span> <span> </span><span class="NLM_article-title">Temsirolimus, an MTOR Inhibitor for Treatment of Patients with Advanced Renal Cell Carcinoma</span>. <i>Clin. J. Oncol. Nurs.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1188/08.CJON.639-646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1188%2F08.CJON.639-646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=18676330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpsFSjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=639-646&issue=4&author=L.+J.+Malizziaauthor=A.+Hsu&title=Temsirolimus%2C+an+MTOR+Inhibitor+for+Treatment+of+Patients+with+Advanced+Renal+Cell+Carcinoma&doi=10.1188%2F08.CJON.639-646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma</span></div><div class="casAuthors">Malizzia Lois J; Hsu Arlene</div><div class="citationInfo"><span class="NLM_cas:title">Clinical journal of oncology nursing</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">639-46</span>
        ISSN:<span class="NLM_cas:issn">1092-1095</span>.
    </div><div class="casAbstract">Temsirolimus is a targeted therapy that inhibits mammalian target of rapamycin (mTOR), a central regulator of tumor cell responses to growth stimuli.  Temsirolimus has a broad anticancer activity profile that impacts tumor cell growth, proliferation, and survival through its specific inhibition of mTOR.  In a randomized phase III trial that enrolled previously untreated patients with advanced renal cell carcinoma (RCC) and poor prognostic features, temsirolimus significantly prolonged overall survival compared with interferon-alpha, a standard therapy (p = 0.008).  Because of the results, temsirolimus was approved by the U.  S.  Food and Drug Administration for treatment and is considered a first-line treatment for patients with advanced RCC with poor prognostic features.  Temsirolimus is administered at a flat weekly IV dose of 25 mg given over 30-60 minutes.  Gastrointestinal disorders (stomatitis, anorexia, nausea, diarrhea, and vomiting), rash, fatigue, edema, infections, and dyspnea, as well as hematologic and metabolic laboratory abnormalities occur in patients receiving temsirolimus.  Metabolic side effects include hyperglycemia, hypercholesterolemia, hypertriglyceridemia, and hypophosphatemia.  Most adverse reactions associated with temsirolimus can be managed medically or addressed by supportive measures.  Nurses can improve patient outcomes through early recognition of side effects and prompt interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhGd6q3qw8O8ERNNga7KD-fW6udTcc2eYlHUxDBPhO37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpsFSjuw%253D%253D&md5=9557444f6d23c2572ac8e1957e6b1f08</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1188%2F08.CJON.639-646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1188%252F08.CJON.639-646%26sid%3Dliteratum%253Aachs%26aulast%3DMalizzia%26aufirst%3DL.%2BJ.%26aulast%3DHsu%26aufirst%3DA.%26atitle%3DTemsirolimus%252C%2520an%2520MTOR%2520Inhibitor%2520for%2520Treatment%2520of%2520Patients%2520with%2520Advanced%2520Renal%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520J.%2520Oncol.%2520Nurs.%26date%3D2008%26volume%3D12%26issue%3D4%26spage%3D639%26epage%3D646%26doi%3D10.1188%2F08.CJON.639-646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünwald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollaender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravaud, A.</span></span> <span> </span><span class="NLM_article-title">Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4265</span>, <span class="refDoi"> DOI: 10.1002/cncr.25219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcncr.25219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20549832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2rtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4256-4265&issue=18&author=R.+J.+Motzerauthor=B.+Escudierauthor=S.+Oudardauthor=T.+E.+Hutsonauthor=C.+Portaauthor=S.+Bracardaauthor=V.+Gr%C3%BCnwaldauthor=J.+A.+Thompsonauthor=R.+A.+Figlinauthor=N.+Hollaenderauthor=A.+Kayauthor=A.+Ravaud&title=Phase+3+Trial+of+Everolimus+for+Metastatic+Renal+Cell+Carcinoma%3A+Final+Results+and+Analysis+of+Prognostic+Factors&doi=10.1002%2Fcncr.25219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 trial of everolimus for metastatic renal cell carcinoma</span></div><div class="casAuthors">Motzer, Robert J.; Escudier, Bernard; Oudard, Stephane; Hutson, Thomas E.; Porta, Camillo; Bracarda, Sergio; Grunwald, Viktor; Thompson, John A.; Figlin, Robert A.; Hollaender, Norbert; Kay, Andrea; Ravaud, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4256-4265</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND: A phase 3 trial demonstrated superiority at interim anal. for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor-tyrosine kinase inhibitors.  Final results and anal. of prognostic factors are reported.  METHODS: Patients with mRCC (N = 416) were randomized (2:1) to everolimus 10 mg/d (n = 277) or placebo (n = 139) plus best supportive care.  Progression-free survival (PFS) and safety were assessed to the end of double-blind treatment.  Mature overall survival (OS) data were analyzed, and prognostic factors for survival were investigated by multivariate analyses.  A rank-preserving structural failure time model estd. the effect on OS, correcting for crossover from placebo to everolimus.  RESULTS: The median PFS was 4.9 mo (everolimus) vs. 1.9 mo (placebo) (hazard ratio [HR], 0.33; P < .001) by independent central review and 5.5 mo (everolimus) vs. 1.9 mo (placebo) (HR, 0.32; P < .001) by investigators.  Serious adverse events with everolimus, independent of causality, in ≥5% of patients included infections (all types, 10%), dyspnea (7%), and fatigue (5%).  The median OS was 14.8 mo (everolimus) vs. 14.4 mo (placebo) (HR, 0.87; P = .162), with 80% of patients in the placebo arm crossed over to everolimus.  By the rank-preserving structural failure time model, the survival cor. for crossover was 1.9-fold longer (95% confidence interval, 0.5-8.5) with everolimus compared with placebo only.  Independent prognostic factors for shorter OS in the study included low performance status, high cor. calcium, low Hb, and prior sunitinib (P < .01).  CONCLUSIONS: These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIQ2QwMk40ZLVg90H21EOLACvtfcHk0lgJvS-H0L6WeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2rtrrF&md5=97fc47e5d8c4f3f7e112394e8f98e680</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fcncr.25219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.25219%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBracarda%26aufirst%3DS.%26aulast%3DGr%25C3%25BCnwald%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DHollaender%26aufirst%3DN.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DRavaud%26aufirst%3DA.%26atitle%3DPhase%25203%2520Trial%2520of%2520Everolimus%2520for%2520Metastatic%2520Renal%2520Cell%2520Carcinoma%253A%2520Final%2520Results%2520and%2520Analysis%2520of%2520Prognostic%2520Factors%26jtitle%3DCancer%26date%3D2010%26volume%3D116%26issue%3D18%26spage%3D4256%26epage%3D4265%26doi%3D10.1002%2Fcncr.25219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C. H.</span></span> <span> </span><span class="NLM_article-title">Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">142</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.2533/chimia.2015.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.2533%2Fchimia.2015.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26507218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1antL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2015&pages=142-145&issue=3&author=A.+D.+Williamauthor=A.+C.+H.+Lee&title=Acid+Mediated+Ring+Closing+Metathesis%3A+A+Powerful+Synthetic+Tool+Enabling+the+Synthesis+of+Clinical+Stage+Kinase+Inhibitors&doi=10.2533%2Fchimia.2015.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acid mediated ring closing metathesis: a powerful synthetic tool enabling the synthesis of clinical stage kinase inhibitors</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">142-145</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>;
        ISSN:<span class="NLM_cas:issn">0009-4293</span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">The powerful olefin metathesis reaction was employed for the construction of late-phase clin. agents SB1317 and SB1518.  In both cases RCM seems to proceed only in the presence of an acid and to predominantly furnish trans isomers.  In case of SB1518 it proceeded in the presence of acid HCl, while for SB1317, it mainly proceeds in the presence of TFA (trifluroacetic acid).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG25wFaoHw7Vg90H21EOLACvtfcHk0lgJvS-H0L6WeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1antL4%253D&md5=c2eb64eaebb19fa6fa610f4e4be2218b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2015.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2015.142%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%2BH.%26atitle%3DAcid%2520Mediated%2520Ring%2520Closing%2520Metathesis%253A%2520A%2520Powerful%2520Synthetic%2520Tool%2520Enabling%2520the%2520Synthesis%2520of%2520Clinical%2520Stage%2520Kinase%2520Inhibitors%26jtitle%3DChimia%26date%3D2015%26volume%3D69%26issue%3D3%26spage%3D142%26epage%3D145%26doi%3D10.2533%2Fchimia.2015.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-Yl)Ethoxy)-7,12,25-Trioxa-19,21,24-Triaza-Tetracyclo[18.3.1.1(2,5).1(14,18)]Hexacosa-1(24),2,4,9,14(26),15,17,20,22-Nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-like Tyrosine Kinase-3 (JAK</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2623</span>– <span class="NLM_lpage">2640</span>, <span class="refDoi"> DOI: 10.1021/jm201454n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201454n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFShsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2623-2640&issue=6&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=A.+Poulsenauthor=K.+C.+Gohauthor=B.+Madanauthor=S.+Hartauthor=E.+Tanauthor=H.+Wangauthor=H.+Nagarajauthor=D.+Chenauthor=C.+P.+Leeauthor=E.+T.+Sunauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+Macrocycle+%289E%29-15-%282-%28Pyrrolidin-1-Yl%29Ethoxy%29-7%2C12%2C25-Trioxa-19%2C21%2C24-Triaza-Tetracyclo%5B18.3.1.1%282%2C5%29.1%2814%2C18%29%5DHexacosa-1%2824%29%2C2%2C4%2C9%2C14%2826%29%2C15%2C17%2C20%2C22-Nonaene+%28SB1578%29%2C+a+Potent+Inhibitor+of+Janus+Kinase+2%2FFms-like+Tyrosine+Kinase-3+%28JAK&doi=10.1021%2Fjm201454n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Poulsen, Anders; Goh, Kee Chuan; Madan, Babita; Hart, Stefan; Tan, Evelyn; Wang, Haishan; Nagaraj, Harish; Chen, Dizhong; Lee, Chai Ping; Sun, Eric T.; Jayaraman, Ramesh; Pasha, Mohammad Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2623-2640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we describe the synthesis and SAR of a series of small mol. macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase.  Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly sol. 14l (I) was selected as the optimal compd.  Oral efficacy in the murine collagen-induced arthritis (CIA) model for rheumatoid arthritis (RA) supported 14l as a potential treatment for autoimmune diseases and inflammatory disorders such as psoriasis and RA.  Compd. 14l (SB1578) was progressed into development and is currently undergoing phase 1 clin. trials in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Ig0dX6810bVg90H21EOLACvtfcHk0lgJvS-H0L6WeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFShsLY%253D&md5=efe684c2f2ff0b506d02c2ef911bfb2f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201454n%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520Macrocycle%2520%25289E%2529-15-%25282-%2528Pyrrolidin-1-Yl%2529Ethoxy%2529-7%252C12%252C25-Trioxa-19%252C21%252C24-Triaza-Tetracyclo%255B18.3.1.1%25282%252C5%2529.1%252814%252C18%2529%255DHexacosa-1%252824%2529%252C2%252C4%252C9%252C14%252826%2529%252C15%252C17%252C20%252C22-Nonaene%2520%2528SB1578%2529%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Janus%2520Kinase%25202%252FFms-like%2520Tyrosine%2520Kinase-3%2520%2528JAK%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D6%26spage%3D2623%26epage%3D2640%26doi%3D10.1021%2Fjm201454n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-Yl-Ethoxy)-14,19-Dioxa-5,7, 26-Triaza-Tetracyclo[19.3.1.1(2,6).1(8,12)]Heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-Decaene (SB1518), a Potent Janus Kinase 2/Fms-like Tyrosine Kinase-3 (JAK2/FLT3) Inhibito</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4658</span>, <span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&issue=13&author=A.+D.+Williamauthor=A.+C.+H.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+Macrocycle+11-%282-Pyrrolidin-1-Yl-Ethoxy%29-14%2C19-Dioxa-5%2C7%2C+26-Triaza-Tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5DHeptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-Decaene+%28SB1518%29%2C+a+Potent+Janus+Kinase+2%2FFms-like+Tyrosine+Kinase-3+%28JAK2%2FFLT3%29+Inhibito&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lh6DdxjozKShg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%2BH.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520Macrocycle%252011-%25282-Pyrrolidin-1-Yl-Ethoxy%2529-14%252C19-Dioxa-5%252C7%252C%252026-Triaza-Tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255DHeptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-Decaene%2520%2528SB1518%2529%252C%2520a%2520Potent%2520Janus%2520Kinase%25202%252FFms-like%2520Tyrosine%2520Kinase-3%2520%2528JAK2%252FFLT3%2529%2520Inhibito%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D13%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentze, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. W.</span></span> <span> </span><span class="NLM_article-title">SB1518, a Novel Macrocyclic Pyrimidine-Based JAK2 Inhibitor for the Treatment of Myeloid and Lymphoid Malignancies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fleu.2011.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21691275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&issue=11&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+Novel+Macrocyclic+Pyrimidine-Based+JAK2+Inhibitor+for+the+Treatment+of+Myeloid+and+Lymphoid+Malignancies&doi=10.1038%2Fleu.2011.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span></div><div class="casAuthors">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A. D.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ong, K. H.; Ethirajulu, K.; Dymock, B. W.; Wood, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 n for JAK2WT and JAK2V617F, resp.) within the JAK family (IC50=1280, 520 and 50 n for JAK1, JK3 and TYK2, resp.) and fms-like tyrosine kinase-3 (FLT3; IC50=22 n).  SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs.  As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.  SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2V617F-driven disease model.  SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a s.c. model generated with SET-2 cells derived from a JAK2V617F patient with megakaryoblastic leukemia.  Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease.  In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models.  These favorable properties are now being confirmed in clin. studies in patients with myelofibrosis and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOG8Fk52CR87Vg90H21EOLACvtfcHk0lh6DdxjozKShg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL&md5=ae5a5ae0efaaa8f51909e8c82c84610d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.148%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520Novel%2520Macrocyclic%2520Pyrimidine-Based%2520JAK2%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Myeloid%2520and%2520Lymphoid%2520Malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26issue%3D11%26spage%3D1751%26epage%3D1759%26doi%3D10.1038%2Fleu.2011.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannucchi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egyed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvorov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakucs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Boekhorst, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nangalia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiladjian, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span> <span> </span><span class="NLM_article-title">Pacritinib versus Best Available Therapy for the Treatment of Myelofibrosis Irrespective of Baseline Cytopenias (PERSIST-1): An International, Randomised, Phase 3 Trial</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e225</span> <span class="refDoi"> DOI: 10.1016/S2352-3026(17)30027-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS2352-3026%2817%2930027-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=28336242" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&author=R.+A.+Mesaauthor=A.+M.+Vannucchiauthor=A.+Meadauthor=M.+Egyedauthor=A.+Szokeauthor=A.+Suvorovauthor=J.+Jakucsauthor=A.+Perkinsauthor=R.+Prasadauthor=J.+Mayerauthor=J.+Demeterauthor=P.+Ganlyauthor=J.+W.+Singerauthor=H.+Zhouauthor=J.+P.+Deanauthor=P.+A.+Te+Boekhorstauthor=J.+Nangaliaauthor=J.-J.+Kiladjianauthor=C.+N.+Harrison&title=Pacritinib+versus+Best+Available+Therapy+for+the+Treatment+of+Myelofibrosis+Irrespective+of+Baseline+Cytopenias+%28PERSIST-1%29%3A+An+International%2C+Randomised%2C+Phase+3+Trial&doi=10.1016%2FS2352-3026%2817%2930027-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2817%2930027-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252817%252930027-3%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DMead%26aufirst%3DA.%26aulast%3DEgyed%26aufirst%3DM.%26aulast%3DSzoke%26aufirst%3DA.%26aulast%3DSuvorov%26aufirst%3DA.%26aulast%3DJakucs%26aufirst%3DJ.%26aulast%3DPerkins%26aufirst%3DA.%26aulast%3DPrasad%26aufirst%3DR.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DDemeter%26aufirst%3DJ.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DJ.%2BW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DDean%26aufirst%3DJ.%2BP.%26aulast%3DTe%2BBoekhorst%26aufirst%3DP.%2BA.%26aulast%3DNangalia%26aufirst%3DJ.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26atitle%3DPacritinib%2520versus%2520Best%2520Available%2520Therapy%2520for%2520the%2520Treatment%2520of%2520Myelofibrosis%2520Irrespective%2520of%2520Baseline%2520Cytopenias%2520%2528PERSIST-1%2529%253A%2520An%2520International%252C%2520Randomised%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Haematol.%26date%3D2017%26volume%3D4%26doi%3D10.1016%2FS2352-3026%2817%2930027-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-Oxa-5,7,14,26-Tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]Heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-Decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus K</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1021/jm201112g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201112g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=169-196&issue=1&author=A.+D.+Williamauthor=A.+C.-H.+Leeauthor=K.+C.+Gohauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.-L.+Teoauthor=H.+Nagarajauthor=C.+P.+Leeauthor=H.+Wangauthor=M.+Williamsauthor=E.+T.+Sunauthor=C.+Huauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+Kinase+Spectrum+Selective+Macrocycle+%2816E%29-14-Methyl-20-Oxa-5%2C7%2C14%2C26-Tetraazatetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5DHeptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2827%29%2C9%2C11%2C16%2C21%2C23-Decaene+%28SB1317%2FTG02%29%2C+a+Potent+Inhibitor+of+Cyclin+Dependent+Kinases+%28CDKs%29%2C+Janus+K&doi=10.1021%2Fjm201112g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Goh, Kee Chuan; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Lee, Chai Ping; Wang, Haishan; Williams, Meredith; Sun, Eric T.; Hu, Changyong; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we describe the design, synthesis, and SAR of a series of unique small mol. macrocycles that show spectrum selective kinase inhibition of CDKs, JAK2, and FLT3.  The most promising leads were assessed in vitro for their inhibition of cancer cell proliferation, soly., CYP450 inhibition, and microsomal stability.  This screening cascade revealed 26h (I) as a preferred compd. with target IC50 of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, resp.  Pharmacokinetic (PK) studies of 26h in preclin. species showed good oral exposures.  Oral efficacy was obsd. in colon (HCT-116) and lymphoma (Ramos) xenograft studies, in line with the obsd. PK/PD correlation.  26H (SB1317/TG02) was progressed into development in 2010 and is currently undergoing phase 1 clin. trials in advanced leukemias and multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotMvOv-_pFzbVg90H21EOLACvtfcHk0lj-V2UWG9p_qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylur7P&md5=50affe14bd28594735131d6b5841502a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201112g%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.-H.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.-L.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520Kinase%2520Spectrum%2520Selective%2520Macrocycle%2520%252816E%2529-14-Methyl-20-Oxa-5%252C7%252C14%252C26-Tetraazatetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255DHeptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252827%2529%252C9%252C11%252C16%252C21%252C23-Decaene%2520%2528SB1317%252FTG02%2529%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin%2520Dependent%2520Kinases%2520%2528CDKs%2529%252C%2520Janus%2520K%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D1%26spage%3D169%26epage%3D196%26doi%3D10.1021%2Fjm201112g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Aziz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seedhouse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N.</span></span> <span> </span><span class="NLM_article-title">The Multi-Kinase Inhibitor TG02 Overcomes Signalling Activation by Survival Factors to Deplete MCL1 and XIAP and Induce Cell Death in Primary Acute Myeloid Leukaemia Cells</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>159</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1111/bjh.12018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1111%2Fbjh.12018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22934750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2012&pages=191-203&issue=2&author=M.+Pallisauthor=A.+Abdul-Azizauthor=F.+Burrowsauthor=C.+Seedhouseauthor=M.+Grundyauthor=N.+Russell&title=The+Multi-Kinase+Inhibitor+TG02+Overcomes+Signalling+Activation+by+Survival+Factors+to+Deplete+MCL1+and+XIAP+and+Induce+Cell+Death+in+Primary+Acute+Myeloid+Leukaemia+Cells&doi=10.1111%2Fbjh.12018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells</span></div><div class="casAuthors">Pallis, Monica; Abdul-Aziz, Amina; Burrows, Francis; Seedhouse, Claire; Grundy, Martin; Russell, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-203</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summmary : The novel multi-kinase inhibitor TG02 has selectivity against cell cycle and transcriptional cyclin dependent kinases (CDKs) as well as fms-like tyrosine kinase receptor-3 (FLT3).  Inhibition of transcriptional CDKs preferentially depletes short-lived proteins such as MCL1.  We evaluated the in vitro toxicity of TG02 to primary acute myeloid leukemia (AML) cells in the presence of survival signalling pathway activation by cytokines and fibronectin.  One hundred nanomolar TG02 induced a median decrease of 40% in bulk cell survival and 43% in the CD34+CD38-CD123+subset.  A 90% inhibitory concn. of 500 nmol/l indicated that TG02 toxicity is not halted by protective cell cycle arrest.  Samples with FLT3 internal tandem duplication were not preferentially targeted.  By flow cytometry, TG02 treatment caused loss of RNA Polymerase II serine 2 phosphorylation in patient samples, which correlated strongly with BAX activation (R2=0·89), suggesting these as potential biomarkers for clin. studies.  MCL1 and XIAP expression also decreased.  Repeated brief exposure to TG02 in MOLM-13 cells did not result in compensatory up-regulation of survival protein expression.  In conclusion, TG02 is potently cytotoxic towards CD34+CD38-CD123+ and bulk AML cells, despite protective signalling pathway activation.  This antitumor activity is most likely mediated by dephosphorylation of RNA Polymerase II leading to depletion of survival mols. such as MCL1 and XIAP, with subsequent BAX activation and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB3mvr_3yc0bVg90H21EOLACvtfcHk0lj-V2UWG9p_qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2qs73J&md5=e8da0f2e7a1a5fcf03f90e68311ab294</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12018%26sid%3Dliteratum%253Aachs%26aulast%3DPallis%26aufirst%3DM.%26aulast%3DAbdul-Aziz%26aufirst%3DA.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DSeedhouse%26aufirst%3DC.%26aulast%3DGrundy%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DN.%26atitle%3DThe%2520Multi-Kinase%2520Inhibitor%2520TG02%2520Overcomes%2520Signalling%2520Activation%2520by%2520Survival%2520Factors%2520to%2520Deplete%2520MCL1%2520and%2520XIAP%2520and%2520Induce%2520Cell%2520Death%2520in%2520Primary%2520Acute%2520Myeloid%2520Leukaemia%2520Cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2012%26volume%3D159%26issue%3D2%26spage%3D191%26epage%3D203%26doi%3D10.1111%2Fbjh.12018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>189</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">4123</span>– <span class="NLM_lpage">4134</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1200675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.4049%2Fjimmunol.1200675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22962687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKrtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2012&pages=4123-4134&issue=8&author=B.+Madanauthor=K.+C.+Gohauthor=S.+Hartauthor=A.+D.+Williamauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+M.+Wood&title=SB1578%2C+a+Novel+Inhibitor+of+JAK2%2C+FLT3%2C+and+c-Fms+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.4049%2Fjimmunol.1200675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Madan, Babita; Goh, Kee Chuan; Hart, Stefan; William, Anthony D.; Jayaraman, Ramesh; Ethirajulu, Kantharaj; Dymock, Brian W.; Wood, Jeanette M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4123-4134</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">SB1578 is a novel, orally bioavailable JAK2 inhibitor with specificity for JAK2 within the JAK family and also potent activity against FLT3 and c-Fms.  These three tyrosine kinases play a pivotal role in activation of pathways that underlie the pathogenesis of rheumatoid arthritis.  SB1578 blocks the activation of these kinases and their downstream signaling in pertinent cells, leading to inhibition of pathol. cellular responses.  The biochem. and cellular activities of SB1578 translate into its high efficacy in two rodent models of arthritis.  SB1578 not only prevents the onset of arthritis but is also potent in treating established disease in collagen-induced arthritis mice with beneficial effects on histopathol. parameters of bone resorption and cartilage damage.  SB1578 abrogates the inflammatory response and prevents the infiltration of macrophages and neutrophils into affected joints.  It also leads to inhibition of Ag-presenting dendritic cells and inhibits the autoimmune component of the disease.  In summary, SB1578 has a unique kinase spectrum, and its pharmacol. profile provides a strong rationale for the ongoing clin. development in autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_db10A8l4KrVg90H21EOLACvtfcHk0liFV5res-amyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKrtL%252FK&md5=ccdccb1155e1186b96ffc3d91f179a20</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1200675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1200675%26sid%3Dliteratum%253Aachs%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DSB1578%252C%2520a%2520Novel%2520Inhibitor%2520of%2520JAK2%252C%2520FLT3%252C%2520and%2520c-Fms%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D189%26issue%3D8%26spage%3D4123%26epage%3D4134%26doi%3D10.4049%2Fjimmunol.1200675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirota, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusovsky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemelin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikemori-Kawada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaderbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Anti-Inflammatory Clinical Candidate E6201, Inspired from Resorcylic Lactone LL-Z1640–2, III</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3155</span>– <span class="NLM_lpage">3157</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmcl.2010.03.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20399648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3155-3157&issue=10&author=Y.+Shenauthor=R.+Boivinauthor=N.+Yonedaauthor=H.+Duauthor=S.+Schillerauthor=T.+Matsushimaauthor=M.+Gotoauthor=H.+Shirotaauthor=F.+Gusovskyauthor=C.+Lemelinauthor=Y.+Jiangauthor=Z.+Zhangauthor=R.+Pelletierauthor=M.+Ikemori-Kawadaauthor=Y.+Kawakamiauthor=A.+Inoueauthor=M.+Schnaderbeckauthor=Y.+Wang&title=Discovery+of+Anti-Inflammatory+Clinical+Candidate+E6201%2C+Inspired+from+Resorcylic+Lactone+LL-Z1640%E2%80%932%2C+III&doi=10.1016%2Fj.bmcl.2010.03.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III</span></div><div class="casAuthors">Shen, Yongchun; Boivin, Roch; Yoneda, Naoki; Du, Hong; Schiller, Shawn; Matsushima, Tomohiro; Goto, Masaki; Shirota, Hiroshi; Gusovsky, Fabian; Lemelin, Charles; Jiang, Yimin; Zhang, Zhiyi; Pelletier, Robert; Ikemori-Kawada, Megumi; Kawakami, Yoshiyuki; Inoue, Atsushi; Schnaderbeck, Matthew; Wang, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3155-3157</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inspired by natural product, LL-Z1640-2, clin. candidate, E6201 (22) was discovered in a medicinal chem. effort through total synthesis.  The modification on C14-position to N-alkyl substitution showed to be potent in vitro and orally active in vivo in anti-inflammatory assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBJwF8hgoEbVg90H21EOLACvtfcHk0liFV5res-amyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLY%253D&md5=c4748deae07e6ec54747db568955c962</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.087%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DBoivin%26aufirst%3DR.%26aulast%3DYoneda%26aufirst%3DN.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DSchiller%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DShirota%26aufirst%3DH.%26aulast%3DGusovsky%26aufirst%3DF.%26aulast%3DLemelin%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DPelletier%26aufirst%3DR.%26aulast%3DIkemori-Kawada%26aufirst%3DM.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DSchnaderbeck%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Anti-Inflammatory%2520Clinical%2520Candidate%2520E6201%252C%2520Inspired%2520from%2520Resorcylic%2520Lactone%2520LL-Z1640%25E2%2580%25932%252C%2520III%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D10%26spage%3D3155%26epage%3D3157%26doi%3D10.1016%2Fj.bmcl.2010.03.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreeff, M.</span></span> <span> </span><span class="NLM_article-title">The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3Mutations</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1528</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-1580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1158%2F0008-5472.CAN-15-1580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26822154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlWqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1528-1537&issue=6&author=W.+Zhangauthor=G.+Borthakurauthor=C.+Gaoauthor=Y.+Chenauthor=H.+Muauthor=V.+R.+Ruvoloauthor=K.+Nomotoauthor=N.+Zhaoauthor=M.+Konoplevaauthor=M.+Andreeff&title=The+Dual+MEK%2FFLT3+Inhibitor+E6201+Exerts+Cytotoxic+Activity+against+Acute+Myeloid+Leukemia+Cells+Harboring+Resistance-Conferring+FLT3Mutations&doi=10.1158%2F0008-5472.CAN-15-1580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations</span></div><div class="casAuthors">Zhang, Weiguo; Borthakur, Gautam; Gao, Chen; Chen, Ye; Mu, Hong; Ruvolo, Vivian R.; Nomoto, Kenichi; Zhao, Nanding; Konopleva, Marina; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1528-1537</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fms-like tyrosine kinase 3 (FLT3) inhibition has elicited encouraging responses in acute myeloid leukemia (AML) therapy.  Unfortunately, unless combined with a bone marrow transplant, disease relapse is frequent.  In addn. to the acquired point mutations in the FLT3 kinase domain that contribute to FLT3 inhibitor resistance, MEK/ERK signaling is persistently activated in AML cells even when FLT3 phosphorylation is continually suppressed.  Thus, concomitant targeting of FLT3 and MAPK may potentially exert synergistic activity to counteract the resistance of AML cells to FLT3-targeted therapy.  In this study, we investigated the antileukemia activity of a MEK1 and FLT3 dual inhibitor, E6201, in AML cells resistant to FLT3 inhibition.  We found that E6201 exerted profound apoptogenic effects on AML cells harboring resistance-conferring FLT3 mutations.  This activity appeared to be p53 dependent, and E6201-induced cytotoxicity was retained under hypoxic culture conditions and during coculture with mesenchymal stem cells that mimic the AML microenvironment.  Furthermore, E6201 markedly reduced leukemia burden and improved the survival of mice in a human FLT3-mutated AML model.  Collectively, our data provide a preclin. basis for the clin. evaluation of E6201 in AML patients harboring FLT3 mutations, including those who relapse following FLT3-targeted monotherapy.  Cancer Res; 76(6); 1528-37. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXaiNWtNG2yLVg90H21EOLACvtfcHk0liFV5res-amyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlWqurg%253D&md5=49f08d90208542c13413f1e772b2a5af</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-1580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-1580%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMu%26aufirst%3DH.%26aulast%3DRuvolo%26aufirst%3DV.%2BR.%26aulast%3DNomoto%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DN.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DThe%2520Dual%2520MEK%252FFLT3%2520Inhibitor%2520E6201%2520Exerts%2520Cytotoxic%2520Activity%2520against%2520Acute%2520Myeloid%2520Leukemia%2520Cells%2520Harboring%2520Resistance-Conferring%2520FLT3Mutations%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26issue%3D6%26spage%3D1528%26epage%3D1537%26doi%3D10.1158%2F0008-5472.CAN-15-1580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Babiker, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byron, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, W. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vondrak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyugan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borad, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cridebring, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Hoff, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpten, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span> <span> </span><span class="NLM_article-title">E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1007/s10637-018-0668-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs10637-018-0668-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30264293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSqsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=636-645&issue=4&author=H.+M.+Babikerauthor=S.+A.+Byronauthor=W.+P.+D.+Hendricksauthor=W.+F.+Elmquistauthor=G.+Gampaauthor=J.+Vondrakauthor=J.+Aldrichauthor=L.+Cuyuganauthor=J.+Adkinsauthor=V.+De+Lucaauthor=R.+Tibesauthor=M.+J.+Boradauthor=K.+Marceauauthor=T.+J.+Myersauthor=L.+J.+Paradisoauthor=W.+S.+Liangauthor=R.+L.+Kornauthor=D.+Cridebringauthor=D.+D.+Von+Hoffauthor=J.+D.+Carptenauthor=D.+W.+Craigauthor=J.+M.+Trentauthor=M.+S.+Gordon&title=E6201%2C+an+Intravenous+MEK1+Inhibitor%2C+Achieves+an+Exceptional+Response+in+BRAF+V600E-Mutated+Metastatic+Malignant+Melanoma+with+Brain+Metastases&doi=10.1007%2Fs10637-018-0668-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases</span></div><div class="casAuthors">Babiker, Hani M.; Byron, Sara A.; Hendricks, William P. D.; Elmquist, William F.; Gampa, Gautham; Vondrak, Jessica; Aldrich, Jessica; Cuyugan, Lori; Adkins, Jonathan; De Luca, Valerie; Tibes, Raoul; Borad, Mitesh J.; Marceau, Katie; Myers, Thomas J.; Paradiso, Linda J.; Liang, Winnie S.; Korn, Ronald L.; Cridebring, Derek; Von Hoff, Daniel D.; Carpten, John D.; Craig, David W.; Trent, Jeffrey M.; Gordon, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">636-645</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Malignant melanoma (MM) exhibits a high propensity for central nervous system dissemination with ∼50% of metastatic MM patients developing brain metastases (BM).  Targeted therapies and immune checkpoint inhibitors have improved overall survival for MM patients with BM.  However, responses are usually of short duration and new agents that effectively penetrate the blood brain barrier (BBB) are needed.  Here, we report a MM patient with BM who experienced an exceptional response to E6201, an ATP-competitive MEK1 inhibitor, on a Phase 1 study, with ongoing near-complete response and overall survival extending beyond 8 years.  Whole exome and transcriptome sequencing revealed a high mutational burden tumor (22 mutations/Megabase) with homozygous BRAF V600E mutation.  Correlative preclin. studies demonstrated broad activity for E6201 across BRAF V600E mutant melanoma cell lines and effective BBB penetration in vivo.  Together, these results suggest that E6201 may represent a potential new treatment option for BRAF-mutant MM patients with BM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDJhKT3i3KfbVg90H21EOLACvtfcHk0lh_Wc4uPizVvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSqsL7O&md5=7fe6fca66cd369e222a7238443fbc8cf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs10637-018-0668-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-018-0668-8%26sid%3Dliteratum%253Aachs%26aulast%3DBabiker%26aufirst%3DH.%2BM.%26aulast%3DByron%26aufirst%3DS.%2BA.%26aulast%3DHendricks%26aufirst%3DW.%2BP.%2BD.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26aulast%3DGampa%26aufirst%3DG.%26aulast%3DVondrak%26aufirst%3DJ.%26aulast%3DAldrich%26aufirst%3DJ.%26aulast%3DCuyugan%26aufirst%3DL.%26aulast%3DAdkins%26aufirst%3DJ.%26aulast%3DDe%2BLuca%26aufirst%3DV.%26aulast%3DTibes%26aufirst%3DR.%26aulast%3DBorad%26aufirst%3DM.%2BJ.%26aulast%3DMarceau%26aufirst%3DK.%26aulast%3DMyers%26aufirst%3DT.%2BJ.%26aulast%3DParadiso%26aufirst%3DL.%2BJ.%26aulast%3DLiang%26aufirst%3DW.%2BS.%26aulast%3DKorn%26aufirst%3DR.%2BL.%26aulast%3DCridebring%26aufirst%3DD.%26aulast%3DVon%2BHoff%26aufirst%3DD.%2BD.%26aulast%3DCarpten%26aufirst%3DJ.%2BD.%26aulast%3DCraig%26aufirst%3DD.%2BW.%26aulast%3DTrent%26aufirst%3DJ.%2BM.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26atitle%3DE6201%252C%2520an%2520Intravenous%2520MEK1%2520Inhibitor%252C%2520Achieves%2520an%2520Exceptional%2520Response%2520in%2520BRAF%2520V600E-Mutated%2520Metastatic%2520Malignant%2520Melanoma%2520with%2520Brain%2520Metastases%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26issue%3D4%26spage%3D636%26epage%3D645%26doi%3D10.1007%2Fs10637-018-0668-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhilber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecules with Anti-Inflammatory Properties in Clinical Development</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.pharmthera.2015.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26627986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2016&pages=163-187&author=T.+Hankeauthor=D.+Merkauthor=D.+Steinhilberauthor=G.+Geisslingerauthor=M.+Schubert-Zsilavecz&title=Small+Molecules+with+Anti-Inflammatory+Properties+in+Clinical+Development&doi=10.1016%2Fj.pharmthera.2015.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules with anti-inflammatory properties in clinical development</span></div><div class="casAuthors">Hanke, Thomas; Merk, Daniel; Steinhilber, Dieter; Geisslinger, Gerd; Schubert-Zsilavecz, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">163-187</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inflammation is a crucial physiol. response of our body to any kind of noxa be it an infection or tissue injury.  However, this physiol. process can be detrimental if dysregulated, and when the acute inflammatory response fails to resolve the cause of inflammation, there can be a switch to chronification.  According to ICD 10 (WHO) over 3.000 diseases exist with the suffix "-itis" which terms an inflammatory disease.  For the treatment of inflammation, non-steroidal anti-inflammatory drugs (NSAIDs) are the most widespread drugs while glucocorticoids are among our strongest weapons against inflammation, making them emergency treatments for acute episodes of chronic inflammation.  For the treatment of many inflammatory disorders, both are not satisfying.  Consequently, industrial and academic research on anti-inflammatory drugs is very intensive.  In this review, we evaluate current treatments and unmet needs of chronic inflammatory diseases with high prevalence (rheumatoid arthritis, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, and psoriasis), and systematically review small mols. with anti-inflammatory properties presently in clin. trials for the aforementioned diseases.  As the pathophysiol. knowledge of diseases increased over the last decades, a more specific intervention of inflammatory pathways becomes possible.  After one hundred years of NSAIDs and over fifty years of glucocorticoids, more specific drugs for anti-inflammatory therapy such as roflumilast or fingolimod are rising.  The aim of this article is to critically review the literature on small anti-inflammatory mols. in clin. trials to generate an idea of what we can expect in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOd16UM0wRSbVg90H21EOLACvtfcHk0lh_Wc4uPizVvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFertbfM&md5=a9f5e04d82aad54d600e21307ca4bfb2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DGeisslinger%26aufirst%3DG.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DSmall%2520Molecules%2520with%2520Anti-Inflammatory%2520Properties%2520in%2520Clinical%2520Development%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D157%26spage%3D163%26epage%3D187%26doi%3D10.1016%2Fj.pharmthera.2015.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Spencer, S.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Haas, J.</span>; <span class="NLM_string-name">Eary, C. T.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Pyrazolo[1,5-A]Pyrimidines and Salts Thereof</span>. International Patent WO <span class="NLM_patent">2019005796</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Q.+Zhao&author=S.+Spencer&author=Y.+Jiang&author=J.+Haas&author=C.+T.+Eary&title=Process+for+the+Preparation+of+Pyrazolo%5B1%2C5-A%5DPyrimidines+and+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Pyrazolo%255B1%252C5-A%255DPyrimidines%2520and%2520Salts%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">TRK Inhibitors in TRK Fusion-Positive Cancers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">VIII23</span>– <span class="NLM_lpage">VIII30</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdz282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1093%2Fannonc%2Fmdz282" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=VIII23-VIII30&author=A.+Drilon&title=TRK+Inhibitors+in+TRK+Fusion-Positive+Cancers&doi=10.1093%2Fannonc%2Fmdz282"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz282%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DTRK%2520Inhibitors%2520in%2520TRK%2520Fusion-Positive%2520Cancers%26jtitle%3DAnn.%2520Oncol.%26date%3D2019%26volume%3D30%26spage%3DVIII23%26epage%3DVIII30%26doi%3D10.1093%2Fannonc%2Fmdz282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Janssen Pharmaceutica N. V.</span> <span> </span><span class="NLM_article-title">MTKI Quinazoline
Derivatives</span>. International Patent WO <span class="NLM_patent">2006061417</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Janssen+Pharmaceutica+N.+V.&title=MTKI+Quinazoline%0ADerivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DMTKI%2520Quinazoline%250ADerivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konings, I. R. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De
Jonge, M. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Gaast, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beijsterveldt, L. E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eskens, F. A. L. M.</span></span> <span> </span><span class="NLM_article-title">Phase 1 and Pharmacological Study of the Broad-Spectrum Tyrosine Kinase Inhibitor JNJ-26483327 in Patients with Advanced Solid Tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fsj.bjc.6605867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20823884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=987-992&issue=7&author=I.+R.+H.+M.+Koningsauthor=M.+J.+A.+De%0AJongeauthor=H.+Burgerauthor=A.+Van+Der%0AGaastauthor=L.+E.+C.+Van+Beijsterveldtauthor=H.+Winklerauthor=J.+Verweijauthor=Z.+Yuanauthor=P.+Hellemansauthor=F.+A.+L.+M.+Eskens&title=Phase+1+and+Pharmacological+Study+of+the+Broad-Spectrum+Tyrosine+Kinase+Inhibitor+JNJ-26483327+in+Patients+with+Advanced+Solid+Tumours&doi=10.1038%2Fsj.bjc.6605867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours</span></div><div class="casAuthors">Konings, I. R. H. M.; de Jonge, M. J. A.; Burger, H.; van der Gaast, A.; van Beijsterveldt, L. E. C.; Winkler, H.; Verweij, J.; Yuan, Z.; Hellemans, P.; Eskens, F. A. L. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor receptor (VEGFR)-3 and Src family (Lyn, Fyn, Yes) at low nanomolar concns.  This phase I, accelerated titrn. study assessed max. tolerated dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327.  Methods: Nineteen patients with advanced cancers received JNJ-26483327 continuous twice daily (BID) in escalating dose cohorts ranging from 100 to 2100 mg.  Pharmacodynamic effects were assessed in paired skin biopsies and blood.  Results: JNJ-26483327 was well tolerated in doses up to 1500 mg BID, with target-inhibition-related toxicity such as diarrhea and skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue.  At 2100 mg, two episodes of dose-limiting toxicity were obsd., consisting of grade 3 anorexia and a combination of grade 3 anorexia and fatigue, resp.  Pharmacokinetics were dose proportional up to 1500 mg in which plasma levels were obtained showing anti-tumor activity in xenograft mouse models.  Pharmacodynamic anal. did not show a substantial effect on expression of Ki-67, p27kip1, phosphorylated mitogen-activated protein kinase, phosphorylated Akt and EGFR, and serum levels of sVEGFR-2, VEGF-C and VEGF-D remained unchanged.  Stable disease was noted in six patients (32%).  Conclusion: JNJ-26483327 is well tolerated and shows a predictable pharmacokinetic profile; the recommended dose for further studies is 1500 mg BID.  British Journal of Cancer (2010) 103, 987-992; doi:10.1038/sj.bjc.6605867 www.bjcancer.com Published online 7 Sept. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP2g2VkUKueLVg90H21EOLACvtfcHk0lh_Wc4uPizVvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrbL&md5=5f8f04fc2656ce1ec6c55e5ee4c870c6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605867%26sid%3Dliteratum%253Aachs%26aulast%3DKonings%26aufirst%3DI.%2BR.%2BH.%2BM.%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BJ.%2BA.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DVan%2BDer%2BGaast%26aufirst%3DA.%26aulast%3DVan%2BBeijsterveldt%26aufirst%3DL.%2BE.%2BC.%26aulast%3DWinkler%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26atitle%3DPhase%25201%2520and%2520Pharmacological%2520Study%2520of%2520the%2520Broad-Spectrum%2520Tyrosine%2520Kinase%2520Inhibitor%2520JNJ-26483327%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26issue%3D7%26spage%3D987%26epage%3D992%26doi%3D10.1038%2Fsj.bjc.6605867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span> <span> </span><span class="NLM_article-title">First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2029</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2027187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1056%2FNEJMoa2027187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=33207094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=2018-2029&issue=21&author=A.+T.+Shawauthor=T.+M.+Bauerauthor=F.+de+Marinisauthor=E.+Felipauthor=Y.+Gotoauthor=G.+Liuauthor=J.+Mazieresauthor=D.-W.+Kimauthor=T.+Mokauthor=A.+Polliauthor=H.+Thurmauthor=G.+Calellaauthor=G.+Peltzauthor=B.+J.+Solomon&title=First-Line+Lorlatinib+or+Crizotinib+in+Advanced+ALK-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa2027187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Liu, Geoffrey; Mazieres, Julien; Kim, Dong-Wan; Mok, Tony; Polli, Anna; Thurm, Holger; Calella, Anna M.; Peltz, Gerson; Solomon, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2018-2029</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-pos. non-small-cell lung cancer (NSCLC).  The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-pos. NSCLC is unclear.  We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-pos. NSCLC who had received no previous systemic treatment for metastatic disease.  The primary end point was progression-free survival as assessed by blinded independent central review.  Secondary end points included independently assessed objective response and intracranial response.  An interim anal. of efficacy was planned after approx. 133 of 177 (75%) expected events of disease progression or death had occurred.  The percentage of patients who were alive without disease progression at 12 mo was 78% (95% confidence interval [CI], 70 to 84) in the lorlatinib group and 39% (95% CI, 30 to 48) in the crizotinib group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.19 to 0.41; P<0.001).  An objective response occurred in 76% (95% CI, 68 to 83) of the patients in the lorlatinib group and 58% (95% CI, 49 to 66) of those in the crizotinib group; among those with measurable brain metastases, 82% (95% CI, 57 to 96) and 23% (95% CI, 5 to 54), resp., had an intracranial response, and 71% of the patients who received lorlatinib had an intracranial complete response.  The most common adverse events with lorlatinib were hyperlipidemia, edema, increased wt., peripheral neuropathy, and cognitive effects.  Lorlatinib was assocd. with more grade 3 or 4 adverse events (mainly altered lipid levels) than crizotinib (in 72% vs. 56%).  Discontinuation of treatment because of adverse events occurred in 7% and 9% of the patients, resp.  In an interim anal. of results among patients with previously untreated advanced ALK-pos. NSCLC, those who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response than those who received crizotinib.  The incidence of grade 3 or 4 adverse events was higher with lorlatinib than with crizotinib because of the frequent occurrence of altered lipid levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAPkJPLVUj8rVg90H21EOLACvtfcHk0lhX65dhI-SdAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlyku7%252FN&md5=97baa919b685e4ece2c03e7788c76702</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2027187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2027187%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DCalella%26aufirst%3DG.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26atitle%3DFirst-Line%2520Lorlatinib%2520or%2520Crizotinib%2520in%2520Advanced%2520ALK-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26issue%3D21%26spage%3D2018%26epage%3D2029%26doi%3D10.1056%2FNEJMoa2027187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pithavala, Y. K.</span></span> <span> </span><span class="NLM_article-title">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1007/s12325-019-01198-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs12325-019-01198-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=31863284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=745-758&issue=2&author=J.+Chenauthor=H.+Xuauthor=S.+Pawlakauthor=L.+P.+Jamesauthor=G.+Peltzauthor=K.+Leeauthor=K.+Ginmanauthor=M.+Bergersonauthor=Y.+K.+Pithavala&title=The+Effect+of+Rifampin+on+the+Pharmacokinetics+and+Safety+of+Lorlatinib%3A+Results+of+a+Phase+One%2C+Open-Label%2C+Crossover+Study+in+Healthy+Participants&doi=10.1007%2Fs12325-019-01198-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span></div><div class="casAuthors">Chen, Joseph; Xu, Huiping; Pawlak, Sylvester; James, Leonard P.; Peltz, Gerson; Lee, Kimberly; Ginman, Katherine; Bergeron, Michelle; Pithavala, Yazdi K.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">745-758</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-pos. metastatic non-small cell lung cancer; cytochrome P 450 (CYP) 3A plays an important role in the metab. of lorlatinib.  Methods: This phase 1, open-label, two-period, crossover study estd. the effect of oral rifampin (a strong CYP3A inducer) on the pharmacokinetics and safety of oral lorlatinib (NCT02804399).  Healthy participants received single-dose lorlatinib 100 mg in period 1 followed by rifampin 600 mg/day (days 1-12) and single-dose lorlatinib 100 mg (day 8) in period 2.  Blood samples were collected for 120 h after each dose of lorlatinib.  Results: When a single dose of lorlatinib was administered during daily dosing with rifampin (period 2), the area under the plasma concn.-time profile extrapolated to infinity (AUCinf) and max. plasma concn. (Cmax) of lorlatinib were 14.74% [90% confidence interval (CI) 12.78%, 17.01%] and 23.88% (90% CI 21.58%, 26.43%), resp., of those in period 1 (lorlatinib alone).  A single dose of lorlatinib was well tolerated in period 1, but elevations in transaminase values were obsd. in all participants (grade 2-4 in 11 participants) within 1-3 days after a single dose of lorlatinib was administered with ongoing rifampin in period 2.  Rifampin dosing was therefore halted.  Transaminase levels subsequently returned to normal (median time to recovery: 15 days).  No elevations in bilirubin were obsd.  Conclusions: The addn. of a single dose of lorlatinib to daily dosing with rifampin significantly reduced lorlatinib plasma exposure relative to a single dose of lorlatinib administered alone and was assocd. with severe but self-limiting transaminase elevations in all healthy participants.  These observations support the contraindication in the product label against concomitant use of lorlatinib with all strong CYP3A inducers.  Trial registration: ClinicalTrials.gov identifier, NCT02804399.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7FDPfToKTLVg90H21EOLACvtfcHk0lhX65dhI-SdAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL&md5=8ce821a071e701d5cea6934b6cbf0bcb</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs12325-019-01198-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-019-01198-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPawlak%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DGinman%26aufirst%3DK.%26aulast%3DBergerson%26aufirst%3DM.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26atitle%3DThe%2520Effect%2520of%2520Rifampin%2520on%2520the%2520Pharmacokinetics%2520and%2520Safety%2520of%2520Lorlatinib%253A%2520Results%2520of%2520a%2520Phase%2520One%252C%2520Open-Label%252C%2520Crossover%2520Study%2520in%2520Healthy%2520Participants%26jtitle%3DAdv.%2520Ther.%26date%3D2020%26volume%3D37%26issue%3D2%26spage%3D745%26epage%3D758%26doi%3D10.1007%2Fs12325-019-01198-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loong, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, Y. L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ock, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchekmedyian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syn, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span> <span> </span><span class="NLM_article-title">An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2020.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.jtho.2020.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=32360579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsFCiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1484-1496&issue=9&author=V.+W.+Zhuauthor=Y.+T.+Linauthor=D.+W.+Kimauthor=H.+H.+Loongauthor=M.+Nagasakaauthor=H.+Toauthor=Y.+L.+E.+Angauthor=C.+Y.+Ockauthor=N.+Tchekmedyianauthor=S.+H.+I.+Ouauthor=N.+L.+Synauthor=T.+Reungwetwattanaauthor=C.+C.+Linauthor=R.+A.+Soo&title=An+International+Real-World+Analysis+of+the+Efficacy+and+Safety+of+Lorlatinib+Through+Early+or+Expanded+Access+Programs+in+Patients+With+Tyrosine+Kinase+Inhibitor-Refractory+ALK-Positive+or+ROS1-Positive+NSCLC&doi=10.1016%2Fj.jtho.2020.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC</span></div><div class="casAuthors">Zhu, Viola W.; Lin, Yen-Ting; Kim, Dong-Wan; Loong, Herbert H.; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L.; Reungwetwattana, Thanyanan; Lin, Chia-Chi; Soo, Ross A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1484-1496</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-1380</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Lorlatinib, next-generation central nervous system-penetrant ALK/ROS1 tyrosine kinase inhibitor approved to treat TKI-refractory ALK-pos. NSCLC based on results from phase 2 study.  A real-world anal. was performed on ALK+ or ROS1-pos. patients with NSCLC enrolled in lorlatinib early or expanded access programs in Hong Kong, Singapore, South Korea, Taiwan, Thailand, and the United States.  A total of 95 patients with NSCLC were analyzed.  ALK+ patients treated with less than two previous TKIs, two or more previous TKIs, and three or more previous TKIs, objective response rates and median progression-free survival were 42% and not reached, 35% (95% CI: 22-49; n = 55) and 11.2 mo (95% CI: 4.5-NR; n = 66), and 18% (95% CI: 4-43; n = 17) and 6.5 mo (95% CI: 3.5-11.6; n = 21), resp.  The ORRs and mPFSs were 13% (95% CI: 0-53; n = 8) and 9.2 mo (95% CI: 3.3-NR; n = 9) for patients treated with one second-generation ALK TKI as the only ALK TKI received.  For ROS1+ patients, ORRs and mPFSs were 41% (95% CI: 18-67; n = 17) and 11.9 mo (95% CI: 6.4-NR; n = 19).  The intracranial ORRs were 35% (95% CI: 22-49) and 55% (95% CI: 23-83) for 52 ALK+ and 11 ROS1+ patients. mPFS was 9.3 mo (95% CI: 1.0-NR; n = 13) for patients with leptomeningeal carcinomatosis.  No new safety signals were noted.Lorlatinib exhibited meaningful activity in TKI-refractory ALK+ or ROS1+ patients with NSCLC enrolled in early or expanded access programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh3Zns3D0a1bVg90H21EOLACvtfcHk0lgl2jZoM1yYIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsFCiu7o%253D&md5=3734803a1595600ce93e77f0dfd01e91</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2020.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2020.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DLin%26aufirst%3DY.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DLoong%26aufirst%3DH.%2BH.%26aulast%3DNagasaka%26aufirst%3DM.%26aulast%3DTo%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DY.%2BL.%2BE.%26aulast%3DOck%26aufirst%3DC.%2BY.%26aulast%3DTchekmedyian%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DS.%2BH.%2BI.%26aulast%3DSyn%26aufirst%3DN.%2BL.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DC.%2BC.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26atitle%3DAn%2520International%2520Real-World%2520Analysis%2520of%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Lorlatinib%2520Through%2520Early%2520or%2520Expanded%2520Access%2520Programs%2520in%2520Patients%2520With%2520Tyrosine%2520Kinase%2520Inhibitor-Refractory%2520ALK-Positive%2520or%2520ROS1-Positive%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3D1484%26epage%3D1496%26doi%3D10.1016%2Fj.jtho.2020.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pithavala, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span> <span> </span><span class="NLM_article-title">Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1007/s11523-020-00702-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs11523-020-00702-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=32060867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BB387itl2jtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=55-65&issue=1&author=T.+M.+Bauerauthor=A.+T.+Shawauthor=M.+L.+Johnsonauthor=A.+Navarroauthor=J.+F.+Gainorauthor=H.+Thurmauthor=Y.+K.+Pithavalaauthor=A.+Abbattistaauthor=G.+Peltzauthor=E.+Felip&title=Brain+Penetration+of+Lorlatinib%3A+Cumulative+Incidences+of+CNS+and+Non-CNS+Progression+with+Lorlatinib+in+Patients+with+Previously+Treated+ALK-Positive+Non-Small-Cell+Lung+Cancer&doi=10.1007%2Fs11523-020-00702-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Bauer Todd M; Johnson Melissa L; Shaw Alice T; Gainor Justin F; Navarro Alejandro; Felip Enriqueta; Thurm Holger; Pithavala Yazdi K; Abbattista Antonello; Peltz Gerson</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-65</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lorlatinib is a potent, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) designed to penetrate the blood-brain barrier.  OBJECTIVE:  We report the cumulative incidence of central nervous system (CNS) and non-CNS progression with lorlatinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) previously treated with ALK TKIs.  PATIENTS AND METHODS:  In an ongoing phase II study (NCT01970865), 198 patients with ALK-positive NSCLC with ≥ 1 prior ALK TKI were enrolled into expansion cohorts (EXP) based on treatment history.  Patients received lorlatinib 100 mg once daily.  Patients were analyzed for progressive disease, categorized as CNS or non-CNS progression, by independent central review.  Cumulative incidence probabilities were calculated adopting a competing risks approach.  RESULTS:  Fifty-nine patients received crizotinib as their only prior ALK TKI (EXP2-3A); cumulative incidence rates (CIRs) of CNS and non-CNS progression were both 22% at 12 months in patients with baseline CNS metastases (n = 37), and CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients without baseline CNS metastases [43% vs. 9% (n = 22)].  In patients who received ≥ 1 prior second-generation ALK TKI [EXP3B-5 (n = 139)], CIR of non-CNS progression at 12 months was higher versus that for CNS progression in patients both with and without baseline CNS metastases (35% vs. 23% (n = 94) and 55% vs. 12% (n = 45), respectively).  CONCLUSIONS:  Lorlatinib showed substantial intracranial activity in patients with pretreated ALK-positive NSCLC, with or without baseline CNS metastases, whose disease progressed on crizotinib or second-generation ALK TKIs.  CLINICALTRIALS.  GOV IDENTIFIER:  NCT01970865.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA-ZQG6zODSBpyrDyM_m9cfW6udTcc2eahxrHCzGEf4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387itl2jtg%253D%253D&md5=4cda9ece660ae5f1bb736770b4e35dbd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs11523-020-00702-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-020-00702-4%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DFelip%26aufirst%3DE.%26atitle%3DBrain%2520Penetration%2520of%2520Lorlatinib%253A%2520Cumulative%2520Incidences%2520of%2520CNS%2520and%2520Non-CNS%2520Progression%2520with%2520Lorlatinib%2520in%2520Patients%2520with%2520Previously%2520Treated%2520ALK-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DTarget%2520Oncol.%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D55%26epage%3D65%26doi%3D10.1007%2Fs11523-020-00702-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10 R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17- Tetrahydro- 2H −8,4-(Metheno)Pyrazolo[4,3- h ][2,5,11]- Benzoxadiazacyclotetradecine-3-Carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) And</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810+R%29-7-Amino-12-Fluoro-2%2C10%2C16-Trimethyl-15-Oxo-10%2C15%2C16%2C17-+Tetrahydro-+2H+%E2%88%928%2C4-%28Metheno%29Pyrazolo%5B4%2C3-+h+%5D%5B2%2C5%2C11%5D-+Benzoxadiazacyclotetradecine-3-Carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+And&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lgl2jZoM1yYIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810%2520R%2529-7-Amino-12-Fluoro-2%252C10%252C16-Trimethyl-15-Oxo-10%252C15%252C16%252C17-%2520Tetrahydro-%25202H%2520%25E2%2588%25928%252C4-%2528Metheno%2529Pyrazolo%255B4%252C3-%2520h%2520%255D%255B2%252C5%252C11%255D-%2520Benzoxadiazacyclotetradecine-3-Carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520And%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affolter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span> <span> </span><span class="NLM_article-title">PF-06463922 Is a Potent and Selective next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-Resistant ROS1Mutations</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3493</span>– <span class="NLM_lpage">3498</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420785112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1073%2Fpnas.1420785112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=25733882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=3493-3498&issue=11&author=H.+Y.+Zouauthor=Q.+Liauthor=L.+D.+Engstromauthor=M.+Westauthor=V.+Applemanauthor=K.+A.+Wongauthor=M.+McTigueauthor=Y.+L.+Dengauthor=W.+Liuauthor=A.+Broounauthor=S.+Timofeevskiauthor=S.+R.+P.+McDonnellauthor=P.+Jiangauthor=M.+D.+Falkauthor=P.+B.+Lappinauthor=T.+Affolterauthor=T.+Nicholsauthor=W.+Huauthor=J.+Lamauthor=T.+W.+Johnsonauthor=T.+Smealauthor=A.+Charestauthor=V.+R.+Fantin&title=PF-06463922+Is+a+Potent+and+Selective+next-Generation+ROS1%2FALK+Inhibitor+Capable+of+Blocking+Crizotinib-Resistant+ROS1Mutations&doi=10.1073%2Fpnas.1420785112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Engstrom, Lars D.; West, Melissa; Appleman, Vicky; Wong, Katy A.; McTigue, Michele; Deng, Ya-Li; Liu, Wei; Brooun, Alexei; Timofeevski, Sergei; McDonnell, Scott R. P.; Jiang, Ping; Falk, Matthew D.; Lappin, Patrick B.; Affolter, Timothy; Nichols, Tim; Hu, Wenyue; Lam, Justine; Johnson, Ted W.; Smeal, Tod; Charest, Al; Fantin, Valeria R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3493-3498</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Oncogenic c-ros oncogene 1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy.  The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clin. activity in ROS1 fusion-pos. non-small cell lung cancer.  However, emerging clin. evidence has shown that patients can develop resistance by acquiring secondary point mutations in ROS1 kinase.  In this study the authors characterized the ROS1 activity of PF-06463922, a novel, orally available, CNS-penetrant, ATP-competitive small-mol. inhibitor of ALK/ROS1.  In vitro, PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1G2032R mutation and the ROS1G2026M gatekeeper mutation.  Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase.  A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable interactions contributing to the high-affinity binding.  In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1G2032R mutation.  Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.  Taken together, the authors' results indicate that PF-06463922 has potential for treating ROS1 fusion-pos. cancers, including those requiring agents with CNS-penetrating properties, as well as for overcoming crizotinib resistance driven by ROS1 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5t2o5BKPhK7Vg90H21EOLACvtfcHk0ljO80QRS0YSng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Grur8%253D&md5=8f549572dfac12c74b88705d57979c09</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420785112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420785112%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DAppleman%26aufirst%3DV.%26aulast%3DWong%26aufirst%3DK.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%2BP.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DFalk%26aufirst%3DM.%2BD.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DNichols%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLam%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DCharest%26aufirst%3DA.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26atitle%3DPF-06463922%2520Is%2520a%2520Potent%2520and%2520Selective%2520next-Generation%2520ROS1%252FALK%2520Inhibitor%2520Capable%2520of%2520Blocking%2520Crizotinib-Resistant%2520ROS1Mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26issue%3D11%26spage%3D3493%26epage%3D3498%26doi%3D10.1073%2Fpnas.1420785112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stukalov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göktürk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strömberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colinge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Stereospecific Targeting of MTH1 by (S)-Crizotinib as an Anticancer Strategy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span> (<span class="NLM_issue">7495</span>),  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1038/nature13194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnature13194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=24695225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlWrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=222-227&issue=7495&author=K.+V.+M.+Huberauthor=E.+Salahauthor=B.+Radicauthor=M.+Gridlingauthor=J.+M.+Elkinsauthor=A.+Stukalovauthor=A.+S.+Jemthauthor=C.+G%C3%B6kt%C3%BCrkauthor=K.+Sanjivauthor=K.+Str%C3%B6mbergauthor=T.+Phamauthor=U.+W.+Berglundauthor=J.+Colingeauthor=K.+L.+Bennettauthor=J.+I.+Loizouauthor=T.+Helledayauthor=S.+Knappauthor=G.+Superti-Furga&title=Stereospecific+Targeting+of+MTH1+by+%28S%29-Crizotinib+as+an+Anticancer+Strategy&doi=10.1038%2Fnature13194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy</span></div><div class="casAuthors">Huber, Kilian V. M.; Salah, Eidarus; Radic, Branka; Gridling, Manuela; Elkins, Jonathan M.; Stukalov, Alexey; Jemth, Ann-Sofie; Gokturk, Camilla; Sanjiv, Kumar; Stroemberg, Kia; Pham, Therese; Berglund, Ulrika Warpman; Colinge, Jacques; Bennett, Keiryn L.; Loizou, Joanna I.; Helleday, Thomas; Knapp, Stefan; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7495</span>),
    <span class="NLM_cas:pages">222-227</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activated RAS GTPase signaling is a crit. driver of oncogenic transformation and malignant disease.  Cellular models of RAS-dependent cancers have been used to identify exptl. small mols., such as SCH51344, but their mol. mechanism of action remains generally unknown.  Here, using a chem. proteomic approach, the authors identify the target of SCH51344 as the human mutT homolog MTH1 (also known as NUDT1), a nucleotide pool sanitizing enzyme.  Loss-of-function of MTH1 impaired growth of KRAS tumor cells, whereas MTH1 overexpression mitigated sensitivity towards SCH51344.  Searching for more drug-like inhibitors, the authors identified the kinase inhibitor crizotinib as a nanomolar suppressor of MTH1 activity.  Surprisingly, the clin. used (R)-enantiomer of the drug was inactive, whereas the (S)-enantiomer selectively inhibited MTH1 catalytic activity.  Enzymic assays, chem. proteomic profiling, kinome-wide activity surveys and MTH1 co-crystal structures of both enantiomers provide a rationale for this remarkable stereospecificity.  Disruption of nucleotide pool homeostasis via MTH1 inhibition by (S)-crizotinib induced an increase in DNA single-strand breaks, activated DNA repair in human colon carcinoma cells, and effectively suppressed tumor growth in animal models.  The authors' results propose (S)-crizotinib as an attractive chem. entity for further pre-clin. evaluation, and small-mol. inhibitors of MTH1 in general as a promising novel class of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrbUm7UP6kIrVg90H21EOLACvtfcHk0ljO80QRS0YSng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlWrsb4%253D&md5=ca3df11a6782fd9140b6d8ba0c16e5ab</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature13194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13194%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DRadic%26aufirst%3DB.%26aulast%3DGridling%26aufirst%3DM.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DStukalov%26aufirst%3DA.%26aulast%3DJemth%26aufirst%3DA.%2BS.%26aulast%3DG%25C3%25B6kt%25C3%25BCrk%26aufirst%3DC.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DStr%25C3%25B6mberg%26aufirst%3DK.%26aulast%3DPham%26aufirst%3DT.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DStereospecific%2520Targeting%2520of%2520MTH1%2520by%2520%2528S%2529-Crizotinib%2520as%2520an%2520Anticancer%2520Strategy%26jtitle%3DNature%26date%3D2014%26volume%3D508%26issue%3D7495%26spage%3D222%26epage%3D227%26doi%3D10.1038%2Fnature13194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mireles, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiszewski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Morais, S. M.</span></span> <span> </span><span class="NLM_article-title">In Vitro P-Glycoprotein Assays to Predict the in Vivo Interactions of P-Glycoprotein with Drugs in the Central Nervous System</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1124%2Fdmd.107.017434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=17962372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=268-275&issue=2&author=B.+Fengauthor=J.+B.+Millsauthor=R.+E.+Davidsonauthor=R.+J.+Mirelesauthor=J.+S.+Janiszewskiauthor=M.+D.+Troutmanauthor=S.+M.+de+Morais&title=In+Vitro+P-Glycoprotein+Assays+to+Predict+the+in+Vivo+Interactions+of+P-Glycoprotein+with+Drugs+in+the+Central+Nervous+System&doi=10.1124%2Fdmd.107.017434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system</span></div><div class="casAuthors">Feng, Bo; Mills, Jessica B.; Davidson, Ralph E.; Mireles, Rouchelle J.; Janiszewski, John S.; Troutman, Matthew D.; de Morais, Sonia M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-275</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compds. were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.  Addnl., the permeability for these compds. was measured in two in vitro models: parallel artificial membrane permeation assay and apical-to-basolateral apparent permeability in MDCK.  The exposure of the same set of compds. in brain and plasma was measured in P-gp knockout (KO) and wild-type (WT) mice after s.c. administration.  One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compds., and 6 of the 7 non-CNS drugs were detd. to have pos. efflux using ratio of ratios in MDR1-MDCK vs. MDCK transwell assays.  Data from transwell studies correlated well with the brain-to-plasma area under the curve ratios between P-gp KO and WT mice for the 32 CNS compds.  In addn., 3300 Pfizer compds. were tested in MDR1-MDCK and Mdr1a-MDCK transwell assays, with a good correlation (R2 = 0.92) between the efflux ratios in human MDR1-MDCK and mouse Mdr1a-MDCK cells.  Permeability data showed that the majority of the 32 CNS compds. have moderate to high passive permeability.  This work has demonstrated that in vitro transporter assays help in understanding the role of P-gp-mediated efflux activity in detg. the disposition of CNS drugs in vivo, and the transwell assay is a valuable in vitro assay to evaluate human P-gp interaction with compds. for assessing brain penetration of new chem. entities to treat CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsQyRSOySyGLVg90H21EOLACvtfcHk0ljZngjdjCqyTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yktbc%253D&md5=bbf8b6969bd6d6b3d741b6ef9e7853f3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017434%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DJ.%2BB.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DMireles%26aufirst%3DR.%2BJ.%26aulast%3DJaniszewski%26aufirst%3DJ.%2BS.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3Dde%2BMorais%26aufirst%3DS.%2BM.%26atitle%3DIn%2520Vitro%2520P-Glycoprotein%2520Assays%2520to%2520Predict%2520the%2520in%2520Vivo%2520Interactions%2520of%2520P-Glycoprotein%2520with%2520Drugs%2520in%2520the%2520Central%2520Nervous%2520System%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26issue%3D2%26spage%3D268%26epage%3D275%26doi%3D10.1124%2Fdmd.107.017434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dack, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1021/jm401805h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401805h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1170-1187&issue=4&author=Q.+Huangauthor=T.+W.+Johnsonauthor=S.+Baileyauthor=A.+Broounauthor=K.+D.+Bunkerauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=A.+S.+Cookauthor=J.+J.+Cuiauthor=K.+N.+Dackauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=P.+S.+Johnsonauthor=R.+S.+Kaniaauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=Q.+Liauthor=L.+Lingardoauthor=W.+Liuauthor=M.+W.+Luauthor=M.+McTigueauthor=C.+L.+Palmerauthor=P.+F.+Richardsonauthor=N.+W.+Sachauthor=H.+Shenauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=K.+Tsaparikosauthor=H.+Wangauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Design+of+Potent+and+Selective+Inhibitors+to+Overcome+Clinical+Anaplastic+Lymphoma+Kinase+Mutations+Resistant+to+Crizotinib&doi=10.1021%2Fjm401805h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib</span></div><div class="casAuthors">Huang, Qinhua; Johnson, Ted W.; Bailey, Simon; Brooun, Alexei; Bunker, Kevin D.; Burke, Benjamin J.; Collins, Michael R.; Cook, Andrew S.; Cui, J. Jean; Dack, Kevin N.; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Johnson, Patrick S.; Kania, Robert S.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Li, Qiuhua; Lingardo, Laura; Liu, Wei; Lu, Melissa West; McTigue, Michele; Palmer, Cynthia L.; Richardson, Paul F.; Sach, Neal W.; Shen, Hong; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Tsaparikos, Konstantinos; Wang, Hui; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1170-1187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crizotinib, an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S.  Food and Drug Administration in 2011, is efficacious in ALK and ROS pos. patients.  Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease.  The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine (I), which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclin. pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhF6vRWLUrrVg90H21EOLACvtfcHk0ljZngjdjCqyTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFaqsg%253D%253D&md5=c12e0400ac92eb3321fde81ee13a5e92</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm401805h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401805h%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBunker%26aufirst%3DK.%2BD.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCook%26aufirst%3DA.%2BS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDack%26aufirst%3DK.%2BN.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DJohnson%26aufirst%3DP.%2BS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DM.%2BW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520to%2520Overcome%2520Clinical%2520Anaplastic%2520Lymphoma%2520Kinase%2520Mutations%2520Resistant%2520to%2520Crizotinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D4%26spage%3D1170%26epage%3D1187%26doi%3D10.1021%2Fjm401805h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latif, M.</span></span> <span> </span><span class="NLM_article-title">First Macrocyclic 3rd-Generation ALK Inhibitor for Treatment of ALK/ROS1 Cancer: Clinical and Designing Strategy Update of Lorlatinib</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.ejmech.2017.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=28431340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2017&pages=348-356&author=S.+Basitauthor=Z.+Ashrafauthor=K.+Leeauthor=M.+Latif&title=First+Macrocyclic+3rd-Generation+ALK+Inhibitor+for+Treatment+of+ALK%2FROS1+Cancer%3A+Clinical+and+Designing+Strategy+Update+of+Lorlatinib&doi=10.1016%2Fj.ejmech.2017.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib</span></div><div class="casAuthors">Basit, Sulman; Ashraf, Zaman; Lee, Kwangho; Latif, Muhammad</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">348-356</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to 2nd-generation ALK inhibitors.  Lorlatinib (PF-06463922) is a 3rd-generation macrocyclic ALK-TKI that demonstrates many advantages over 2nd-generation ALK inhibitors.  Lorlatinib has demonstrated decent kinase selectivity, promising pharmacokinetic profile, selective brain-penetration and strong antiproliferative activity in several ALK/ROS1-driven tumor models.  The current review describes the activity spectrum, key events from discovery to clin. applications and the evidences that lorlatinib acts as an ALK/ROS1 inhibitor in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqgvg4dapRHrVg90H21EOLACvtfcHk0ljZngjdjCqyTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlKnt74%253D&md5=13f3886be0e0973a5627f33c6c50cf26</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DBasit%26aufirst%3DS.%26aulast%3DAshraf%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DLatif%26aufirst%3DM.%26atitle%3DFirst%2520Macrocyclic%25203rd-Generation%2520ALK%2520Inhibitor%2520for%2520Treatment%2520of%2520ALK%252FROS1%2520Cancer%253A%2520Clinical%2520and%2520Designing%2520Strategy%2520Update%2520of%2520Lorlatinib%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D134%26spage%3D348%26epage%3D356%26doi%3D10.1016%2Fj.ejmech.2017.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akamine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyokawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span> <span> </span><span class="NLM_article-title">Spotlight on Lorlatinib and Its Potential in the Treatment of NSCLC: The Evidence to Date</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5093</span>– <span class="NLM_lpage">5101</span>, <span class="refDoi"> DOI: 10.2147/OTT.S165511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.2147%2FOTT.S165511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30174447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOisrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=5093-5101&author=T.+Akamineauthor=G.+Toyokawaauthor=T.+Tagawaauthor=T.+Seto&title=Spotlight+on+Lorlatinib+and+Its+Potential+in+the+Treatment+of+NSCLC%3A+The+Evidence+to+Date&doi=10.2147%2FOTT.S165511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date</span></div><div class="casAuthors">Akamine, Takaki; Toyokawa, Gouji; Tagawa, Tetsuzo; Seto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5093-5101</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The identification of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of non-small cell lung cancer (NSCLC).  Targeting ALK using tyrosine kinase inhibitors (TKI) has dramatically improved the prognosis of patients with ALK-rearranged NSCLC.  However, most patients relapse on ALK-TKI therapy within a few years because of acquired resistance.  One mechanism of acquiring resistance is a second mutation on the ALK gene, and the representative mutation is L1996M in the gatekeeper residue.  In particular, the solvent-front ALK G1202R mutation is the common cause of resistance against first- and second-generation ALK-TKIs.  Another major concern regarding ALK-TKI is metastasis to the central nervous system, commonly obsd. in patients relapsing after ALK-TKI therapy.  The next-generation ALK inhibitor lorlatinib (PF-06463922) has therefore been developed to inhibit resistant ALK mutations, including ALK G1202R, and to penetrate the blood-brain barrier.  In a Phase I/II trial, the safety and efficacy of lorlatinib were demonstrated in patients with advanced ALK-pos. NSCLC, most of whom had central nervous system metastases and had previous ALK-TKI treatment.  In this review, we discuss the structure, pharmacodynamics, and pharmacokinetics of lorlatinib and compare its characteristics with those of other ALK inhibitors.  Furthermore, clin. trials for lorlatinib are summarized, and future perspectives in the management of patients with ALK-rearranged NSCLC are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXh2qxSCiqKrVg90H21EOLACvtfcHk0ljjuSqKpVWh3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOisrfL&md5=ea74baa4efdbdbc7f06c95f1aa2b34db</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2147%2FOTT.S165511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S165511%26sid%3Dliteratum%253Aachs%26aulast%3DAkamine%26aufirst%3DT.%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DTagawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DT.%26atitle%3DSpotlight%2520on%2520Lorlatinib%2520and%2520Its%2520Potential%2520in%2520the%2520Treatment%2520of%2520NSCLC%253A%2520The%2520Evidence%2520to%2520Date%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D5093%26epage%3D5101%26doi%3D10.2147%2FOTT.S165511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pithavala, Y. K.</span></span> <span> </span><span class="NLM_article-title">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1007/s12325-019-01198-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs12325-019-01198-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=31863284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=745-758&issue=2&author=J.+Chenauthor=H.+Xuauthor=S.+Pawlakauthor=L.+P.+Jamesauthor=G.+Peltzauthor=K.+Leeauthor=K.+Ginmanauthor=M.+Bergeronauthor=Y.+K.+Pithavala&title=The+Effect+of+Rifampin+on+the+Pharmacokinetics+and+Safety+of+Lorlatinib%3A+Results+of+a+Phase+One%2C+Open-Label%2C+Crossover+Study+in+Healthy+Participants&doi=10.1007%2Fs12325-019-01198-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants</span></div><div class="casAuthors">Chen, Joseph; Xu, Huiping; Pawlak, Sylvester; James, Leonard P.; Peltz, Gerson; Lee, Kimberly; Ginman, Katherine; Bergeron, Michelle; Pithavala, Yazdi K.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">745-758</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Introduction: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-pos. metastatic non-small cell lung cancer; cytochrome P 450 (CYP) 3A plays an important role in the metab. of lorlatinib.  Methods: This phase 1, open-label, two-period, crossover study estd. the effect of oral rifampin (a strong CYP3A inducer) on the pharmacokinetics and safety of oral lorlatinib (NCT02804399).  Healthy participants received single-dose lorlatinib 100 mg in period 1 followed by rifampin 600 mg/day (days 1-12) and single-dose lorlatinib 100 mg (day 8) in period 2.  Blood samples were collected for 120 h after each dose of lorlatinib.  Results: When a single dose of lorlatinib was administered during daily dosing with rifampin (period 2), the area under the plasma concn.-time profile extrapolated to infinity (AUCinf) and max. plasma concn. (Cmax) of lorlatinib were 14.74% [90% confidence interval (CI) 12.78%, 17.01%] and 23.88% (90% CI 21.58%, 26.43%), resp., of those in period 1 (lorlatinib alone).  A single dose of lorlatinib was well tolerated in period 1, but elevations in transaminase values were obsd. in all participants (grade 2-4 in 11 participants) within 1-3 days after a single dose of lorlatinib was administered with ongoing rifampin in period 2.  Rifampin dosing was therefore halted.  Transaminase levels subsequently returned to normal (median time to recovery: 15 days).  No elevations in bilirubin were obsd.  Conclusions: The addn. of a single dose of lorlatinib to daily dosing with rifampin significantly reduced lorlatinib plasma exposure relative to a single dose of lorlatinib administered alone and was assocd. with severe but self-limiting transaminase elevations in all healthy participants.  These observations support the contraindication in the product label against concomitant use of lorlatinib with all strong CYP3A inducers.  Trial registration: ClinicalTrials.gov identifier, NCT02804399.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod7FDPfToKTLVg90H21EOLACvtfcHk0ljjuSqKpVWh3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyhs7rL&md5=8ce821a071e701d5cea6934b6cbf0bcb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs12325-019-01198-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-019-01198-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPawlak%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DGinman%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DM.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26atitle%3DThe%2520Effect%2520of%2520Rifampin%2520on%2520the%2520Pharmacokinetics%2520and%2520Safety%2520of%2520Lorlatinib%253A%2520Results%2520of%2520a%2520Phase%2520One%252C%2520Open-Label%252C%2520Crossover%2520Study%2520in%2520Healthy%2520Participants%26jtitle%3DAdv.%2520Ther.%26date%3D2020%26volume%3D37%26issue%3D2%26spage%3D745%26epage%3D758%26doi%3D10.1007%2Fs12325-019-01198-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Midha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, R.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (MutMapII)</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26609494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=2892-2911&issue=9&author=A.+Midhaauthor=S.+Deardenauthor=R.+McCormack&title=EGFR+Mutation+Incidence+in+Non-Small-Cell+Lung+Cancer+of+Adenocarcinoma+Histology%3A+A+Systematic+Review+and+Global+Map+by+Ethnicity+%28MutMapII%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)</span></div><div class="casAuthors">Midha Anita; Dearden Simon; McCormack Rose</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2892-911</span>
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) histology (NSCLC/ADC).  Robust data exist regarding the prevalence of EGFR mutations in Western and Asian patients with NSCLC/ADC, yet there is a lack of data for patients of other ethnicities.  This review collated available data with the aim of creating a complete, global picture of EGFR mutation frequency in patients with NSCLC/ADC by ethnicity.  Worldwide literature reporting EGFR mutation frequency in patients with NSCLC/ADC was reviewed, to create a map of the world populated with EGFR mutation frequency by country (a 'global EGFR mutMap').  A total of 151 worldwide studies (n=33162 patients with NSCLC/ADC, of which 9749 patients had EGFR mutation-positive NSCLC/ADC) were included.  There was substantial variation in EGFR mutation frequency between studies, even when grouped by geographic region or individual country.  As expected, the Asia-Pacific NSCLC/ADC subgroup had the highest EGFR mutation frequency (47% [5958/12819; 87 studies; range 20%-76%]) and the lowest EGFR mutation frequency occurred in the Oceania NSCLC/ADC subgroup (12% [69/570; 4 studies; range 7%-36%]); however, comparisons between regions were limited due to the varying sizes of the patient populations studied.  In all regional (geographic) subgroups where data were available, EGFR mutation frequency in NSCLC/ADC was higher in women compared with men, and in never-compared with ever-smokers.  This review provides the foundation for a global map of EGFR mutation frequency in patients with NSCLC/ADC.  The substantial lack of data from several large geographic regions of the world, notably Africa, the Middle East, Central Asia, and Central and South America, highlights a potential lack of routine mutation testing and the need for further investigations in these regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1x7LyD77C4UH3Rlp_k91zfW6udTcc2eYRdBc_5U0dd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D&md5=9ea4c9ffa42551cb066bb04142991fd4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMidha%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DR.%26atitle%3DEGFR%2520Mutation%2520Incidence%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520of%2520Adenocarcinoma%2520Histology%253A%2520A%2520Systematic%2520Review%2520and%2520Global%2520Map%2520by%2520Ethnicity%2520%2528MutMapII%2529%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26issue%3D9%26spage%3D2892%26epage%3D2911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-Small-Cell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70364-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS1470-2045%2809%2970364-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=20022809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=121-128&issue=2&author=T.+Mitsudomiauthor=S.+Moritaauthor=Y.+Yatabeauthor=S.+Negoroauthor=I.+Okamotoauthor=J.+Tsurutaniauthor=T.+Setoauthor=M.+Satouchiauthor=H.+Tadaauthor=T.+Hirashimaauthor=K.+Asamiauthor=N.+Katakamiauthor=M.+Takadaauthor=H.+Yoshiokaauthor=K.+Shibataauthor=S.+Kudohauthor=E.+Shimizuauthor=H.+Saitoauthor=S.+Toyookaauthor=K.+Nakagawaauthor=M.+Fukuoka&title=Gefitinib+versus+Cisplatin+plus+Docetaxel+in+Patients+with+Non-Small-Cell+Lung+Cancer+Harbouring+Mutations+of+the+Epidermal+Growth+Factor+Receptor+%28WJTOG3405%29%3A+An+Open+Label%2C+Randomised+Phase+3+Trial&doi=10.1016%2FS1470-2045%2809%2970364-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span></div><div class="casAuthors">Mitsudomi, Tetsuya; Morita, Satoshi; Yatabe, Yasushi; Negoro, Shunichi; Okamoto, Isamu; Tsurutani, Junji; Seto, Takashi; Satouchi, Miyako; Tada, Hirohito; Hirashima, Tomonori; Asami, Kazuhiro; Katakami, Nobuyuki; Takada, Minoru; Yoshioka, Hiroshige; Shibata, Kazuhiko; Kudoh, Shinzoh; Shimizu, Eiji; Saito, Hiroshi; Toyooka, Shinichi; Nakagawa, Kazuhiko; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer harboring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib.  However, whether gefitinib is better than std. platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.  We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harboring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimization technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m2, i.v.) plus docetaxel (60 mg/m2, i.v.; n=89), administered every 21 days for three to six cycles.  The primary endpoint was progression-free survival.  Survival anal. was done with the modified intention-to-treat population.  This study is registered with UMIN (University Hospital Medical Information Network in Japan), no. 000000539.  Five patients were excluded (two patients were found to have thyroid and colon cancer after randomization, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel).  Thus, 172 patients (86 in each group) were included in the survival analyses.  The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel group, with a median progression-free survival time of 9.2 mo (95% CI 8.0-13.9) vs. 6.3 mo (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001).  Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhea were more frequent in the gefitinib group.  Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.  Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.  Funding: West Japan Oncol. Group (WJOG): a non-profit organization supported by unrestricted donations from several pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKXuDlK2x9o7Vg90H21EOLACvtfcHk0ljr0ZeVAnvdYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D&md5=5856ce118d00919627e3f21525abe453</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970364-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970364-X%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNegoro%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DHirashima%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DK.%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520versus%2520Cisplatin%2520plus%2520Docetaxel%2520in%2520Patients%2520with%2520Non-Small-Cell%2520Lung%2520Cancer%2520Harbouring%2520Mutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528WJTOG3405%2529%253A%2520An%2520Open%2520Label%252C%2520Randomised%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26issue%3D2%26spage%3D121%26epage%3D128%26doi%3D10.1016%2FS1470-2045%2809%2970364-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kölbeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazulina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30033-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS1470-2045%2816%2930033-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=27083334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=577-589&issue=5&author=K.+Parkauthor=E.+H.+Tanauthor=K.+O%E2%80%99Byrneauthor=L.+Zhangauthor=M.+Boyerauthor=T.+Mokauthor=V.+Hirshauthor=J.+C.+H.+Yangauthor=K.+H.+Leeauthor=S.+Luauthor=Y.+Shiauthor=S.+W.+Kimauthor=J.+Laskinauthor=D.+W.+Kimauthor=C.+D.+Arvisauthor=K.+K%C3%B6lbeckauthor=S.+A.+Laurieauthor=C.+M.+Tsaiauthor=M.+Shahidiauthor=M.+Kimauthor=D.+Masseyauthor=V.+Zazulinaauthor=L.+Paz-Ares&title=Afatinib+versus+Gefitinib+as+First-Line+Treatment+of+Patients+with+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28LUX-Lung+7%29%3A+A+Phase+2B%2C+Open-Label%2C+Randomised+Controlled+Trial&doi=10.1016%2FS1470-2045%2816%2930033-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial</span></div><div class="casAuthors">Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-589</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-pos. non-small-cell lung cancer (NSCLC).  We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.  This multicentre, international, open-label, exploratory, randomised controlled phase 2B trial (LUX-Lung 7) was done at 64 centers in 13 countries.  Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator.  Randomisation, stratified by EGFR mutation type and status of brain metastases, was done centrally using a validated no. generating system implemented via an interactive voice or web-based response system with a block size of four.  Clinicians and patients were not masked to treatment allocation; independent review of tumor response was done in a blinded manner.  Coprimary endpoints were progression-free survival by independent central review, time-to-treatment failure, and overall survival.  Efficacy analyses were done in the intention-to-treat population and safety analyses were done in patients who received at least one dose of study drug.  This ongoing study is registered with ClinicalTrials.gov, no. NCT01466660.  Between Dec 13, 2011, and Aug 8, 2013, 319 patients were randomly assigned (160 to afatinib and 159 to gefitinib).  Median follow-up was 27·3 mo (IQR 15·3-33·9).  Progression-free survival (median 11·0 mo [95% CI 10·6-12·9] with afatinib vs 10·9 mo [9·1-11·5] with gefitinib; hazard ratio [HR] 0·73 [95% CI 0·57-0·95], p=0·017) and time-to-treatment failure (median 13·7 mo [95% CI 11·9-15·0] with afatinib vs 11·5 mo [10·1-13·1] with gefitinib; HR 0·73 [95% CI 0·58-0·92], p=0·0073) were significantly longer with afatinib than with gefitinib.  Overall survival data are not mature.  The most common treatment-related grade 3 or 4 adverse events were diarrhoea (20 [13%] of 160 patients given afatinib vs two [1%] of 159 given gefitinib) and rash or acne (15 [9%] patients given afatinib vs five [3%] of those given gefitinib) and liver enzyme elevations (no patients given afatinib vs 14 [9%] of those given gefitinib).  Serious treatment-related adverse events occurred in 17 (11%) patients in the afatinib group and seven (4%) in the gefitinib group.  Ten (6%) patients in each group discontinued treatment due to drug-related adverse events. 15 (9%) fatal adverse events occurred in the afatinib group and ten (6%) in the gefitinib group.  All but one of these deaths were considered unrelated to treatment; one patient in the gefitinib group died from drug-related hepatic and renal failure.  Afatinib significantly improved outcomes in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable tolerability profile.  These data are potentially important for clin. decision making in this patient population.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSTXQpDomR7Vg90H21EOLACvtfcHk0ljr0ZeVAnvdYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D&md5=33d5697aa6a01e4f3fc89a34cb3b1e61</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930033-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930033-X%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DLaskin%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DK%25C3%25B6lbeck%26aufirst%3DK.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DTsai%26aufirst%3DC.%2BM.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DMassey%26aufirst%3DD.%26aulast%3DZazulina%26aufirst%3DV.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DAfatinib%2520versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520of%2520Patients%2520with%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528LUX-Lung%25207%2529%253A%2520A%2520Phase%25202B%252C%2520Open-Label%252C%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D5%26spage%3D577%26epage%3D589%26doi%3D10.1016%2FS1470-2045%2816%2930033-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in Untreated EGFR -Mutated Advanced Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.-C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.-C.+Suauthor=J.+E.+Grayauthor=S.-M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimertinib+in+Untreated+EGFR+-Mutated+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0lidyfXefFgGpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.-M.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimertinib%2520in%2520Untreated%2520EGFR%2520-Mutated%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, C.</span></span> <span> </span><span class="NLM_article-title">Erlotinib versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70184-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS1470-2045%2811%2970184-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21783417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=735-742&issue=8&author=C.+Zhouauthor=Y.+L.+Wuauthor=G.+Chenauthor=J.+Fengauthor=X.+Q.+Liuauthor=C.+Wangauthor=S.+Zhangauthor=J.+Wangauthor=S.+Zhouauthor=S.+Renauthor=S.+Luauthor=L.+Zhangauthor=C.+Huauthor=C.+Huauthor=Y.+Luoauthor=L.+Chenauthor=M.+Yeauthor=J.+Huangauthor=X.+Zhiauthor=Y.+Zhangauthor=Q.+Xiuauthor=J.+Maauthor=L.+Zhangauthor=C.+You&title=Erlotinib+versus+Chemotherapy+as+First-Line+Treatment+for+Patients+with+Advanced+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28OPTIMAL%2C+CTONG-0802%29%3A+A+Multicentre%2C+Open-Label%2C+Randomised%2C+Phase+3+Study&doi=10.1016%2FS1470-2045%2811%2970184-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study</span></div><div class="casAuthors">Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">735-742</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC).  The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib vs. std. chemotherapy in the first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  We undertook an open-label, randomised, phase 3 trial at 22 centers in China.  Patients older than 18 years with histol. confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received either oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects, or up to four cycles of gemcitabine plus carboplatin.  Patients were randomly assigned (1:1) with a minimization procedure and were stratified according to EGFR mutation type, histol. subtype (adenocarcinoma vs non-adenocarcinoma), and smoking status.  The primary outcome was progression-free survival, analyzed in patients with confirmed disease who received at least one dose of study treatment.  The trial is registered at ClinicalTrials.gov, no. NCT00874419, and has completed enrollment; patients are still in follow-up.  83 Patients were randomly assigned to receive erlotinib and 82 to receive gemcitabine plus carboplatin; 82 in the erlotinib group and 72 in the chemotherapy group were included in anal. of the primary endpoint.  Median progression-free survival was significantly longer in erlotinib-treated patients than in those on chemotherapy (13.1 [95% CI 10.58-16.53] vs 4.6 [4.21-5.42] months; hazard ratio 0.16, 95% CI 0.10-0.26; p<0.0001).  Chemotherapy was assocd. with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concns. (three [4%] of 83 patients) and skin rash (two [2%] patients).  Chemotherapy was also assocd. with increased treatment-related serious adverse events (ten [14%] of 72 patients [decreased platelet count, n = 8; decreased neutrophil count, n = 1; hepatic dysfunction, n = 1] vs two [2%] of 83 patients [both hepatic dysfunction]).  Compared with std. chemotherapy, erlotinib conferred a significant progression-free survival benefit in patients with advanced EGFR mutation-pos. NSCLC and was assocd. with more favorable tolerability.  These findings suggest that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  Funding: F Hoffmann-La Roche Ltd (China); Science and Technol. Commission of Shanghai Municipality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNzw1hk1km7Vg90H21EOLACvtfcHk0lj5XucrRKbJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D&md5=92097cc6e942e9137a40fd6cae675297</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970184-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970184-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%2BQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DC.%26atitle%3DErlotinib%2520versus%2520Chemotherapy%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520Advanced%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528OPTIMAL%252C%2520CTONG-0802%2529%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26issue%3D8%26spage%3D735%26epage%3D742%26doi%3D10.1016%2FS1470-2045%2811%2970184-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">872</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1158%2F2159-8290.CD-12-0387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=23071030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=872-875&issue=10&author=C.+M.+Blakelyauthor=T.+G.+Bivona&title=Resiliency+of+Lung+Cancers+to+EGFR+Inhibitor+Treatment+Unveiled+Offering+Opportunities+to+Divide+and+Conquer+EGFR+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-12-0387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span></div><div class="casAuthors">Blakely, Collin M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">872-875</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Summary: The clin. success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance.  Two reports in this issue of Cancer Discovery uncover addnl. mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment.  These findings pave the way for clin. testing of new rational therapeutic strategies to prevent or overcome resistance to EGFR kinase inhibitors in the clinic.  Cancer Discov; 2(10); 872-5. ©2012 AACR.  Commentary on Ercan et al., p. 934.  Commentary on Takezawa et al., p. 922.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiyRcMFbYgYrVg90H21EOLACvtfcHk0lj5XucrRKbJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM&md5=ec81e2c701acb7c836306926ca9b5074</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0387%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DResiliency%2520of%2520Lung%2520Cancers%2520to%2520EGFR%2520Inhibitor%2520Treatment%2520Unveiled%2520Offering%2520Opportunities%2520to%2520Divide%2520and%2520Conquer%2520EGFR%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D10%26spage%3D872%26epage%3D875%26doi%3D10.1158%2F2159-8290.CD-12-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Third-Generation Inhibitors Targeting EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26733151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSjt7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=1-7&issue=1&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-Generation+Inhibitors+Targeting+EGFR+T790M+Mutation+in+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2</span></div><div class="casAuthors">Ma, De-Ning; Chai, Zong-Tao; Zhu, Xiao-Dong; Zhang, Ning; Zhan, Di-Hua; Ye, Bo-Gen; Wang, Cheng-Hao; Qin, Cheng-Dong; Zhao, Yi-Ming; Zhu, Wei-Ping; Cao, Man-Qing; Gao, Dong-Mei; Sun, Hui-Chuan; Tang, Zhao-You</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1/1-1/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Our previous study reported that microRNA-26a (miR-26a) inhibited tumor progression by inhibiting tumor angiogenesis and intratumoral macrophage infiltration in hepatocellular carcinoma (HCC).  The direct roles of miR-26a on tumor cell invasion remain poorly understood.  In this study, we aim to explore the mechanism of miR- 26a in modulating epithelial-mesenchymal transition (EMT) in HCC.  Methods: In vitro cell morphol. and cell migration were compared between the hepatoma cell lines HCCLM3 and HepG2, which were established in the previous study.  Overexpression and down-regulation of miR-26a were induced in these cell lines, and Western blot and immunofluorescence assays were used to detect the expression of EMT markers.  Xenograft nude mouse models were used to observe tumor growth and pulmonary metastasis.  Immunohistochem. assays were conducted to study the relationships between miR-26a expression and enhancer of zeste homolog 2 (EZH2) and E-cadherin expression in human HCC samples.  Results: Down-regulation of miR-26a in HCCLM3 and HepG2 cells resulted in an EMT-like cell morphol. and high motility in vitro and increased in tumor growth and pulmonary metastasis in vivo.  Through down-regulation of EZH2 expression and up-regulation of E-cadherin expression, miR-26a inhibited the EMT process in vitro and in vivo.  Luciferase reporter assay showed that miR-26a directly interacted with EZH2 mRNA (mRNA).  Furthermore, the expression of miR-26a was pos. correlated with E-cadherin expression and inversely correlated with EZH2 expression in human HCC tissue.  Conclusions: miR-26a inhibited the EMT process in HCC by down-regulating EZH2 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDsPy-LLFpBbVg90H21EOLACvtfcHk0lgkzd0Qz6uk-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSjt7jP&md5=62d073e3eb93ec6ae477d46992a3acda</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-Generation%2520Inhibitors%2520Targeting%2520EGFR%2520T790M%2520Mutation%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26issue%3D1%26spage%3D1%26epage%3D7%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mediates Resistance to AZD9291 in Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=A.+P.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mediates+Resistance+to+AZD9291+in+Advanced+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lgkzd0Qz6uk-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DA.%2BP.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+Novel+Resistance+Mechanisms+to+Third-Generation+EGFR+Tyrosine+Kinase+Inhibitor+Osimertinib+in+Non-Small+Cell+Lung+Cancer+Patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lgkzd0Qz6uk-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520Novel%2520Resistance%2520Mechanisms%2520to%2520Third-Generation%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitor%2520Osimertinib%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&issue=22&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+Selective+and+Rigidify%3A+The+Discovery+Path+toward+a+Next+Generation+of+EGFR+Tyrosine+Kinase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lj6GwgpjCM42Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520Selective%2520and%2520Rigidify%253A%2520The%2520Discovery%2520Path%2520toward%2520a%2520Next%2520Generation%2520of%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, M. L.</span></span> <span> </span><span class="NLM_article-title">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1961</span>– <span class="NLM_lpage">2004</span>, <span class="refDoi"> DOI: 10.1021/jm1012374</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1012374" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1961-2004&author=E.+Marsaultauthor=M.+L.+Peterson&title=Macrocycles+Are+Great+Cycles%3A+Applications%2C+Opportunities%2C+and+Challenges+of+Synthetic+Macrocycles+in+Drug+Discovery&doi=10.1021%2Fjm1012374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery</span></div><div class="casAuthors">Marsault, Eric; Peterson, Mark L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1961-2004</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Macrocycles occupy a unique segment of chem. space.  In the past decade, their chem. diversity expanded significantly, supported by advances in bioinformatics and synthetic methodol.  As a consequence, this structural type has now been successfully tested on most biol. target classes.  The goal of this article is to put into perspective the current applications, opportunities, and challenges assocd. with synthetic macrocycles in drug discovery.  Accordingly, the first part of this article is dedicated to the drug discovery aspects of macrocycles and highlights salient features of their medicinal chem.  This section is organized by target class, a choice aimed at providing the reader an appreciation of the structural diversity generated for each class.  To give the reader an appreciation of the tools available to construct macrocyclic scaffolds, the site and method of the pivotal macrocyclization step are indicated in the figures.  Readers are referred to the source articles for further details.  In the second part, the technologies and synthetic approaches that already have demonstrated utility or possess a high potential for macrocycle-based drug discovery are discussed.  Finally, a perspective on the future of synthetic macrocycles in medicinal chem. is offered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrygQLE6JraHrVg90H21EOLACvtfcHk0ljiPLtY2p5MXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSjtbo%253D&md5=97c1120896e90a85790a9ac1274259f3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm1012374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1012374%26sid%3Dliteratum%253Aachs%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DPeterson%26aufirst%3DM.%2BL.%26atitle%3DMacrocycles%2520Are%2520Great%2520Cycles%253A%2520Applications%252C%2520Opportunities%252C%2520and%2520Challenges%2520of%2520Synthetic%2520Macrocycles%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1961%26epage%3D2004%26doi%3D10.1021%2Fjm1012374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span> <span> </span><span class="NLM_article-title">Emac - A Comparative Index for the Assessment of Macrocyclization Efficiency</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1039/C2MD20176C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC2MD20176C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1489-1495&issue=12&author=J.+C.+Collinsauthor=K.+James&title=Emac+-+A+Comparative+Index+for+the+Assessment+of+Macrocyclization+Efficiency&doi=10.1039%2FC2MD20176C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Emac - a comparative index for the assessment of macrocyclization efficiency</span></div><div class="casAuthors">Collins, James C.; James, Keith</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1489-1495</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Macrocycle-based drug design represents an exciting new frontier in drug discovery, and consequently there is considerable interest in methodologies for the efficient construction of macrocyclic motifs.  However, typical high-diln. macrocyclization conditions are inefficient and impractical in a pharmaceutical setting from cost, capacity and green chem. perspectives.  This crit. review reports the results of a comprehensive literature survey of recent macrocyclization reactions and proposes a macrocyclization efficiency index, Emac, which takes into account both reaction yield and concn.  Anal. and discussion of the literature dataset using this novel metric are presented, along with selected examples of high and low efficiency macrocyclizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7MQcJUad-wrVg90H21EOLACvtfcHk0ljiPLtY2p5MXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsrzK&md5=5d44068e847eb24e7fdb318404a7c590</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FC2MD20176C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20176C%26sid%3Dliteratum%253Aachs%26aulast%3DCollins%26aufirst%3DJ.%2BC.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DEmac%2520-%2520A%2520Comparative%2520Index%2520for%2520the%2520Assessment%2520of%2520Macrocyclization%2520Efficiency%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D1489%26epage%3D1495%26doi%3D10.1039%2FC2MD20176C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martí-Centelles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burguete, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luis, S. V.</span></span> <span> </span><span class="NLM_article-title">Macrocyclization Reactions: The Importance of Conformational, Configurational, and Template-Induced Preorganization</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">8736</span>– <span class="NLM_lpage">8834</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12lu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=8736-8834&author=V.+Mart%C3%AD-Centellesauthor=M.+D.+Pandeyauthor=M.+I.+Burgueteauthor=S.+V.+Luis&title=Macrocyclization+Reactions%3A+The+Importance+of+Conformational%2C+Configurational%2C+and+Template-Induced+Preorganization&doi=10.1021%2Facs.chemrev.5b00056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclization Reactions: The Importance of Conformational, Configurational, and Template-Induced Preorganization</span></div><div class="casAuthors">Marti-Centelles, Vicente; Pandey, Mrituanjay D.; Burguete, M. Isabel; Luis, Santiago V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8736-8834</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Structural preorganization of precursors is of importance for macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnstxniwDETrVg90H21EOLACvtfcHk0ljiPLtY2p5MXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12lu7nJ&md5=bf3407bbbde3460506b709d2f0167f42</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00056%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25AD-Centelles%26aufirst%3DV.%26aulast%3DPandey%26aufirst%3DM.%2BD.%26aulast%3DBurguete%26aufirst%3DM.%2BI.%26aulast%3DLuis%26aufirst%3DS.%2BV.%26atitle%3DMacrocyclization%2520Reactions%253A%2520The%2520Importance%2520of%2520Conformational%252C%2520Configurational%252C%2520and%2520Template-Induced%2520Preorganization%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D8736%26epage%3D8834%26doi%3D10.1021%2Facs.chemrev.5b00056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankenstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Conformation-Directed Macrocyclization Reactions</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1949</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200400751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fejoc.200400751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=1949&issue=10&author=J.+Blankensteinauthor=J.+Zhu&title=Conformation-Directed+Macrocyclization+Reactions&doi=10.1002%2Fejoc.200400751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200400751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200400751%26sid%3Dliteratum%253Aachs%26aulast%3DBlankenstein%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DConformation-Directed%2520Macrocyclization%2520Reactions%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2005%26volume%3D2005%26issue%3D10%26spage%3D1949%26doi%3D10.1002%2Fejoc.200400751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gradillas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castells, J.</span></span> <span> </span><span class="NLM_article-title">Macrocyclization by Ring-Closing Metathesis in the Total Synthesis of Natural Products: Reaction Conditions and Limitations</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">6086</span>– <span class="NLM_lpage">6101</span>, <span class="refDoi"> DOI: 10.1002/anie.200600641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fanie.200600641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVWnsr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6086-6101&issue=37&author=A.+Gradillasauthor=J.+P%C3%A9rez-Castells&title=Macrocyclization+by+Ring-Closing+Metathesis+in+the+Total+Synthesis+of+Natural+Products%3A+Reaction+Conditions+and+Limitations&doi=10.1002%2Fanie.200600641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclization by ring-closing metathesis in the total synthesis of natural products: reaction conditions and limitations</span></div><div class="casAuthors">Gradillas, Ana; Perez-Castells, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">6086-6101</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The construction of macrocycles by ring-closing metathesis (RCM) is often used as the key step in the synthesis of natural products contg. large rings.  This reaction is attractive because of its high functional group compatibility and the possibility for further transformations.  The finding of suitable reaction conditions is crit. for the success of the synthesis.  This review summarizes the efficient RCM reactions of the total synthesis of natural macrocyclic products and should reduce the time-consuming phase of the optimization of the reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YDIbEWf4ALVg90H21EOLACvtfcHk0ljiPLtY2p5MXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVWnsr3P&md5=b1430b45488e86d48f29848cd4b2f725</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fanie.200600641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200600641%26sid%3Dliteratum%253Aachs%26aulast%3DGradillas%26aufirst%3DA.%26aulast%3DP%25C3%25A9rez-Castells%26aufirst%3DJ.%26atitle%3DMacrocyclization%2520by%2520Ring-Closing%2520Metathesis%2520in%2520the%2520Total%2520Synthesis%2520of%2520Natural%2520Products%253A%2520Reaction%2520Conditions%2520and%2520Limitations%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26issue%3D37%26spage%3D6086%26epage%3D6101%26doi%3D10.1002%2Fanie.200600641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, I.</span></span> <span> </span><span class="NLM_article-title">An Effective Method for the Synthesis of Carboxylic Esters and Lactones Using Substituted Benzoic Anhydrides with Lewis Acid Catalysts</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1587</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2003.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.tet.2003.12.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1587-1599&issue=7&author=I.+Shiina&title=An+Effective+Method+for+the+Synthesis+of+Carboxylic+Esters+and+Lactones+Using+Substituted+Benzoic+Anhydrides+with+Lewis+Acid+Catalysts&doi=10.1016%2Fj.tet.2003.12.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">An effective method for the synthesis of carboxylic esters and lactones using substituted benzoic anhydrides with Lewis acid catalysts</span></div><div class="casAuthors">Shiina, Isamu</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1587-1599</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">An efficient mixed-anhydride method for the synthesis of carboxylic esters and lactones using benzoic anhydride having electron withdrawing substituent(s) is developed by the promotion of Lewis acid catalysts.  In the presence of a catalytic amt. of TiCl2(ClO4)2, various carboxylic esters are prepd. in high yields through the formation of the corresponding mixed-anhydrides from 3,5-bis(trifluoromethyl)benzoic anhydride and carboxylic acids.  The combined catalyst consisting of TiCl2(ClO4)2 together with chlorotrimethylsilane functions as an effective catalyst for the synthesis of carboxylic esters from free carboxylic acids and alcs. with 4-(trifluoromethyl)benzoic anhydride.  Various macrolactones are prepd. from the free ω-hydroxycarboxylic acids by the combined use of 4-(trifluoromethyl)benzoic anhydride and titanium(IV) catalysts together with chlorotrimethylsilane under mild reaction conditions.  The lactonization of trimethylsilyl ω-(trimethylsiloxy)carboxylates using 4-(trifluoromethyl)benzoic anhydride is also promoted at room temp. in the presence of a catalytic amt. of TiCl2(ClO4)2.  An 8-membered ring lactone, a synthetic intermediate of cephalosporolide D, is successfully synthesized according to this mixed-anhydride method using 4-(trifluoromethyl)benzoic anhydride by the promotion of a catalytic amt. of Hf(OTf)4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDJAtkgZ5nkrVg90H21EOLACvtfcHk0liBFHYbjbuhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFWktQ%253D%253D&md5=af46a2832f81bab0c3aed26731e83aaa</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2003.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2003.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DShiina%26aufirst%3DI.%26atitle%3DAn%2520Effective%2520Method%2520for%2520the%2520Synthesis%2520of%2520Carboxylic%2520Esters%2520and%2520Lactones%2520Using%2520Substituted%2520Benzoic%2520Anhydrides%2520with%2520Lewis%2520Acid%2520Catalysts%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26issue%3D7%26spage%3D1587%26epage%3D1599%26doi%3D10.1016%2Fj.tet.2003.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibuka, R.</span></span> <span> </span><span class="NLM_article-title">A Novel and Efficient Macrolactonization of ω-Hydroxycarboxylic Acids Using 2-Methyl-6-Nitrobenzoic Anhydride (MNBA)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">42</span>),  <span class="NLM_fpage">7535</span>– <span class="NLM_lpage">7539</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(02)01819-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS0040-4039%2802%2901819-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVWlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=7535-7539&issue=42&author=I.+Shiinaauthor=M.+Kubotaauthor=R.+Ibuka&title=A+Novel+and+Efficient+Macrolactonization+of+%CF%89-Hydroxycarboxylic+Acids+Using+2-Methyl-6-Nitrobenzoic+Anhydride+%28MNBA%29&doi=10.1016%2FS0040-4039%2802%2901819-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A novel and efficient macrolactonization of ω-hydroxycarboxylic acids using 2-methyl-6-nitrobenzoic anhydride (MNBA)</span></div><div class="casAuthors">Shiina, Isamu; Kubota, Mari; Ibuka, Ryoutarou</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">7535-7539</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A variety of lactones were prepd. in high yields at room temp. from the corresponding ω-hydroxycarboxylic acids using 2-methyl-6-nitrobenzoic anhydride in the presence of 4-(dimethylamino)pyridine.  A similar reaction also occurs with triethylamine when using a catalytic amt. of 4-(dimethylamino)pyridine 1-oxide as an effective promoter for the intramol. condensation reaction.  These methods were successfully applied to the synthesis of erythro-aleuritic acid lactone and the efficiency of the cyclizations is compared to those of other reported mixed anhydride methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3QFqUhehBf7Vg90H21EOLACvtfcHk0liBFHYbjbuhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVWlu7k%253D&md5=827022b65e6972fc385da3978701fc55</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2802%2901819-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252802%252901819-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiina%26aufirst%3DI.%26aulast%3DKubota%26aufirst%3DM.%26aulast%3DIbuka%26aufirst%3DR.%26atitle%3DA%2520Novel%2520and%2520Efficient%2520Macrolactonization%2520of%2520%25CF%2589-Hydroxycarboxylic%2520Acids%2520Using%25202-Methyl-6-Nitrobenzoic%2520Anhydride%2520%2528MNBA%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2002%26volume%3D43%26issue%3D42%26spage%3D7535%26epage%3D7539%26doi%3D10.1016%2FS0040-4039%2802%2901819-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wender, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeChristopher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, A. J.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Driven Macrocyclization Strategy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">6658</span>– <span class="NLM_lpage">6659</span>, <span class="refDoi"> DOI: 10.1021/ja8015632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja8015632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlamt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=6658-6659&issue=21&author=P.+A.+Wenderauthor=B.+A.+DeChristopherauthor=A.+J.+Schrier&title=Efficient+Synthetic+Access+to+a+New+Family+of+Highly+Potent+Bryostatin+Analogues+via+a+Prins-Driven+Macrocyclization+Strategy&doi=10.1021%2Fja8015632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Driven Macrocyclization Strategy</span></div><div class="casAuthors">Wender, Paul A.; DeChristopher, Brian A.; Schrier, Adam J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6658-6659</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The step-economical synthesis of a new class of bryostatin analogs, e.g. I, that contain the complete oxycarbocyclic core ring system of the bryostatin natural products is reported.  These agents are convergently assembled via a highly efficient, functional-group-tolerant, and stereoselective Prins-driven macrocyclization.  These tetrahydropyranyl B-ring analogs are among our most potent and efficacious analogs to date, exhibiting nanomolar and picomolar activities in protein kinase C affinity assays as well as in cellular antiproliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcrnxjdmrRLVg90H21EOLACvtfcHk0liBFHYbjbuhjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlamt74%253D&md5=96423f7f8731ac6230323622201cf547</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fja8015632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja8015632%26sid%3Dliteratum%253Aachs%26aulast%3DWender%26aufirst%3DP.%2BA.%26aulast%3DDeChristopher%26aufirst%3DB.%2BA.%26aulast%3DSchrier%26aufirst%3DA.%2BJ.%26atitle%3DEfficient%2520Synthetic%2520Access%2520to%2520a%2520New%2520Family%2520of%2520Highly%2520Potent%2520Bryostatin%2520Analogues%2520via%2520a%2520Prins-Driven%2520Macrocyclization%2520Strategy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26issue%3D21%26spage%3D6658%26epage%3D6659%26doi%3D10.1021%2Fja8015632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubbs, R. H.</span></span> <span> </span><span class="NLM_article-title">Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">40</span>),  <span class="NLM_fpage">9606</span>– <span class="NLM_lpage">9614</span>, <span class="refDoi"> DOI: 10.1021/ja961626l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja961626l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaK28Xls12ltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=9606-9614&issue=40&author=S.+J.+Millerauthor=H.+E.+Blackwellauthor=R.+H.+Grubbs&title=Application+of+Ring-Closing+Metathesis+to+the+Synthesis+of+Rigidified+Amino+Acids+and+Peptides&doi=10.1021%2Fja961626l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides</span></div><div class="casAuthors">Miller, Scott J.; Blackwell, Helen E.; Grubbs, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">9606-9614</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ruthenium complexes I (R = Ph, CH:CPh2) have been applied to the ring-closing metathesis (RCM) reactions of a no. of dienic substrates.  The substrate scope includes rings of 6 to 20 members.  In addressing macrocyclic peptides, a class of tetrapeptide disulfides inspired the synthesis of the carbon-carbon bond analogs.  Replacement of cysteine residues with allylglycines resulted in the acyclic precursors which were subjected to RCM to afford the corresponding macrocycles.  In addn., several macrocycles were prepd. which were not based upon disulfide-bridge-contg. species found in nature.  The method was found to function on dienic peptides which were either dissolved in org. solvents or bound to solid supports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom4hQK1LSVhbVg90H21EOLACvtfcHk0lixZJC4mjolzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xls12ltLo%253D&md5=7085a5ca04b442050a953ec5146934c2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fja961626l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja961626l%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DS.%2BJ.%26aulast%3DBlackwell%26aufirst%3DH.%2BE.%26aulast%3DGrubbs%26aufirst%3DR.%2BH.%26atitle%3DApplication%2520of%2520Ring-Closing%2520Metathesis%2520to%2520the%2520Synthesis%2520of%2520Rigidified%2520Amino%2520Acids%2520and%2520Peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26issue%3D40%26spage%3D9606%26epage%3D9614%26doi%3D10.1021%2Fja961626l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fürstner, A.</span></span> <span> </span><span class="NLM_article-title">Olefin Metathesis and Beyond</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3012</span>– <span class="NLM_lpage">3043</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20000901)39:17<3012::AID-ANIE3012>3.0.CO;2-G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFWgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=3012-3043&issue=17&author=A.+F%C3%BCrstner&title=Olefin+Metathesis+and+Beyond&doi=10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Olefin metathesis and beyond</span></div><div class="casAuthors">Fuerstner, Alois</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3012-3043</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">A review.  The advent of well-defined catalysts for olefin metathesis which combine high activity, durability, and excellent tolerance towards polar functional groups has revolutionized the field.  The past decade has seen the rapid embrace of these reagents as tools for advanced org. and polymer chem. and the success of this development is witnessed by a plethora of elegant applications to the synthesis of natural and nonnatural products.  This review article, with >200 refs., provides an overview of these developments and familiarizes the reader with some very recent advances which hold the promise to expand the scope of the reaction even further.  Moreover, the pos. impact of metathesis on the fundamental logic of retrosynthetic planning is shown by means of typical examples.  Finally, metathesis is by no means restricted to alkene substrates, and some comments on metathesis reactions following unconventional mechanistic pathways are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEFuxPpFyvl7Vg90H21EOLACvtfcHk0lixZJC4mjolzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFWgtLg%253D&md5=34a56b85c96f16750f2f75d8e55fea92</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820000901%252939%253A17%253C3012%253A%253AAID-ANIE3012%253E3.0.CO%253B2-G%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26atitle%3DOlefin%2520Metathesis%2520and%2520Beyond%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2000%26volume%3D39%26issue%3D17%26spage%3D3012%26epage%3D3043%26doi%3D10.1002%2F1521-3773%2820000901%2939%3A17%3C3012%3A%3AAID-ANIE3012%3E3.0.CO%3B2-G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lücking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Aminopyrimidines as Multitarget CDK and VEGF-R Inhibitors with Potent Antiproliferative Activities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcmdc.200600199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=17131463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=63-77&issue=1&author=U.+L%C3%BCckingauthor=G.+Siemeisterauthor=M.+Sch%C3%A4ferauthor=H.+Briemauthor=M.+Kr%C3%BCgerauthor=P.+Lienauauthor=R.+Jautelat&title=Macrocyclic+Aminopyrimidines+as+Multitarget+CDK+and+VEGF-R+Inhibitors+with+Potent+Antiproliferative+Activities&doi=10.1002%2Fcmdc.200600199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities</span></div><div class="casAuthors">Luecking, Ulrich; Siemeister, Gerhard; Schaefer, Martina; Briem, Hans; Krueger, Martin; Lienau, Philip; Jautelat, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-77</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">X-ray structures from CDK2-aminopyrimidine inhibitor complexes led to the idea to stabilize the active conformation of aminopyrimidine inhibitors by incorporating the recognition site into a macrocyclic framework.  A modular synthesis approach that relies on a new late-stage macrocyclization protocol that enables fast and efficient synthesis of macrocyclic aminopyrimidines was developed.  A set of structurally diverse derivs. was prepd.  Macrocyclic aminopyrimidines were shown to be multitarget inhibitors of CDK1/2 and VEGF-RTKs.  In addn., potent antiproliferative activities toward various human tumor cells and a human tumor xenograft model were demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJSYJjccvBpLVg90H21EOLACvtfcHk0lixZJC4mjolzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbY%253D&md5=80a2329d666086a24e0e98070305841c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600199%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BCcking%26aufirst%3DU.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DKr%25C3%25BCger%26aufirst%3DM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DJautelat%26aufirst%3DR.%26atitle%3DMacrocyclic%2520Aminopyrimidines%2520as%2520Multitarget%2520CDK%2520and%2520VEGF-R%2520Inhibitors%2520with%2520Potent%2520Antiproliferative%2520Activities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D1%26spage%3D63%26epage%3D77%26doi%3D10.1002%2Fcmdc.200600199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Himmelbauer, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyedy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilfillan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Turiso, F. G. L.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10740</span>– <span class="NLM_lpage">10756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01206</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01206" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqsrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10740-10756&issue=23&author=M.+K.+Himmelbauerauthor=Z.+Xinauthor=J.+H.+Jonesauthor=I.+Enyedyauthor=K.+Kingauthor=D.+J.+Marcotteauthor=P.+Muruganauthor=J.+C.+Santoroauthor=T.+Hessonauthor=K.+Spilkerauthor=J.+L.+Johnsonauthor=M.+J.+Luzzioauthor=R.+Gilfillanauthor=F.+G.+L.+De+Turiso&title=Rational+Design+and+Optimization+of+a+Novel+Class+of+Macrocyclic+Apoptosis+Signal-Regulating+Kinase+1+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors</span></div><div class="casAuthors">Himmelbauer, Martin K.; Xin, Zhili; Jones, J. Howard; Enyedy, Istvan; King, Kristopher; Marcotte, Douglas J.; Murugan, Paramasivam; Santoro, Joseph C.; Hesson, Thomas; Spilker, Kerri; Johnson, Joshua L.; Luzzio, Michael J.; Gilfillan, Rab; de Turiso, Felix Gonzalez-Lopez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10740-10756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural anal. of a known ASK1 inhibitor bound to its kinase domain led to the design and synthesis of the novel macrocyclic inhibitor I (cell IC50 = 1.2μM).  The profile of this compd. was optimized for CNS penetration following two independent strategies: a rational design approach leading to II and a parallel synthesis approach leading to III.  Both analogs are potent ASK1 inhibitors in biochem. and cellular assays (II, cell IC50 = 95 nM; III, cell IC50 = 123 nM) and have moderate to low efflux ratio (ER) in an MDR1-MDCK assay (II, ER = 5.2; III, ER = 1.5).  In vivo PK studies revealed that inhibitor II had moderate CNS penetration (Kp,uu = 0.17) and analog III had high CNS penetration (Kp,uu = 1.0).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriuHDeLuhp8bVg90H21EOLACvtfcHk0lixZJC4mjolzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqsrnL&md5=bceb203a92c314a775b1d8d116cafcad</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01206%26sid%3Dliteratum%253Aachs%26aulast%3DHimmelbauer%26aufirst%3DM.%2BK.%26aulast%3DXin%26aufirst%3DZ.%26aulast%3DJones%26aufirst%3DJ.%2BH.%26aulast%3DEnyedy%26aufirst%3DI.%26aulast%3DKing%26aufirst%3DK.%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DMurugan%26aufirst%3DP.%26aulast%3DSantoro%26aufirst%3DJ.%2BC.%26aulast%3DHesson%26aufirst%3DT.%26aulast%3DSpilker%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DJ.%2BL.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DGilfillan%26aufirst%3DR.%26aulast%3DDe%2BTuriso%26aufirst%3DF.%2BG.%2BL.%26atitle%3DRational%2520Design%2520and%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520Macrocyclic%2520Apoptosis%2520Signal-Regulating%2520Kinase%25201%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D23%26spage%3D10740%26epage%3D10756%26doi%3D10.1021%2Facs.jmedchem.9b01206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Recent Development of Peptide Coupling Reagents in Organic Synthesis</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2447</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.01.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.tet.2004.01.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFeqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2447-2467&issue=11&author=S.-Y.+Hanauthor=Y.-A.+Kim&title=Recent+Development+of+Peptide+Coupling+Reagents+in+Organic+Synthesis&doi=10.1016%2Fj.tet.2004.01.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Recent development of peptide coupling reagents in organic synthesis</span></div><div class="casAuthors">Han, So-Yeop; Kim, Young-Ah</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2447-2467</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Various types of peptide coupling reagents (i.e., phosphonium, uronium, immonium, carbodiimide, imidazolium, organophosphorus, acid halogenating compds., chloroformate, pyridinium, etc.) are discussed for the synthesis of bioactive mols. contg. peptide linkages.  Methods used to suppress racemization during the peptide coupling step are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MxkBBhDXubVg90H21EOLACvtfcHk0livRwv-mCzIaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFeqsro%253D&md5=8c9ca02776710dd0e204262a85da630b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.01.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.01.020%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.-Y.%26aulast%3DKim%26aufirst%3DY.-A.%26atitle%3DRecent%2520Development%2520of%2520Peptide%2520Coupling%2520Reagents%2520in%2520Organic%2520Synthesis%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26issue%3D11%26spage%3D2447%26epage%3D2467%26doi%3D10.1016%2Fj.tet.2004.01.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIver, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcmdc.201600589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=28032464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=207-213&issue=3&author=A.+L.+McIverauthor=W.+Zhangauthor=Q.+Liuauthor=X.+Jiangauthor=M.+A.+Stashkoauthor=J.+Nicholsauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=M.+Machiusauthor=D.+DeRyckereauthor=E.+Woodauthor=D.+K.+Grahamauthor=H.+S.+Earpauthor=D.+Kireevauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+Macrocyclic+Pyrimidines+as+MerTK-Specific+Inhibitors&doi=10.1002%2Fcmdc.201600589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors</span></div><div class="casAuthors">McIver, Andrew L.; Zhang, Weihe; Liu, Qingyang; Jiang, Xinpeng; Stashko, Michael A.; Nichols, James; Miley, Michael J.; Norris-Drouin, Jacqueline; Machius, Mischa; DeRyckere, Deborah; Wood, Edgar; Graham, Douglas K.; Earp, H. Shelton; Kireev, Dmitri; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocycles have attracted significant attention in drug discovery recently.  In fact, a few de novo designed macrocyclic kinase inhibitors are currently in clin. trials with good potency and selectivity for their intended target.  In this study, we successfully engaged a structure-based drug design approach to discover macrocyclic pyrimidines as potent Mer tyrosine kinase (MerTK)-specific inhibitors.  An ELISA (ELISA) in 384-well format was employed to evaluate the inhibitory activity of macrocycles in a cell-based assay assessing tyrosine phosphorylation of MerTK.  Through structure-activity relationship (SAR) studies, analog 11 [UNC2541; (S)-7-amino-N-(4-fluorobenzyl)-8-oxo-2,9,16-triaza-1(2,4)-pyrimidinacyclohexadecaphane-1-carboxamide] was identified as a potent and MerTK-specific inhibitor that exhibits sub-micromolar inhibitory activity in the cell-based ELISA.  In addn., an X-ray structure of MerTK protein in complex with 11 was resolved to show that these macrocycles bind in the MerTK ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOfJewlO7H8bVg90H21EOLACvtfcHk0livRwv-mCzIaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVamsQ%253D%253D&md5=09a963efb36d595e3f4a301676b685f1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600589%26sid%3Dliteratum%253Aachs%26aulast%3DMcIver%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DJ.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520Macrocyclic%2520Pyrimidines%2520as%2520MerTK-Specific%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26issue%3D3%26spage%3D207%26epage%3D213%26doi%3D10.1002%2Fcmdc.201600589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiratori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, T.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Macrocyclic 2-Amino-6-Arylpyrimidine Hsp90 Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1141</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.11.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmcl.2011.11.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22192591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFalsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1136-1141&issue=2&author=A.+Sudaauthor=H.+Koyanoauthor=T.+Hayaseauthor=K.+Hadaauthor=K.+I.+Kawasakiauthor=S.+Komiyamaauthor=K.+Hasegawaauthor=T.+A.+Fukamiauthor=S.+Satoauthor=T.+Miuraauthor=N.+Onoauthor=T.+Yamazakiauthor=R.+Saitohauthor=N.+Shimmaauthor=Y.+Shiratoriauthor=T.+Tsukuda&title=Design+and+Synthesis+of+Novel+Macrocyclic+2-Amino-6-Arylpyrimidine+Hsp90+Inhibitors&doi=10.1016%2Fj.bmcl.2011.11.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors</span></div><div class="casAuthors">Suda, Atsushi; Koyano, Hiroshi; Hayase, Tadakatsu; Hada, Kihito; Kawasaki, Ken-ichi; Komiyama, Susumu; Hasegawa, Kiyoshi; Fukami, Takaaki A.; Sato, Shigeo; Miura, Takaaki; Ono, Naomi; Yamazaki, Toshikazu; Saitoh, Ryoichi; Shimma, Nobuo; Shiratori, Yasuhiko; Tsukuda, Takuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1136-1141</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Macrocyclic compds. bearing a 2-amino-6-arylpyrimidine moiety were identified as potent heat shock protein 90 (Hsp90) inhibitors by modification of 2-amino-6-aryltriazine deriv. (CH5015765).  We employed a macrocyclic structure as a skeleton of new inhibitors to mimic the geldanamycin-Hsp90 interactions.  Among the identified inhibitors, CH5164840 showed high binding affinity for N-terminal Hsp90α (K d = 0.52 nM) and strong anti-proliferative activity against human cancer cell lines (HCT116 IC50 = 0.15 μM, NCI-N87 IC50 = 0.066 μM).  CH5164840 displayed high oral bioavailability in mice (F = 70.8%) and potent antitumor efficacy in a HCT116 human colorectal cancer xenograft model (tumor growth inhibition = 83%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPCQV64QCJ6LVg90H21EOLACvtfcHk0livRwv-mCzIaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFalsw%253D%253D&md5=3bfb99b56abd1ee3cceb584edf12d2db</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.100%26sid%3Dliteratum%253Aachs%26aulast%3DSuda%26aufirst%3DA.%26aulast%3DKoyano%26aufirst%3DH.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DHada%26aufirst%3DK.%26aulast%3DKawasaki%26aufirst%3DK.%2BI.%26aulast%3DKomiyama%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DSaitoh%26aufirst%3DR.%26aulast%3DShimma%26aufirst%3DN.%26aulast%3DShiratori%26aufirst%3DY.%26aulast%3DTsukuda%26aufirst%3DT.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Macrocyclic%25202-Amino-6-Arylpyrimidine%2520Hsp90%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D1136%26epage%3D1141%26doi%3D10.1016%2Fj.bmcl.2011.11.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raggon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J.</span></span> <span> </span><span class="NLM_article-title">Exploratory Process Development of Lorlatinib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1289-1293&issue=9&author=B.+Liauthor=R.+W.+Barnhartauthor=J.+E.+Hoffmanauthor=A.+Nematallaauthor=J.+Raggonauthor=P.+Richardsonauthor=N.+Sachauthor=J.+Weaver&title=Exploratory+Process+Development+of+Lorlatinib&doi=10.1021%2Facs.oprd.8b00210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Exploratory Process Development of Lorlatinib</span></div><div class="casAuthors">Li, Bryan; Barnhart, Richard W.; Hoffman, Jacqui E.; Nematalla, Asaad; Raggon, Jeffrey; Richardson, Paul; Sach, Neal; Weaver, John</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1289-1293</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The original synthesis of lorlatinib (I) was applied and improved in the first GMP campaign.  In this approach, a slow addn. of the boronate ester was crit. in suppressing the formation of a homocoupled impurity in the Suzuki-Miyaura coupling, and the chemoselective hydrolysis of Me ester was accomplished by potassium trimethylsilanoate.  The synthesis was completed with macrocyclic amidation followed by deprotection of the Boc groups.  A thorough process safety evaluation of HATU enabled its use as the coupling reagent for the macrocyclic amidation, which improved the yield and eliminated the only chromatog. operation in the synthetic sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRVJZSwiHBgrVg90H21EOLACvtfcHk0lgs4zWTNzLuNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI&md5=4bb70a5071d2a8cb45661a3d223fb96f</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00210%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DBarnhart%26aufirst%3DR.%2BW.%26aulast%3DHoffman%26aufirst%3DJ.%2BE.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DRaggon%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DWeaver%26aufirst%3DJ.%26atitle%3DExploratory%2520Process%2520Development%2520of%2520Lorlatinib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26issue%3D9%26spage%3D1289%26epage%3D1293%26doi%3D10.1021%2Facs.oprd.8b00210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parenty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagne, J.-M.</span></span> <span> </span><span class="NLM_article-title">Macrolactonizations in the Total Synthesis of Natural Products</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">911</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1021/cr0301402</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0301402" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD28XoslWqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=911-939&issue=3&author=A.+Parentyauthor=X.+Moreauauthor=J.-M.+Campagne&title=Macrolactonizations+in+the+Total+Synthesis+of+Natural+Products&doi=10.1021%2Fcr0301402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Macrolactonizations in the total synthesis of natural products</span></div><div class="casAuthors">Parenty, A.; Moreau, X.; Campagne, J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">911-939</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review was presented of the macrolactonization of seco acids in the total synthesis of natural products.  The need for macrolactonizations has inspired many clever solns. either by activation of the alc. or activation of the acid moiety.  Among future challenges will be further developments of enantio-, atrop- and diastereoselective macrolactonizations and the development of a truly atom-economic macrolactonization method under moderate diln. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBvzQqeR5E1rVg90H21EOLACvtfcHk0lgs4zWTNzLuNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XoslWqtw%253D%253D&md5=b79baebd6aec74f1f19163ae025237b8</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fcr0301402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0301402%26sid%3Dliteratum%253Aachs%26aulast%3DParenty%26aufirst%3DA.%26aulast%3DMoreau%26aufirst%3DX.%26aulast%3DCampagne%26aufirst%3DJ.-M.%26atitle%3DMacrolactonizations%2520in%2520the%2520Total%2520Synthesis%2520of%2520Natural%2520Products%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26issue%3D3%26spage%3D911%26epage%3D939%26doi%3D10.1021%2Fcr0301402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inanaga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span> <span> </span><span class="NLM_article-title">A Rapid Esterification by Means of Mixed Anhydride and Its Application to Large-Ring Lactonization</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1993</span>, <span class="refDoi"> DOI: 10.1246/bcsj.52.1989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1246%2Fbcsj.52.1989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaE1MXltl2rt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1979&pages=1989-1993&issue=7&author=J.+Inanagaauthor=K.+Hirataauthor=H.+Saekiauthor=T.+Katsukiauthor=M.+Yamaguchi&title=A+Rapid+Esterification+by+Means+of+Mixed+Anhydride+and+Its+Application+to+Large-Ring+Lactonization&doi=10.1246%2Fbcsj.52.1989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid esterification by mixed anhydride and its application to large-ring lactonization</span></div><div class="casAuthors">Inanaga, Junji; Hirata, Kuniko; Saeki, Hiroko; Katsuki, Tsutomu; Yamaguchi, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1989-93</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">A rapid and mild esterification method using carboxylic 2,4,6-trichlorobenzoic anhydrides in the presence of 4-(dimethylamino)pyridine was developed.  The method was also successfully applied to the synthesis of large-ring lactones, including DL-2,4,6-tridemethyl-3-deoxymethynolide (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwvGlZSKrReLVg90H21EOLACvtfcHk0lgs4zWTNzLuNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltl2rt78%253D&md5=73880dc7e3aebc06844628a0e9ff6a68</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.52.1989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.52.1989%26sid%3Dliteratum%253Aachs%26aulast%3DInanaga%26aufirst%3DJ.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DKatsuki%26aufirst%3DT.%26aulast%3DYamaguchi%26aufirst%3DM.%26atitle%3DA%2520Rapid%2520Esterification%2520by%2520Means%2520of%2520Mixed%2520Anhydride%2520and%2520Its%2520Application%2520to%2520Large-Ring%2520Lactonization%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1979%26volume%3D52%26issue%3D7%26spage%3D1989%26epage%3D1993%26doi%3D10.1246%2Fbcsj.52.1989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poudel, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peach, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, G. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Des-B-Ring Bryostatin Analogue Leads to an Unexpected Ring Expansion of the Bryolactone Core</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">38</span>),  <span class="NLM_fpage">13202</span>– <span class="NLM_lpage">13208</span>, <span class="refDoi"> DOI: 10.1021/ja5078188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5078188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFamsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=13202-13208&issue=38&author=M.+B.+Kraftauthor=Y.+B.+Poudelauthor=N.+Kedeiauthor=N.+E.+Lewinauthor=M.+L.+Peachauthor=P.+M.+Blumbergauthor=G.+E.+Keck&title=Synthesis+of+a+Des-B-Ring+Bryostatin+Analogue+Leads+to+an+Unexpected+Ring+Expansion+of+the+Bryolactone+Core&doi=10.1021%2Fja5078188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a des-B-Ring Bryostatin Analogue Leads to an Unexpected Ring Expansion of the Bryolactone Core</span></div><div class="casAuthors">Kraft, Matthew B.; Poudel, Yam B.; Kedei, Noemi; Lewin, Nancy E.; Peach, Megan L.; Blumberg, Peter M.; Keck, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13202-13208</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convergent synthesis of a des-B-ring bryostatin analog (I) is described.  This analog was found to undergo an unexpected ring expansion of the bryolactone core to generate the corresponding 21-membered macrocycle.  The parent analog and the ring-expanded product both displayed nanomolar binding affinity for PKC.  Despite contg. A-ring substitution identical to that of bryostatin 1 and displaying bryostatin-like biol. function, the des-B-ring analogs displayed a phorbol-like biol. function in cells.  These studies shed new light on the role of the bryostatin B-ring in conferring bryo-like biol. function to bryostatin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIYnyXd1FAILVg90H21EOLACvtfcHk0lhUH7012_KwSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFamsLvK&md5=a61875f7e73cc25267c03622605d735c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fja5078188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5078188%26sid%3Dliteratum%253Aachs%26aulast%3DKraft%26aufirst%3DM.%2BB.%26aulast%3DPoudel%26aufirst%3DY.%2BB.%26aulast%3DKedei%26aufirst%3DN.%26aulast%3DLewin%26aufirst%3DN.%2BE.%26aulast%3DPeach%26aufirst%3DM.%2BL.%26aulast%3DBlumberg%26aufirst%3DP.%2BM.%26aulast%3DKeck%26aufirst%3DG.%2BE.%26atitle%3DSynthesis%2520of%2520a%2520Des-B-Ring%2520Bryostatin%2520Analogue%2520Leads%2520to%2520an%2520Unexpected%2520Ring%2520Expansion%2520of%2520the%2520Bryolactone%2520Core%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26issue%3D38%26spage%3D13202%26epage%3D13208%26doi%3D10.1021%2Fja5078188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saigo, K.</span></span> <span> </span><span class="NLM_article-title">A Convenient Method for the Synthesis of Carboxylic Esters</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1246/cl.1975.1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1246%2Fcl.1975.1045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1975&pages=1045-1048&author=T.+Mukaiyamaauthor=M.+Usuiauthor=E.+Shimadaauthor=K.+Saigo&title=A+Convenient+Method+for+the+Synthesis+of+Carboxylic+Esters&doi=10.1246%2Fcl.1975.1045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1246%2Fcl.1975.1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.1975.1045%26sid%3Dliteratum%253Aachs%26aulast%3DMukaiyama%26aufirst%3DT.%26aulast%3DUsui%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DE.%26aulast%3DSaigo%26aufirst%3DK.%26atitle%3DA%2520Convenient%2520Method%2520for%2520the%2520Synthesis%2520of%2520Carboxylic%2520Esters%26jtitle%3DChem.%2520Lett.%26date%3D1975%26volume%3D4%26spage%3D1045%26epage%3D1048%26doi%3D10.1246%2Fcl.1975.1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Novosjolova, I.</span></span> <span> </span><span class="NLM_article-title">The Mukaiyama Reagent: An Efficient Condensation Agent</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1055/s-0032-1317530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1055%2Fs-0032-1317530" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=135-136&issue=1&author=I.+Novosjolova&title=The+Mukaiyama+Reagent%3A+An+Efficient+Condensation+Agent&doi=10.1055%2Fs-0032-1317530"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1055%2Fs-0032-1317530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0032-1317530%26sid%3Dliteratum%253Aachs%26aulast%3DNovosjolova%26aufirst%3DI.%26atitle%3DThe%2520Mukaiyama%2520Reagent%253A%2520An%2520Efficient%2520Condensation%2520Agent%26jtitle%3DSynlett%26date%3D2012%26volume%3D24%26issue%3D1%26spage%3D135%26epage%3D136%26doi%3D10.1055%2Fs-0032-1317530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lograsso, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micalizio, G. C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Benzoquinone Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">4800</span>– <span class="NLM_lpage">4804</span>, <span class="refDoi"> DOI: 10.1002/anie.201301323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fanie.201301323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1altLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=4800-4804&issue=18&author=V.+Jesoauthor=S.+Iqbalauthor=P.+Hernandezauthor=M.+D.+Cameronauthor=H.+Parkauthor=P.+V.+Lograssoauthor=G.+C.+Micalizio&title=Synthesis+of+Benzoquinone+Ansamycin-Inspired+Macrocyclic+Lactams+from+Shikimic+Acid&doi=10.1002%2Fanie.201301323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Benzoquinone Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid</span></div><div class="casAuthors">Jeso, Valer; Iqbal, Sarah; Hernandez, Pamela; Cameron, Michael D.; Park, Ha Jeung; LoGrasso, Philip V.; Micalizio, Glenn C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4800-4804</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The authors describe a stereoselective route to natural product-inspired agents from shikimic acid.  The route is selective, flexible, and convergent, delivering complex macrocyclic lactams in just 7 steps form simple coupling partners I, (E)-HC≡C(CH2)2CH:CHCO2Et, and II (X = CH, N, Y = Br; X = CH, Y = NHMe).  The authors also discovered a natural product-inspired skeleton, which is uniquely isoform selective (compared to natural products and known analogs), thus favoring inhibition of cytosolic and nuclear Hsp90 over the ER-assocd. Grp94.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL-Gwt2H6cH7Vg90H21EOLACvtfcHk0lhUH7012_KwSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1altLY%253D&md5=fdc9df6f2b04f2640c24ec588e0cf5f8</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fanie.201301323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201301323%26sid%3Dliteratum%253Aachs%26aulast%3DJeso%26aufirst%3DV.%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLograsso%26aufirst%3DP.%2BV.%26aulast%3DMicalizio%26aufirst%3DG.%2BC.%26atitle%3DSynthesis%2520of%2520Benzoquinone%2520Ansamycin-Inspired%2520Macrocyclic%2520Lactams%2520from%2520Shikimic%2520Acid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26issue%3D18%26spage%3D4800%26epage%3D4804%26doi%3D10.1002%2Fanie.201301323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, M.</span></span> <span> </span><span class="NLM_article-title">An Effective Use of Benzoic Anhydride and Its Derivatives for the Synthesis of Carboxylic Esters and Lactones: A Powerful and Convenient Mixed Anhydride Method Promoted by Basic Catalysts</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/jo030367x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo030367x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVGhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=1822-1830&issue=6&author=I.+Shiinaauthor=M.+Kubotaauthor=H.+Oshiumiauthor=M.+Hashizume&title=An+Effective+Use+of+Benzoic+Anhydride+and+Its+Derivatives+for+the+Synthesis+of+Carboxylic+Esters+and+Lactones%3A+A+Powerful+and+Convenient+Mixed+Anhydride+Method+Promoted+by+Basic+Catalysts&doi=10.1021%2Fjo030367x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">An Effective Use of Benzoic Anhydride and Its Derivatives for the Synthesis of Carboxylic Esters and Lactones: A Powerful and Convenient Mixed Anhydride Method Promoted by Basic Catalysts</span></div><div class="casAuthors">Shiina, Isamu; Kubota, Mari; Oshiumi, Hiromi; Hashizume, Minako</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1822-1830</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Various carboxylic esters are obtained at room temp. in excellent yields with high chemoselectivities from nearly equimolar amts. of carboxylic acids and alcs. using 2-methyl-6-nitrobenzoic anhydride with triethylamine by the promotion of a basic catalyst such as 4-(dimethylamino)pyridine.  A variety of lactones are also prepd. in high yields at room temp. from the corresponding ω-hydroxycarboxylic acids with use of 2-methyl-6-nitrobenzoic anhydride in the presence of 4-(dimethylamino)pyridine.  A similar reaction occurs with triethylamine when using a catalytic amt. of 4-(dimethylamino)pyridine 1-oxide as an effective promoter for the intramol. condensation reaction.  These methods are successfully applied to the synthesis of erythro-aleuritic acid lactone and an eight-membered-ring lactone moiety of octalactin A and oxalactin B.  The efficiency of the cyclizations is compared to those of other reported lactonizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWPmid5ViEPLVg90H21EOLACvtfcHk0lhUH7012_KwSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVGhsLk%253D&md5=69490a7a809afcf8b71b04e42d1abf94</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjo030367x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030367x%26sid%3Dliteratum%253Aachs%26aulast%3DShiina%26aufirst%3DI.%26aulast%3DKubota%26aufirst%3DM.%26aulast%3DOshiumi%26aufirst%3DH.%26aulast%3DHashizume%26aufirst%3DM.%26atitle%3DAn%2520Effective%2520Use%2520of%2520Benzoic%2520Anhydride%2520and%2520Its%2520Derivatives%2520for%2520the%2520Synthesis%2520of%2520Carboxylic%2520Esters%2520and%2520Lactones%253A%2520A%2520Powerful%2520and%2520Convenient%2520Mixed%2520Anhydride%2520Method%2520Promoted%2520by%2520Basic%2520Catalysts%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26issue%3D6%26spage%3D1822%26epage%3D1830%26doi%3D10.1021%2Fjo030367x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ketcham, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volchkov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedei, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krische, M. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">40</span>),  <span class="NLM_fpage">13415</span>– <span class="NLM_lpage">13423</span>, <span class="refDoi"> DOI: 10.1021/jacs.6b08695</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b08695" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKis77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=13415-13423&issue=40&author=J.+M.+Ketchamauthor=I.+Volchkovauthor=T.+Y.+Chenauthor=P.+M.+Blumbergauthor=N.+Kedeiauthor=N.+E.+Lewinauthor=M.+J.+Krische&title=Evaluation+of+Chromane-Based+Bryostatin+Analogues+Prepared+via+Hydrogen-Mediated+C-C+Bond+Formation%3A+Potency+Does+Not+Confer+Bryostatin-like+Biology&doi=10.1021%2Fjacs.6b08695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology</span></div><div class="casAuthors">Ketcham, John M.; Volchkov, Ivan; Chen, Te-Yu; Blumberg, Peter M.; Kedei, Noemi; Lewin, Nancy E.; Krische, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">13415-13423</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of chromane-contg. bryostatin analogs WN-2-WN-7 and the previously reported salicylate-based analog WN-8 are described.  Analogs WN-2-WN-7 are prepd. through convergent assembly of the chromane-contg. fragment B-I (I) with the "binding domain" fragment A-I (II) or its C26-des-Me congener, fragment A-II (III).  The synthesis of fragment B-I features enantioselective double C-H allylation of 1,3-propanediol to form the C2-sym. diol 3 (IV) and Heck cyclization of bromo-diene 5 (V) to form the chromane core.  The synthesis of salicylate WN-8 is accomplished through the union of fragments A-III (VI) and B-II (VII).  The highest binding affinities for PKCα are obsd. for the C26-des-Me analogs WN-3 (Ki = 63.9 nM) and WN-7 (Ki = 63.1 nM).  All analogs, WN-2-WN-8, inhibited growth of Toledo cells, with the most potent analog being WN-7.  This response, however, does not distinguish between phorbol ester-like and bryostatin-like behavior.  In contrast, while many of the analogs contain a conserved C-ring in the binding domain and other features common to analogs with bryostatin-like properties, all analogs evaluated in the U937 proliferation and cell attachment assays displayed phorbol ester-like and/or toxic behavior, including WN-8, for which "bryostatin-like PKC modulatory activities" previously was suggested solely on the basis of PKC binding.  These results underscore the importance of considering downstream biol. effects, as tumor suppression cannot be inferred from potent PKC binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCS-pZRlnpQbVg90H21EOLACvtfcHk0ljZ_KawnmCJog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKis77O&md5=f0d36e2a731f6355841be2968f1ca4bc</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b08695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b08695%26sid%3Dliteratum%253Aachs%26aulast%3DKetcham%26aufirst%3DJ.%2BM.%26aulast%3DVolchkov%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DT.%2BY.%26aulast%3DBlumberg%26aufirst%3DP.%2BM.%26aulast%3DKedei%26aufirst%3DN.%26aulast%3DLewin%26aufirst%3DN.%2BE.%26aulast%3DKrische%26aufirst%3DM.%2BJ.%26atitle%3DEvaluation%2520of%2520Chromane-Based%2520Bryostatin%2520Analogues%2520Prepared%2520via%2520Hydrogen-Mediated%2520C-C%2520Bond%2520Formation%253A%2520Potency%2520Does%2520Not%2520Confer%2520Bryostatin-like%2520Biology%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26issue%3D40%26spage%3D13415%26epage%3D13423%26doi%3D10.1021%2Fjacs.6b08695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tackett, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddess, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappi, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helgen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouklovsky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomero, M. Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavey, J. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaubelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilling, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, M. C.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of Rapamycin</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2874</span>– <span class="NLM_lpage">2914</span>, <span class="refDoi"> DOI: 10.1002/chem.200801656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fchem.200801656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=19204960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Ggsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=2874-2914&issue=12&author=S.+V.+Leyauthor=M.+N.+Tackettauthor=M.+L.+Maddessauthor=J.+C.+Andersonauthor=P.+E.+Brennanauthor=M.+W.+Cappiauthor=J.+P.+Heerauthor=C.+Helgenauthor=M.+Koriauthor=C.+Kouklovskyauthor=S.+P.+Marsdenauthor=J.+Normanauthor=D.+P.+Osbornauthor=M.+%C3%81.+Palomeroauthor=J.+B.+J.+Paveyauthor=C.+Pinelauthor=L.+A.+Robinsonauthor=J.+Schnaubeltauthor=J.+S.+Scottauthor=C.+D.+Spillingauthor=H.+Watanabeauthor=K.+E.+Wessonauthor=M.+C.+Willis&title=Total+Synthesis+of+Rapamycin&doi=10.1002%2Fchem.200801656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of rapamycin</span></div><div class="casAuthors">Ley, Steven V.; Tackett, Miles N.; Maddess, Matthew L.; Anderson, James C.; Brennan, Paul E.; Cappi, Michael W.; Heer, Jag P.; Helgen, Celine; Kori, Masakuni; Kouklovsky, Cyrille; Marsden, Stephen P.; Norman, Joanne; Osborn, David P.; Palomero, Maria A.; Pavey, John B. J.; Pinel, Catherine; Robinson, Lesley A.; Schnaubelt, Jurgen; Scott, James S.; Spilling, Christopher D.; Watanabe, Hidenori; Wesson, Kieron E.; Willis, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2874-2914</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Rapamycin I is prepd. stereoselectively and enantioselectively using the Dieckmann condensation of a catechol-contg. macrolactone as the key steps.  Degrdn. studies of I as well as unsuccessful attempts at its synthesis are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DlWNgMxlXbVg90H21EOLACvtfcHk0lgkDu3nEMjUCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Ggsr8%253D&md5=fd1c331d95e457f002e474419b38df13</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fchem.200801656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200801656%26sid%3Dliteratum%253Aachs%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DTackett%26aufirst%3DM.%2BN.%26aulast%3DMaddess%26aufirst%3DM.%2BL.%26aulast%3DAnderson%26aufirst%3DJ.%2BC.%26aulast%3DBrennan%26aufirst%3DP.%2BE.%26aulast%3DCappi%26aufirst%3DM.%2BW.%26aulast%3DHeer%26aufirst%3DJ.%2BP.%26aulast%3DHelgen%26aufirst%3DC.%26aulast%3DKori%26aufirst%3DM.%26aulast%3DKouklovsky%26aufirst%3DC.%26aulast%3DMarsden%26aufirst%3DS.%2BP.%26aulast%3DNorman%26aufirst%3DJ.%26aulast%3DOsborn%26aufirst%3DD.%2BP.%26aulast%3DPalomero%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DPavey%26aufirst%3DJ.%2BB.%2BJ.%26aulast%3DPinel%26aufirst%3DC.%26aulast%3DRobinson%26aufirst%3DL.%2BA.%26aulast%3DSchnaubelt%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DSpilling%26aufirst%3DC.%2BD.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DWesson%26aufirst%3DK.%2BE.%26aulast%3DWillis%26aufirst%3DM.%2BC.%26atitle%3DTotal%2520Synthesis%2520of%2520Rapamycin%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2009%26volume%3D15%26issue%3D12%26spage%3D2874%26epage%3D2914%26doi%3D10.1002%2Fchem.200801656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neises, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steglich, W.</span></span> <span> </span><span class="NLM_article-title">Esterification of Carboxylic Acids with Dicyclohexylcarbodiimide/4-Dimethylaminopyridine: Tert-Butyl Ethyl Fumarate</span>. <i>Org. Synth.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">183</span>, <span class="refDoi"> DOI: 10.15227/orgsyn.063.0183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.15227%2Forgsyn.063.0183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaL28Xht12ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1985&pages=183&author=B.+Neisesauthor=W.+Steglich&title=Esterification+of+Carboxylic+Acids+with+Dicyclohexylcarbodiimide%2F4-Dimethylaminopyridine%3A+Tert-Butyl+Ethyl+Fumarate&doi=10.15227%2Forgsyn.063.0183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Esterification of carboxylic acids with dicyclohexylcarbodiimide/4-dimethylaminopyridine: tert-butyl ethyl fumarate ((E)-2-butenedioic acid, ethyl 1,1-dimethylethyl ester)</span></div><div class="casAuthors">Neises, B.; Steglich, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Organic Syntheses</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-7</span>CODEN:
                <span class="NLM_cas:coden">ORSYAT</span>;
        ISSN:<span class="NLM_cas:issn">0078-6209</span>.
    </div><div class="casAbstract">(E)-EtO2CCH:CHCO2H is esterified with Me3COH in CH2Cl2 contg. DCC and 4-dimethylaminopyridine as catalyst.  The yields are 76-81%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobzFGRV_FW_rVg90H21EOLACvtfcHk0lgkDu3nEMjUCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xht12ntbo%253D&md5=112932d6384d4106d6f2755b248a9fa7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.15227%2Forgsyn.063.0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15227%252Forgsyn.063.0183%26sid%3Dliteratum%253Aachs%26aulast%3DNeises%26aufirst%3DB.%26aulast%3DSteglich%26aufirst%3DW.%26atitle%3DEsterification%2520of%2520Carboxylic%2520Acids%2520with%2520Dicyclohexylcarbodiimide%252F4-Dimethylaminopyridine%253A%2520Tert-Butyl%2520Ethyl%2520Fumarate%26jtitle%3DOrg.%2520Synth.%26date%3D1985%26volume%3D63%26spage%3D183%26doi%3D10.15227%2Forgsyn.063.0183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biffis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centomo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Zotto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecca, M.</span></span> <span> </span><span class="NLM_article-title">Pd Metal Catalysts for Cross-Couplings and Related Reactions in the 21st Century: A Critical Review</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2249</span>– <span class="NLM_lpage">2295</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=2249-2295&issue=4&author=A.+Biffisauthor=P.+Centomoauthor=A.+Del+Zottoauthor=M.+Zecca&title=Pd+Metal+Catalysts+for+Cross-Couplings+and+Related+Reactions+in+the+21st+Century%3A+A+Critical+Review&doi=10.1021%2Facs.chemrev.7b00443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Pd Metal Catalysts for Cross-Couplings and Related Reactions in the 21st Century: A Critical Review</span></div><div class="casAuthors">Biffis, Andrea; Centomo, Paolo; Del Zotto, Alessandro; Zecca, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2249-2295</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review provides a crit. overview on the recent applications of Pd metal catalysts.  Particular attention is devoted to the discussion of the mechanistic pathways that was proposed to explain the catalytic role of Pd metal.  Furthermore, the most outstanding Pd metal based catalytic systems that had emerged are illustrated, together with the development of novel approaches to boost the reactivity of Pd metal.  A section summarizing the current industrial applications of Pd metal catalyzed reactions of this kind concludes the review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzHQ_wn0ZpA7Vg90H21EOLACvtfcHk0lgkDu3nEMjUCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgur8%253D&md5=b940a8d24f44a28175a49f103d89ee5c</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00443%26sid%3Dliteratum%253Aachs%26aulast%3DBiffis%26aufirst%3DA.%26aulast%3DCentomo%26aufirst%3DP.%26aulast%3DDel%2BZotto%26aufirst%3DA.%26aulast%3DZecca%26aufirst%3DM.%26atitle%3DPd%2520Metal%2520Catalysts%2520for%2520Cross-Couplings%2520and%2520Related%2520Reactions%2520in%2520the%252021st%2520Century%253A%2520A%2520Critical%2520Review%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26issue%3D4%26spage%3D2249%26epage%3D2295%26doi%3D10.1021%2Facs.chemrev.7b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4443</span>– <span class="NLM_lpage">4458</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4443-4458&issue=10&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Analysis+of+Past+and+Present+Synthetic+Methodologies+on+Medicinal+Chemistry%3A+Where+Have+All+the+New+Reactions+Gone%3F&doi=10.1021%2Facs.jmedchem.5b01409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4443-4458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  An anal. of chem. reactions used in current medicinal chem. (2014), three decades ago (1984), and in natural product total synthesis has been conducted.  The anal. revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and 1990s (Suzuki-Miyaura and Buchwald-Hartwig).  This suggests an inherent high bar of impact for new synthetic reactions in drug discovery.  The most frequently used reactions were amide bond formation, Suzuki-Miyaura coupling, and SNAr reactions, most likely due to com. availability of reagents, high chemoselectivity, and a pressure on delivery.  The authors show that these practices result in overpopulation of certain types of mol. shapes to the exclusion of others using simple PMI plots.  The authors hope that these results will help catalyze improvements in integration of new synthetic methodologies as well as new library design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLWvt5DxktAbVg90H21EOLACvtfcHk0lgkDu3nEMjUCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM&md5=fd56ba8418f6d4e8c271f4e977ee2a93</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01409%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DAnalysis%2520of%2520Past%2520and%2520Present%2520Synthetic%2520Methodologies%2520on%2520Medicinal%2520Chemistry%253A%2520Where%2520Have%2520All%2520the%2520New%2520Reactions%2520Gone%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D10%26spage%3D4443%26epage%3D4458%26doi%3D10.1021%2Facs.jmedchem.5b01409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">A New Stereospecific Cross-Coupling by the Palladium-Catalyzed Reaction of 1-Alkenylboranes with 1-Alkenyl or 1-Alkynyl Halides</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">3437</span>– <span class="NLM_lpage">3440</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)95429-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2FS0040-4039%2801%2995429-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1979&pages=3437-3440&issue=36&author=N.+Miyauraauthor=K.+Yamadaauthor=A.+Suzuki&title=A+New+Stereospecific+Cross-Coupling+by+the+Palladium-Catalyzed+Reaction+of+1-Alkenylboranes+with+1-Alkenyl+or+1-Alkynyl+Halides&doi=10.1016%2FS0040-4039%2801%2995429-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2995429-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252995429-2%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DA%2520New%2520Stereospecific%2520Cross-Coupling%2520by%2520the%2520Palladium-Catalyzed%2520Reaction%2520of%25201-Alkenylboranes%2520with%25201-Alkenyl%2520or%25201-Alkynyl%2520Halides%26jtitle%3DTetrahedron%2520Lett.%26date%3D1979%26volume%3D20%26issue%3D36%26spage%3D3437%26epage%3D3440%26doi%3D10.1016%2FS0040-4039%2801%2995429-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheprakov, A. V.</span></span> <span> </span><span class="NLM_article-title">The Heck Reaction as a Sharpening Stone of Palladium Catalysis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3009</span>– <span class="NLM_lpage">3066</span>, <span class="refDoi"> DOI: 10.1021/cr9903048</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9903048" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVSitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=3009-3066&issue=8&author=I.+P.+Beletskayaauthor=A.+V.+Cheprakov&title=The+Heck+Reaction+as+a+Sharpening+Stone+of+Palladium+Catalysis&doi=10.1021%2Fcr9903048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Heck Reaction as a Sharpening Stone of Palladium Catalysis</span></div><div class="casAuthors">Beletskaya, Irina P.; Cheprakov, Andrei V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3009-3066</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 419 refs. concerning the title topics including the Heck catalytic engine, studies to det. highest activity, and extensions of common Heck chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZu0ODgrh7gLVg90H21EOLACvtfcHk0li_PJT6Nai3IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVSitb8%253D&md5=2acb213d2ab82a99253b339cdf57ccdc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fcr9903048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9903048%26sid%3Dliteratum%253Aachs%26aulast%3DBeletskaya%26aufirst%3DI.%2BP.%26aulast%3DCheprakov%26aufirst%3DA.%2BV.%26atitle%3DThe%2520Heck%2520Reaction%2520as%2520a%2520Sharpening%2520Stone%2520of%2520Palladium%2520Catalysis%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26issue%3D8%26spage%3D3009%26epage%3D3066%26doi%3D10.1021%2Fcr9903048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forero-Cortés, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydl, A. M.</span></span> <span> </span><span class="NLM_article-title">The 25th Anniversary of the Buchwald-Hartwig Amination: Development, Applications, and Outlook</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yhs77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1478-1483&issue=8&author=P.+A.+Forero-Cort%C3%A9sauthor=A.+M.+Haydl&title=The+25th+Anniversary+of+the+Buchwald-Hartwig+Amination%3A+Development%2C+Applications%2C+and+Outlook&doi=10.1021%2Facs.oprd.9b00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The 25th Anniversary of the Buchwald-Hartwig Amination: Development, Applications, and Outlook</span></div><div class="casAuthors">Forero-Cortes, Paola A.; Haydl, Alexander M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1478-1483</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The palladium-catalyzed cross-coupling of amines and aryl (pseudo)halides, now commonly referred to as the Buchwald-Hartwig amination was first reported 25 years ago.  Since the simultaneous breakthrough reports of Buchwald and Hartwig dating 1995, this reaction has transformed the way synthetic chemists think about synthesizing arom. amines.  In this highlight article, a short showcasing discussion about the genesis of this reaction is provided, as well as selected examples showing the impact of this transformation in synthetic chem., both in academic and industrial settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDqjUPVJ2XvrVg90H21EOLACvtfcHk0li_PJT6Nai3IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yhs77J&md5=11ee132c194b07792110102e2ed63bf7</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00161%26sid%3Dliteratum%253Aachs%26aulast%3DForero-Cort%25C3%25A9s%26aufirst%3DP.%2BA.%26aulast%3DHaydl%26aufirst%3DA.%2BM.%26atitle%3DThe%252025th%2520Anniversary%2520of%2520the%2520Buchwald-Hartwig%2520Amination%253A%2520Development%252C%2520Applications%252C%2520and%2520Outlook%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26issue%3D8%26spage%3D1478%26epage%3D1483%26doi%3D10.1021%2Facs.oprd.9b00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of a Series of Novel Macrocycle Janus Kinase 2 Inhibitors</span>. <i>Chin. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1263</span>, <span class="refDoi"> DOI: 10.1002/cjoc.201900316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcjoc.201900316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1259-1263&issue=12&author=Y.+Wangauthor=H.+Geauthor=D.+Wangauthor=H.+Heauthor=L.+Liauthor=Y.+Diaoauthor=Z.+Shenauthor=L.+Zhuauthor=S.+Liauthor=Z.+Zhaoauthor=H.+Li&title=Design+and+Synthesis+of+a+Series+of+Novel+Macrocycle+Janus+Kinase+2+Inhibitors&doi=10.1002%2Fcjoc.201900316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Series of Novel Macrocycle Janus Kinase 2 Inhibitors</span></div><div class="casAuthors">Wang, Yanling; Ge, Huan; Wang, Disha; He, Huan; Li, Lu; Diao, Yanyan; Shen, Zihao; Zhu, Lili; Li, Shiliang; Zhao, Zhenjiang; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1259-1263</span>CODEN:
                <span class="NLM_cas:coden">CJOCEV</span>;
        ISSN:<span class="NLM_cas:issn">1001-604X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of macrocyclic derivs. I [R = H, CN] and II [X = NH, O; X1 = X2, X3 = CH, N] designed from anaplastic lymphoma kinase (ALK) inhibitor lorlatinib were synthesized as Janus kinase 2 (JAK2) selective inhibitors.  Among them, III had the best inhibitory activity (IC50 = 0.177 μmol·L-1) and selectivity for JAK2 over JAK1 and JAK3, which indicated that design of the macrocyclic derivs. might be a feasible strategy for the discovery of novel selective JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM_ELqqWSDU7Vg90H21EOLACvtfcHk0li_PJT6Nai3IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjsbzP&md5=fb3dc497dabb9d95b36b6bb299a37d94</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fcjoc.201900316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcjoc.201900316%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDiao%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520a%2520Series%2520of%2520Novel%2520Macrocycle%2520Janus%2520Kinase%25202%2520Inhibitors%26jtitle%3DChin.%2520J.%2520Chem.%26date%3D2019%26volume%3D37%26issue%3D12%26spage%3D1259%26epage%3D1263%26doi%3D10.1002%2Fcjoc.201900316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsunobu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Esters of Carboxylic and Phosphoric Acid via Quaternary Phosphonium Salts</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2382</span>, <span class="refDoi"> DOI: 10.1246/bcsj.40.2380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1246%2Fbcsj.40.2380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaF1cXht1Citw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1967&pages=2380-2382&author=O.+Mitsunobuauthor=M.+Yamada&title=Preparation+of+Esters+of+Carboxylic+and+Phosphoric+Acid+via+Quaternary+Phosphonium+Salts&doi=10.1246%2Fbcsj.40.2380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of esters of carboxylic and phosphoric acid via quaternary phosphonium salts</span></div><div class="casAuthors">Mitsunobu, Oyo; Yamada, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2380-2</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">When n-valeric acid was treated with (EtO)2POCH2CH:CH2 and EtO2CN:NCO2Et (I), allyl valerate and EtO2CN[P(O)(OEt)2]NHCO2Et were obtained in good yields.  Similarly PhCO2Et was obtained in nearly quant. yield by the reaction of PhCO2H with P(OEt)3 and I.  The reaction of carboxylic acids with Ph3P and I in the presence of an alc. resulted in the formation of the corresponding esters of the carboxylic acid, Ph3PO, and EtO2CNHNHCO2Et.  The mechanisms of these reactions were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPl9JLDIoZHrVg90H21EOLACvtfcHk0liFBeGlBsvu6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXht1Citw%253D%253D&md5=bfaa7d793e6e2a0f5cc7cd97436f039f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.40.2380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.40.2380%26sid%3Dliteratum%253Aachs%26aulast%3DMitsunobu%26aufirst%3DO.%26aulast%3DYamada%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Esters%2520of%2520Carboxylic%2520and%2520Phosphoric%2520Acid%2520via%2520Quaternary%2520Phosphonium%2520Salts%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1967%26volume%3D40%26spage%3D2380%26epage%3D2382%26doi%3D10.1246%2Fbcsj.40.2380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsakos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffert, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villadsen, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, T. B.</span></span> <span> </span><span class="NLM_article-title">Ester Coupling Reactions-an Enduring Challenge in the Chemical Synthesis of Bioactive Natural Products</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1039/C4NP00106K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC4NP00106K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=25572105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvF2nug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=605-632&issue=4&author=M.+Tsakosauthor=E.+S.+Schaffertauthor=L.+L.+Clementauthor=N.+L.+Villadsenauthor=T.+B.+Poulsen&title=Ester+Coupling+Reactions-an+Enduring+Challenge+in+the+Chemical+Synthesis+of+Bioactive+Natural+Products&doi=10.1039%2FC4NP00106K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ester coupling reactions - an enduring challenge in the chemical synthesis of bioactive natural products</span></div><div class="casAuthors">Tsakos, Michail; Schaffert, Eva S.; Clement, Lise L.; Villadsen, Nikolaj L.; Poulsen, Thomas B.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">605-632</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  In this review we investigate the use of complex ester fragment couplings within natural product total synthesis campaigns.  We first outline the different biosynthetic and chem. strategies for performing complex ester couplings and on this mechanistic background we then present and discuss a collection of successful examples from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCI9sqkIswyrVg90H21EOLACvtfcHk0liFBeGlBsvu6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvF2nug%253D%253D&md5=b1f30f5e0d109c06a28307e80d201f65</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1039%2FC4NP00106K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4NP00106K%26sid%3Dliteratum%253Aachs%26aulast%3DTsakos%26aufirst%3DM.%26aulast%3DSchaffert%26aufirst%3DE.%2BS.%26aulast%3DClement%26aufirst%3DL.%2BL.%26aulast%3DVilladsen%26aufirst%3DN.%2BL.%26aulast%3DPoulsen%26aufirst%3DT.%2BB.%26atitle%3DEster%2520Coupling%2520Reactions-an%2520Enduring%2520Challenge%2520in%2520the%2520Chemical%2520Synthesis%2520of%2520Bioactive%2520Natural%2520Products%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2015%26volume%3D32%26issue%3D4%26spage%3D605%26epage%3D632%26doi%3D10.1039%2FC4NP00106K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celik, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjaden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span> <span> </span><span class="NLM_article-title">Optimization of Pyrazolo[1,5-a]Pyrimidines Lead to the Identification of a Highly Selective Casein Kinase 2 Inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>,  <span class="NLM_fpage">112770</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.ejmech.2020.112770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=32883634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BB38bkt1Crsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&pages=112770&author=A.+Kr%C3%A4merauthor=C.+G.+Kurzauthor=B.+T.+Bergerauthor=I.+E.+Celikauthor=A.+Tjadenauthor=F.+A.+Grecoauthor=S.+Knappauthor=T.+Hanke&title=Optimization+of+Pyrazolo%5B1%2C5-a%5DPyrimidines+Lead+to+the+Identification+of+a+Highly+Selective+Casein+Kinase+2+Inhibitor&doi=10.1016%2Fj.ejmech.2020.112770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor</span></div><div class="casAuthors">Kramer Andreas; Kurz Christian Georg; Berger Benedict-Tilman; Tjaden Amelie; Greco Francesco Aleksy; Celik Ibrahim Ethem; Knapp Stefan; Hanke Thomas</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112770</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Casein kinase 2 (CK2) is a constitutively expressed serine/threonine kinase that has a large diversity of cellular substrates.  Thus, CK2 has been associated with a plethora of regulatory functions and dysregulation of CK2 has been linked to disease development in particular to cancer.  The broad implications in disease pathology makes CK2 an attractive target.  To date, the most advanced CK2 inhibitor is silmitasertib, which has been investigated in clinical trials for treatment of various cancers, albeit several off-targets for silmitasertib have been described.  To ascertain the role of CK2 inhibition in cancer, other disease and normal physiology the development of a selective CK2 inhibitor would be highly desirable.  In this study we explored the pyrazolo [1,5-a]pyrimidine hinge-binding moiety for the development of selective CK2 inhibitors.  Optimization of this scaffold, which included macrocyclization, led to IC20 (31) a compound that displayed high in vitro potency for CK2 (KD = 12 nM) and exclusive selectivity for CK2.  X-ray analysis revealed a canonical type-I binding mode for IC20 (31).  However, the polar carboxylic acid moiety that is shared by many CK2 inhibitors including silmitasertib was required for potency but limits the cellular activity of IC20 (31) and the cellular IC50 dropped to the low micromolar range.  In summary, IC20 (31) represents a highly selective and potent inhibitor of CK2, which can be used as a tool compound to study CK2 biology and potential new applications for the treatment of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQ1mfNnMQs-wHqQV89nF-2fW6udTcc2eYsT6bkVhW5VLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bkt1Crsg%253D%253D&md5=43588eec2c74d87f8904febeb28e8cfc</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112770%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DC.%2BG.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DCelik%26aufirst%3DI.%2BE.%26aulast%3DTjaden%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DHanke%26aufirst%3DT.%26atitle%3DOptimization%2520of%2520Pyrazolo%255B1%252C5-a%255DPyrimidines%2520Lead%2520to%2520the%2520Identification%2520of%2520a%2520Highly%2520Selective%2520Casein%2520Kinase%25202%2520Inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26spage%3D112770%26doi%3D10.1016%2Fj.ejmech.2020.112770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arundale, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikeska, L. A.</span></span> <span> </span><span class="NLM_article-title">The Olefin-Aldehyde Condensation. The Prins Reaction</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1952</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1021/cr60160a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr60160a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaG3sXjtFOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1952&pages=505-555&issue=3&author=E.+Arundaleauthor=L.+A.+Mikeska&title=The+Olefin-Aldehyde+Condensation.+The+Prins+Reaction&doi=10.1021%2Fcr60160a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The olefin-aldehyde condensation. The Prins reaction</span></div><div class="casAuthors">Arundale, E.; Mikeska, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">505-55</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">A review with 156 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUXzX7veRoJrVg90H21EOLACvtfcHk0ljbafqsDTCLmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG3sXjtFOlsg%253D%253D&md5=f2f45ad6e4954f97a8183e1d9d19abdc</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fcr60160a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr60160a004%26sid%3Dliteratum%253Aachs%26aulast%3DArundale%26aufirst%3DE.%26aulast%3DMikeska%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Olefin-Aldehyde%2520Condensation.%2520The%2520Prins%2520Reaction%26jtitle%3DChem.%2520Rev.%26date%3D1952%26volume%3D51%26issue%3D3%26spage%3D505%26epage%3D555%26doi%3D10.1021%2Fcr60160a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-López, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temps, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco-Montalban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">21620</span>– <span class="NLM_lpage">21626</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b03525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b03525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Ojs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=21620-21626&issue=25&author=O.+Cruz-L%C3%B3pezauthor=C.+Tempsauthor=B.+Longoauthor=S.+H.+Myersauthor=F.+Franco-Montalbanauthor=A.+Unciti-Broceta&title=Synthesis+and+Characterization+of+a+Click-Assembled+18-Atom+Macrocycle+That+Displays+Selective+AXL+Kinase+Inhibitory+Activity&doi=10.1021%2Facsomega.9b03525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity</span></div><div class="casAuthors">Cruz-Lopez, Olga; Temps, Carolin; Longo, Beatrice; Myers, Samuel H.; Franco-Montalban, Francisco; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">21620-21626</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel macrocyclic construct consisting of a pyrazolopyrimidine scaffold concatenated to a benzene ring through two triazoles has been developed to investigate uncharted chem. space with bioactive potential.  The 18-atom macrocycle was assembled via a double copper-catalyzed alkyne-azide cycloaddn. (CuAAC) reaction between 1,3-bis(azidomethyl)benzene and a bis-propargylated pyrazolo[3,4-d]pyrimidine core.  The resulting macrocycle was functionalized further into a multicyclic analog that displays selective inhibitory activity against the receptor tyrosine kinase AXL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdmd6LYVlXM7Vg90H21EOLACvtfcHk0ljbafqsDTCLmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Ojs7bL&md5=c09116dea662095311dba7cdcb308015</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b03525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b03525%26sid%3Dliteratum%253Aachs%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DO.%26aulast%3DTemps%26aufirst%3DC.%26aulast%3DLongo%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DFranco-Montalban%26aufirst%3DF.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520Characterization%2520of%2520a%2520Click-Assembled%252018-Atom%2520Macrocycle%2520That%2520Displays%2520Selective%2520AXL%2520Kinase%2520Inhibitory%2520Activity%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26issue%3D25%26spage%3D21620%26epage%3D21626%26doi%3D10.1021%2Facsomega.9b03525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rostovtsev, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2596</span>– <span class="NLM_lpage">2599</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=2596-2599&issue=14&author=V.+V.+Rostovtsevauthor=L.+G.+Greenauthor=V.+V.+Fokinauthor=K.+B.+Sharpless&title=A+Stepwise+Huisgen+Cycloaddition+Process%3A+Copper%28I%29-Catalyzed+Regioselective+%E2%80%9CLigation%E2%80%9D+of+Azides+and+Terminal+Alkynes&doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes</span></div><div class="casAuthors">Rostovtsev, Vsevolod V.; Green, Luke G.; Fokin, Valery V.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2596-2599</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">1,4-Disubstituted 1,2,3-triazoles I (R1 = PhCH2, PhCH2OCH2, 1-adamantyl, etc.; R2 = HO2C, Ph, PhOCH2, Et2NCH2, etc.) were readily and cleanly prepd. via highly efficient and regioselective copper(I)-catalyzed cycloaddn. of azides R1N3 with terminal alkynes R2C≡CH in 82-93% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptcW2JUNM1r7Vg90H21EOLACvtfcHk0ljbafqsDTCLmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D&md5=4603664be6639353b5e70f19b9f8d59f</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820020715%252941%253A14%253C2596%253A%253AAID-ANIE2596%253E3.0.CO%253B2-4%26sid%3Dliteratum%253Aachs%26aulast%3DRostovtsev%26aufirst%3DV.%2BV.%26aulast%3DGreen%26aufirst%3DL.%2BG.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DA%2520Stepwise%2520Huisgen%2520Cycloaddition%2520Process%253A%2520Copper%2528I%2529-Catalyzed%2520Regioselective%2520%25E2%2580%259CLigation%25E2%2580%259D%2520of%2520Azides%2520and%2520Terminal%2520Alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2002%26volume%3D41%26issue%3D14%26spage%3D2596%26epage%3D2599%26doi%3D10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, J. S.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of the Hsp90 Inhibitor Geldanamycin</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2477</span>– <span class="NLM_lpage">2479</span>, <span class="refDoi"> DOI: 10.1021/ol800749w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol800749w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=2477-2479&issue=12&author=H.-L.+Qinauthor=J.+S.+Panek&title=Total+Synthesis+of+the+Hsp90+Inhibitor+Geldanamycin&doi=10.1021%2Fol800749w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of the Hsp90 Inhibitor Geldanamycin</span></div><div class="casAuthors">Qin, Hua-Li; Panek, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2477-2479</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An enantioselective synthesis of the Hsp90 inhibitor geldanamycin (I) was achieved in 20 linear steps and 2.0% overall yield from 2-methoxyhydroquinone.  The synthesis is highlighted by a regio- and stereoselective hydroboration reaction; a Sc(OTf)3/Et3SiH-mediated pyran ring-opening reaction; an enantioselective crotylation to simultaneously install the C8-C9 (E)-trisubstituted olefin, the C10 and C11 stereocenters; a chelation-controlled asym. metalated acetylide addn.; and an intramol. copper(I)-mediated aryl amidation reaction to close the 19-membered macrolactam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSqIH-BMiIm7Vg90H21EOLACvtfcHk0ljbafqsDTCLmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsbs%253D&md5=5551b7fe64071cd24303cdf6e95e6ca6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fol800749w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol800749w%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DH.-L.%26aulast%3DPanek%26aufirst%3DJ.%2BS.%26atitle%3DTotal%2520Synthesis%2520of%2520the%2520Hsp90%2520Inhibitor%2520Geldanamycin%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26issue%3D12%26spage%3D2477%26epage%3D2479%26doi%3D10.1021%2Fol800749w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A General and Efficient Copper Catalyst for the Amidation of Aryl Halides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">7421</span>– <span class="NLM_lpage">7428</span>, <span class="refDoi"> DOI: 10.1021/ja0260465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0260465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFagt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=7421-7428&issue=25&author=A.+Klaparsauthor=X.+Huangauthor=S.+L.+Buchwald&title=A+General+and+Efficient+Copper+Catalyst+for+the+Amidation+of+Aryl+Halides&doi=10.1021%2Fja0260465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A General and Efficient Copper Catalyst for the Amidation of Aryl Halides</span></div><div class="casAuthors">Klapars, Artis; Huang, Xiaohua; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7421-7428</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An exptl. simple and inexpensive catalyst system was developed for the amidation of aryl halides by using 0.2-10 mol % of CuI, 5-20 mol % of a 1,2-diamine ligand, and K3PO4, K2CO3, or Cs2CO3 as base.  Catalyst systems based on N,N'-dimethylethylenediamine or trans-N,N'-dimethyl-1,2-cyclohexanediamine were found to be the most active even though several other 1,2-diamine ligands could be used in the easiest cases.  Aryl iodides, bromides, and in some cases even aryl chlorides can be efficiently amidated.  A variety of functional groups are tolerated in the reaction, including many that are not compatible with Pd-catalyzed amidation or amination methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFC_EwXo2vprVg90H21EOLACvtfcHk0lh5zBNkLPX2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFagt70%253D&md5=648d4f16f8ea9223e4548dc898654784</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fja0260465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0260465%26sid%3Dliteratum%253Aachs%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520General%2520and%2520Efficient%2520Copper%2520Catalyst%2520for%2520the%2520Amidation%2520of%2520Aryl%2520Halides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26issue%3D25%26spage%3D7421%26epage%3D7428%26doi%3D10.1021%2Fja0260465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaubach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungeheuer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmeister, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirtz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürstner, A.</span></span> <span> </span><span class="NLM_article-title">A Two-Component Alkyne Metathesis Catalyst System with an Improved Substrate Scope and Functional Group Tolerance: Development and Applications to Natural Product Synthesis</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">8494</span>– <span class="NLM_lpage">8507</span>, <span class="refDoi"> DOI: 10.1002/chem.201601163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fchem.201601163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=27203803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Kgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=8494-8507&issue=25&author=S.+Schaubachauthor=K.+Gebauerauthor=F.+Ungeheuerauthor=L.+Hoffmeisterauthor=M.+K.+Ilgauthor=C.+Wirtzauthor=A.+F%C3%BCrstner&title=A+Two-Component+Alkyne+Metathesis+Catalyst+System+with+an+Improved+Substrate+Scope+and+Functional+Group+Tolerance%3A+Development+and+Applications+to+Natural+Product+Synthesis&doi=10.1002%2Fchem.201601163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A Two-Component Alkyne Metathesis Catalyst System with an Improved Substrate Scope and Functional Group Tolerance: Development and Applications to Natural Product Synthesis</span></div><div class="casAuthors">Schaubach, Sebastian; Gebauer, Konrad; Ungeheuer, Felix; Hoffmeister, Laura; Ilg, Marina K.; Wirtz, Conny; Fuerstner, Alois</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8494-8507</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although molybdenum alkylidyne complexes such as 1 (I; R = OSiPh3) endowed with triarylsilanolate ligands are excellent catalysts for alkyne metathesis, they can encounter limitations when (multiple) protic sites are present in a given substrate and/or when forcing conditions are necessary.  In such cases, a catalyst formed in situ upon mixing of the trisamidomolybenum alkylidyne complex 3 [III; R' = tert-butyl(3,5-dimethylphenyl)amino] and the readily available trisilanol derivs. 8 = R''Si[CH2CH2(SiPh2OH)]3 (VIII; R'' = Me, Ph) or 11 (XI; X = [CH2CH2CH2(SiPh2OH)]3; R''' = H, Et) shows significantly better performance.  This two-component system worked well for a series of model compds. comprising primary, secondary or phenolic -OH groups, as well as for a set of challenging (bis)propargylic substrates.  Its remarkable efficiency is also evident from applications to the total syntheses of manshurolide, a highly strained sesquiterpene lactone with kinase inhibitory activity, and the structurally demanding immunosuppressive cyclodiyne ivorenolide A; in either case, the std. catalyst 1 largely failed to effect the crit. macrocyclization, whereas the two-component system was fully operative.  A study directed toward the quinolizidine alkaloid lythrancepine I features yet another instructive example, in that a triyne substrate was metathesized with the help of 3/11 such that two of the triple bonds participated in ring closure, while the third one passed uncompromised.  As a spin-off of this project, a much improved ruthenium catalyst for the redox isomerization of propargyl alcs. to the corresponding enones was developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcab5j8I9PGLVg90H21EOLACvtfcHk0lh5zBNkLPX2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Kgsrc%253D&md5=c1b5a9e5489627fb345618e96611f953</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1002%2Fchem.201601163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201601163%26sid%3Dliteratum%253Aachs%26aulast%3DSchaubach%26aufirst%3DS.%26aulast%3DGebauer%26aufirst%3DK.%26aulast%3DUngeheuer%26aufirst%3DF.%26aulast%3DHoffmeister%26aufirst%3DL.%26aulast%3DIlg%26aufirst%3DM.%2BK.%26aulast%3DWirtz%26aufirst%3DC.%26aulast%3DF%25C3%25BCrstner%26aufirst%3DA.%26atitle%3DA%2520Two-Component%2520Alkyne%2520Metathesis%2520Catalyst%2520System%2520with%2520an%2520Improved%2520Substrate%2520Scope%2520and%2520Functional%2520Group%2520Tolerance%253A%2520Development%2520and%2520Applications%2520to%2520Natural%2520Product%2520Synthesis%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2016%26volume%3D22%26issue%3D25%26spage%3D8494%26epage%3D8507%26doi%3D10.1002%2Fchem.201601163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, S.</span></span> <span> </span><span class="NLM_article-title">Extracellular Signal-Regulated Kinases (ERK) Inhibitors from Aristolochia Yunnanensis</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1021/np300887d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np300887d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2ntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=664-671&issue=4&author=Z.+B.+Chengauthor=W.-W.+Shaoauthor=Y.-N.+Liuauthor=Q.+Liaoauthor=T.-T.+Linauthor=X.-Y.+Shenauthor=S.+Yin&title=Extracellular+Signal-Regulated+Kinases+%28ERK%29+Inhibitors+from+Aristolochia+Yunnanensis&doi=10.1021%2Fnp300887d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Signal-Regulated Kinases (ERK) Inhibitors from Aristolochia yunnanensis</span></div><div class="casAuthors">Cheng, Zhong-Bin; Shao, Wei-Wei; Liu, Ye-Na; Liao, Qiong; Lin, Ting-Ting; Shen, Xiao-Yan; Yin, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">664-671</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Six new sesquiterpenoids, aristoyunnolins A-F (1-6), an artifact of isolation [7-O-Et madolin W (7)], and 12 known analogs were isolated from stems of Aristolochia yunnanensis.  The structures were detd. by combined chem. and spectral methods, and the abs. configurations of compds. 2, 3, 5-7, 9, 14, and 17 were detd. by the modified Mosher's method and CD anal.  Compds. 1-19 were screened using a bioassay system designed to evaluate the effect on mitogen-activated protein kinases (MAPKs) signaling pathways.  Among three MAPKs (ERK1/2, JNK, and p38), compds. 1, 4, 10-13, 16, 18, and 19 exhibited selective inhibition of the phosphorylation of ERK1/2.  Compds. 16 and 19 were more active than the pos. control PD98059, a known inhibitor of the ERK1/2 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoomMv6jzPozrVg90H21EOLACvtfcHk0lh5zBNkLPX2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2ntrg%253D&md5=662de2f3c6bd40093d137360864967b7</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fnp300887d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp300887d%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.%2BB.%26aulast%3DShao%26aufirst%3DW.-W.%26aulast%3DLiu%26aufirst%3DY.-N.%26aulast%3DLiao%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DT.-T.%26aulast%3DShen%26aufirst%3DX.-Y.%26aulast%3DYin%26aufirst%3DS.%26atitle%3DExtracellular%2520Signal-Regulated%2520Kinases%2520%2528ERK%2529%2520Inhibitors%2520from%2520Aristolochia%2520Yunnanensis%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2013%26volume%3D76%26issue%3D4%26spage%3D664%26epage%3D671%26doi%3D10.1021%2Fnp300887d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rücker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Güllmann, A.</span></span> <span> </span><span class="NLM_article-title">Manshurolide, a Sesquiterpene Lactone from Aristolochia Manshuriensis</span>. <i>Phytochemistry</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">985</span>, <span class="refDoi"> DOI: 10.1016/0031-9422(90)80062-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2F0031-9422%2890%2980062-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaK3cXksFGrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=983-985&issue=3&author=G.+R%C3%BCckerauthor=C.+W.+Mingauthor=R.+Mayerauthor=G.+Willauthor=A.+G%C3%BCllmann&title=Manshurolide%2C+a+Sesquiterpene+Lactone+from+Aristolochia+Manshuriensis&doi=10.1016%2F0031-9422%2890%2980062-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Manshurolide, a sesquiterpene lactone from Aristolochia manshuriensis</span></div><div class="casAuthors">Ruecker, Gerhard; Ming, Chen Wei; Mayer, Ralf; Will, Georg; Guellmann, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">983-5</span>CODEN:
                <span class="NLM_cas:coden">PYTCAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-9422</span>.
    </div><div class="casAbstract">A sesquiterpene lactone, manshurolide (I), with a previously unknown carbon skeleton was isolated from the stems of A. manshuriensis.  Its structure was elucidated by spectroscopic means and x-ray anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKQ-6AQoXFkLVg90H21EOLACvtfcHk0liJ7DxssuorFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXksFGrt7g%253D&md5=1d7a7e63f0b2119d8ca98181f02e0781</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2F0031-9422%2890%2980062-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0031-9422%252890%252980062-L%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCcker%26aufirst%3DG.%26aulast%3DMing%26aufirst%3DC.%2BW.%26aulast%3DMayer%26aufirst%3DR.%26aulast%3DWill%26aufirst%3DG.%26aulast%3DG%25C3%25BCllmann%26aufirst%3DA.%26atitle%3DManshurolide%252C%2520a%2520Sesquiterpene%2520Lactone%2520from%2520Aristolochia%2520Manshuriensis%26jtitle%3DPhytochemistry%26date%3D1990%26volume%3D29%26issue%3D3%26spage%3D983%26epage%3D985%26doi%3D10.1016%2F0031-9422%2890%2980062-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castells, J.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in [2 + 2+2] Cycloaddition Reactions</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">3430</span>– <span class="NLM_lpage">3444</span>, <span class="refDoi"> DOI: 10.1039/c1cs15029d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2Fc1cs15029d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21431173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns12msrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=3430-3444&author=G.+Dom%C3%ADnguezauthor=J.+P%C3%A9rez-Castells&title=Recent+Advances+in+%5B2+%2B+2%2B2%5D+Cycloaddition+Reactions&doi=10.1039%2Fc1cs15029d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in [2+2+2] cycloaddition reactions</span></div><div class="casAuthors">Dominguez, Gema; Perez-Castells, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3430-3444</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The [2+2+2] cycloaddn. is an elegant, atom-efficient and group tolerant process for the synthesis of carbo- and heterocycles, mostly arom., involving the formation of several C-C bonds in a single step.  Cyclotrimerization is catalyzed by a variety of organometallic complexes, including more than 15 different metals.  The aim of this tutorial review is to point out the most recent advances in this field and to encourage the use of this reaction enroute to complex mols.  After summarizing the most common catalysts and reaction conditions generally used, the mechanistic features currently accepted for this reaction were surveyed.  Section 4 covered the scope of the different [2+2+2] cycloaddn. versions starting with the cyclotrimerization of three triple bonds, including nitriles, with especial emphasis on asym. reactions that create central, axial or planar chirality.  Then, reactions that use double bonds are addressed.  Finally, the most outstanding examples of natural products synthesis using [2+2+2] cycloaddn. as a key step reported recently were shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE2nLfnG73B7Vg90H21EOLACvtfcHk0liJ7DxssuorFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns12msrs%253D&md5=ba2e8a6b5234865072b485c3612f0318</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1039%2Fc1cs15029d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cs15029d%26sid%3Dliteratum%253Aachs%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DG.%26aulast%3DP%25C3%25A9rez-Castells%26aufirst%3DJ.%26atitle%3DRecent%2520Advances%2520in%2520%255B2%2520%252B%25202%252B2%255D%2520Cycloaddition%2520Reactions%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2011%26volume%3D40%26spage%3D3430%26epage%3D3444%26doi%3D10.1039%2Fc1cs15029d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boñaga, L. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derian, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Novel Bis(Indolyl)Maleimide Pyridinophanes That Are Potent, Selective Inhibitors of Glycogen Synthase Kinase-3</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2863</span>– <span class="NLM_lpage">2868</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.02.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmcl.2007.02.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=17350261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslyjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2863-2868&issue=10&author=H.+C.+Zhangauthor=L.+V.+R.+Bo%C3%B1agaauthor=H.+Yeauthor=C.+K.+Derianauthor=B.+P.+Damianoauthor=B.+E.+Maryanoff&title=Novel+Bis%28Indolyl%29Maleimide+Pyridinophanes+That+Are+Potent%2C+Selective+Inhibitors+of+Glycogen+Synthase+Kinase-3&doi=10.1016%2Fj.bmcl.2007.02.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3</span></div><div class="casAuthors">Zhang, Han-Cheng; Bonaga, Llorente V. R.; Ye, Hong; Derian, Claudia K.; Damiano, Bruce P.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2863-2868</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Novel bis(indolyl)maleimide pyridinophanes, e.g., I, were prepd. by cobalt-mediated [2+2+2] cycloaddn. of an appropriate α,ω-diynes with an N,N-dialkylcyanamides.  These macrocyclic heterophanes were found to be potent and selective inhibitors of glycogen synthase kinase-3β.  An X-ray structure of a co-crystal of GSK-3β and I (IC50 = 3 nM) depicts the hydrogen bonding and hydrophobic interactions in the ATP-binding pocket of this serine/threonine protein kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv2DI3JjEomrVg90H21EOLACvtfcHk0liJ7DxssuorFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslyjsrk%253D&md5=91c6530b0cb6ef7e291ce7d98d5668d3</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.02.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.02.059%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%2BC.%26aulast%3DBo%25C3%25B1aga%26aufirst%3DL.%2BV.%2BR.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DDerian%26aufirst%3DC.%2BK.%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DNovel%2520Bis%2528Indolyl%2529Maleimide%2520Pyridinophanes%2520That%2520Are%2520Potent%252C%2520Selective%2520Inhibitors%2520of%2520Glycogen%2520Synthase%2520Kinase-3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D10%26spage%3D2863%26epage%3D2868%26doi%3D10.1016%2Fj.bmcl.2007.02.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, C. L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span> <span> </span><span class="NLM_article-title">An Efficient Synthesis of an Exo-Enone Analogue of LL-Z1640–2 and Evaluation of Its Protein Kinase Inhibitory Activities</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1039/C5OB01948F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC5OB01948F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26541872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCms7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=639-645&issue=2&author=S.+Q.+Wangauthor=S.+S.+Gohauthor=C.+L.+L.+Chaiauthor=A.+Chen&title=An+Efficient+Synthesis+of+an+Exo-Enone+Analogue+of+LL-Z1640%E2%80%932+and+Evaluation+of+Its+Protein+Kinase+Inhibitory+Activities&doi=10.1039%2FC5OB01948F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient synthesis of an exo-enone analogue of LL-Z1640-2 and evaluation of its protein kinase inhibitory activities</span></div><div class="casAuthors">Wang, Stephanie Q.; Goh, Shermin S.; Chai, Christina L. L.; Chen, Anqi</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">639-645</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient synthesis of an exo-enone analog of resorcylic acid lactone (RAL), natural product LL-Z1640-2 (1), has been achieved using a Ni-catalyzed regioselective reductive coupling macrocyclization of an alkyne-aldehyde as a key step.  The synthetic route is significantly shorter than those for the natural product and avoids the isomerization problem of the cis-double bond in the mol.  The preliminary biol. evaluation showed that the exo-enone analog is a potent inhibitor of several important kinases relevant to cancer drug development.  The synthesis of the target compd. was achieved using 5-[(1E)-3-[(4S,5R)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-propen-1-yl]-7-methoxy-2,2-dimethyl-4H-1,3-Benzodioxin-4-one [i.e., a deriv. of 2-deoxy-3,4-O-(1-methylethylidene)-D-erythro-pentose] as a starting material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMRPSd-zdwdrVg90H21EOLACvtfcHk0liJ7DxssuorFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCms7rM&md5=6f6f624e54fabb249706677ea5da56a2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1039%2FC5OB01948F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB01948F%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DGoh%26aufirst%3DS.%2BS.%26aulast%3DChai%26aufirst%3DC.%2BL.%2BL.%26aulast%3DChen%26aufirst%3DA.%26atitle%3DAn%2520Efficient%2520Synthesis%2520of%2520an%2520Exo-Enone%2520Analogue%2520of%2520LL-Z1640%25E2%2580%25932%2520and%2520Evaluation%2520of%2520Its%2520Protein%2520Kinase%2520Inhibitory%2520Activities%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26issue%3D2%26spage%3D639%26epage%3D645%26doi%3D10.1039%2FC5OB01948F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauff, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span> <span> </span><span class="NLM_article-title">Exo-Selective Reductive Macrocyclization of Ynals</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1493</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.5b00381</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.5b00381" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1493-1496&issue=6&author=H.+Wangauthor=S.+Negrettiauthor=A.+R.+Knauffauthor=J.+Montgomery&title=Exo-Selective+Reductive+Macrocyclization+of+Ynals&doi=10.1021%2Facs.orglett.5b00381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Exo-Selective Reductive Macrocyclization of Ynals</span></div><div class="casAuthors">Wang, Hengbin; Negretti, Solymar; Knauff, Allison R.; Montgomery, John</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1496</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general protocol for the highly exo-selective macrocyclization of ynals using a nickel/N-heterocyclic carbene catalyst system has been developed [e.g., I → II (69%, regioselective ratio >95:5)].  A series of 10- to 21-membered macrocycles bearing an exomethylene substituent was synthesized in good yields with excellent regioselectivity (exo/endo >95:5).  Very high levels of long-range diastereocontrol can also be achieved for some classes of macrocycles.  Complementary to previously reported endo-selective macrocyclizations, this method provides accesses to exoalkylidene macrocycles from simple ynals in high selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnrsETnKnxzbVg90H21EOLACvtfcHk0lhLpYYuZ08CUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsrw%253D&md5=668004eeb4654c4205450ae3c9727e12</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.5b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.5b00381%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNegretti%26aufirst%3DS.%26aulast%3DKnauff%26aufirst%3DA.%2BR.%26aulast%3DMontgomery%26aufirst%3DJ.%26atitle%3DExo-Selective%2520Reductive%2520Macrocyclization%2520of%2520Ynals%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26issue%3D6%26spage%3D1493%26epage%3D1496%26doi%3D10.1021%2Facs.orglett.5b00381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaumlöffel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, G.</span></span> <span> </span><span class="NLM_article-title">A Synthesis-Driven Structure Revision of “Plagiochin E”, a Highly Bioactive Bisbibenzyl</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2009</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1852</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1217510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1055%2Fs-0029-1217510" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=1852-1858&issue=11&author=A.+Speicherauthor=M.+Grohauthor=J.+Zappauthor=A.+Schauml%C3%B6ffelauthor=M.+Knauerauthor=G.+Bringmann&title=A+Synthesis-Driven+Structure+Revision+of+%E2%80%9CPlagiochin+E%E2%80%9D%2C+a+Highly+Bioactive+Bisbibenzyl&doi=10.1055%2Fs-0029-1217510"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1217510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1217510%26sid%3Dliteratum%253Aachs%26aulast%3DSpeicher%26aufirst%3DA.%26aulast%3DGroh%26aufirst%3DM.%26aulast%3DZapp%26aufirst%3DJ.%26aulast%3DSchauml%25C3%25B6ffel%26aufirst%3DA.%26aulast%3DKnauer%26aufirst%3DM.%26aulast%3DBringmann%26aufirst%3DG.%26atitle%3DA%2520Synthesis-Driven%2520Structure%2520Revision%2520of%2520%25E2%2580%259CPlagiochin%2520E%25E2%2580%259D%252C%2520a%2520Highly%2520Bioactive%2520Bisbibenzyl%26jtitle%3DSynlett%26date%3D2009%26volume%3D2009%26issue%3D11%26spage%3D1852%26epage%3D1858%26doi%3D10.1055%2Fs-0029-1217510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Macrocyclic Bisbibenzyl Derivatives and Their Anticancer Effects as Anti-Tubulin Agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2382</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.bmc.2012.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22365913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVOrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2382-2391&issue=7&author=J.+Jiangauthor=B.+Sunauthor=Y.+Y.+Wangauthor=M.+Cuiauthor=L.+Zhangauthor=C.+Z.+Cuiauthor=Y.+F.+Wangauthor=X.+G.+Liuauthor=H.+X.+Lou&title=Synthesis+of+Macrocyclic+Bisbibenzyl+Derivatives+and+Their+Anticancer+Effects+as+Anti-Tubulin+Agents&doi=10.1016%2Fj.bmc.2012.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents</span></div><div class="casAuthors">Jiang, Juan; Sun, Bin; Wang, Yan-yan; Cui, Min; Zhang, Li; Cui, Chang-zhi; Wang, Yan-feng; Liu, Xi-gong; Lou, Hong-xiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2382-2391</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on the core skeleton of the total synthesized bisbibenzyl marchantin C, riccardin D and plagiochin E, a series of brominated and aminomethylated derivs. of above three bisbibenzyls have been synthesized and their cytotoxic activity against KB, MCF-7 and PC3 cell lines has been preliminary evaluated.  The bio-test results revealed that the brominated derivs. exhibited excellent antiproliferative activity, with IC50 value lower than their parent compds.  As a most potent microtubule depolymn. agent, compd. I was found to arrest cells at the G2/M phase of the cell cycle as detd. by the flow cytometry assay in PC3 cell line.  The remarkable biol. profile and novel structure of these bisbibenzyl derivs. make them possible as promising candidates for clin. development as chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrJouJ_QomvbVg90H21EOLACvtfcHk0lhLpYYuZ08CUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVOrt78%253D&md5=54e75255e4c183b84158abcc67c5394b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BY.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DC.%2BZ.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BG.%26aulast%3DLou%26aufirst%3DH.%2BX.%26atitle%3DSynthesis%2520of%2520Macrocyclic%2520Bisbibenzyl%2520Derivatives%2520and%2520Their%2520Anticancer%2520Effects%2520as%2520Anti-Tubulin%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26issue%3D7%26spage%3D2382%26epage%3D2391%26doi%3D10.1016%2Fj.bmc.2012.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ephritikhine, M.</span></span> <span> </span><span class="NLM_article-title">A New Look at the McMurry Reaction</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_fpage">2549</span>– <span class="NLM_lpage">2554</span>, <span class="refDoi"> DOI: 10.1039/a804394i</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2Fa804394i" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=2549-2554&author=M.+Ephritikhine&title=A+New+Look+at+the+McMurry+Reaction&doi=10.1039%2Fa804394i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A new look at the McMurry reaction</span></div><div class="casAuthors">Ephritikhine, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2549-2554</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The article emphasizes the contradictory features of the McMurry reaction.  The historical view shows how chemists were firmly convinced of the occurrence of pinacolate intermediates and rejected, in spite of some evidence, the alternative pathway via carbenoid species.  The McMurry reaction continues to find new important applications but suffers from problems of reproducibility.  New practical reagents and simplified methods have been developed but rather complicated systems have been designed for obtaining higher selectivities.  Recent investigations confirmed that pinacolates would be the precursors to alkenes but also revealed the possible involvement of carbenoid species, putting forward the dual nature of the mechanism of the McMurry reaction.  Review with 50 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj6X1RHknSH7Vg90H21EOLACvtfcHk0lhMkka1C5K1Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVCms7s%253D&md5=daa4c62b4a97e1f93839cac5397e4596</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1039%2Fa804394i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa804394i%26sid%3Dliteratum%253Aachs%26aulast%3DEphritikhine%26aufirst%3DM.%26atitle%3DA%2520New%2520Look%2520at%2520the%2520McMurry%2520Reaction%26jtitle%3DChem.%2520Commun.%26date%3D1998%26spage%3D2549%26epage%3D2554%26doi%3D10.1039%2Fa804394i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okude, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozaki, H.</span></span> <span> </span><span class="NLM_article-title">Grignard-Type Carbonyl Addition of Allyl Halides by Means of Chromous Salt. A Chemospecific Synthesis of Homoallyl Alcohols</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>99</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3179</span>– <span class="NLM_lpage">3181</span>, <span class="refDoi"> DOI: 10.1021/ja00451a061</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00451a061" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaE2sXktVGgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1977&pages=3179-3181&issue=9&author=Y.+Okudeauthor=S.+Hiranoauthor=T.+Hiyamaauthor=H.+Nozaki&title=Grignard-Type+Carbonyl+Addition+of+Allyl+Halides+by+Means+of+Chromous+Salt.+A+Chemospecific+Synthesis+of+Homoallyl+Alcohols&doi=10.1021%2Fja00451a061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Grignard-type carbonyl addition of allyl halides by means of chromous salt.  A chemospecific synthesis of homoallyl alcohols</span></div><div class="casAuthors">Okude, Yoshitaka; Hirano, Shigeo; Hiyama, Tamejiro; Nozaki, Hitosi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3179-81</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Addn. reaction of R2C:CHCH2X (R = H, Me; X = Br, iodo, Cl) with CrCl2 and R1CHO [R1 = 1-hexyl, alkenyl, Ph, oxoalkyl, (CH2)4CO2Me, ω-cyanoalkenyl] yielded the resp. R1CH(OH)CR2C:CH2.  Cyclohexanone, CrCl2, and prenyl bromide gave 1-(1,1-dimethylallyl)cyclohexanol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotzMfBlwrNkLVg90H21EOLACvtfcHk0lhMkka1C5K1Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXktVGgsLc%253D&md5=816d991c69609e85aa20431aaffeee3f</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fja00451a061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00451a061%26sid%3Dliteratum%253Aachs%26aulast%3DOkude%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DS.%26aulast%3DHiyama%26aufirst%3DT.%26aulast%3DNozaki%26aufirst%3DH.%26atitle%3DGrignard-Type%2520Carbonyl%2520Addition%2520of%2520Allyl%2520Halides%2520by%2520Means%2520of%2520Chromous%2520Salt.%2520A%2520Chemospecific%2520Synthesis%2520of%2520Homoallyl%2520Alcohols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1977%26volume%3D99%26issue%3D9%26spage%3D3179%26epage%3D3181%26doi%3D10.1021%2Fja00451a061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargaden, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiry, P. J.</span></span> <span> </span><span class="NLM_article-title">The Development of the Asymmetric Nozaki-Hiyama-KishiReaction</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">2407</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.1002/adsc.200700324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fadsc.200700324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVahtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2007&pages=2407-2424&author=G.+C.+Hargadenauthor=P.+J.+Guiry&title=The+Development+of+the+Asymmetric+Nozaki-Hiyama-KishiReaction&doi=10.1002%2Fadsc.200700324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The development of the asymmetric Nozaki-Hiyama-Kishi reaction</span></div><div class="casAuthors">Hargaden, Grainne C.; Guiry, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2407-2424</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review collates the literature to date on the development of the Nozaki-Hiyama-Kishi (NHK) reaction into an important chromium-mediated, carbon-carbon bond forming process.  The initial research employed stoichiometric quantities of chromium and this was exploited in the key steps of a range of total syntheses.  Thereafter, the NHK reaction was further developed with the discovery of the catalytic variant.  The focus of recent investigations is on the application of this reaction in asym. synthesis.  The asym. NHK typically employed a range of salen- and oxazoline-derived chiral ligands and tethered bis(8-quinolinato)-chromium complexes.  To date, good to high enantioselectivities were obtained in a variety of NHK-type processes, including allylation, crotylation, methallylation, allenylation, propargylation, and vinylation of a range of aldehydes, with limited examples employing ketones as substrates.  Selected examples of the asym. NHK in total synthesis will also be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbV_I8rG5D37Vg90H21EOLACvtfcHk0lhMkka1C5K1Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVahtb%252FN&md5=7e9cf193e4761a9e585d436d98ce2a83</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200700324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200700324%26sid%3Dliteratum%253Aachs%26aulast%3DHargaden%26aufirst%3DG.%2BC.%26aulast%3DGuiry%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520Development%2520of%2520the%2520Asymmetric%2520Nozaki-Hiyama-KishiReaction%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2007%26volume%3D349%26spage%3D2407%26epage%3D2424%26doi%3D10.1002%2Fadsc.200700324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeClair, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of LL-Z1640–2 Utilizing a Late-Stage Intramolecular Nozaki-Hiyama-Kishi Reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">6852</span>– <span class="NLM_lpage">6855</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.10.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1016%2Fj.tetlet.2010.10.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21516235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2ksbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=6852-6855&issue=52&author=C.+A.+LeClairauthor=M.+B.+Boxerauthor=C.+J.+Thomasauthor=D.+J.+Maloney&title=Total+Synthesis+of+LL-Z1640%E2%80%932+Utilizing+a+Late-Stage+Intramolecular+Nozaki-Hiyama-Kishi+Reaction&doi=10.1016%2Fj.tetlet.2010.10.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of LL-Z1640-2 utilizing a late-stage intramolecular Nozaki-Hiyama-Kishi reaction</span></div><div class="casAuthors">LeClair, Christopher A.; Boxer, Matthew B.; Thomas, Craig J.; Maloney, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">6852-6855</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A total synthesis of LL-Z1640-2 (I), a potent and selective kinase inhibitor, has been completed.  The key step of the convergent synthesis utilized a late-stage intramol. Nozaki-Hiyama-Kishi (NHK) reaction to close the macrocycle at the C6'-C7' bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpggHqdk4VerbVg90H21EOLACvtfcHk0lgYu2UnXc1k8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2ksbzF&md5=0b5964303dab3d692ed30205473609dc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.10.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.10.092%26sid%3Dliteratum%253Aachs%26aulast%3DLeClair%26aufirst%3DC.%2BA.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26atitle%3DTotal%2520Synthesis%2520of%2520LL-Z1640%25E2%2580%25932%2520Utilizing%2520a%2520Late-Stage%2520Intramolecular%2520Nozaki-Hiyama-Kishi%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26issue%3D52%26spage%3D6852%26epage%3D6855%26doi%3D10.1016%2Fj.tetlet.2010.10.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Oxygen-Linked Macrocyclic Kinase Inhibitors: Discovery of SB1518 and SB1578, Potent Inhibitors of Janus Kinase 2 (JAK2) and Fms-like Tyrosine Kinase-3 (FLT3)</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1007/s10822-012-9572-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs10822-012-9572-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22527961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVKjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&issue=4&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-Based+Design+of+Oxygen-Linked+Macrocyclic+Kinase+Inhibitors%3A+Discovery+of+SB1518+and+SB1578%2C+Potent+Inhibitors+of+Janus+Kinase+2+%28JAK2%29+and+Fms-like+Tyrosine+Kinase-3+%28FLT3%29&doi=10.1007%2Fs10822-012-9572-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Lee, Angeline; Nagaraj, Harish; Wang, Haishan; Teo, Eeling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-450</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Macrocycles from our Aurora project were screened in a kinase panel and were found to be active on other kinase targets, mainly JAKs, FLT3 and CDKs.  Subsequently these compds. became leads in our JAK2 project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  This residue is conserved in most CDKs resulting in potent pan CDK inhibition.  One of the main project objectives was to achieve JAK2 potency with 100-fold selectivity against CDKs.  Macrocycles with an ether linker have potent JAK2 activity with the ether oxygen forming a hydrogen bond to Ser936.  A hydrogen bond to the equiv. residues of JAK3 and most CDKs cannot be formed resulting in good selectivity for JAK2 over JAK3 and CDKs.  Further optimization of the macrocyclic linker and side chain increased JAK2 and FLT3 activity as well as improving DMPK properties.  The selective JAK2/FLT3 inhibitor 11 (Pacritinib, SB1518) has successfully finished phase 2 clin. trials for myelofibrosis and lymphoma.  Another selective JAK2/FLT3 inhibitor, 33 (SB1578), has entered phase 1 clin. development for the non-oncol. indication rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkXiVkwLI_T7Vg90H21EOLACvtfcHk0lgYu2UnXc1k8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVKjsrc%253D&md5=41bffa51612967861695c5ea27cb38f5</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9572-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9572-z%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-Based%2520Design%2520of%2520Oxygen-Linked%2520Macrocyclic%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520Potent%2520Inhibitors%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26issue%3D4%26spage%3D437%26epage%3D450%26doi%3D10.1007%2Fs10822-012-9572-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Nitrogen-Linked Macrocyclic Kinase Inhibitors Leading to the Clinical Candidate SB1317/TG02, a Potent Inhibitor of Cyclin Dependant Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3)</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1007/s00894-012-1528-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1007%2Fs00894-012-1528-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22820730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=119-130&issue=1&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=H.+Nagarajauthor=M.+Williamsauthor=H.+Wangauthor=A.+Leeauthor=E.+Sunauthor=E.-L.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-Based+Design+of+Nitrogen-Linked+Macrocyclic+Kinase+Inhibitors+Leading+to+the+Clinical+Candidate+SB1317%2FTG02%2C+a+Potent+Inhibitor+of+Cyclin+Dependant+Kinases+%28CDKs%29%2C+Janus+Kinase+2+%28JAK2%29%2C+and+Fms-like+Tyrosine+Kinase-3+%28FLT3%29&doi=10.1007%2Fs00894-012-1528-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</span></div><div class="casAuthors">Poulsen, Anders; William, Anthony; Blanchard, Stephanie; Nagaraj, Harish; Williams, Meredith; Wang, Haishan; Lee, Angeline; Sun, Eric; Teo, Ee-Ling; Tan, Evelyn; Goh, Kee Chuan; Dymock, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A high-throughput screen against Aurora A kinase revealed several promising submicromolar pyrimidine-aniline leads.  The bioactive conformation found by docking these leads into the Aurora A ATP-binding site had a semicircular shape.  Macrocycle formation was proposed to achieve novelty and selectivity via ring-closing metathesis of a diene precursor.  The nature of the optimal linker and its size was directed by docking.  In a kinase panel screen, selected macrocycles were active on other kinase targets, mainly FLT3, JAK2, and CDKs.  These compds. then became leads in a CDK/FLT3/JAK2 inhibitor project.  Macrocycles with a basic nitrogen in the linker form a salt bridge with Asp86 in CDK2 and Asp698 in FLT3.  Interaction with this residue explains the obsd. selectivity.  The Asp86 residue is conserved in most CDKs, resulting in potent pan-CDK inhibition by these compds.  Optimized macrocycles generally have good DMPK properties, and are efficacious in mouse models of cancer.  Compd. 5 (SB1317/TG02), a pan-CDK/FLT3/JAK2 inhibitor, was selected for preclin. development, and is now in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnGiv82CuwbVg90H21EOLACvtfcHk0lgYu2UnXc1k8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtVegug%253D%253D&md5=3f65c0a7f61329cabb9e85656a2c3dcf</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1007%2Fs00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DTeo%26aufirst%3DE.-L.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-Based%2520Design%2520of%2520Nitrogen-Linked%2520Macrocyclic%2520Kinase%2520Inhibitors%2520Leading%2520to%2520the%2520Clinical%2520Candidate%2520SB1317%252FTG02%252C%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin%2520Dependant%2520Kinases%2520%2528CDKs%2529%252C%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%252C%2520and%2520Fms-like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26issue%3D1%26spage%3D119%26epage%3D130%26doi%3D10.1007%2Fs00894-012-1528-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantharaj, E.</span></span> <span> </span><span class="NLM_article-title">Preclinical Metabolism and Pharmacokinetics of SB1317 (TG02), a Potent CDK/JAK2/FLT3 Inhibitor</span>. <i>Drug Metab. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.2174/187231212800229336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.2174%2F187231212800229336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=22372550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=33-42&issue=1&author=M.+K.+Pashaauthor=R.+Jayaramanauthor=V.+P.+Reddyauthor=P.+Yeoauthor=E.+Gohauthor=A.+Williamsauthor=K.+C.+Gohauthor=E.+Kantharaj&title=Preclinical+Metabolism+and+Pharmacokinetics+of+SB1317+%28TG02%29%2C+a+Potent+CDK%2FJAK2%2FFLT3+Inhibitor&doi=10.2174%2F187231212800229336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor</span></div><div class="casAuthors">Pasha, Mohammed Khalid; Jayaraman, Ramesh; Reddy, Venkatesh Pilla; Yeo, Pauline; Goh, Evelyn; Williams, Anthony; Goh, Kee Chuan; Kantharaj, Ethirajulu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">DMLRBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-3128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">SB1317 (TG02) is a novel small mol. potent CDK/JAK2/FLT3 inhibitor.  To evaluate full potential of this development candidate, we conducted drug metab. and pharmacokinetic studies of this novel anti-cancer agent.  SB1317 was sol., highly permeable in Caco-2 cells, and showed >99% binding to plasma from mice, dog and humans.  It was metabolically stable in human and dog liver microsomes relative to mouse and rat.  SB1317 was mainly metabolized by CYP3A4 and CY1A2 in vitro.  SB1317 did not inhibit any of the major human CYPs in vitro except CYP2D6 (IC50 = 1 μM).  SB1317 did not significantly induce CYP1A and CYP3A4 in human hepatocytes in vitro.  The metabolic profiles in liver microsomes from preclin. species were qual. similar to humans.  In pharmacokinetic studies SB1317 showed moderate to high systemic clearance (relative to liver blood flow), high vol. of distribution (>0.6 L/kg), oral bioavailability of 24%, ∼4 and 37% in mice, rats and dogs, resp.; and extensive tissue distribution in mice.  The favorable ADME of SB1317 supported its preclin. development as an oral drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIusZ0BdJyPbVg90H21EOLACvtfcHk0lgIM92OYf_Egw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2gsb8%253D&md5=fbc9c2d6453202c5130db50ed1df75c3</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.2174%2F187231212800229336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187231212800229336%26sid%3Dliteratum%253Aachs%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DV.%2BP.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DGoh%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DKantharaj%26aufirst%3DE.%26atitle%3DPreclinical%2520Metabolism%2520and%2520Pharmacokinetics%2520of%2520SB1317%2520%2528TG02%2529%252C%2520a%2520Potent%2520CDK%252FJAK2%252FFLT3%2520Inhibitor%26jtitle%3DDrug%2520Metab.%2520Lett.%26date%3D2012%26volume%3D6%26issue%3D1%26spage%3D33%26epage%3D42%26doi%3D10.2174%2F187231212800229336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a Novel Oral Multi-Kinase Inhibitor of CDKs, JAK2 and FLT3 with Potent Anti-Leukemic Properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&issue=2&author=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+Novel+Oral+Multi-Kinase+Inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+Potent+Anti-Leukemic+Properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0lgIM92OYf_Egw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520Novel%2520Oral%2520Multi-Kinase%2520Inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520Potent%2520Anti-Leukemic%2520Properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D2%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span> <span> </span><span class="NLM_article-title">The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3451</span>– <span class="NLM_lpage">3479</span>, <span class="refDoi"> DOI: 10.1021/jm200187y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200187y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3451-3479&issue=10&author=S.+Roughleyauthor=A.+M.+Jordan&title=The+Medicinal+Chemist%E2%80%99s+Toolbox%3A+An+Analysis+of+Reactions+Used+in+the+Pursuit+of+Drug+Candidates&doi=10.1021%2Fjm200187y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The Medicinal Chemist's Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates</span></div><div class="casAuthors">Roughley, Stephen D.; Jordan, Allan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3451-3479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A survey of selected medicinal chem. literature from 2008 was undertaken in order to det. the most common chem. reactions used in the prepn. of drug candidates.  In addn. to an examn. of the reactions, the frequency of occurrence of various functional groups in the drug targets was analyzed.  The Lipinski parameters and chirality of the surveyed compds. were also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTUrcluTkPBLVg90H21EOLACvtfcHk0lgIM92OYf_Egw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVyhsrg%253D&md5=a94df26d82bbd58b269ed20aa3253f56</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm200187y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200187y%26sid%3Dliteratum%253Aachs%26aulast%3DRoughley%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26atitle%3DThe%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Toolbox%253A%2520An%2520Analysis%2520of%2520Reactions%2520Used%2520in%2520the%2520Pursuit%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D10%26spage%3D3451%26epage%3D3479%26doi%3D10.1021%2Fjm200187y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span> <span> </span><span class="NLM_article-title">Expanding the Medicinal Chemistry Synthetic Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1038%2Fnrd.2018.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30140018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=709-727&issue=10&author=J.+Bostr%C3%B6mauthor=D.+G.+Brownauthor=R.+J.+Youngauthor=G.+M.+Keser%C3%BC&title=Expanding+the+Medicinal+Chemistry+Synthetic+Toolbox&doi=10.1038%2Fnrd.2018.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding the medicinal chemistry synthetic toolbox</span></div><div class="casAuthors">Bostrom Jonas; Brown Dean G; Young Robert J; Keseru Gyorgy M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">709-727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The key objectives of medicinal chemistry are to efficiently design and synthesize bioactive compounds that have the potential to become safe and efficacious drugs.  Most medicinal chemistry programmes rely on screening compound collections populated by a range of molecules derived from a set of known and robust chemistry reactions.  Analysis of the role of synthetic organic chemistry in subsequent hit and lead optimization efforts suggests that only a few reactions dominate.  Thus, the uptake of new synthetic methodologies in drug discovery is limited.  Starting from the known limitations of reaction parameters, synthesis design tools, synthetic strategies and innovative chemistries, here we highlight opportunities for the expansion of the medicinal chemists' synthetic toolbox.  More intense crosstalk between synthetic and medicinal chemists in industry and academia should enable enhanced impact of new methodologies in future drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTy8c_ueHSwcYMcDoIzZtNkfW6udTcc2eag4fEQAxl9Hrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3htlWisw%253D%253D&md5=d87e988602808139597576ced56faa88</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.116%26sid%3Dliteratum%253Aachs%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26atitle%3DExpanding%2520the%2520Medicinal%2520Chemistry%2520Synthetic%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26issue%3D10%26spage%3D709%26epage%3D727%26doi%3D10.1038%2Fnrd.2018.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykstra, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krska, S. W.</span></span> <span> </span><span class="NLM_article-title">The Medicinal Chemist’s Toolbox for Late Stage Functionalization of Drug-like Molecules</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1039/C5CS00628G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2FC5CS00628G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=26507237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslams7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=546-576&issue=3&author=T.+Cernakauthor=K.+D.+Dykstraauthor=S.+Tyagarajanauthor=P.+Vachalauthor=S.+W.+Krska&title=The+Medicinal+Chemist%E2%80%99s+Toolbox+for+Late+Stage+Functionalization+of+Drug-like+Molecules&doi=10.1039%2FC5CS00628G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The medicinal chemist's toolbox for late stage functionalization of drug-like molecules</span></div><div class="casAuthors">Cernak, Tim; Dykstra, Kevin D.; Tyagarajan, Sriram; Vachal, Petr; Krska, Shane W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">546-576</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The advent of modern C-H functionalization chemistries has enabled medicinal chemists to consider a synthetic strategy, late stage functionalization (LSF), which utilizes the C-H bonds of drug leads as points of diversification for generating new analogs.  LSF approaches offer the promise of rapid exploration of structure activity relationships (SAR), the generation of oxidized metabolites, the blocking of metabolic hot spots and the prepn. of biol. probes.  This review details a toolbox of intermol. C-H functionalization chemistries with proven applicability to drug-like mols., classified by regioselectivity patterns, and gives guidance on how to systematically develop LSF strategies using these patterns and other considerations.  In addn., a no. of examples illustrate how LSF approaches have been used to impact actual drug discovery and chem. biol. efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7N9sPaaVAQbVg90H21EOLACvtfcHk0lhqceMiGdG7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslams7nN&md5=a52fc5692f5515e5cadab0f2746fd6f7</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1039%2FC5CS00628G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00628G%26sid%3Dliteratum%253Aachs%26aulast%3DCernak%26aufirst%3DT.%26aulast%3DDykstra%26aufirst%3DK.%2BD.%26aulast%3DTyagarajan%26aufirst%3DS.%26aulast%3DVachal%26aufirst%3DP.%26aulast%3DKrska%26aufirst%3DS.%2BW.%26atitle%3DThe%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Toolbox%2520for%2520Late%2520Stage%2520Functionalization%2520of%2520Drug-like%2520Molecules%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2016%26volume%3D45%26issue%3D3%26spage%3D546%26epage%3D576%26doi%3D10.1039%2FC5CS00628G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campos, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbaccio, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truppo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmee, E. R.</span></span> <span> </span><span class="NLM_article-title">The Importance of Synthetic Chemistry in the Pharmaceutical Industry</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">6424</span>), <span class="NLM_elocation-id">eaat0805</span> <span class="refDoi"> DOI: 10.1126/science.aat0805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1126%2Fscience.aat0805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=30655413" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2019&issue=6424&author=K.+R.+Camposauthor=P.+J.+Colemanauthor=J.+C.+Alvarezauthor=S.+D.+Dreherauthor=R.+M.+Garbaccioauthor=N.+K.+Terrettauthor=R.+D.+Tillyerauthor=M.+D.+Truppoauthor=E.+R.+Parmee&title=The+Importance+of+Synthetic+Chemistry+in+the+Pharmaceutical+Industry&doi=10.1126%2Fscience.aat0805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat0805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat0805%26sid%3Dliteratum%253Aachs%26aulast%3DCampos%26aufirst%3DK.%2BR.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DAlvarez%26aufirst%3DJ.%2BC.%26aulast%3DDreher%26aufirst%3DS.%2BD.%26aulast%3DGarbaccio%26aufirst%3DR.%2BM.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DTillyer%26aufirst%3DR.%2BD.%26aulast%3DTruppo%26aufirst%3DM.%2BD.%26aulast%3DParmee%26aufirst%3DE.%2BR.%26atitle%3DThe%2520Importance%2520of%2520Synthetic%2520Chemistry%2520in%2520the%2520Pharmaceutical%2520Industry%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2019%26volume%3D363%26issue%3D6424%26doi%3D10.1126%2Fscience.aat0805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogdan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span> <span> </span><span class="NLM_article-title">Efficient Access to New Chemical Space through Flow-Construction of Druglike Macrocycles through Copper-Surface-Catalyzed Azide-Alkyne Cycloaddition Reactions</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">14506</span>– <span class="NLM_lpage">14512</span>, <span class="refDoi"> DOI: 10.1002/chem.201002215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fchem.201002215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=21038332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXit1Ghsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=14506-14512&issue=48&author=A.+R.+Bogdanauthor=K.+James&title=Efficient+Access+to+New+Chemical+Space+through+Flow-Construction+of+Druglike+Macrocycles+through+Copper-Surface-Catalyzed+Azide-Alkyne+Cycloaddition+Reactions&doi=10.1002%2Fchem.201002215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Access to New Chemical Space Through Flow-Construction of Drug-like Macrocycles Through Copper-Surface-Catalyzed Azide-Alkyne Cycloaddition Reactions</span></div><div class="casAuthors">Bogdan, Andrew R.; James, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14506-14512, S14506/1-S14506/99</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of 12- to 22-membered macrocycles, with drug-like functionality and properties, have been generated by using a simple and efficient copper-catalyzed azide-acetylene cycloaddn. reaction, conducted in flow in high-temp. copper tubing, under environmentally friendly conditions.  The triazole-contg. macrocycles, e.g. I, have been generated in up to 90 % yield in a 5 min reaction, without resorting to the high-diln. conditions typical of macrocyclization reactions.  This approach represents a very efficient method for constructing this important class of mols., in terms of yield, concn., and environmental considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLlKc9m7WrrVg90H21EOLACvtfcHk0lhqceMiGdG7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXit1Ghsg%253D%253D&md5=6eb1233b27fc48ae1417672c9cc21f5b</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1002%2Fchem.201002215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201002215%26sid%3Dliteratum%253Aachs%26aulast%3DBogdan%26aufirst%3DA.%2BR.%26aulast%3DJames%26aufirst%3DK.%26atitle%3DEfficient%2520Access%2520to%2520New%2520Chemical%2520Space%2520through%2520Flow-Construction%2520of%2520Druglike%2520Macrocycles%2520through%2520Copper-Surface-Catalyzed%2520Azide-Alkyne%2520Cycloaddition%2520Reactions%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2010%26volume%3D16%26issue%3D48%26spage%3D14506%26epage%3D14512%26doi%3D10.1002%2Fchem.201002215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bédard, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Régnier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. K.</span></span> <span> </span><span class="NLM_article-title">Continuous Flow Macrocyclization at High Concentrations: Synthesis of Macrocyclic Lipids</span>. <i>Green Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1962</span>– <span class="NLM_lpage">1966</span>, <span class="refDoi"> DOI: 10.1039/c3gc40872h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1039%2Fc3gc40872h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVejt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1962-1966&issue=7&author=A.+C.+B%C3%A9dardauthor=S.+R%C3%A9gnierauthor=S.+K.+Collins&title=Continuous+Flow+Macrocyclization+at+High+Concentrations%3A+Synthesis+of+Macrocyclic+Lipids&doi=10.1039%2Fc3gc40872h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous flow macrocyclization at high concentrations: synthesis of macrocyclic lipids</span></div><div class="casAuthors">Bedard, Anne-Catherine; Regnier, Sophie; Collins, Shawn K.</div><div class="citationInfo"><span class="NLM_cas:title">Green Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1962-1966</span>CODEN:
                <span class="NLM_cas:coden">GRCHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9262</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A phase sepn./continuous flow macrocyclization protocol eliminates the need for high-diln. conditions and can be used to prep. gram quantities of biol. relevant macrocyclic lipid structures.  The method presents several green advantages towards macrocycle synthesis: (1) the prevention of unwanted oligomers and waste, (2) a redn. in the large quantities of toxic, volatile org. solvents and (3) the use of PEG as an environmentally benign reaction media.  Macrocycles could be synthesized in high yields (up to 99%) in short reaction times (1.5 h) and on gram scales without the need to alter the reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWLZ8f3RBNNrVg90H21EOLACvtfcHk0lhqceMiGdG7SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVejt7o%253D&md5=8194830bfb2277936bc1e9d1c9730918</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1039%2Fc3gc40872h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3gc40872h%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A9dard%26aufirst%3DA.%2BC.%26aulast%3DR%25C3%25A9gnier%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DS.%2BK.%26atitle%3DContinuous%2520Flow%2520Macrocyclization%2520at%2520High%2520Concentrations%253A%2520Synthesis%2520of%2520Macrocyclic%2520Lipids%26jtitle%3DGreen%2520Chem.%26date%3D2013%26volume%3D15%26issue%3D7%26spage%3D1962%26epage%3D1966%26doi%3D10.1039%2Fc3gc40872h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ugi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrückner, C.</span></span> <span> </span><span class="NLM_article-title">Isonitrile, IX. A-Addition von Immonium-Ionen Und Carbonsäure-Anionen an Isonitrile</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">734</span>, <span class="refDoi"> DOI: 10.1002/cber.19610940323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=10.1002%2Fcber.19610940323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADyaF3MXotFKqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1961&pages=734&issue=10&author=I.+Ugiauthor=C.+Steinbr%C3%BCckner&title=Isonitrile%2C+IX.+A-Addition+von+Immonium-Ionen+Und+Carbons%C3%A4ure-Anionen+an+Isonitrile&doi=10.1002%2Fcber.19610940323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Isonitriles. II. Reaction of isonitriles with carbonyl compounds, amines, and hydrazoic acid</span></div><div class="casAuthors">Ugi, Ivar; Steinbrucker, Cornelius</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">734-42</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">cf. CA 54, 9802f.  Isonitriles with aldehydes or ketones, an amine, and NH3 yielded 1,5-disubstituted tetrazoles; instead of carbonyl compds. and amines, their condensation products, such as Schiff bases and enamines could be used.  The mechanism and the scope of the reaction was discussed.  Piperidine (2.55 g.), 3.00 cc. 10N HCl, 3.00 cc. 10M CH2O, and 5.00 cc. MeOH treated with cooling during 5 min. with 2.73 g. cyclohexyl isocyanide (I), the mixt. acidified with 20 cc. 2N HCl, washed with C6H6, treated with 10 cc. 40% aq. NaOH, and extd. with CH2Cl2 gave 5.33 g. N-cyclohexylpiperidinoacetamide, m. 73-4° (1:5 C6H6-petr. ether).  Et2NH (2.19 g.), 3.00 cc. 10M CH2O, 3.28 g. 2,6-Me2C6H3NC in 3.00 cc. 10N HCl, 5 cc. H2O, and 10 cc. Me2CO kept 100 hrs. at 20-5° yielded 4.69 g. N,N-diethylglycine 2,6-dimethylanilide, m. 66-8°.  PhNHMe, CH2O, and I during 5 hrs. at 20° yielded 41% N-methyl-N-phenylglycine cyclohexylamide, m. 200-202°.  Piperidine, iso-PrCHO, and I during 2 days at 20° gave 60% α-piperidinoisovaleric acid cyclohexylamide, m. 170-2°.  BuNH2, CH2O, and I during 24 hrs. at 20° yielded 50% butyliminodiacetic acid bis(cyclohexylamide), m. 120-1°.  Piperidine (2.55 g.) in 30 cc. Me2CO treated with cooling and stirring with 3.0 cc. 10M CH2O, 6.0 cc. 5N HCl, 1.95 g. NaN3 in 15 cc. H2O, and 2.73 g. I, the mixt. warmed during 3 min. to 20°, satd. after 0.5 hr. with K2CO3, the aq. layer extd. with Me2CO, and the org. phase worked up gave 5.83 g. 1-cyclohexyl-5-(piperidinomethyl)tetrazole (II), needles, m. 115-16° (1:1 C6H6-cyclohexane).  Dipiperidinomethane (4.26 g.) and 2.18 g. I in 5.0 cc. MeOH treated with cooling with 27.9 cc. 7.7% NH3-C6H6 and the mixt. worked up after 10 min. gave 4.85 g. II.  PrCHO (4.32 g.), 7.65 g. m-ClC6H4NH2, 10 cc. MeOH, 35.2 cc. 7.3%, HN3-C6H6, and 5.99 g. I kept 1 hr. at 20° gave 16.52 g. 1-cyclohexyl-5-[1-(m-chloroanilino)butyl]tetrazole, m. 107-9° (1:1 C6H6-petr. ether).  Iso-PrCH:NPr (3.40 g.), 2.73 g. I, 1.95 g. NaN3 in 15 cc. H2O, 40 cc. Me2CO, and 3.0 cc. 10N HCl kept 18 hrs. at 20° yielded 3.51 g. 1-cyclohexyl-5-(1-propylamino-2-methylpropyl)tetrazole (III), m. 55-7° (petr. ether).  Iso-PrCH:NPr (3.40 g.), 2.73 g. I, 20 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 0.5 hr. at 20° yielded 6.49 g. III.  Iso-PrCHO (2.16 g.), 2.55 g. piperidine, 1.95 g. NaN3 in 15 cc. H2O, 3.0 cc. 10N HCl, and 2.73 g. I in 30 cc. Me2CO kept 0.5 hr. at 20° gave 5.79 g. (crude) 1-cyclohexyl-5-(1-piperidino-2-methylpropyl)tetrazole (IV), m. 147-8° (1:1 C6H6-cyclohexane).  1-Piperidino-2-methyl-1-propene (3.48 g.), 2.73 g. I, 5 cc. MeOH, and 19.5 cc. 5.5% HN3-C6H6 kept 15 min. at 0° yielded 6.91 g. IV.  Piperazine and 2 mole equivs. each iso-PrCHO, HN3, and I in CHCl3-MeOH kept 10 min. at 0° yielded 97% (crude) 1,4-bis[1-(1-cyclohexyl-5-tetrazolyl)isobutyl] piperazine, m. 281-5° (decompn.) (CHCl3-cyclohexane).  BzH (3.18 g.), 2.55 g. piperidine, 40 cc. Me2CO, 1.95 g. NaN3, 20 cc. H2O, 3.0 cc. 10N HCl, and 2.73 g. I kept 20 hrs. at 20° yielded 3.67 g. 1-cyclohexyl-5-(α-piperidinobenzyl)tetrazole-HCl (V.HCl), m. 225-7° (decompn.) (MeOH); V m. 127-8° (ligroine, b. 80-110°).  BzH (3.18 g.), 2.55 g. piperidine, 10 cc. MeOH, 2.73 g. I, and 23.4 cc. 5.5% HN3-C6H6 kept 3 hrs. at 20° gave 7.41 g. V, m. 127-8°.  Iso-PrN:CMe2 (2.97 g.), 1.95 g. NaN3, 20 cc. H2O, 2.73 g. I, 30 cc. Me2CO, and 3.0 cc. 10N HCl kept 70 hrs. at 20° gave 2.76 g. 1-cyclohexyl-5-(α-isopropylaminoisopropyl)tetrazole (VI), m. 62-2.5° (petr. ether); VI.HCl m. 171-2° (decompn.).  Iso-PrN:CMe2 (2.97 g.), 2.73 g. I, 10 cc. MeOH, and 17.6 cc. 7.3% HN3-C6H6 kept 15 hrs. at 20° yielded 5.81 g. VI.  Piperidine (2.55 g.), 2.73 g. I, 30 cc. Me2CO, 10 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 120 hrs. at 20° yielded 6.46 g. 1-cyclohexyl-5-(α-piperidinoisopropyl)tetrazole, m. 127-8° (1:3 C6H6-petr. ether). p-MeOC6H4NH2 (2.77 g.), 20 cc. Me2CO, 17.6 cc. 7.3% HN3-C6H6, 2.45 g. I, and 5 cc. MeOH kept 12 days at 20° gave 6.39 g. 1-cyclohexyl-5-[α-(p-methoxyanilino)isopropyl]tetrazole, m. 130-2° (2:1 C6H6-petr. ether).  Cyclohexanonebutylimide (VII) (4.60 g.), 2.73 g. I, 1.95 g. NaN3 in 15 cc. H2O, 30 cc. Me2CO, and 3.0 cc. 10N HCl kept 12 hrs. at 20° gave 5.21 g. 1-cyclohexyl-5-(1-butylaminocyclohexyl)tetrazole (VIII), m. 107-9° (petr. ether).  VII (4.60 g.), 2.73 g. I, 20 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 10 min. at 20° yielded 7.56 g. VIII.  1-Piperidinocyclohexene (4.96 g.), 2.73 g. I, 10 cc. MeOH, and 23.4 cc. 5.5% HN3-C6H6 kept 10 min. at 0° gave 7.70 g. 5-(1-piperidinocyclohexyl) analog of VIII, m. 149-50° (petr. ether).  AcPh (7.20 g.), 5.22 g. morpholine, 5.99 g. I, 45 cc. MeOH, and 35.2 cc. 7.3% HN3-C6H6 kept 3 weeks at 20-5° gave 12.98 g. (crude) 5-(1-morpholino-1-phenylethyl) analog (IX) of VIII, m. 213-15° (C6H6).  1-Morpholino-1-phenylethylene (3.31 g.), b1 110-12°, 1.63 g. I, 5 cc. MeOH, and 10.3 cc. 7.3% HN3-C6H6 kept 15 min. at 0-10° gave 4.82 g. IX.  PhCH2Ac (4.02 g.), 2.61 g. morpholine, 20 cc. MeOH, 2.73 g. I, and 17.6 cc. 7.3% HN3-C6H6 kept 72 hrs. at 20-5° gave 8.57 g. (crude) 1-cyclohexyl-5-(α-morpholino-β-phenylisopropyl)tetrazole (X), m. 189-91° (3:1 C6H6-petr. ether).  2-Morpholino-1-phenylpropene (6.09 g.), 2.73 g. I, 5 cc. MeOH, and 17.6 cc. 7.3% HN3-C6H6 kept 5 hrs. at 10-20° yielded 8.39 g.X.  Me3CN:CH2 (5.10 g.), 7.21 g. 2,6-Me2C6H3NC, 30 cc. MeOH, and 35.2 cc. 7.3% HN3-C6H6 kept 15 hrs. at 20° yielded 12.69 g. (crude) 1-(2-6-dimethylphenyl)-5-(tert-butylaminomethyl)tetrazole (XI), m. 79-81° (C6H6).  Iso-PrCHO (4.32 g.), 5.10 g. piperidine, 40 cc. MeOH, 6.56 g. 2,6-Me2C6H3NC, and 35.2 cc. 7.3% HN3-C6H6 kept 5 hrs. at 20° yielded 15.41 g. (crude) 5-(1-piperidino-2-methylpropyl) analog of XI, m. 126-7° (1:2 C6H6-Et2O).  The infrared absorption spectrum of IX was recorded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprIzv-ZuZHBLVg90H21EOLACvtfcHk0lhofr9nFx5YHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXotFKqsQ%253D%253D&md5=dfabc705854ead4af1874007a7b64a31</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fcber.19610940323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19610940323%26sid%3Dliteratum%253Aachs%26aulast%3DUgi%26aufirst%3DI.%26aulast%3DSteinbr%25C3%25BCckner%26aufirst%3DC.%26atitle%3DIsonitrile%252C%2520IX.%2520A-Addition%2520von%2520Immonium-Ionen%2520Und%2520Carbons%25C3%25A4ure-Anionen%2520an%2520Isonitrile%26jtitle%3DChem.%2520Ber.%26date%3D1961%26volume%3D94%26issue%3D10%26spage%3D734%26doi%3D10.1002%2Fcber.19610940323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wessjohann, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vercillo, O. E.</span></span> <span> </span><span class="NLM_article-title">Multiple Multicomponent Macrocyclizations (MiBs): A Strategie Development toward Macrocycle Diversity</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">796</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1021/cr8003407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr8003407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVChtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=796-814&issue=2&author=L.+A.+Wessjohannauthor=D.+G.+Riveraauthor=O.+E.+Vercillo&title=Multiple+Multicomponent+Macrocyclizations+%28MiBs%29%3A+A+Strategie+Development+toward+Macrocycle+Diversity&doi=10.1021%2Fcr8003407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Multicomponent Macrocyclizations (MiBs): A Strategic Development Toward Macrocycle Diversity</span></div><div class="casAuthors">Wessjohann, Ludger A.; Rivera, Daniel G.; Vercillo, Otilie E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">796-814</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review presents basic principles of multiple multi-component macrocyclization methods.  The approach is expected to develop to a valuable strategy for the synthesis of peptide-like or artificial macrocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcgRP4IhK-vbVg90H21EOLACvtfcHk0lhofr9nFx5YHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVChtb0%253D&md5=d32b92ff49300a68adc2fa152e4cd8d0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fcr8003407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr8003407%26sid%3Dliteratum%253Aachs%26aulast%3DWessjohann%26aufirst%3DL.%2BA.%26aulast%3DRivera%26aufirst%3DD.%2BG.%26aulast%3DVercillo%26aufirst%3DO.%2BE.%26atitle%3DMultiple%2520Multicomponent%2520Macrocyclizations%2520%2528MiBs%2529%253A%2520A%2520Strategie%2520Development%2520toward%2520Macrocycle%2520Diversity%26jtitle%3DChem.%2520Rev.%26date%3D2009%26volume%3D109%26issue%3D2%26spage%3D796%26epage%3D814%26doi%3D10.1021%2Fcr8003407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XP2','PDB','2XP2'); return false;">PDB: 2XP2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CLI','PDB','4CLI'); return false;">PDB: 4CLI</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i21"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00217">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43213"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00217?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00217</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figures: Summaries of esterification ring-closing reactions, palladium-catalyzed cross-coupling reactions, C–O, C–N, and C–C bond formation. All references used for the statistical analysis. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00217/suppl_file/jm1c00217_si_001.pdf">jm1c00217_si_001.pdf (355.83 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00217&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00217%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00217" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f7b168ff2458","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
